| Excerpt | Reference |
|---|
| "Gastric cancer is a highly fatal, common form of cancer in many countries and its medical, surgical, radiologic or combined treatment is very problematic." | ( Pfeiffer, CJ, 1976) |
| "But gastric neoplasms are not decreasing in some other geographic areas." | ( Carter, SK; Comis, RL, 1977) |
| "Stomach cancer is one of the major cancers in Asia." | ( Chi, CW; Lui, WY; P'eng, FK; Wu, CW, 1992) |
| "Although gastric cancer is the most common cause of mortality from cancer, its etiology is not yet clear." | ( Cheng, WF; Ji, YS; Mao, DJ; Shi, KX; Xu, LZ, 1991) |
| "Gastric cancer is a very typical cancer related to life styles, including nutrition and dietary conditions." | ( Sugimura, T; Wakabayashi, K, 1990) |
| "Eight patients with stomach cancer are described who had also a striking glandular hyperplasia of the fundic mucosa adjacent and remote from the tumor." | ( Saremaslani, P; Stamm, B, 1989) |
| "Spread of the gastric cancer is multifarious according to its pathological and biophysiological characteristics." | ( Nakajima, T; Nishi, M; Ohta, H, 1986) |
| "Gastric cancer is the most chemotherapy-responsive adenocarcinoma of the major gastrointestinal sites." | ( Ahlgren, JD; Schein, PS; Smith, FP; Woolley, PV, 1982) |
| "Gastric cancer is the major cancer in Japan." | ( Canzian, F; Inoue, R; Nagao, M; Ohgaki, H; Sugimura, T; Ushijima, T, 1995) |
| "Gastric cancer is a leading cause of cancer death in many parts of the world." | ( Burger, A; Li, H; Salesiotis, AN; Seth, A; Wang, CD; Wang, CK, 1995) |
| "Stomach cancer is the most common cancer among Koreans." | ( Ahn, YO; Lee, JK; Park, BJ; Yoo, KY, 1995) |
| "Gastric cancer is one of the most common cancers in Asia." | ( Chang, YF; Chi, CW; Li, LL; Liu, TY; Lui, WY; P'eng, FK; Wu, CW, 1996) |
| "Staging of gastric cancer is limited by the inability of imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) to detect tumor in normal size lymph nodes." | ( Halvorsen, RA; McCormick, VD; Yee, J, 1996) |
| "Stomach cancer is still the most prevalent malignant tumor in Korea." | ( Cho, MJ; Chung, MH; Ko, GH; Lee, WK; Rhee, KH; Youn, HS, 1996) |
| "The incidence of gastric cancer is much higher in men than in woman, and a similar sex difference is also seen in a rat experimental model of gastric cancer." | ( Langman, MJ; Poulsom, R; Sheppard, MC; Singh, S; Wright, NA, 1997) |
| "Gastric cancer is the most chemosensitive adenocarcinoma among digestive neoplasms." | ( Belón, J; de Castro, J; Espinosa, E; Feliu, J; García Alfonso, P; García Girón, C; Garrido, P; González Barón, M; Lomas, M; Ordóñez, A; Zamora, P, 1997) |
| "Scirrhous gastric cancer is characteristic in that cancer cells proliferate and invade with prominent fibrosis." | ( Chung, YS; Hotta, H; Sawada, R; Sowa, M; Tai, T; Yano, I, 1998) |
| "Gastric cancer is no exception." | ( Sugimura, T; Terada, M, 1998) |
| "Gastric cancers are a significant cause of morbidity worldwide." | ( Campbell-Thompson, M; Cromwell, J; Lauwers, GY; Reyher, KK; Shiverick, KT, 1999) |
| "Gastric cancer is the most common cancer in Korea." | ( Cho, MH; Hemminki, K; Jang, JJ; Kim, DY; Kim, JP; Kumar, R; Yang, HK, 1999) |
| "Liver cancer and gastric cancer are the most common solid tumors worldwide." | ( Alvarez, E; Liu, P; Lu, K; Menon, K; Teicher, BA, 2000) |
| "Early gastric cancer is frequently seen with nonspecific dyspeptic symptoms and subtle endoscopic features." | ( Griffin, SM; Hayes, N; Raimes, SA; Wayman, J, 2000) |
| "In Italy, gastric cancer is more frequent in farmers and in iodine-deficient populations, living in mountainous and hilly areas, than in fishermen." | ( Donati, FM; Grossi, L; Guidi, A; Venturi, A; Venturi, M; Venturi, S, 2000) |
| "Gastric cancer is generally thought to arise through a series of gastric mucosal changes, but the determinants of the precancerous lesions are not well understood." | ( Blaser, MJ; Blot, WJ; Chang, YS; Correa, P; Fraumeni, JF; Gail, MH; Hu, YR; Jin, ML; Li, JY; Liu, WD; Ma, JL; Xu, GW; Yang, CS; You, WC; Zhang, L, 2000) |
| "Metastatic gastric cancer is a relatively chemosensitive disease." | ( Köhne, CH; Wilke, HJ; Wils, JA, 2000) |
| "Advanced gastric cancer is classified into four Borrmann types, types 1 to 4." | ( Iwamoto, K; Kagami, M; Kikuchi, S; Kunii, Y; Narushima, Y; Saito, T; Takahashi, M; Teshima, S; Yamada, Y; Yamauchi, H; Yokota, T, 2000) |
| "Gastric cancer is one of the most frequent malignancies and its treatment is far from satisfactory." | ( Díaz-Ruiz, C; Montaner, B; Pérez-Tomás, R, 2001) |
| "Gastric cancer is one of the most frequent neoplasms and a leading cause of the death world-wide." | ( Bielanski, W; Hahn, EG; Karczewska, E; Konturek, PC; Konturek, SJ; Marlicz, K; Meixner, H; Stachura, J; Starzynska, T; Sulekova, Z, 2001) |
| "Gastric cancer is the second most frequent cause of death from cancer in the world and the leading cause of death from cancer in China." | ( Brown, LM; Chang, YS; Fraumeni, JF; Gail, MH; Heinrich, J; Liu, WD; Ma, JL; Xu, GW; Yang, CS; You, WC; Zhang, L, 2001) |
| "SNNS for gastric cancer is a promising technique; further study of various anatomic and pathologic factors will indicate whether it can be used to determine the extent of lymphadenectomy necessary in patients with early gastric cancer." | ( Aikou, T; Baba, M; Higashi, H; Hokita, S; Natsugoe, S; Tako, S, 2001) |
| "Gastric cancers are commonly subdivided into intestinal and diffuse subtypes on a morphologic basis, supported by corollary evidence of differences at the pathogenetic and molecular levels." | ( Clayton, N; Devereux, TR; Flake, G; Portier, M; Sills, RC; Stockton, P; Sun, K, 2001) |
| "Gastric cancer is the second most common cause of cancer-related mortality worldwide and the 14th overall cause of death." | ( Fox, JG; Houghton, J; Wang, TC, 2002) |
| "Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens." | ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003) |
| "18F-FDG uptake by gastric cancers is relatively high but does not parallel histopathologic features of malignancy." | ( Fukuda, H; Ido, T; Kanamaru, R; Kubota, K; Saginoya, T; Takahashi, H; Yamaguchi, K; Yamaura, G; Yamazaki, T; Yoshioka, T, 2003) |
| "Gastric cancer is a cause of significant morbidity and mortality." | ( Mayberry, JF; Podas, T; Raj, A, 2003) |
| "Gastric cancer is one of the leading causes of cancer death throughout the world." | ( Motwani, M; Rizzo, C; Schwartz, GK; She, Y; Sirotnak, F, 2003) |
| "Globally, gastric cancer is one of the most common types of cancer and one of the most frequent causes of cancer-related death." | ( Van Cutsem, E, 2004) |
| "Gastric cancer is an important cause of death among patients with malignancies in Malaysia." | ( Kandasami, P; Norain, K; Tan, WJ, 2003) |
| "Gastric cancer is one of the commonest cancers worldwide and is associated with a poor prognosis." | ( Cunningham, D; Dickson, JL, 2004) |
| "Scirrhous gastric cancer is resistant to chemotherapy in comparison to other types of gastric cancers, and cancer cell-stromal fibroblast interactions play an important role in progression of scirrhous gastric cancer." | ( Matsuda, S; Nakajima, K; Okita, Y, 2004) |
| "The incidence of gastric cancer is decreasing worldwide, but it is also a highly lethal cancer." | ( Dehdashti, F; Siegel, BA, 2004) |
| "Gastric cancer is highly angiogenic and is dependent on VEGF for its growth and progression." | ( Banerjee, S; Basu, S; Chakroborty, D; Dasgupta, PS; Mitra, RB; Sarkar, C, 2004) |
| "Gastric cancer is a major clinical challenge, with poor overall prognosis and limited life expectancy for patients with advanced disease." | ( Baldo, S; Caprioni, F; Comandini, D; Decian, F; Fornarini, G; Mammoliti, S; Sobrero, A, 2004) |
| "Gastric cancer is the fourth most common malignancy worldwide." | ( Adachi, Y; Barker, SD; Curiel, DT; Davydova, JG; Krasnykh, VN; Kunisaki, C; Ono, HA; Reynolds, PN; Shimada, H; Takayama, K; Yamamoto, M, 2005) |
| "Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence." | ( Catalano, G; Ciardiello, F; De Vita, F; Orditura, M, 2005) |
| "Gastric cancer is most chemosensitive among gastrointestinal tumors." | ( Caponigro, F; Facchini, G; Iaffaioli, RV; Nasti, G, 2005) |
| "Gastric cancer is the second most common cause of cancer death worldwide." | ( Philip, PA, 2005) |
| "The etiology of gastric cancer is not well-understood." | ( Ando, T; Goto, H; Goto, Y; Hamajima, N, 2005) |
| "Gastric cancer is often diagnosed in the metastatic stage, and only 10% of patients survive for as long as 2 years." | ( Al-Batran, SE; Goekkurt, E; Hossfeld, DK; Stoehlmacher, J; Wolschke, C, 2005) |
| "Gastric cancer is often diagnosed in locally advanced or metastatic stages and, therefore, of poor prognosis." | ( Meriggi, F; Zaniboni, A, 2005) |
| "Gastric cancer is one of the main health issues in Lithuania." | ( Dregval, L; Dudzevicius, J; Strumylaite, L; Zickute, J, 2006) |
| "A resected case of gastric cancer is described." | ( Aita, K; Moon, Y; Oshiro, Y; Yamamoto, Y, 2006) |
| "Gastric cancer is the second most common malignancy and prognosis remains dismal." | ( Albrecht, W; Deininger, SO; Ebert, MP; Hoffmann, J; Knippig, C; Malfertheiner, P; Niemeyer, D; Röcken, C; Sauer, J; Wex, T, 2006) |
| "Gastric cancer is the second most common cause of death from cancer worldwide and resistant to various chemotherapeutic regimens." | ( Cejka, D; Crevenna, R; Losert, D; Monia, BP; Selzer, E; Sieghart, W; Strommer, S; Wacheck, V, 2006) |
| "Gastric cancer is the second most common cancer worldwide." | ( Anderson, C; Kim, J; Nijagal, A, 2006) |
| "Gastric cancer is one of the most common malignancies worldwide." | ( Aebischer, C; Andrade, O; Bravo, JC; Buiatti, E; Cano, E; Carillo, E; Castro, D; Franceschi, S; Garcia, R; Lopez, G; Muñoz, N; Oliver, W; Peraza, S; Plummer, M; Sánchez, V; Vivas, J, 2007) |
| "Gastric cancer is often diagnosed in advanced stage (AGC) and in elderly patients." | ( Azzarello, D; Costarella, S; Del Medico, P; Falzea, A; Giannicola, R; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M, 2007) |
| "Gastric cancer is the second most frequent cancer in the world." | ( López-Brea, MF; Rivera, F; Vega-Villegas, ME, 2007) |
| "Gastric cancer is one of the most frequent cause of mortality, survival data are insufficient." | ( Ember, A; Esik, O; Horváth, OP; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| "The incidence of gastric cancer is higher in men than women." | ( Fox, JG; García, A; Ge, Z; Marini, RP; Ohtani, M; Rogers, AB; Taylor, NS; Wang, TC; Watanabe, K; Whary, MT; Xu, S, 2007) |
| "Gastric cancer is the second leading cause of cancer mortality worldwide." | ( Fan, D; Zhang, D, 2007) |
| "Using S-1 against gastric cancer is common." | ( Baba, H; Nagahama, T; Sawada, Y; Shimoda, M; Shimoda, S; Suzuki, K, 2007) |
| "Gastric cancer is the second most common cause of death from cancer in Asia." | ( Goh, KL; Gotoda, T; Kachintorn, U; Kakugawa, Y; Kim, JJ; Leung, WK; Lin, JT; Ng, EK; Sollano, J; Sung, JJ; Wu, DC; Wu, KC; Wu, MS; Yeoh, KG; You, WC, 2008) |
| "Gastric cancer is a major health burden in the Asia-Pacific region but consensus on prevention strategies has been lacking." | ( Ang, TL; Azuma, T; Chiba, T; Fock, KM; Goh, KL; Hunt, R; Kim, JG; Kim, N; Lam, SK; Liou, JM; Mahachai, V; Mitchell, H; Moayyedi, P; Rani, AA; Sollano, J; Sugano, K; Talley, N; Uemura, N; Vilaichone, RK; Xiao, SD, 2008) |
| "The risk of gastric cancer is reduced in those without premalignant mucosal abnormalities at the time of eradication." | ( Katelaris, P; Kwok, A; Lam, T; Leong, RW, 2008) |
| "Gastric cancer is the most common cancer in Japan and infection with Epstein-Barr virus (EBV) is responsible for about 10% of gastric cancers worldwide." | ( Fujimoto, M; Fukagawa, Y; Imai, S; Iwakiri, D; Kuramitsu, Y; Nakamura, K; Nishikawa, J; Okamoto, T; Okita, K; Sakaida, I; Satake, M; Takada, K, 2008) |
| "Globally, gastric cancer is the second most common cause of cancer-related death." | ( Barone, C; Pozzo, C, 2008) |
| "Gastric cancer is the second most common cancer worldwide and has a poor prognosis." | ( Bai, S; Chen, L; Huang, C; Lei, Y; Li, Z; Liang, S; Liu, R; Tang, M; Wei, Y; Zhang, H; Zhao, YL, 2009) |
| "Gastric cancer is the second most common cause of cancer death worldwide, and annually it causes over 150,000 deaths in Europe and 700,000 deaths globally." | ( Chandanos, E; Lagergren, J, 2008) |
| "Gastric cancer is a curable disease if diagnosed at early stage." | ( Aguayo, F; Aravena, E; Barrientos, C; Bernal, C; Corvalan, AH; Díaz, I; Ossandon, FJ; Palma, M; Santibáñez, E; Vargas, M; Villarroel, C, 2008) |
| "Gastric cancer is fourth on the incidence list of cancers worldwide with a high disease-related mortality rate." | ( Bosscha, K; Dassen, AE; Hoekstra, CJ; Lips, DJ; Pruijt, JF, 2009) |
| "Cancer of stomach is currently regarded as the final result of a staged multifactor process during which the microenvironment affects cells and causes their changes." | ( Kashin, SV; Kriukova, TV; Maev, IV; Mel'nikova, EV; Nadezhin, AS, 2008) |
| "Stomach cancer is the third most common cancer in South India." | ( Jayanthi, V; Navaneethan, U; Ramalingam, S; Sumathi, B, 2009) |
| "Gastric cancer is the second most common fatal malignancy in the world." | ( Chen, X; Liu, L; Luo, Z; Shi, B; Wu, C; Yao, D; Zhao, P; Zhu, L, 2009) |
| "Intestinal type gastric cancer is a significant cause of mortality, therefore a better understanding of its molecular basis is required." | ( Alcolado, R; Baxter, JN; Cronin, J; Davies, DJ; Doak, SH; Griffiths, AP; Jenkins, GJ; Somasekar, A; Williams, JG; Williams, L, 2009) |
| "The development of gastric cancer is closely associated with Helicobacter pylori (H." | ( Du, YC; Oguma, K; Oshima, H; Oshima, M, 2009) |
| "Gastric cancer is the second most common cause of cancer-related death in the world." | ( Badea, D; Burada, F; Enescu, A; Genunche-Dumitrescu, A; Manea, M; Mitruţ, P; Rogoz, I; Scorei, R, 2009) |
| "Gastric cancer is a deadly disease for which current therapeutic options are extremely limited." | ( Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S, 2009) |
| "Gastric cancer is the second most common cause of cancer deaths worldwide." | ( Baek, SY; Han, ME; Kim, BS; Kim, JB; Lee, YS; Oh, SO, 2009) |
| "Gastric cancers are generally classified into better differentiated intestinal-type tumor and poorly differentiated diffuse-type one according to Lauren's histological categorization." | ( Itadani, H; Kotani, H; Oshima, H; Oshima, M, 2009) |
| "Gastric cancer is one of the leading cancerous diseases worldwide." | ( Chen, CP; Chen, CT; Chung, CT; Han, CH; Huang, CL; Huang, HC; Hwang, LL; Lai, YK; Lee, WS; Shen, CC; Tsai, ML; Tuan, TF; Wang, MH; Yeh, KC, 2010) |
| "Gastric cancer is one of the most common malignancies in the world." | ( Chao, Y; Kuo, JY; Lee, RC; Li, AF; Li, CP; Luo, JC; Yang, KC, 2010) |
| "Gastric cancer is one of the most common cancers and the second leading cause of cancer-related death." | ( Farhat, FS; Ghosn, MG; Kattan, J, 2010) |
| "Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths." | ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011) |
| "Gastric cancer is the second leading cause of cancer death worldwide." | ( Abbott, GW; King, EC; La Perle, KM; Lerner, DJ; Purtell, K; Roepke, TK, 2010) |
| "Gastric cancer is often diagnosed in locally advanced or metastatic stages, which preludes a poor prognosis." | ( Hong, SS; Jung, KH; Lee, H; Lee, JH, 2010) |
| "Gastric cancer is also common among the elderly population, but is sometimes difficult to distinguish from gastric ulcers, especially those stemming from aspirin use." | ( Akamatsu, T; Arakura, N; Ito, T; Iwaya, Y; Nagaya, T; Suga, T, 2010) |
| "Gastric cancer is a complex pathology which represents a worldwide health burden due to its high prevalence and poor prognosis." | ( Badía Martínez, M; García-González, MA, 2011) |
| "Gastric cancer is the fourth most common cancer in the world and the second most prevalent cause of cancer related death." | ( Bardram, L; Bou Kheir, T; Federspiel, B; Friis-Hansen, L; Futoma-Kazmierczak, E; Grønbæk, K; Hother, C; Jacobsen, A; Krogh, A; Lund, AH, 2011) |
| "Gastric cancer is the second most common cause of global cancer-related mortality." | ( Gu, Q; Liu, B; Su, L; Wang, Z; Wei, M; Yang, Z; Yao, H; Yu, Y; Zhang, Q; Zhu, Z, 2011) |
| "Gastric cancer is often diagnosed at advanced stages and there is no accurate method for its screening and diagnosis, especially in small animals." | ( Bathaie, SZ; Miri, H; Mohagheghi, MA; Mokhtari-Dizaji, M; Shahbazfar, AA, 2011) |
| "Gastric cancer is the second most common cause of cancer deaths worldwide and due to its poor prognosis, it is important that specific biomarkers are identified to enable its early detection." | ( Chang, KJ; Chen, CN; Chuang, KN; Huang, HC; Juan, HF; Lai, HS; Lee, PH; Lin, CC; Tseng, CW; Yang, JC, 2011) |
| "Gastric cancer is a leading cause of cancer-related deaths, worldwide being second only to lung cancer as a cause of death." | ( Hong, SC; Jeong, HJ; Jeong, JB; Koo, JS, 2011) |
| "Gastric cancer is the fourth most common malignancy worldwide with Japan, Korea, Taiwan, China, Mongolia and many countries in South America and eastern Europe, as well as parts of the Middle East, contributing to the majority of cases." | ( Ajani, JA; Blum, M; Suzuki, A, 2011) |
| "Gastric cancer is a common human malignancy and a major contributor to cancer-related deaths worldwide." | ( Chuang, SM; Chueh, PJ; Li, YH; Su, YC; Wang, HM, 2011) |
| "Gastric cancer is a multifactorial disease with the involvement of both genetic and environmental risk factors." | ( Ayesha, Q; Bhayal, AC; Jyothy, A; Nallari, P; Penchikala, A; Prabhakar, B; Rao, KP; Venkateshwari, A, 2011) |
| "Gastric cancer is the third most common malignancy among gastrointestinal malignancies." | ( Bulut, G; Erden, A; Göker, E; Karaca, B, 2011) |
| "MSI status in gastric cancer is not itself a prognostic indicator." | ( An, JY; Cheong, JH; Hyung, WJ; Kim, H; Noh, SH, 2012) |
| "Gastric cancer is one of the most common malignant tumors and the second cause of cancer-related deaths worldwide." | ( Heo, K; Hyun, DH; Kim, JA; Kim, ND; Lee, CG; Lee, EK; Lee, JH; Park, SJ; Son, TG; Yang, KM, 2012) |
| "Gastric cancer is the fourth most commonly diagnosed cancer with the second highest mortality rate worldwide." | ( Iqbal, F; Khan, M; Ma, T; Rasul, A; Yang, H; Yu, B; Zhang, K, 2012) |
| "Gastric cancer is the second most common among cancer-related deaths in the world." | ( Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M, 2012) |
| "Stomach cancer is still one of the most prevalent malignancies and is the main cause of cancer deaths worldwide." | ( Baek, SK; Cho, KS; Jeong, JH; Kim, SY; Yoon, HJ, 2012) |
| "Gastric cancer is one of the most common cancers in the world." | ( Corcos, L; Cousin, FJ; Dimanche-Boitrel, MT; Jan, G; Jouan-Lanhouet, S, 2012) |
| "Gastric cancer is one of the most common malignancies worldwide, and the main cause of cancer-related death in Asia." | ( Chang, FR; Huang, YB; Lin, AS; Lin, MW; Wang, SS; Wu, DC; Wu, YC, 2012) |
| "(18)F-FDG uptake of gastric cancer is an independent and significant prognostic factor for tumour recurrence." | ( Lee, JW; Lee, MS; Lee, SM; Shin, HC, 2012) |
| "Gastric cancer is one of the most common types of malignant tumors in China and East Asia and has the highest mortality rate of the malignant gastrointestinal tumors." | ( Cai, J; Chen, RX; Meng, H; Wang, KL; Wang, Y; Wu, GC; Zhang, J; Zhang, ZT, 2012) |
| "Gastric cancer is frequently lethal despite aggressive multimodal therapies, and new treatment approaches are therefore needed." | ( Cao, LY; Chen, FH; Ge, JF; Hu, KW; Li, H, 2012) |
| "Gastric cancer is a malignant disease that arises from the gastric epithelium." | ( Huang, HC; Juan, HF; Lin, LL, 2012) |
| "Gastric cancer is one of the most common digestive malignancies worldwide." | ( Chang, X; Chen, J; Dai, D; Deng, P; Li, Z; Ma, J; Zhang, S; Zhi, Y, 2013) |
| "Gastric cancer is the second most common cause of death from cancer in the world." | ( Everatt, R; Kuzmickiene, I; Milinaviciene, E; Radisauskas, R; Reklaitiene, R; Tamosiunas, A; Virviciute, D, 2012) |
| "Gastric cancer is one of the most common malignant tumors causing death in Fujian Province, China." | ( Aoki, K; Chen, TH; Li, XQ; Lin, S; Lin, SG; Su, C; Wu, BS; You, JW; Zheng, KC; Zhong, WL, 2012) |
| "Chemotherapy for gastric cancer is improving continuously through conducting randomized clinical trials and developing new anti-cancer drugs." | ( Shimada, Y; Terazawa, T, 2012) |
| "Gastric cancer is one of the most common types of malignancies and proteins from the Bcl-2 family are highly expressed in human gastric cancer." | ( Liang, JM; Nie, YZ; Tian, J; Xia, LM; Xin, J; Zhan, YH; Zhu, HW, 2013) |
| "Precise staging of gastric cancer is essential when selecting for the appropriate treatment approach." | ( Fujiwara, H; Harada, Y; Ichikawa, D; Ikoma, H; Koizumi, N; Kokuba, Y; Komatsu, S; Kubota, T; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Takamatsu, T, 2012) |
| "LADG for early gastric cancer is a feasible and safe procedure with short-term clinical results superior to those of ODG." | ( Bax, L; Futawatari, N; Katada, N; Kikuchi, S; Okutomi, T; Sakuramoto, S; Wang, G; Watanabe, M; Yamashita, K, 2013) |
| "Gastric cancer is one of the leading causes of malignancy-related mortality worldwide, and drug resistance hampered the clinical efficacy of chemotherapy." | ( Fan, D; Gang, Y; Guo, X; Huang, R; Li, T; Liu, Z; Pan, Y; Sun, Y; Wang, H; Wu, K; Xu, L; Yang, Z; Zhao, L, 2013) |
| "Gastric cancer is a common and highly lethal malignancy in the world, but its pathogenesis remains elusive." | ( Kong, Y; Liao, ZJ; Nan, KJ; Yao, Y; Zhao, LY; Zheng, Q, 2013) |
| "Gastric cancer is the second most common cause of death from cancer worldwide." | ( Song, Z; Wang, X; Wang, Y; Yang, T; Yang, X, 2013) |
| "Gastric cancer is associated with chronic inflammation and Helicobacter pylori infection." | ( Beswick, EJ; Earley, RB; Ma, TY; Morris, KT; Nofchissey, RA; Pinchuk, IV; Wu, JY, 2013) |
| "Gastric cancer is one of the leading causes of tumor-related deaths in China." | ( Bi, YT; Dong, MS; Gao, SX; Gong, CY; Linq, QX; Miao, XJ; Wang, Y; Xiang, H; Xu, XH; Ye, CF; Zhang, MH, 2013) |
| "Gastric cancer is one of the most common and lethal malignancies worldwide." | ( Castiglione, A; Ceccarelli, M; D'Amelio, P; D'Amico, L; De Giuli, M; Ferracini, R; Garino, M; Mecca, C; Roato, I; Sandrucci, S; Satolli, MA, 2013) |
| "Gastric cancer is the second common cause of cancer related death worldwide and lacks highly effective treatment for advanced disease." | ( Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C, 2013) |
| "The incidence of gastric cancer is high in Japan." | ( Oyama, T, 2013) |
| "Gastric cancer is one of the most common malignant tumors in the world." | ( Cui, A; Cui, J; Dong, X; Li, F; Ni, Z; Suo, J; Wang, G; Xu, Y; Yang, Q; Zhang, G, 2013) |
| "Gastric cancer is increasingly recognized in Zambia." | ( Anderson-Spearie, C; Asombang, AW; Chott, R; Colditz, G; Gyawali, CP; Kayamba, V; Kelly, P; Mudenda, V; Mwanamakondo, S; Mwanza-Lisulo, M; Rubin, DC; Sinkala, E; Yarasheski, K, 2013) |
| "Gastric cancer is 2th most common cancer in China, and is still the second most common cause of cancer-related death in the world." | ( Cui, D; Fu, H; Fu, S; Gao, G; Huang, P; Ma, J; Ni, J; Pan, L; Qian, Q; Song, H; Zhang, C; Zhang, X; Zhi, X; Zhou, Z, 2013) |
| "Gastric cancer is one of the leading causes of cancer death in the world and nearly all patients who respond initially to cisplatin later develop drug resistance, indicating multi-drug resistance is an essential aspect of the failure of treatment." | ( Liu, YF; Song, X; Tang, T; Wang, WY, 2014) |
| "Gastric cancer is the second leading cause of cancer death and remains a major clinical challenge due to poor prognosis and limited treatment options." | ( Chun, KH; Hwang, JA; Kim, SJ; Lee, YS; Ro, JY, 2013) |
| "Gastric cancer is the second most common cause of cancer-related deaths worldwide." | ( Awasthi, N; Schwarz, MA; Schwarz, RE; Zhang, CΗ, 2013) |
| "Gastric cancer is the second leading cause of cancer death worldwide." | ( Wang, J; Wang, W; Zhang, N; Zhao, CH, 2013) |
| "Gastric cancer is one of the major public health problems." | ( Choi, YK; Heo, SH; Jeong, DG; Jeong, ES; Lee, KS; Seo, JH, 2013) |
| "Scirrhous gastric cancer is associated with abundant stroma and frequently develops into peritoneal carcinomatosis with malignant ascites." | ( Kawashima, A; Matsumoto, K; Nakagawa, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Yoshie, O; Zhao, L, 2013) |
| "Gastric cancer is one of the most common human cancers and ranks the second in the global cancer-related mortality." | ( Feng, J; Gao, J; Han, Y; Huang, H; Qu, L; Shen, L; Shou, C; Zhu, L, 2013) |
| "Gastric cancer is one of the most common malignant cancers, with poor prognosis and high mortality rates worldwide." | ( Chen, PW; Chen, WJ; Chen, YL; Hsu, HC; Lin, CC; Pan, WR, 2013) |
| "Gastric cancer is one of the most frequent cancers in the world, almost two-thirds of gastric cancer cases and deaths occur in less developed regions." | ( Gao, P; Li, M; Wang, T; Xuan, X; Zang, W; Zhao, G; Zheng, Y, 2013) |
| "Gastric cancer is a major public health concern as the fourth most common cancer, and it is of particular relevance as the second most common cause of cancer death worldwide." | ( Chen, WT; Jeng, LB; Lai, CC; Lin, CT; Lo, WY; Tsai, FJ, 2014) |
| "Gastric cancer is the second leading cause of cancer-related deaths worldwide and it seems that environmental and lifestyle factors and infection with Helicobacter pylori (H." | ( Azimi, A; Bahrami, M; Farzam, A; HajManouchehri, F; Jahani Hashemi, H; Johari, P; Najafipour, R; Naserpour Farivar, T; Nasirian, N, 2014) |
| "The pathogenesis of gastric cancer is characterized by excessive proliferation, abnormal differentiation, and reduced apoptosis." | ( Bao, Y; Chen, T; Hu, S; Ji, Q; Pan, G; Peng, W; Tang, Q; Tang, Y; Yin, P, 2014) |
| "Gastric cancer is one of the most frequently occurring malignancies in the world." | ( Gao, FL; Lv, YP; Yan, DF; Zhu, CY, 2013) |
| "Gastric cancer is one of the familiar malignant tumors in clinical study." | ( Hao, Y; Jia, Z; Li, W; Wang, R; Xie, H; Yin, Q, 2013) |
| "Gastric cancer is the 4(th) most commonly diagnosed cancer and the second leading cause of cancer death worldwide." | ( Andreozzi, F; Ciardiello, F; De Vita, F; Fabozzi, A; Galizia, G; Gambardella, V; Laterza, MM; Lieto, E; Mabilia, A; Orditura, M; Savastano, B; Sforza, V; Ventriglia, J, 2014) |
| "Gastric cancer is the second most common cause of cancer-related death in males and the fourth in females." | ( Choi, YK; Jeong, ES; Seo, JH, 2014) |
| "Gastric cancer is still the second leading cause of cancer-related death worldwide, even though its incidence and mortality have declined over the recent few decades." | ( Artigiani, R; Assumpção, PP; Burbano, RR; Calcagno, DQ; Chen, ES; Demachki, S; Gigek, CO; Leal, MF; Lourenço, LG; Payão, SL; Pontes, TB; Rasmussen, LT; Santos, LC; Smith, MC; Wisnieski, F, 2014) |
| "As gastric cancer is often diagnosed at an advanced stage, systemic chemotherapy is the mainstay of treatment for these patients." | ( Bilici, A, 2014) |
| "Gastric cancer is a leading cause of cancer death worldwide, and significant effort has been focused on clarifying the pathology of gastric cancer." | ( Fukayama, M; Funata, S; Kaneda, A; Matsusaka, K, 2014) |
| "G-CSF-producing gastric cancer is rare; thus, we take this opportunity to report our case and to summarize the G-CSF-producing gastric cancer cases reported in Japan." | ( Misawa, S; Miyamoto, M, 2014) |
| "Gastric cancer is the second leading cause of cancer mortality worldwide." | ( Wu, CX; Zhu, ZH, 2014) |
| "Gastric cancer is a common malignant tumor." | ( Cao, W; Lu, YF; Xian, SL; Zhang, XD, 2014) |
| "Gastric cancer is the second most common cause of cancer-related death worldwide." | ( Fang, X; Ji, F; Wang, H; Wang, X; Zhao, S, 2014) |
| "Gastric cancer is associated with increased migration and invasion." | ( Bai, ZG; Wu, GC; Yang, Y; Yin, J; Zhang, ZT, 2014) |
| "Gastric cancers are very heterogeneous and separate evaluations of gene amplification and protein expression lead to uncertainties in localizing distinct clones and are time consuming." | ( Al-Batran, SE; Altmannsberger, HM; Battmann, A; Jones, T; Lamb, T; Martinez, M; Steinmetz, K; Werner, D, 2014) |
| "Gastric cancer is the leading cause of cancer death worldwide." | ( Liu, H; Qian, C; Shen, Z, 2014) |
| "Gastric cancer is the second leading cause of death from cancer worldwide, with an approximately 20% 5-year survival rate." | ( Dong, H; Fan, S; Fu, J; Gao, B; Huang, C; Ji, J; Ji, Q; Lv, J; Qian, Z; Su, X; Sun, Y; Tang, L; Wang, M; Yu, D; Zang, J; Zhang, L; Zhang, X; Zhu, G, 2014) |
| "Gastric cancer is a heterogeneous disease, and the strategy of combining chemotherapy with HH inhibition may only be effective in tumors with high CD44 levels." | ( Cohen, DJ; Janjigian, YY; Kim, TS; Lee, HJ; Park, DJ; Schmidt, B; Thomas, NJ; Yoon, C; Yoon, SS, 2014) |
| "Gastric cancer is one of the most lethal tumors in the Chilean population." | ( Isa O, N; López V, H; Russo N, M, 2014) |
| "Gastric cancer is often diagnosed in advanced stage." | ( Aksoy, S; Benekli, M; Ekinci, AS; Günaydın, Y; Oksuzoglu, B; Özatlı, T; Ozdemir, N; Sendur, MA; Yazıcı, O; Yazılıtaş, D; Zengin, N, 2014) |
| "Gastric cancer is the third leading cause of cancer-related mortality in China, and the long-term survival for locally advanced gastric cancer is very poor." | ( Ding, DY; Hou, RZ; Li, YC; Song, B; Sun, LB; Zhao, GJ, 2014) |
| "Gastric cancer is one of the most common malignant tumors worldwide." | ( Bau, DT; Chang, WS; Fu, CK; Hsieh, YH; Hsu, CM; Huang, CY; Kuo, HW; Liao, CH; Tsai, CW, 2014) |
| "Stomach cancer is the second most common cause of cancer-related deaths in the world." | ( Sonkusale, SR; Zilberman, Y, 2015) |
| "Stomach cancer is one of malignancies that may result in pulmonary tumor embolism." | ( Kim, H; Kim, SJ; Pak, K; Shin, S, 2015) |
| "Gastric cancer is the second most common cause of cancer-related deaths worldwide." | ( Luo, HS; Tan, W; Yu, HG, 2014) |
| "Gastric cancer is one of the most frequent neoplasms and a main cause of death worldwide, especially in China and Japan." | ( Li, XL; Shao, Y; Shen, H; Sun, K; Sun, WH; Xu, W, 2014) |
| "Stomach cancer is one of the most common cancers in Korea." | ( Chin, HJ; Kim, S; Kim, YC; Koo, HS; Oh, SW; Park, JH, 2014) |
| "Gastric cancer is a common malignancy with a poor prognosis." | ( Chang, S; Che, XM; Chen, R; Fan, L; He, SC; Li, L; Liu, JS; Qiu, GL; Zhang, ZL, 2014) |
| "Gastric cancer is one of the leading causes of cancer-related death worldwide." | ( Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS, 2015) |
| "Gastric cancer is one of the most common forms of malignant tumor, and the development of anti‑gastric cancer drugs with minimal toxicity is of clinical importance." | ( Duan, W; Feng, C; He, X; Zhang, X; Zhu, Y, 2015) |
| "Gastric cancer is the fourth most common cancer worldwide and the leading cause of tumor-related death in China." | ( Bu, ZD; Ji, JF; Ji, X; Li, SX; Li, ZY; Shan, F; Wu, AW; Wu, XJ; Zhang, LH; Zong, XL, 2014) |
| "Gastric cancer is the second leading cause of cancer death worldwide and screening programs have had a significant impact on reducing mortality." | ( Beccani, M; Caprara, R; Di Natali, C; Morgan, DR; Obstein, KL; Scozzarro, G; Valdastri, P, 2015) |
| "Gastric cancer is one of the most common cancers and responds poorly to current chemotherapy." | ( He, ZX; Wang, D; Wang, NJ; Yang, T; Yang, YX; Yuan, CX; Zhang, X; Zhao, RJ; Zhou, SF; Zhou, ZW, 2015) |
| "Gastric cancer is the fourth most common cancer and is one of the leading causes of cancer-related mortality worldwide." | ( Jin, H; Kim, SM; Park, MH, 2015) |
| "Gastric cancer is one of the leading causes of cancer mortality in the world, and finding novel agents and strategies for the treatment of advanced gastric cancer is of urgent need." | ( Chen, W; Guo, G; Huang, Y; Kanchana, K; Liang, G; Wang, Z; Xia, Y; Yang, S; Zhang, J; Zou, P, 2015) |
| "Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare." | ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014) |
| "Gastric cancer is now the fourth most common malignancy and the second leading cause of death because of cancer." | ( Hang, Q; Jiang, C; Li, Y; Sun, R, 2015) |
| "Gastric cancer is the second leading cause of cancer-related death worldwide, with a poor response to current chemotherapy." | ( Chen, XW; He, ZX; Pan, SY; Wang, D; Yang, T; Yang, YX; Yuan, CX; Zhang, X; Zhou, SF; Zhou, ZW, 2015) |
| "Gastric cancer is one of the most common types of cancer worldwide." | ( Liu, B; Luo, ZY; Xiao, F; Ye, HL; Yu, HH, 2015) |
| "Gastric cancer is the second most common cause of cancer cell death worldwide." | ( Beppu, H; Chihara, T; Kaneko, T; Shimpo, K; Sonoda, S; Wakamatsu, K; Yamamoto, N, 2015) |
| "Gastric cancer is one of the leading causes of cancer mortality in the world." | ( Chen, M; Chen, T; Chen, W; Kanchana, K; Liang, G; Wang, Z; Xia, Y; Yang, S; Zhang, J; Zou, P, 2016) |
| "Gastric cancer is the second most common cause of cancer mortality worldwide." | ( Chang, YJ; Chen, CL; Chen, WY; Cheng, WL; Huang, CY; Huang, MT; Hung, CS; Liu, YN; Tai, CJ, 2015) |
| "Gastric cancer is the second leading cause of cancer related deaths after lung cancer globally." | ( Jiang, YH; Li, Y; Meng, FD; Sui, CG, 2015) |
| "Gastric cancer is the second most common cause of cancer-related death worldwide." | ( Chin, HM; Choi, HJ; Jun, KH; Jung, JH; Kim, SH; Kim, YI; Lee, JE; Yang, SH, 2015) |
| "Gastric cancer is the fourth most common malignancy in the world; however, the dysregulation and function of miR‑33 family members in gastric cancer have not been extensively studied." | ( Chang, L; Fan, X; Han, J; Liu, W; Lv, Y; Shan, B; Wang, F; Wang, Y; Zhou, X, 2015) |
| "The gastric cancer is one of the most common and mortal cancer worldwide." | ( Abramowicz, A; Gdowicz-Klosok, A; Namysl-Kaletka, A; Pietrowska, M; Polanowski, P; Polanska, J; Rodziewicz, P; Widlak, P; Wojakowska, A; Wydmanski, J, 2015) |
| "Gastric cancer is the fourth most common cancer type and the second leading cause of cancer‑associated mortality worldwide." | ( Bu, JY; Cui, RJ; Du, YD; Huang, N; Li, D; Lin, P; Sun, H; Tang, JB; Xu, CY; Yang, ZK; Yu, XG, 2015) |
| "Gastric cancer is a leading cause of cancer death and is associated with poor prognosis." | ( Choi, M; Kim, R; Mahipal, A, 2015) |
| "BAK expression in gastric cancer is thus predictive of chemotherapeutic responses to docetaxel and clinical prognosis in patients treated with preoperative chemotherapy." | ( Hasegawa, T; Himuro, N; Hirata, K; Ishikawa, K; Kato, J; Kawano, Y; Kobune, M; Kubo, T; Miyanishi, K; Mori, M; Murase, K; Nobuoka, T; Sato, T; Sato, Y; Sugita, S; Takada, K; Takayama, T; Takimoto, R, 2016) |
| "Gastric cancer is difficult to cure because most patients are diagnosed at an advanced disease stage." | ( Chang, YJ; Cheng, WL; Huang, CY; Hung, CS; Tu, CC; Uyanga, B; Wei, PL, 2016) |
| "Unresectable gastric cancer is associated with poor outcomes, with few treatment options available after failure of cytotoxic chemotherapy." | ( Huynh, H; Ong, R; Zopf, D, 2015) |
| "Gastric cancer is the third leading cause of cancer-related death in China." | ( Liu, Y; Lu, LP; Qin, XS; Tong, GH; Tong, WW, 2015) |
| "Gastric cancer is one of the most virulent malignant diseases and is the second leading cause of cancer mortality in the world." | ( Fang, X; Huang, G; Ji, F; Liu, X; Wu, Y, 2015) |
| "Gastric cancer is one of the most common malignant cancers, with high death rates, poor prognosis and limited treatment methods." | ( Chen, J; Dong, C; Tan, Z; Wu, J, 2015) |
| "Gastric cancer is the one of the most common cancers around the world." | ( Chen, L; Li, Q; Wang, LA; Wei, X, 2016) |
| "Gastric cancer is the second leading cause of cancer-related death worldwide." | ( Chen, CJ; Chen, YA; Feng, CL; Hsu, YM; Kao, CH; Kao, MC; Lai, CH; Liao, WC; Lin, CJ; Lin, CL; Lin, HJ, 2016) |
| "Gastric cancer is one of the most common malignancies in India." | ( Bankura, B; Das, M; Ghatak, S; Ghosh, S; Guha, M; Maity, B; Maji, S; Nachimuthu, SK; Panda, CK; Pattanayak, AK; Sadhukhan, S; Saha, ML, 2016) |
| "Gastric cancer is a big threat to human health." | ( Chen, L; Li, B; Li, Z; Sun, G; Wang, J; Wang, L; Xu, H; Xu, Z; Zhang, L; Zhang, Q; Zhi, X, 2016) |
| "Scirrhous gastric cancer is associated with peritoneal dissemination and advanced lymph node metastasis from an early stage, and the prognosis is still poor." | ( Fujiwara, D; Iwanuma, Y; Kajiyama, Y; Kato, K; Nohara, S; Sakuragi, N; Yanagihara, K, 2016) |
| "Gastric cancer is ranked as the third leading cause of cancer-related death in the world." | ( Cao, Z; Fu, S; Gu, Z; Han, H; Yang, P; Zhang, B; Zhou, Q, 2016) |
| "Gastric cancer is an important health issue worldwide." | ( Chang, YJ; Cheng, WL; Huang, CY; Hung, CS; Tu, CC; Wei, PL, 2016) |
| "Metastatic gastric cancer is a lethal disease characterized by a very short overall survival, underlining a critical need of new therapeutic options." | ( Generali, D; Marano, L; Marrelli, D; Petrioli, R; Polom, K; Ravelli, A; Roviello, F; Roviello, G, 2016) |
| "Gastric cancer is the third leading cause of cancer-related mortality worldwide." | ( Ernst, M; O'Donoghue, RJ; Poh, AR; Putoczki, TL, 2016) |
| "Gastric cancer is the fifth most common cancer and the second most common cause of cancer-related death worldwide." | ( Acharya, A; Hanna, GB; Khanderia, E; Kim, Y; Kim, YW; Markar, SR, 2016) |
| "Gastric cancer is one of the main causes of global mortality." | ( Contreras-Zentella, ML; Echegaray-Donde, A; Escalante-Tatersfield, T; Hernández-Espinosa, DR; Hernández-Muñoz, R; Herrera, MF; Mendieta-Condado, E; Montalvo-Javé, EE; Morán, J; Olguín-Martínez, M; Oñate-Ocaña, LF; Ruiz-Molina, JM; Sánchez-Sevilla, L, 2016) |
| "Gastric cancer is classified into two subtypes, diffuse and intestinal." | ( Fujimoto, M; Fukuyo, M; Ishige, T; Kado, S; Kaneda, A; Matsubara, H; Matsushita, K; Nishimura, M; Nomura, F; Satoh, M; Sawai, S; Semba, T; Togawa, A; Tsuchida, S, 2016) |
| "Gastric cancer is one of the leading causes of cancer mortality worldwide." | ( Li, Y; Song, A; Wei, Y; Zhao, L, 2016) |
| "(18)F-FDG uptake by gastric cancer is associated with HER2 expression." | ( Chen, R; Huang, G; Liu, J; Zhou, X, 2016) |
| "Gastric cancer is closely associated with Helicobacter pylori infection, which stimulates innate immune responses through Toll-like receptors (TLRs), inducing COX-2/PGE2 pathway through nuclear factor-κB activation." | ( Echizen, K; Hirose, O; Maeda, Y; Oshima, M, 2016) |
| "Gastric cancer is a common and heterogeneous disease; however, global standard and biomarkers for selecting chemotherapy regimens have not been established." | ( Esaki, T; Fujiya, T; Furukawa, H; Horita, Y; Imamoto, H; Imamura, H; Kimura, Y; Morita, S; Ninomiya, M; Nishikawa, K; Oono, R; Sasako, M; Sugimoto, N; Taguri, M; Takayama, O; Tan, P; Tsuburaya, A; Tsujinaka, T; Yabusaki, H; Yamada, Y, 2016) |
| "Gastric cancer is the third most common cause of cancer deaths in the world, prompting high-risk countries like South Korea and Japan to establish nationwide screening programmes." | ( Hillard, JR; Laird-Fick, HS; Saini, S, 2016) |
| "Gastric Cancer is one of the major leading causes of death by cancer worldwide, but the chemotherapeutics, one of the preferred approaches, bring about extensive side effects when systemically injected." | ( Nie, J; Wang, W; Wang, Y, 2016) |
| "Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide." | ( Brennan, PE; Burbano, R; Ceroni, A; Clark, PG; Dixon, D; Ebner, D; Fedorov, O; Gamble, V; Howarth, A; Knapp, S; Monteiro, O; Montenegro, RC; Müller, S; Nunez-Alonso, GA; O'Neill, E; Rogers, C; Siejka, P; Tallant, C; Wan, X, 2016) |
| "Gastric cancer is the second leading cause of cancer-associated mortality worldwide." | ( Li, HL; Shi, HL; Wu, H; Wu, XJ; Zhang, BB, 2016) |
| "BACKGROUND Gastric cancer is a malignant tumor with a high morbidity and mortality." | ( Xu, Y; Zou, J, 2016) |
| "Gastric cancer is the fourth most common cancer in the world." | ( Li, Y; Lin, N; Wang, L; Wang, M; Yan, Y; Zeng, J; Zhang, B; Zhang, D, 2016) |
| "Gastric cancer is highly prevalent in Kashmir, as are lower gastrointestinal (LGI) malignancies." | ( Bindroo, MA; Farooq, A; Kadla, SA; Khan, BA; Shah, NA; Wani, BA; Yousf, W, 2016) |
| "Gastric cancer is the most common epithelial malignancy and the second leading cause of cancer-related death worldwide; metastasis is a crucial factor in the progression of gastric cancer." | ( Han, K; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhuang, K, 2016) |
| "Gastric cancer is one of the leading causes for cancer death." | ( Cui, P; Jia, N; Li, Y; Liu, Y; Tan, BB; Wang, D; Zhang, ZD; Zhao, Q, 2016) |
| "Gastric cancer is one of the leading causes of tumor-related deaths in the world." | ( Dong, H; Jie, MM; Li, JM; Tang, B; Wang, SM; Xiao, YF; Yang, SM; Yang, XC; Yong, X, 2016) |
| "Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide." | ( Esmaeilpour, K; Haghighi, S; Kasbkar, H; Yasaei, M, 2016) |
| "Gastric cancer is the fourth most common cancer worldwide and more frequently detected in Asian countries including Korea and Japan." | ( Kim, IH; Lee, J; Lee, MA; Roh, SY, 2016) |
| "Gastric cancer is the third most common cause of cancer mortality worldwide, and paclitaxel (PTX) is one of the most widely used traditional drugs in gastric cancer therapy." | ( Chang, L; Dou, Y; Ke, Y; Liu, H; Liu, Y; Shi, H; Shi, X; Wang, C; Wang, J; Wang, R; Wang, S; Xu, X; Yang, D; Zhang, X; Zhou, K, 2016) |
| "Gastric cancer is a common malignancy, and is one of the most frequent causes of cancer deaths worldwide." | ( Chen, Z; Huang, H; Ni, X, 2017) |
| "Gastric cancer is among the leading causes of cancer-related death, and the symptoms are commonly characterized in advanced stages." | ( Araei, Y; Faghihloo, E; Mirzaei, H; Mohammadi, HR; Mohammadi, M; Mokhtari-Azad, T, 2016) |
| "Gastric cancer is one of the major causes of cancer-related deaths." | ( Cheng, SY; Du, J; Li, J; Li, KC, 2016) |
| "Gastric cancer is one of the major causes of cancer-related mortality worldwide." | ( Li, J; Liu, D; Niu, H; Xu, J; Xu, Y; Ye, D; Zhang, Q; Zhu, G, 2017) |
| "Gastric cancer is the third leading cause of cancer related mortality worldwide with poor survival rates." | ( Alsaied, O; Arora, N; Banerjee, S; Dauer, P; Dudeja, V; Giri, B; Majumder, K; Modi, S; Saluja, A; Von Hoff, D, 2017) |
| "Gastric cancer is a common digestive tract tumor in clinic with increasing incidence." | ( Abudoureyimu, A; Muhemaitibake, A, 2017) |
| "Gastric cancer is one of the leading causes of morbidity and mortality worldwide." | ( Chen, W; Chen, X; Dai, X; Feng, C; Liang, G; Qiu, C; Rajamanickam, V; Ye, Q; Zhang, X; Zhuge, W; Zou, P, 2017) |
| "Gastric Cancer is one of the most lethal malignancies worldwide." | ( Chen, W; Chen, Y; Dong, M; Dong, Y; Huang, Y; Qi, X; Shen, J; Shu, X; Teng, R; Wang, L; Wang, Q; Wei, Q; Xie, S; Yuan, X; Zhang, W; Zhao, W; Zhou, J, 2017) |
| "Gastric cancer is the most common type of tumor in developing countries and the fourth most frequently diagnosed cancer worldwide." | ( Guo, Q; Li, G; Li, Z; Lu, N; Yao, Y; Zhao, K; Zhou, Y, 2017) |
| "Gastric cancer is difficult to cure due to its clinical heterogeneity and the complexity of its molecular mechanisms." | ( Cui, H; Hou, J; Huang, M; Jiang, X; Tang, C; Wang, F; Weng, X; Zhang, D; Zhao, E; Zhong, X, 2017) |
| "Gastric cancer is one of the common malignant diseases." | ( Chen, F; Feng, JD; Ge, L; Li, B; Li, DS; Wang, TJ, 2017) |
| "Scirrhous gastric cancer is an intractable disease with a high incidence of peritoneal dissemination and obstructive symptoms (e." | ( Fushida, S; Harada, S; Kinoshita, J; Miyashita, T; Ninomiya, I; Ohta, T; Oyama, K; Saito, H; Tajima, H; Tsukada, T; Yamaguchi, T, 2018) |
| "Gastric cancer is a great threat to the health of the people worldwide and lacks effective therapeutic regimens." | ( Hu, L; Li, J; Liu, B; Yan, M; Zang, M; Zhang, B; Zhu, Z, 2017) |
| "Gastric cancer is one of the most factors, leading to cancer-related death worldwide." | ( Gao, CC; Ma, TH; Wang, HG; Wu, SN; Xie, R; Yan, W; Yang, XZ; Zhang, JL, 2017) |
| "Gastric cancer is one of the leading causes of cancer‑related deaths worldwide." | ( Chen, J; Gu, H; Ji, R; Liang, Z; Mao, F; Qian, H; Sun, Z; Xu, W; Yan, Y; Zhang, X, 2017) |
| "Gastric cancer is one of the most of common cancers in the world." | ( Cao, G; Gao, Q; Sun, X; Xing, Y; Zhang, D; Zhang, L, 2017) |
| "Gastric cancer is the third leading cause of cancer-related deaths worldwide and has still a poor prognosis." | ( Bessède, E; Courtois, S; Durán, RV; Giraud, J; Izotte, J; Lehours, P; Mégraud, F; Sifré, E; Varon, C, 2017) |
| "Gastric cancer is one of the most common causes of cancer-related death worldwide." | ( Azimi, H; Haghi, A; Rahimi, R, 2017) |
| "Gastric cancer is a leading cause of cancer-related mortality worldwide, and options to treat gastric cancer are limited." | ( Gu, D; Liu, B; Xie, J; Yu, B; Zhang, X, 2017) |
| "Gastric cancer is the fifth most common cancer worldwide." | ( Grothe, W; Ho, J; Moehler, M; Syn, NL; Tai, BC; Unverzagt, S; Wagner, AD; Yong, WP, 2017) |
| "Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide." | ( Jun, M; Niu, W; Shen, J; Zhang, H, 2018) |
| "Gastric cancer is an important disease due to its high mortality." | ( Fossmark, R; Mjønes, P; Nordrum, IS; Sagatun, L; Sandvik, A; Sørdal, Ø; Waldum, HL, 2018) |
| "Gastric cancer is an important killer disease, and its therapy methods still need improvement." | ( Xin, L; Yang, W; Zhang, H, 2018) |
| "Gastric cancer is a common malignancy with increasing worldwide incidence, and chemotherapeutic drugs for gastric cancer are not effective." | ( Chunyan, Q; Ga, Y; He, Q; Ma, Y; Wang, L; Wang, X; Zhou, Y, 2017) |
| "Gastric cancer is reported as one of the leading factors resulting in tumor-related death worldwide." | ( Gao, HY; Gao, SH; Jiang, X; Wei, F, 2017) |
| "Although, gastric cancer is one of the most common cancers worldwide, alpha-fetoprotein (AFP) producing human epidermal growth factor receptor 2 (HER2) positive gastric cancers are rare." | ( Arakawa, Y; Hayashi, K; Nagasaki, E; Nakada, K; Tamura, M; Uwagawa, T; Yano, S, 2018) |
| "Gastric cancer is a malignancy that starts from the cells in the stomach with relatively low overall survival rate." | ( Han, X; Li, D; Sun, X; Wang, G; Wang, Y; Yin, B, 2018) |
| "Gastric cancer is the fourth most common type of cancer." | ( Cai, YS; Chen, W; Han, Z; Huang, X; Liu, M; Liu, WJ; Tan, J; Tian, X; Wang, YF; Zhu, QX; Zou, YL, 2018) |
| "Gastric cancer is the fifth most common malignancy in the world, with Eastern Asia as one of areas with the highest incidence rates." | ( Fan, Z; Han, J; Liu, XD; Lv, Y; Men, X; Sang, M; Shan, B; Wang, Y; Zhao, L; Zhao, R; Zhou, X; Zuo, J, 2018) |
| "Gastric cancer is worldwide the third major cause of cancer related death." | ( Gautam, M; Gopal, G; Pavithra, D; Rajkumar, T; Rama, R; Ramakrishnan, AS; Swaminathan, R, 2018) |
| "Gastric cancer is one of the most frequent malignant tumors in the world." | ( Bestetti, RB; Couto, LB; de Andrade, BV; de Castro França, S; Fachin, AL; Garcia, ME; Lucas, TG; Marins, M; Mendes Lourenço, AL; Polaquini, CR; Regasini, LO; Seba, V; Silva, G; Teixeira Lima, F; Torrezan, GS, 2018) |
| "Gastric cancer is the third common cause of cancer mortality in the world with poor prognosis and high recurrence due to lack of effective medicines." | ( Ding, Y; He, H; Hong, D; Hu, Y; Qian, F; Shi, C; Sun, L; Sun, S; Wang, G; Yu, K; Zhang, D; Zheng, JN, 2018) |
| "Gastric cancer is one of the most common cancers in the world; taxol displayed modest efficacy as first-line chemotherapy for gastric cancer, conversely, it has limitations used alone." | ( Du, P; Han, L; Jiang, K; Liu, X; Zhang, A; Zhang, Q, 2018) |
| "Gastric cancer is common malignancy and exhibits a poor prognosis." | ( Al-Batran, SE; Galle, PR; Gehrke, N; Goepfert, K; Grimminger, P; Hegewisch-Becker, S; Maderer, A; Möhler, M; Nagel, M; Schattenberg, JM; Schulz, J; Thomaidis, T; Thuss-Patience, PC, 2018) |
| "Gastric cancer is the third leading cause of cancer-associated death worldwide." | ( Chen, GX; Wang, YR; Wei, P; Yang, SY, 2018) |
| "Gastric cancer is one of the most common malignant gastrointestinal tumors." | ( Du, H; Jiao, Z; Ren, Y; Wang, K; Wang, Z; Zhang, G, 2018) |
| "Gastric cancer is one of the most common malignant cancers with a poor prognosis and high mortality rate worldwide." | ( Chiu, YM; Ho, TY; Hsieh, CT; Lee, YJ; Shieh, DC; Tsai, CL; Tsay, GJ; Wu, YY, 2018) |
| "Gastric cancer is the second leading cause of cancer-related deaths and the fifth most common malignancy worldwide." | ( Aust, DE; Baretton, GB; Gaebler, AM; Grützmann, K; Klink, B; Koo, BK; Krause, M; Merker, SR; Rothe, A; Schölch, S; Schweitzer, C; Seidlitz, T; Sommer, U; Stange, DE; Uhlemann, H; von Neubeck, C; Weitz, J; Welsch, T; Werner, K; Zakrzewski, F, 2019) |
| "Gastric Cancer is one of the most common types of cancer." | ( Cai, D; Cai, H; Cai, T; Chen, X; Li, S; Liu, W; Pan, H; Xie, K; Yan, Y; Zeng, X; Zhang, C; Zhao, Z, 2018) |
| "Gastric cancer is the most common gastrointestinal malignant tumour in China, which rarely metastasizes into the central nervous system." | ( Pei, X; Yang, M; Yang, Y, 2018) |
| "Background: Gastric cancer is one of the most common malignancies worldwide." | ( Felipe, AV; Forones, NM; França, JP; Moraes, AA; Oliveira, J; Silva, TD, 2018) |
| "Gastric cancer is one of the leading factors, causing tumor-associated death worldwide." | ( Wang, ZH; Zhan-Sheng, H, 2018) |
| "Gastric cancer is the third leading cause of cancer-related mortality worldwide." | ( Almeida, C; Azevedo, NF; Carvalho, J; Cerqueira, L; Figueiredo, C; Lima, JF; Oliveira, C; Pinto-Ribeiro, I; Wengel, J, 2018) |
| "Gastric cancer is the most common gastrointestinal malignancy and the leading cause of cancer-related deaths in East Asia." | ( -Y-Xie, D; Chen, H; Li, LQ; Pan, D; Zhang, SW; Zheng, XL, 2018) |
| "Gastric cancer is the third leading cause of cancer mortality all over the world." | ( Chang, SF; Chen, CN; Huang, WS; Lee, KC; Liu, JL; Tung, SY, 2018) |
| "Gastric cancer is highly prevalent amongst men and women." | ( Brezden-Masley, C; Hart, R; Sholzberg, M; Tang, GH, 2018) |
| "Gastric cancer is the third leading cause of cancer-related death worldwide, but the mechanisms of gastric carcinogenesis are not completely understood." | ( Aubert, P; Bruley des Varannes, S; Duchalais, E; Durand, T; Matysiak-Budnik, T; Neunlist, M; Nguyen, PH; Touchefeu, Y; Varon, C, 2018) |
| "BACKGROUND Gastric cancer is one of most commonly diagnosed cancers and causes significant mortality worldwide." | ( Gu, W; Shen, Z; Wang, F; Xu, M, 2018) |
| "Gastric cancer is one of the most common malignant tumor types worldwide, with a high morbidity and associated mortality." | ( An, F; Cao, J; Chen, G; Liu, S; Tang, Z; Wu, Q; Yu, C; Zhan, Q; Zhang, S; Zhu, J, 2019) |
| "Gastric cancer is one of the most common human epithelial malignancies, and using nanoparticles (NPs) in the diagnosis and treatment of cancer has been extensively studied." | ( Li, A; Liu, H; Yang, F; Zhang, H, 2018) |
| "Gastric cancer is the third leading cause of cancer-related mortality worldwide." | ( Assaraf, YG; Bar-Zeev, M; Kelmansky, D; Livney, YD, 2018) |
| "Gastric cancer is the fifth commonest cancer and the third cause of cancer-related deaths all over the world." | ( Chen, L; Gu, C; Jiang, H; Jin, Y; Luan, J; Shen, J; Wang, L; Wu, Y; Xiao, Z; Xu, Z; Zhang, W; Zhou, D; Zhu, Y; Zuo, J, 2018) |
| "Gastric cancer is the second most prevalent cancer across the globe and accounts for about 10% of new cancer cases." | ( Li, DC; Yu, L; Zhou, GQ, 2018) |
| "Gastric cancer is one of the most common cancers worldwide." | ( Chen, P; Liu, S; Mao, Q; Qi, Y; Wang, Y; Xue, W; Zhang, X; Zhou, Q, 2019) |
| "Stomach cancers are typically localized to one of the three mucosae; cardial, oxyntic and antral." | ( Fossmark, R; Waldum, HL, 2018) |
| "Gastric cancer is one of the most important common tumors in the world." | ( Jiao, S; Ju, Y; Sun, S, 2018) |
| "Gastric cancer is one of the leading causes of cancer-related deaths." | ( Cai, Y; Cao, P; Chen, X; Liang, G; Rajamanickam, V; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhou, H, 2019) |
| "Gastric cancer is the third-leading cause of cancer-related mortality and the fifth most common cancer globally." | ( Dolatkhah, H; Estakhri, R; Khojastehfard, M; Naghizadeh, M; Nazari Soltan Ahmad, S; Rahmati-Yamchi, M; Sharifi, R; Somi, MH, 2019) |
| "Gastric cancer is common cancer worldwide." | ( Cao, L; Chen, J; Chen, Y; Ge, M; Li, X; Li, Y; Meng, Y; Shao, J; Wang, X; Xie, C; Zhang, L; Zhang, Q; Zhong, C, 2019) |
| "Gastric cancer is the most common cancer in Korea and the fifth most common cancer globally." | ( Choi, IJ, 2018) |
| "Most gastric cancers are diagnosed at an advanced or metastatic stage with poor prognosis and survival rate." | ( Abumrad, NA; He, S; Huang, X; Li, T; Su, X; Sun, L; Sun, S; Yang, X; Yao, Y; Zhang, W; Zhou, D; Zhu, X, 2019) |
| "Gastric cancer is the fourth most common cancer and second leading cause of cancer death worldwide." | ( Li, C; Li, M; Wang, Y; Xue, Y; Zhang, H; Zhu, Z, 2019) |
| "BACKGROUND Gastric cancer is a common gastrointestinal tumor." | ( Gao, M; Jiang, D; Li, H; Sun, Y; Wang, H; Xiang, H; Xiong, M; Yin, C, 2019) |
| "Gastric cancer is one of the top causes of cancer-related death around the world, and poor prognosis of gastric cancer is due to the lack of early detection and effective treatment especially in male." | ( Chen, Z; Cheng, G; Du, P; Hu, K; Shen, X; Xu, L; Zhuang, Z, 2019) |
| "Gastric cancer is a common malignancy worldwide, and is associated with high morbidity and mortality rates." | ( An, RB; Chen, LY; Li, ZH; Lin, ZH; Liu, TS; Lv, Y; Piao, YS; Ren, XS; Wang, Y; Yan, WD, 2019) |
| "Gastric cancer is the second leading cause of cancer-related mortality and the fourth most common cancer globally." | ( Liao, X; Liu, H; Lu, KP; Lu, W; Wang, J; Wang, L; Yang, D; Yu, W; Zhang, S; Zhang, Z; Zheng, M; Zhou, XZ, 2019) |
| "Gastric cancer is one of the most common and deadly malignancies worldwide." | ( Bu, BG; Cui, XL; Li, KJ; Liu, XD; Ren, HX; Wang, L; Zhang, YJ, 2019) |
| "Gastric cancer is a malignant tumor with high incidence rate and mortality rate." | ( Bi, R; Cao, X; He, Y; Kong, Y; Liu, J; Wang, S; Xia, Y, 2019) |
| "Gastric cancer is an important cancer type worldwide, the anti‑angiogenic agent BC001 can target the vascular endothelial growth factor receptor 2 (VEGFR2), and significantly suppresses the growth of gastric cancer BGC823 cells in vitro and in vivo." | ( Fang, Q; Gao, F; Jiang, J; Liu, L; Tan, X; Wang, W; Xuan, ZX; Yang, X; Ye, Q; Ye, Z; Zhang, G; Zhou, Y, 2019) |
| "The gastric cancer is the second most malignant tumor in the world." | ( Han, F; Hu, Y; Li, Y; Zhang, J; Zhao, T, 2019) |
| "Gastric cancer is the third leading cause of cancer-related death worldwide." | ( Chen, M; Chen, R; Cui, B; Gao, D; Huang, J; Kuai, X; Li, J; Li, L; Qin, J; Wang, K; Wang, Z; Wei, W; Zhang, Y; Zhou, H; Zhu, H, 2019) |
| "Gastric cancer is one of the most prevalent cancers in northern Iran." | ( Azarhoush, R; Behnampour, N; Besharat, S; Joshaghani, HR; Safarzad, M; Salimi, S, 2019) |
| "Gastric cancer is a common oncological disease." | ( Antonyová, V; Dytrych, P; Hromádka, R; Jakubek, M; Kaplánek, R; Kejík, Z; Král, V; Martásek, P; Mikula, I; Šandriková, V; Sýkora, D; Urban, M, 2019) |
| "Gastric cancer is the third leading cause of cancer-related death worldwide, with half of patients developing metastasis within 5 years after curative treatment." | ( Barros, A; Fernandes, E; Ferreira, D; Ferreira, JA; Freitas, R; Martins, G; Palmeira, C; Peixoto, A; Relvas-Santos, M; Santos, LL; Sarmento, B, 2019) |
| "Since gastric cancer is one of the most common cancers and represents the second cause of death in the world, we performed the study in NCI-N87 gastric cancer cell line." | ( Albi, E; Beccari, T; Cataldi, S; Ceccarini, MR; Codini, M; Conte, C; Ferri, I; Fettucciari, K; Patria, FF, 2019) |
| "Gastric cancer is one of the most common gastrointestinal tumors." | ( Hou, GX; Song, BB, 2019) |
| "The incidence of gastric cancer is extremely high in China, prompting the development of effective therapeutic strategies." | ( Fang, X; Ge, J; Huang, C; Li, X; Sun, J; Tan, Z; Wu, B; Zhang, Z, 2019) |
| "Gastric cancer is one of the most common cancers leading to tumor-related deaths worldwide." | ( Ma, S; Sun, X; Zhai, H; Zhang, D; Zhang, X, 2019) |
| "Gastric cancer is heavily influenced by aberrant DNA methylation that alters multiple cancer-related pathways, and may respond to DNA demethylating agents, such as 5-aza-2'-deoxycytidine (5-aza-dC)." | ( Hattori, N; Imai, T; Kimura, K; Maeda, M; Moro, H; Nakamura, Y; Ushijima, T; Yashiro, M, 2020) |
| "Gastric cancer is one of the most lethal cancers with unmet clinical treatment and low 5-year survival rate." | ( Cao, X; Gao, Z; Hu, T; Hu, Y; Qian, F; Su, F; Wang, Z; Yang, Y; Yu, K, 2020) |
| "Gastric cancer is recognized as one of the most common cancer." | ( Cai, T; Lin, L; Pan, H; Wu, L; Yan, Y; Yu, X; Zeng, X; Zhang, C; Zhao, Z, 2019) |
| "Gastric cancer is the fourth most common cancer in the world." | ( Khin, PP; Po, WW; Sohn, UD; Thein, W, 2020) |
| "Gastric cancer is a malignancy of very poor prognosis and survival rates." | ( Dang, Y; Liu, T; Reinhardt, JD; Yan, J; Ye, F; Yin, C; Zhang, G, 2020) |
| "Gastric cancer is the third leading cause of cancer-related death worldwide." | ( Barbosa-Jobim, GS; Burbano, RR; Calcagno, DQ; Costa-Lira, É; Gregório, L; Lemos, TLG; Montenegro, RC; Ralph, ACL; Smith, MAC; Vasconcellos, MC, 2020) |
| "Diffuse-type gastric cancer is an aggressive tumor that is frequently associated with ARID1A deficiency." | ( Chiwaki, F; Kohno, T; Komatsu, M; Kuroda, T; Matsusaki, K; Ogiwara, H; Sasaki, H; Sasaki, M, 2020) |
| "Gastric cancer is a common malignant tumor with high morbidity and mortality worldwide, which seriously affects human health." | ( Cao, X; Chen, T; Hu, Y; Peng, Y; Qian, F; Su, F; Wang, Y; Wang, Z; Xu, H; Yang, Y; Yu, K, 2019) |
| "Gastric cancer is the third leading cause of cancer-related death worldwide." | ( Liao, XH; Liu, HK; Lu, KP; Lu, WX; Wang, JC; Wang, L; Yang, DY; Yu, WX; Zhang, S; Zhang, ZZ; Zheng, M; Zhou, XZ, 2020) |
| "Gastric cancer is among the most lethal human malignancies." | ( An, JY; Bae, JM; Cho, HJ; Choi, MG; Her, NG; Hong, JY; Kang, WK; Kim, HJ; Kim, JS; Kim, JY; Kim, KM; Kim, M; Kim, S; Kim, ST; Koo, H; Lee, IK; Lee, J; Lee, JH; Lee, Y; Lim, HY; Nam, DH; Park, JO; Park, SH; Sa, JK; Seo, YJ; Shin, YJ; Sim, MH; Sohn, TS, 2020) |
| "Gastric cancer is a frequently occurring cancer with high mortality each year worldwide." | ( Liang, JR; Yang, H, 2020) |
| "Gastric cancer is the second leading cause of death in the world." | ( Coros, M; Ilie-Mihai, RM; Magerusan, L; Pruneanu, S; Stefan-van Staden, RI, 2020) |
| "Stomach cancer is a widespread health condition associated with environmental and genetic factors." | ( Azizova, TV; Grigoryeva, ES; Zhuntova, GV, 2020) |
| "Gastric cancer is the fourth most common cancer and the second most frequent cause of cancer death worldwide." | ( Chen, S; Chen, T; Lin, X; Nan, K; Sun, H; Tao, Y; Wang, L; Wang, Z; Wu, W; Zeng, T; Zhang, Y; Zhao, L; Zheng, W; Zhong, Y; Zhu, Z, 2020) |
| "Stomach cancer is the most common cancer in Korea." | ( Bae, YJ; Choi, EA; Hyun, HJ; Kang, HT; Kim, J; Kim, Y, 2020) |
| "Gastric cancer is known as the fourth most common cancer and the second main cause of cancer-related deaths." | ( Asemi, Z; Hallajzadeh, J; Mansournia, MA; Nikfar, B; Shafabakhsh, R; Yousefi, B, 2020) |
| "Gastric cancer is a leading cause of cancer death worldwide." | ( Kang, X; Li, D; Li, Y; Zhang, S; Zhao, L, 2020) |
| "Gastric cancer is one of the most common malignancies in China and the fifth most common cancer in the world." | ( Gong, L; Shi, J; Wang, Y, 2020) |
| "Gastric cancer is one of the most common malignancies diagnosed worldwide." | ( Chiyo, T; Fujihara, S; Fujita, K; Fujita, N; Himoto, T; Hirata, M; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Kono, T; Masaki, T; Morishita, A; Namima, D; Okano, K; Suzuki, Y; Takuma, K; Tsutsui, K; Yamana, H, 2020) |
| "Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-related death worldwide." | ( Karamouzis, MV; Koustas, E; Papavassiliou, AG; Sarantis, P; Schizas, D, 2020) |
| "Gastric cancer is the common type of malignancy positioned at second in mortality rate causing burden worldwide with increasing treatment options." | ( Bhosale, PB; Ha, SE; Kim, GS; Kim, HH; Kim, SM; Senthil, K; Vetrivel, P, 2020) |
| "Gastric cancer is one of the most common malignancies worldwide, with high morbidity and poor survival rate." | ( Cai, GQ; Liao, GQ; Liu, S; Liu, WH; Qi, J; Xie, FJ; Yao, CY, 2020) |
| "Gastric cancer is the most common malignant tumor." | ( Li, CH; Liu, M; Pan, LH; Sun, Y, 2020) |
| "Incidence of gastric cancer is associated with mid age (40-59 years) group male patients and lymph node metastasis." | ( Ghosh, P; Mandal, S; Mitra Mustafi, S; Murmu, N, 2021) |
| "Gastric cancer is the most common malignant tumor of the digestive tract and is great challenge in clinical treatment." | ( Chen, Y; Gu, M; Jiang, X; Li, C; Li, X; Shen, Z; Shi, L; Xie, H; Yang, W; Yu, L, 2020) |
| "Gastric cancer is one of the four major tumors in the world and the second leading cause of cancer-related death." | ( Guo, XD; Sha, L; Zhang, N, 2020) |
| "Human gastric cancer is one of the most common malignant tumors with a poor prognosis." | ( Chang, J; Yu, X; Zhang, J; Zhang, Z; Zhou, B, 2020) |
| "Gastric cancer is a disease with high mortality, which threatens the health of people for a long time." | ( Chen, HG; Gong, XJ; Tian, YM; Zhao, C; Zhou, X, 2020) |
| "Gastric cancer is one of the most common causes of cancer-related death worldwide." | ( Dai, Y; Li, Y; Lu, X; Tao, M; Xu, J; Xu, Q; Yang, W, 2021) |
| "Gastric cancer is one of the most prevalent cancers worldwide and the second most common cause for cancer associated mortality." | ( Akrami, H; Khanipouyani, F, 2021) |
| "Gastric cancer is one of the most common cancers and ranks third in cancer-related deaths across globe." | ( Balakrishnan, K; Ganesan, K, 2020) |
| "Gastric cancer is a common gastrointestinal cancer characterized by poor prognosis and chemoresistance." | ( Fatehi-Agdam, M; Jeddi, F; Najafzadeh, N; Panahizadeh, R; Vatankhah, MA, 2021) |
| "Gastric cancer is a common malignancy worldwide." | ( Chen, H; Deng, Y; Duan, G; Li, X; Liu, H; Ma, Z; Qiu, L; Xiao, L; Xu, X; Zhao, LE; Zhu, Z, 2020) |
| "Gastric cancer is a frequently occurring cancer with high mortality each year worldwide." | ( Deng, Z; Gao, Y; Li, F; Xiao, Y, 2020) |
| "Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer death worldwide." | ( Arnold, R; Barbaria, E; Ebert, K; Geffers, R; Hasenauer, J; Heck, C; Hollerieth, V; Keller, S; Luber, B; Mattes, J; Raimúndez, E; Zwingenberger, G, 2020) |
| "Gastric cancer is one of the most common malignant tumors of the digestive system worldwide, posing a serious danger to human health." | ( He, XP; Hua, J; Huang, PY; Liu, GS; Qi, Q; Sun, MX; Sun, WH, 2020) |
| "Gastric cancer is a major cause of mortality worldwide." | ( Awaleh Moumin, F; Cai, J; Chen, J; Chen, X; Jia, L; Xu, L, 2020) |
| "Gastric cancer is one of the most common malignancies worldwide and the third leading cause of cancer-related death." | ( Du, S; Guan, W; Li, Z; Miao, J; Wang, F; Wang, X; Xia, X; Xu, E; Xu, F; Zheng, C; Zhu, H, 2021) |
| "Gastric cancer is one of the leading causes of cancer-related death worldwide with a poor prognosis." | ( Jing, M; Li, QQ; Li, QS; Li, XY; Shi, LX; Wang, YL; Yao, XM, 2021) |
| "Gastric cancer is one of the most common cancers in Asia, and recently, various cases of resistance to fluorouracil treatment have been reported." | ( Kim, GD; Ngabire, D; Niyonizigiye, I; Patil, MP; Seo, YB; Seong, YA, 2020) |
| "Gastric cancer is the most typical oncological illness globally." | ( Liu, W; Zhang, J; Zhao, Y, 2020) |
| "Gastric cancer is a global health problem with high incidence rate and mortality rate." | ( He, X; Wu, L; Wu, Y; Zhang, T; Zhou, X, 2021) |
| "Gastric cancer is one of the most common cancers in the world." | ( Fang, TY; Li, LB; Xu, WJ, 2021) |
| "Gastric cancer is a common malignancy worldwide and is associated with high morbidity and mortality rates." | ( Chen, L; Jia, N; Jin, J; Jin, N; Lin, Z; Piao, Y; Qiao, D; Ren, X; Xing, J; Zhang, Y, 2021) |
| "Gastric cancer is one of the most common and deadly cancers among men and women and is the third leading cause of cancer mortality worldwide." | ( Bai, Y; Fan, Y; Li, D; Li, S; Li, Y; Lin, S; Wang, Z; Zhang, S; Zhang, Y, 2021) |
| "Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death worldwide." | ( Chatterjee, A; Gowda, H; Modi, PK; Najar, MA; Prasad, TSK; Ramesh, P; Sidransky, D, 2021) |
| "Gastric cancer is a malignant tumor with a poor prognosis, and the interaction between tumor cells and cancer-associated fibroblasts (CAFs) further contributes to progression and treatment failure." | ( Chen, F; Fu, M; Liu, D; Shi, K, 2021) |
| "Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide." | ( Chae, OH; Jin, H; Kim, DY; Kim, SH; Kim, SM; Lee, NR; Meng, R; Park, BH, 2021) |
| "Gastric cancer is one of the most common malignancies with a high mortality rate world." | ( Li, F; Niu, M; Wang, S, 2021) |
| "Gastric cancer is a malignant tumor with a poor prognosis." | ( Chen, F; Fu, M; Liu, D; Shi, K, 2021) |
| "In India, gastric cancer is one of the most common cancers in males as well as in females." | ( Agrawal, R; Misra, V; Pandey, AT; Pandey, I; Ramteke, PW, 2021) |
| "Gastric cancer is a global cancer with a high mortality rate." | ( Cao, Y; He, Y; Li, W; Ling, H; Lu, Y; Luo, Y; Wu, J; Xie, M; Xu, S; Zeng, T; Zhou, Y, 2022) |
| "The incidence of gastric cancer is higher in men than in women, but for the diffuse types of gastric cancer, the trend is opposite." | ( Jung, J; Kim, KM; Lee, S; Lee, SY, 2021) |
| "Gastric cancer is one of the most common malignant cancers globally." | ( Bi, J; Deng, Z; Fan, H; Huang, X; Li, G; Ou, Q; Su, Q, 2021) |
| "Gastric cancer is a common malignant cancer, which is one of the most affected cancers by PI3K/AKT signaling." | ( Li, X; Lin, Q; Lv, J; Wang, Z, 2021) |
| "Gastric cancer is the sixth common malignancy worldwide." | ( Feng, Z; Hu, W; Liu, J; Song, M; Zheng, X; Zhou, X, 2021) |
| "Stomach cancer is the fourth most common type of cancer worldwide." | ( Hou, D; Huang, H; Jiang, X; Ma, M; Xing PhD, C; Zhou, G; Zhu, X, 2022) |
| "Breast and stomach cancer is reported as a leading cause for human mortality across the world." | ( Ananthan, R; Das Gupta, D; Das, R; Das, SK; Hui, PK; Jambhulkar, S; Mahanta, S; Paul, D; Tag, H; Tanti, B, 2022) |
| "Gastric cancer is associated with glycosylation alterations in glycoproteins and glycolipids on the cell surface." | ( Aziz, F; Bajpai, VK; Chakraborty, A; Dey, DK; Haldorai, Y; Han, YK; Huh, YS; Hwang, SK; Khan, I; Lee, H; Shukla, S; Sonwal, S; Xiao, J; Yan, Q; Yoshitomi, H, 2022) |
| "Gastric cancer is a prevalent malignant cancer with a high incidence and significantly affects the health of modern people globally." | ( Chen, J; Cui, HY; Guo, J; Qi, JM; Rong, JS; Ruan, M; Zhang, BH; Zhang, SS; Zhu, JQ; Zuo, RR, 2021) |
| "Gastric cancer is a common gastrointestinal cancer and currently has the third-highest mortality rate." | ( Deng, H; He, X; Li, X; Liu, Y; Shi, X; Tang, Y; Yuan, Y, 2021) |
| "Stomach cancer is the 4th most common cancer diagnosed worldwide." | ( Czyż, J; Krakowska, A; Król, K; Krzysiek-Mączka, G; Muszyńska, B; Pudełek, M; Ryszawy, D; Sułkowska-Ziaja, K; Wierdak, M, 2021) |
| "Gastric cancer is the fifth most common tumor and has the third-highest mortality rate among various malignant tumors, and the survival rate of patients is low." | ( Chu, Z; Dai, X; Liu, Y; Ni, T; Ou, S; Wang, H; Zhang, X, 2022) |
| "Gastric cancer is a prevalent malignant tumor that seriously affects human health." | ( Fan, J; Huang, L; Li, X; Ren, L; Xu, M; Ye, X; Zhou, L, 2022) |
| "Because recurrent gastric cancer is often a progressive condition, post-treatment might be promptly transferred to the other posterior regimen without 5-FU as required." | ( Hirano, S; Ichinokawa, M; Kumagai, K; Kuwabara, S; Matsumoto, J; Murakawa, K; Ono, K; Takeuchi, Y; Wada, H, 2022) |
| "Gastric cancer is the second leading cause of cancer-related deaths, with a 5-year survival rate of about 20-25%." | ( Alacacioğlu, A; Avci, A; Cengiz, F; Eren Kalender, M; Güç, ZG; Turgut, B, 2022) |
| "Gastric cancer is one of the most common cancers with few effective treatments, a new treatment agent is desperately needed." | ( Choi, Y; Guo, Y; Jin, CY; Jing, QQ; Kim, G; Li, YW; Liu, L; Liu, XJ; Wang, X; Xie, Q; Xu, F; Xu, YC; Zhang, E, 2022) |
| "Gastric cancer is a type of malignant tumor that seriously threatens human life and health." | ( Chu, Z; Feng, X; Liu, Y; Luo, Y; Ni, T; Wang, H; Zhu, M, 2022) |
| "Gastric cancer is still the fifth most common malignant tumor in the world and has the fourth highest mortality rate in the world." | ( Ai, K; Yuan, D; Zheng, J, 2022) |
| "Gastric cancer is a common gastrointestinal malignancy worldwide, with a high mortality rate and poor prognosis." | ( Ba, N; Du, J; Jia, X; Peng, F; Xu, Q; Zhang, Z; Zhao, H, 2022) |
| "Worldwide, gastric cancer is ranked the fifth malignancy in incidence and the third malignancy in mortality." | ( Chavez-Blanco, A; Diaz-Romero, C; Dominguez-Gomez, G; Duenas-Gonzalez, A; Gonzalez-Fierro, A; Lopez-Basave, HN; Romo-Perez, A; Taja-Chayeb, L, 2022) |
| "Gastric cancer is common worldwide, and while multiple therapeutic options exist, the prognosis remains poor." | ( Heltzel, C; Kalmuk, J; Lockhart, AC; Rinder, D, 2022) |
| "Gastric cancer is a very common gastrointestinal malignancy." | ( Ma, X; Wang, C; Yu, J; Zhang, Y, 2023) |
| "Gastric cancer is one of the most common gastrointestinal malignancies, and the incidence and mortality of gastric cancer remain high in China." | ( Cai, TY; Liu, FL, 2022) |
| "Gastric cancer is the second most frequent cause of cancer death worldwide, although much geographical variation in incidence exists." | ( Dou, Y; Wang, J, 2022) |
| "Gastric cancer is one of the most common malignant tumors, and it ranks third in global cancer-related mortality." | ( Cai, Y; Jia, Y; Li, C; Pan, X; Wu, S, 2022) |
| "Gastric cancer is a common global disease." | ( Chu, Z; Feng, G; Liu, Y; Wang, H; Zhu, F, 2022) |
| "Gastric cancer is one of the malignant tumors in the world." | ( Chen, M; Li, F; Li, J; Li, X; Yuan, Y, 2022) |
| "Gastric cancer is one of the most lethal malignancies in the world." | ( Ding, P; Huang, C; Li, M; Liu, H; Liu, Z; Xin, Y; Zhang, Y; Zhao, X; Zhou, H, 2022) |
| "Stomach cancer is a global health concern as millions of cases are reported each year." | ( Bang, D; Choi, E; Darmawan, BA; Go, G; Gong, D; Jeong, S; Kim, CS; Kim, H; Kim, S; Nan, M; Nguyen, KT; Nguyen, VD; Park, H; Park, JO; Zheng, S, 2022) |
| "Gastric cancer is one of the most common digestive carcinomas throughout the world and represents high mortality." | ( Fan, L; Fan, S; Jian, B; Jin, M; Li, Y; Pan, H; Qian, J; Wang, N; Zhang, H, 2022) |
| "Gastric cancer is a prevalent malignant tumor with high morbidity and poor prognosis." | ( Chen, Z; Ji, X; Yao, Z; Zhang, C, 2022) |
| "Gastric cancer is one of the most common cancers worldwide." | ( Wang, J; Zhou, R; Zhu, M, 2022) |
| "Gastric cancer is one of the most common malignant tumors in the world." | ( Cheng, X; Mahendra Upadhyay, A; Nie, W; Wang, Q; Wang, Y; Yan, Z; Yang, F; Zhang, M, 2022) |
| "In Japan, most gastric cancers are associated with gastric mucosal atrophy caused by chronic infection with Helicobacter pylori (H." | ( Kikuchi, S; Saito, Y, 2022) |
| "Currently, gastric cancer is considered one of the major causes of high mortality and morbidity worldwide." | ( Li, F; Li, Y; Zhou, H, 2022) |
| "Gastric cancer is the second most lethal cancer across the world." | ( Gan, C; He, H; Liu, H; Liu, Z; Ouyang, L; Que, H; Su, X; Wei, W; Wu, X; Ye, T; Yue, L; Zhang, Q, 2022) |
| "Accurate staging of gastric cancer is essential for the selection and optimization of therapy." | ( Chan, WH; Chen, AH; Chen, CM; Lai, YC; Lee, YH, 2022) |
| "Gastric cancer is a malignant neoplasm of the gastrointestinal tract, with one of the standard treatment methods remaining gastrectomy." | ( Bergler-Czop, B; Frątczak, A; Miziołek, B; Muszyński, T; Polak, K; Szczepanik, A, 2022) |
| "Early detection of gastric cancer is an effective way to decrease the associated mortality." | ( Guo, L; Lai, Z; Li, Z; Wang, L; Wu, X; Yang, A; Zhou, W; Zhu, C; Zou, L, 2022) |
| "Gastric cancer is the common type of malignancy positioned at second in mortality rate causing burden worldwide with increasing treatment options." | ( Abuyaseer, A; Bhosale, PB; Ha, SE; Kim, GS; Kim, HH; Nachimuthu, S; Park, MY; Vetrivel, P, 2022) |
| "Gastric cancer is among the most common gastrointestinal malignancies." | ( Chen, Z; Li, X; Xu, Z; Yu, J; Yuan, L, 2022) |
| "Gastric cancer is a worldwide health problem." | ( Chen, X; Li, L; Liu, B; Liu, F; Liu, Q; Yan, J; Yu, X, 2022) |
| "Gastric cancer is the second leading cause of cancer deaths worldwide, and more understanding of its molecular basis is urgently needed." | ( Fujii, C; Harumiya, S; Kawakubo, M; Matoba, H; Nakayama, J; Sato, Y, 2022) |
| "Gastric cancer is the most common digestive tract malignancy in China and has a poor prognosis, with a 5-year overall survival rate of only 35." | ( Chai, Y; Di, J; Jiang, B; Shang, H; Shi, X; Yang, X; Zhang, C, 2022) |
| "Stomach cancer is the fifth most common cancer in terms of prevalence and incidence and the fourth leading cause of mortality in men and women worldwide." | ( Chenkual, S; Dkhar, H; Ghosh, S; Khongsti, S; Lamare, FA; Maitra, A; Marthong, L, 2022) |
| "Gastric cancer is a common malignant tumor of the human digestive system." | ( Chen, Z; Li, X; Mu, M; Qu, C; Shi, J; Sun, X; Wang, X; Ye, C; Zhao, C; Zhao, W; Zhu, L, 2023) |
| "Gastric cancer is a leading cause of tumor-associated death worldwide." | ( Du, YS; Liu, GJ; Liu, SX; Sun, J; Zhao, L; Zhou, LS; Zhou, Y; Zhou, YN, 2022) |
| "Gastric cancer is one of the most common malignancies around the world, and a variety of neoadjuvant chemotherapies with different drug combinations are available for the treatment." | ( Herng, SC; Htet, NH; Naing, C, 2022) |
| "Globally, gastric cancer is the third most common cancer and the third leading cause of cancer death." | ( Chen, X; Chen, Y; Dai, D; Huang, Y; Jin, W; Lin, W; Teng, L; Wang, H; Wang, W; Yang, Y; Zhang, H; Zhang, J; Zhang, Y, 2022) |
| "Gastric cancer is often comorbid with hypertension and diabetes mellitus and increases the mortality risk." | ( Chen, X; Fan, Z; Hu, D; Lin, J; Lin, X; Lin, Y; Peng, F; Wang, L; Yan, X; Yu, J; Zhang, S, 2022) |
| "The pathogenesis of gastric cancer is a multistage process that involves glucose metabolism, inflammation, oxidative damage, angiogenesis, autophagy, and apoptosis." | ( Akbari, A; Deng, B; Liu, Q; Xiao, Q; Zhu, B, 2022) |
| "Gastric cancer is one of the most common and deadly cancers worldwide." | ( Li, Z; Liang, R; Wei, Y; Yin, L, 2022) |
| "gastric cancer is the fifth most prevalent cancer and the fourth cause of death because of cancer." | ( Ahmadi, M; Alizadeh-Navaei, R; Amjadi, O; Azadeh, H; Hedayatizadeh-Omran, A; Moosazadeh, M; Omrani-Nava, V; Rezapour, M; Zaboli, E, 2022) |
| "As gastric cancer is associated with poor prognosis, the preferred management of locally advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer in European patients is perioperative chemotherapy using the FLOT regimen." | ( Jóźwiak, M; Kolasińska-Ćwikła, A; Marcisz-Grzanka, K; Olesiński, T; Pałucki, J; Samsel, R; Sułkowska, U; Wieszczy, P; Winiarek, M; Wyrwicz, LS, 2022) |
| "Gastric cancer is a common malignancy that is the second cancer-associated mortality worldwide." | ( Jadidi, A; Maadani, AM; Sardari, S; Shokrgozar, MA, 2022) |
| "Management of gastric cancer is still challenging due to resistance to current chemotherapeutics and recurrent disease." | ( Bozgeyik, E; Bozgeyik, I; Ege, M; Elmastas, M; Erdal, B; Koyuncu, I; Temiz, C; Temiz, E, 2023) |
| "Management of gastric cancer is still challenging due to resistance to current chemotherapeutics and recurrent disease." | ( Bozgeyik, E; Bozgeyik, I; Ege, M; Elmastas, M; Erdal, B; Koyuncu, I; Temiz, C; Temiz, E, 2023) |
| "Stomach cancer is a leading cause of cancer death." | ( Allaman, MM; Asim, M; Barry, DP; Blanca Piazuelo, M; Delgado, AG; Gobert, AP; Hawkins, CV; McNamara, KM; Rathmacher, JA; Smith, TM; Williams, KJ; Wilson, KT, 2023) |
| "Stomach cancer is a leading cause of cancer death." | ( Allaman, MM; Asim, M; Barry, DP; Blanca Piazuelo, M; Delgado, AG; Gobert, AP; Hawkins, CV; McNamara, KM; Rathmacher, JA; Smith, TM; Williams, KJ; Wilson, KT, 2023) |
| "Gastric cancer is one of the most prevalent cancers in the world." | ( Alavi Dana, SMM; Aschner, M; Darroudi, M; Farkhondeh, T; Samarghandian, S; Samini, H, 2023) |
| "Gastric cancer is the world's fifth most prevalent cancer and its treatments are associated with issues." | ( Ashrafi, F; Kazazi, I; Malekloo, M, 2023) |
| "Gastric cancer is one of the cancers with high morbidity and mortality worldwide." | ( Chen, T; Jiang, H; Li, D; Li, Y; Lu, C; Lu, J; Ma, J; Pu, Z; Qiao, C; Sun, W; Wang, X; Wang, Y; Xu, G, 2023) |
| "Gastric cancer is one of the leading causes of cancer-related death worldwide." | ( Fu, R; Liu, W; Tong, Z; Yang, M; Zhou, Y, 2023) |
| "Early gastric cancer is a common, malignant, tumor disease." | ( Luo, H; Zhang, F, 2023) |
| "Gastric cancer is a leading cause of cancer mortality and health disparities in Latinos." | ( Bohorquez-Lozano, ME; Carvajal-Carmona, LG; Castro-Valencia, F; Echeverry de Polanco, M; Estrada-Florez, AP; Guevara-Tique, AA; Kirane, A; Lott, PC; Mantilla, A; Medrano, R; Morales-Arana, A; Polanco-Echeverry, GM; Rios-Sarabia, N; Rocha, S; Sahasrabudhe, RM; Suarez-Olaya, JJ; Toal, TW; Torres, J; Urayama, S; Wei, D, 2022) |
| "Gastric cancer is a common cause of death from cancer and an important global health care issue." | ( Xie, L; Yan, J, 2023) |
| "Gastric cancer is a dominating cause of cancer-associated mortality with limited therapeutic options." | ( Afonso, LP; Batista, S; Belting, M; Cavadas, B; Costa-Silva, B; Faria-Ramos, I; Ferreira, JA; Ferreira, M; Gomes, C; Lima, L; Macedo, JA; Magalhães, A; Maia, J; Marques, C; Matos, R; Osório, H; Otake, AH; Pinto, F; Poças, J; Polónia, A; Reis, CA; Ribeiro, AR; Santos, LL; Senra, E; Silva, T, 2023) |
| "Gastric cancer is a common cancer worldwide, particularly in East Asia." | ( Chang, YL; Chen, CF; Fang, WL; Huang, KH; Hung, GY; Lee, HC; Li, AF; Wang, SF; Yeh, TS, 2023) |
| "Advanced gastric cancer is associated with poor survival despite chemotherapy." | ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| "Gastric cancer is the third leading cause of cancer death, and gastric precancerous lesions (GPLs) are an important stage in the transformation of normal gastric mucosa to gastric cancer." | ( Cheng, W; Hu, A; Lin, X; Lv, Y; Qian, S; Tang, M; Wang, L; Wang, M; Wang, T; Xia, T; Xu, F; Yang, W; Zhang, D; Zhang, M; Zhang, X; Zhang, Y; Zhao, Q, 2023) |
| "Gastric cancer is one of the deadliest malignant tumors, and half of the patients develop recurrences or metastasis within 5 years after eradication therapy." | ( Cao, H; Cao, W; Chen, Y; Ge, M; Geng, S; Han, H; Jiang, Z; Li, X; Wang, M; Wu, J; Xie, C; Yi, K; Zhong, C; Zhu, J, 2023) |
| "Gastric cancer is one of the most frequent types of neoplasms worldwide, usually presenting as aggressive and difficult-to-manage tumors." | ( Alves, FS; Assumpção, PP; Barros Brasil, DDS; Costa, MLD; Cruz, JN; da Silva, MF; do Rego, JAR; Khayat, AS; Lopes, JMS; Ramos, INF, 2023) |
| "Gastric cancer is one of the most common and deadliest malignancies in the world." | ( Abdolmohammadi, MH; Fallahian, F; Hamzeloo-Moghadam, M; Heidari, F; Roozbehani, M, 2023) |
| "Gastric cancer is the most fatal malignancy in many parts of the world and it is generally related to harmful dietetic factors." | ( Demir, K; Güler, EM; Koçyiğit, A; Özer, ÖF; Türkdoğan, MK; Uğur, H, 2023) |
| Excerpt | Reference |
|---|
| "Fifty patients with a stomach cancer received regional chemotherapy by infusion." | ( Bessot, M; Colombel, P; Duprez, A; Fays, J; Lorenzini, G; Mauuary, G, 1975) |
| "Seven gastric cancer and 2 gastric polyp cases were treated in this manner and in addition 2 gastric cancer patients were treated with NCS alone, to serve as the control." | ( Ishida, N; Nakazawa, I; Ouchi, E; Ouchi, K; Wagai, K, 1978) |
| "Studies on non-curative stomach cancer patients treated with the same dose schedule gave encouraging results." | ( Akao, T; Fujimoto, S; Itoh, B; Koshizuka, I; Koyano, K, 1977) |
| "Fifteen patients with advanced gastric cancer were treated with the combination of Ftorafur, Adriamycin and mitomycin-C (FAM II)." | ( Haller, DG; Hoth, DF; MacDonald, JS; Rosenoff, S; Schein, PS; Smythe, T; Woolley, PV, 1979) |
| "Up to date of the total number of gastric cancer patients, who referred to the polyclinic, only 13% were found to be curable, 27%--may be treated without any guarantee of success, while 60% of patients were incurable." | ( Gusarov, IuP, 1979) |
| "A series of 156 patients with gastric cancer during a 15-year period were reviewed retrospectively to determine the effectiveness of combined surgery and adjuvant chemotherapy." | ( Cruz, AB; Franz, JL, 1977) |
| "Group 7 was untreated." | ( Hananouchi, M; Hirose, M; Shirai, T; Takahashi, M; Tatematsu, M, 1976) |
| "The experimental induction of gastric cancer was studied in four dogs given oral administration of N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG) in solution." | ( Doi, H; Kojima, S; Nagai, S; Sekizuka, H; Sunagawa, M, 1975) |
| "One patient with gastric cancer (stage IIIb) was treated with intraperitoneal administration of IFN-gamma and OK-432 in combination with intraarterial infusion of MMC, ADM, 5-FU and CDDP." | ( Morinaga, S; Takekoshi, H; Yoshida, K, 1992) |
| "50 patients with gastric cancer and serosal infiltration were randomly assigned intraperitoneal treatment with M-CH (50 mg mitomycin intraoperatively) or no anticancer prophylaxis (control)." | ( Hagiwara, A; Kitamura, K; Kojima, O; Noguchi, A; Sawai, K; Seiki, K; Takahashi, T; Taniguchi, H; Yamaguchi, T; Yamane, T, 1992) |
| "We describe a case of gastric cancer with multiple liver metastasis that clearly decreased in size after administration of 5'-DFUR." | ( Itoh, N; Kurimoto, N; Tamura, T; Yasuzawa, Y; Yoshimoto, I, 1992) |
| "However, metastatic bone tumors from gastric cancer usually resist any treatments." | ( Furuya, K; Kashu, Y; Kiyasu, Y; Moriuchi, A; Sakai, K; Satoh, H; Shigematsu, S; Tanaka, T, 1992) |
| "A clinical trial for patients with gastric cancer amenable to curative resection was undertaken to determine feasibility and response to preoperative systemic chemotherapy followed by postoperative intraperitoneal (IP) chemotherapy." | ( Kiyabu, M; Laine, L; Leichman, CG; Leichman, L; Muggia, FM; Radin, R; Ray, M; Silberman, H; Spears, CP; Stain, S, 1992) |
| "Thus patients with gastric cancers whose tumors were positive for both ER and c-erbB-2 gene expression, may benefit from estrogen therapy rather than tamoxifen therapy." | ( Chi, CW; Lui, WY; P'eng, FK; Wu, CW, 1992) |
| "Work has been done in gastric cancer, pancreatic cancer, and colon and rectal cancer, all of which demonstrate an advantage in certain clinical situations for combined-modality therapy." | ( Tepper, JE, 1992) |
| "Peripheral blood lymphocytes (PBL) of gastric cancer patients in advanced stages showed lymphokine activated killer (LAK) activities comparable to those of healthy donors, suggesting potential applicability of LAK cells induced from PBL stimulated with recombinant interleukin-2 (rIL-2) in adoptive immunotherapy (AIT) for gastric cancer." | ( Fujimoto, T; Mai, M; Natsuume-Sakai, S; Omote, K, 1992) |
| "Eighty-one cases of advanced gastric cancer, who had been treated by intra-arterial infusion chemotherapy, were examined for complications related to catheter indwelling." | ( Arai, K; Kitamura, M; Miyashita, K, 1992) |
| "A 74-year-old man with advanced gastric cancer of Borrmann type III and liver metastasis was treated by combined administration of UFT (400 mg/day, p." | ( Hatayama, H; Kitamura, H; Mashiko, H; Satoh, J, 1992) |
| "An advanced gastric cancer with liver metastasis was treated with the combination MMC, Etoposide and UFT." | ( Bandou, H; Kobayashi, T; Mura, T; Nomura, T; Watanabe, K, 1992) |
| "A group of 293 gastric cancer patients were examined to see if the preoperative value of glycosidically bound sialic acid is a predictor of prognosis and effectiveness of postoperative adjuvant therapy." | ( Kondoh, Y; Mitomi, T; Ogoshi, K; Tajima, T, 1992) |
| "A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with alpha-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo)." | ( Barranco, SC; Ford, PJ; Ho, BY; Koester, SK; Reumont, KJ; Townsend, CM, 1990) |
| "Fifty patients with advanced gastric cancer underwent chemotherapy in accordance with the FAMTX protocol." | ( Henne-Bruns, D; Kremer, B; Weh, HJ, 1990) |
| "A group of 20 patients with gastric cancer, refractory to or with no change after two or three cycles of carboplatin were treated with etoposide/folinic acid/5-fluorouracil (ELF)." | ( Achterrath, W; Harstrick, A; Meyer, HJ; Preusser, P; Schmoll, HJ; Seeber, S; Stahl, M; Wilke, H, 1991) |
| "Eighteen patients with advanced gastric cancer were treated with cisplatin 80 mg/m2 d 1, doxorubicin 30 mg/m2 d 3 and mitomycin-C 12 mg/m2 d 3." | ( Cady, J; de Gramont, A; Demuynck, B; Krulik, M; Lagadec, B; Louvet, C; Varette, C, 1991) |
| "Ten patients with non-resectable gastric cancer were subjected to a neo-adjuvant chemotherapy (FLEP therapy), consisting of 4 drugs (leucovorin and 5-FU i." | ( Ishihara, S; Mizuno, S; Nakajima, T; Nishi, M; Ohashi, Y; Ohta, K; Okumura, S; Toyoda, S; Tsuchiya, S, 1991) |
| "(1) In hepatic metastasis of gastric cancer, the 50% survival period was 149 days in local injection therapy, 132 days in arterial infusion therapy and 117 days with no chemotherapy." | ( Aogi, K; Jinushi, K; Sawamura, A; Toge, T, 1991) |
| "Thermochemotherapy was performed on gastric cancer cases of hepato-metastasis." | ( Fujimura, T; Fushida, S; Kamata, T; Matuki, N; Matumoto, H; Sawa, T; Takegawa, S; Tsugawa, K; Urade, M; Yonemura, Y, 1991) |
| "In CHPP therapy for advanced gastric cancer, a perfusate containing 20 mg CDDP and 8 mg MMC in 1,000 ml physiologic saline warmed at 47 degrees C was infused at a constant rate of 200 ml/min into the pouch of Douglas." | ( Gasa, F; Hada, R; Hakamada, K; Konn, M; Mikami, Y; Miyagishima, K; Ono, K; Seino, K; Sugiyama, Y; Suzuki, H, 1991) |
| "A total of 22 patients (12 cases of gastric cancer, 6 of colon cancer, 2 of pancreas cancer, 1 of gall bladder cancer and 1 of biliary tract carcinoid) were treated according to the following schedule: both 10 mg of ADM (or MMC) and 0." | ( Azuma, S; Furuta, T; Kawai, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tanemura, H; Umemoto, T, 1991) |
| "Treatment of gastric cancer still presents a challenge in cancer chemotherapy." | ( Crivellari, D; Figoli, F; Frustaci, S; Galligioni, E; Lo Re, G; Monfardini, S; Saracchini, S; Sorio, R; Talamini, R; Tumolo, S, 1991) |
| "Twenty patients with metastatic gastric cancer were treated with methotrexate (MTX, M), 100 to 160 mg/m2 at 0 h, and, in sequence, 5-fluorouracil (FU, F), 600 to 1000 mg/m2 at 4 h; leucovorin (LV, L), 200 mg/m2 at 18 h, then 20 mg/m2 every 6 h x 12; 5-fluorouracil, 600 mg/m2 at 19 h; and high-dose cisplatin (DDP, P), 100 mg/m2 at 20 h." | ( Bruckner, HW; Chesser, MR; Mandeli, J; Wong, H, 1991) |
| "For inoperable advanced gastric cancer, radiotherapy combined with anticancer drugs proved a worthwhile therapy, and it was necessary to use the pharmacological characteristics of the drugs." | ( Arai, S; Arai, Y; Imai, H; Ozawa, H; Tomiyasu, T; Uchimura, Y; Yamanaka, M, 1991) |
| "A total of 31 patients with gastric cancer showing peritoneal dissemination received continuous hyperthermic peritoneal perfusion (CHPP) in combination with the administration of cisplatin (CDDP) and mitomycin C (MMC)." | ( Fujimura, T; Fushida, S; Hasegawa, H; Kamata, T; Katayama, K; Miwa, K; Sugiyama, K; Takegawa, S; Urade, M; Yonemura, Y, 1990) |
| "Forty-four patients with advanced gastric cancer were treated with a combination including 5-fluorouracil, 4-epi-doxorubicin and mitomycin C." | ( Kolarić, K; Luetić, J; Roth, A; Zupanc, D, 1990) |
| "Nine advanced gastric cancer patients were given 17 courses of cisplatin administrations by means of a 24-hour intravenous infusion at a dose of 100 mg/m2." | ( Aoki, Y; Horiuchi, Y; Kamikawa, R; Kyokane, K; Miwa, Y; Nagai, H; Ninomiya, E; Noro, T; Suga, S; Yasue, K, 1990) |
| "One hundred and thirty-seven cases of stomach cancer given fluoropyrimidines (UFT: 66 cases, Tegafur: 58 cases, 5-FU: 13 cases) after gastrectomy as the adjuvant chemotherapy were examined as to appearance of macrocytic anemia." | ( Arai, K; Awane, Y; Kitamura, M; Miyashita, K, 1990) |
| "Some 74 of 469 patients of gastric cancer, who underwent surgical treatment over the last 7 years in our department, had peritoneal dissemination and 24 of them were treated with the drugs described above." | ( Azuma, S; Furuta, T; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tanemura, H; Yoshida, A, 1990) |
| "Thirty four patients with advanced gastric cancer (GC), colon cancer (CC) biliary tract cancer (BC) and pancreatic cancer (PC) were treated with a combined chemotherapy of UFT with ADM (UFT-A), or UFT with ADM and CDDP (UFT-AC)." | ( Koda, K; Kure, T; Matsunaga, T; Miyazaki, E; Morii, K; Morita, K; Nakajima, K; Nakazawa, O; Terada, S; Tsuji, Y, 1990) |
| "In 93 cases of stomach cancer with liver metastasis, the influence of surgery and chemotherapy on the patients' prognosis was examined." | ( Fujimura, T; Hasegawa, H; Kamata, T; Katayama, K; Kimura, H; Matsuki, N; Ohyama, S; Sakuma, H; Sawa, T; Yonemura, Y, 1990) |
| "Furthermore, an analysis of a gastric cancer patient treated with systemic administration of 3 BRMs and intratumoral injection of OK-432 indicated that infiltration of cytotoxic T cells and NK cells augmented by cytokines such as IFN-gamma produced from activated helper/inducer T cells and NK cells." | ( Kambe, M; Kanamaru, R; Mitachi, Y; Murakawa, Y; Okuno, M; Takahasi, H; Wakui, A, 1990) |
| "In 12 patients with gastric cancer and in 14 with large bowel neoplasia, classified according to the TNM system, some major blood indices of hemostasis, platelet activation and fibrinolysis were assessed before and for 1 month after surgery, to show whether possible variations of such indices may provide useful clues to follow-up, treatment effectiveness and prognosis." | ( Abbasciano, V; Guerra, S; Guglielmini, C; Reali, MG, 1990) |
| "Twenty-five patients with advanced gastric cancer were treated with a combination chemotherapy." | ( Imamura, Y; Masuda, T; Matsushita, K; Ohno, S; Oya, M; Tokisue, M; Yasutake, K; Yoshimura, Y, 1990) |
| "Ninety-one stomach cancer patients were randomly assigned into 7 groups and were administered a placebo or OK-432 at a dose of 5, 20 or 40 KE, once or 3 times a week before their operation (5 KE X 1/W, 20 KE X 1/W, 40 KE X 1/W, or X3/W)." | ( Imai, S; Kitamura, O; Morimoto, H; Nio, Y; Sakanashi, S; Shiraishi, T; Tanaka, T; Tobe, T; Tseng, CC; Tsubono, M, 1990) |
| "Ninety one stomach cancer patients were randomly assigned into 7 groups and were administered a placebo or OK-432 at a dose of 5, 20 or 40KE, once or 3 times a week before operation (5KE X 1/W, 20KE X 1/W, 40KE X 1/W, or X 3/W)." | ( Imai, S; Kitamura, O; Morimoto, H; Nio, Y; Sakanashi, S; Shiraishi, T; Tanaka, T; Tobe, T; Tseng, CC; Tsubono, M, 1990) |
| "Ten previously untreated patients with gastric cancer were treated with etoposide, 120 mg/m2 intravenously (i." | ( Pizzillo, MF; Salva, KM; Schwartz, EL; Sparano, JA; Wadler, S; Wiernik, PH, 1990) |
| "Forty-eight patients with advanced gastric cancer and measurable areas of malignant disease were treated with etoposide (130 mg/m2/day X 3 days) plus cisplatin (45 mg/m2day on days 2 and 3)." | ( Elliott, TE; Gerstner, JB; Hahn, RG; Mailliard, JA; Moertel, CG; Tschetter, LK; Wieand, HS, 1990) |
| "Three patients with advanced gastric cancer (one recurrent and 2 inoperable) with measurable lesions were treated with high dose EAP therapy consisting of VP-16 1200 mg/m2, ADM 80 mg/m2 and CDDP 80-120 mg/m2, and then 1 x 10(7)/kg of cryopreserved autologous bone marrow cells were transfused intravenously." | ( Asano, T; Gunji, Y; Hori, S; Isono, K; Koide, Y; Nabeya, Y; Ochiai, T; Ozaki, M; Shu, S; Suzuki, T, 1990) |
| "Twenty-four patients with advanced stomach cancer were treated with OK-432 combined adoptive immunotherapy [AIT] as prophylaxis or therapy against peritoneal metastases." | ( Inoue, K; Kan, N; Mise, K; Nakanishi, M; Ohgaki, K; Okino, T; Satoh, K; Teramura, Y; Tobe, T; Yamasaki, S, 1990) |
| "In patients with gastric cancer, depending on location of a tumor, the left gastric or right gastroepiploic artery was catheterized via a puncture of the femoral artery, the course of polychemotherapy with fluorouracil and adriablastin was carried out, then the operative treatment was performed." | ( Chernyĭ, VA; Eremenko, VN; Galakhin, KA; Iugrinov, OG; Shchepotin, IB; Tofan, AV, 1990) |
| "A 64-year-old male with advanced gastric cancer with multiple liver metastasis was treated with intensive chemotherapy including mitomycin C and tegafur after palliative gastrectomy." | ( Akita, N; Furukawa, H; Iwanaga, T; Koyama, H; Wada, A; Wada, T; Yasutomi, M, 1988) |
| "In treating advanced gastric cancer cases, 100 mg/m2 of cisplatin (CDDP) was given to such patients by means of a 24 hr continuous iv infusion once a month." | ( Horiuchi, Y; Ibayashi, J; Koyama, Y; Nagai, H; Ohkita, T; Suga, S, 1989) |
| "In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases)." | ( Hosoi, H; Kitagawa, M; Sinmyo, K; Susaki, H; Suwa, H; Yamaguchi, K, 1989) |
| "Nineteen far-advanced gastric cancer patients, including peritoneal dissemination, underwent surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP)." | ( Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Konno, C; Okui, K; Shrestha, RD; Takahashi, M, 1989) |
| "Fifty-five gastric cancer patients with liver metastasis received arterial infusion chemotherapy." | ( Arai, K; Kitamura, M; Kosaki, G; Miyashita, K, 1989) |
| "Sixteen cases of gastric cancer with liver metastases (H2 less than) as group A, fifteen with distant peritoneal metastases (P2 less than) as group B, twenty-five with distant lymph nodes metastases (N3 less than) as group C, twenty-eight with two prognostic factors as group D, and seven with three factors as group E were treated." | ( Ishiguro, E; Iwa, T; Kawaura, Y; Munemoto, Y; Omura, K; Sasaki, M; Sekido, N, 1989) |
| "Two cases with advanced gastric cancer and synchronous hepatic metastasis were treated by hepatic arterial infusion after surgical removal of primary lesion." | ( Hamada, H; Mori, N; Nakajima, I; Nakamura, T; Nakamura, Y; Tanaka, A; Wada, T; Yasutomi, M, 1989) |
| "Thirty-four patients with advanced gastric cancers had received continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination (PD)." | ( Fujimura, T; Hasegawa, H; Hashimoto, T; Katayama, K; Matsuda, Y; Miyata, R; Sugiyama, K; Urade, M; Yamaguchi, A; Yonemura, Y, 1989) |
| "We report a case of advanced gastric cancer with Virchow's node metastasis which responded to concomitant plasma exchange and immunochemotherapy." | ( Iga, C; Kawashima, Y; Nishimura, J; Okajima, K; Sakuramoto, K; Toyoda, M, 1989) |
| "140 patients with advanced gastric cancer confirmed by pathology were treated by UFT (Uracil, FT-207) and mitomycin C (MMC) from Sept." | ( Jin, ML, 1989) |
| "Fourteen patients with advanced gastric cancer consisting of seven primary cases and seven recurrent cases were treated with the combination of etoposide, adriamycin and cisplatin (EAP)." | ( Andoh, T; Hayashi, H; Kiyama, T; Miyamoto, M; Mizutani, T; Nishi, K; Nomura, T; Onda, M; Tokunaga, A; Umehara, M, 1989) |
| "Patients with advanced gastric cancer were treated with methotrexate-5-fluorouracil sequential therapy." | ( Akai, S; Inada, S; Nashimoto, A; Sasaki, J; Sato, T, 1989) |
| "Twenty-four patients with advanced gastric cancer and 4 patients with advanced esophageal cancer were treated with cisplatin at a dose of 80-100 mg/m2 for one day or 10-20 mg/m2 for 5 consecutive days every 3-4 weeks." | ( Itoh, T; Matsukawa, M; Munakata, A; Saitoh, S; Sakata, Y; Sasaki, H; Tamura, Y; Tsuge, M; Tsushima, K; Yoshida, Y, 1989) |
| "Until now advanced gastric cancer has been generally treated with the FAM chemotherapy protocol." | ( Bleiberg, H; Buyse, M; Duez, N; Klein, HO; Wils, J, 1989) |
| "The effect of cimetidine treatment in cancer of the stomach was investigated in a double-blind, multicentre study comprising eight departments in Greater Copenhagen." | ( Bülow, S; Damm, P; Fischerman, K; Hesselfeldt, P; Hjortrup, A; Knigge, UP; Pedersen, IK; Pedersen, VM; Siemssen, OJ; Tønnesen, H, 1989) |
| "In immunohistochemical examination of gastric cancer tissues, sialidase treatment revealed a positive staining with anti-Forssman antibody." | ( Hattori, H; Ogata, H; Ono, K; Taketomi, T; Uemura, K, 1989) |
| "No correlation was found in gastric cancer patients between T3 concentration, degree of blood--T3 level decrease and tissue T3 deficiency, on the one hand, and stage and histologic pattern of tumor, radical surgery and postoperative treatment, on the other." | ( Klimenkov, AA; Sarkisian, RG; Vereshchagina, GV, 1989) |
| "Endoscopic treatment of early gastric cancer (type Ila in all patients) was performed in four patients undergoing chronic hemodialysis." | ( Ida, K; Katoh, S; Katoh, T; Kawata, K; Nakagawa, M; Okuda, J; Sawada, K; Tsunemitsu, K; Yamamoto, S, 1989) |
| "In eleven patients with gastric cancer who could not be operated on because of advanced age, refusal of surgery, or the presence of complications, the streptococcal preparation OK-432 was administered, both intradermally and by direct injection into the tumor under endoscopic guidance." | ( Kijima, Y; Mizutani, K; Nakazawa, S; Ohhashi, S; Yasumasa, N; Yoshino, J, 1989) |
| "In an advanced stomach cancer with recurrence of regional lymph node metastasis, cis-diamminedichloro-platinum (CDDP) was administered intravenously (IV) according to the following doses and schedules." | ( Fukaya, Y; Kimura, K; Saito, S; Shiraishi, Y; Suzuki, K; Takamura, H; Tsurui, S; Yamazaki, T, 1989) |
| "For the response of advanced gastric cancer to chemotherapy in the National Cancer Center Hospital, the combined use of UFT and Mitomycin C gave the highest rate, 46%." | ( Akine, Y; Egawa, S; Hijikata, J; Kajiura, Y; Kitagawa, T; Ogino, T; Tsukiyama, I; Yamashita, K, 1988) |
| "Twenty-six patients with unresectable gastric cancer, divided into two groups, were treated with combination chemotherapy of FEP (14 patients) or FAP (12 patients)." | ( Hayakawa, M; Hayashi, N; Kaneshiro, K; Morise, K; Oka, Y; Suga, S; Suzuki, T; Tsunekawa, H; Umemura, K; Yoshida, H, 1988) |
| "In three cases of stomach cancer and one case of malignant lymphoma, cranial polyneuropathy, progressive hydrocephalus and positive cytology of the CSF were found during treatment of malignant tumors." | ( Fujioka, S; Kuratsu, J; Matsukado, Y; Ohtsuka, T; Sonoda, H; Uemura, S; Yano, T; Yoshioka, S, 1985) |
| "The criteria for cancer chemotherapy of gastric cancers proposed by the Japanese Research Society for Gastric Cancer is introduced with several effective cases." | ( Kurihara, M; Taguchi, S, 1986) |
| "A 56-year-old woman with recurrent gastric cancer treated with PMU therapy, combined CDDP 75 mg/m2 i." | ( Matsuki, N; Miyata, R; Miyazaka, I; Noto, H; Ogino, S; Ohyama, S; Sakuma, H; Sawa, T; Yagi, M; Yonemura, Y, 1986) |
| "A patient with gastric cancer (mucinous adenocarcinoma), classified as Borrmann Type 4, refused surgery and a chemotherapy regimen was applied." | ( Iwao, N; Koda, T; Kurahori, T; Miyaji, J; Okahisa, N; Sonoda, T; Sumi, S; Yanagimoto, H, 1987) |
| "A total of 48 patients with gastric cancer were randomly assigned to receive either endoscopic injections of OK-432 plus systemic treatment with intravenously administered 5-fluorouracil and intradermally injected OK-432 (group A) or systemic therapy alone (group B)." | ( Nakazawa, S; Okamura, S; Yamao, K; Yoshino, J, 1988) |
| "The cumulative survival rate of 166 gastric cancer patients after noncurative resection and nonresection treated by combination therapy using carmofur (HCFU), mitomycin C (MMC) and immunopotentiators was investigated." | ( Nakanishi, Y, 1986) |
| "An aged female patient with inoperable gastric cancer was treated with a combined chemotherapy using UFT and Mitomycin C." | ( Adachi, M; Sasaki, M, 1986) |
| "Treatment of human gastric cancer clones in vitro with low doses of DFMO (5 mM) produced elongation of the cell population doubling times and lowering of the saturation densities." | ( Barranco, SC; Ford, PJ; Townsend, CM, 1986) |
| "Thirty three patients with gastric cancer and 17 with colon cancer were treated by tegafur suppository at a dose of 1,500 mg/day and GSH, 1,200 mg/day intravenously." | ( Fukuzumi, N; Ikeda, Y; Kaga, F; Kitajima, M; Kiuchi, T; Okada, N, 1987) |
| "A 65-year-old man with gastric cancer showing multiple liver metastases was treated with recombinant interferon-gamma (KW-2202) and 5-fluorouracil (5-FU)." | ( Hisatsugu, T; Katano, M; Kitajima, Y; Sato, S; Uchida, Y; Yamamoto, H, 1987) |
| "Twenty patients with advanced gastric cancer were treated with FAP." | ( Horikoshi, N; Imajo, K; Inoue, K; Ito, Y; Mukaiyama, T; Nagamine, D; Ogawa, M; Ozeki, H; Shinagawa, K, 1988) |
| "Combined chemotherapy for human gastric cancer Transplanted into nude mice has been performed to determine whether misonidazole (MIS) and metronidazole (MTR), derivatives of nitroimidazole, would enhance the antitumor activity of MMC." | ( Arimizu, N; Fujimoto, S; Kobayashi, K; Kokubun, M; Miyoshi, T; Mori, T; Ohta, M; Okui, K; Shrestha, RD, 1988) |
| "Fifteen patients with far-advanced gastric cancer were given surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug." | ( Arimizu, N; Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Miyoshi, T; Ohta, M; Okui, K; Shrestha, RD; Takahashi, M, 1988) |
| "Fifteen patients with stomach cancer and colorectal cancer were orally administered 600 mg of UFT before operation and the concentration of tegafur, 5-fluorouracil (5-FU) and uracil in the tissues and serum were measured by chemical assay." | ( Kikuchi, K; Kunii, Y; Mori, Y; Nitta, A; Saitou, T; Takahashi, N, 1988) |
| "In 8 cases of advanced and/or relapsed gastric cancer (7 cases advanced, 1 case relapsed), we undertook combination chemotherapy with systemic administration of cisplatin and celiac arterial infusion of carboquone intermittently under continuous administration of OK-432 i." | ( Horiuchi, M; Nakarai, I; Nasu, K; Shinoda, A, 1988) |
| "A 75-year-old man with gastric cancer metastatic to the liver was treated by combined administration of Tegafur (800 mg/body/day), 5-fluorouracil (300 mg/body/day) and Mitomycin C (hepatic arterial infusion of 20 mg/body and intravenous infusion of 8 mg/body)." | ( Ito, T; Nehashi, Y; Sasaki, J; Sasaki, Y, 1988) |
| "Fourteen patients with far-advanced gastric cancer were treated surgically followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug." | ( Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Ohta, M; Okui, K; Shrestha, RD, 1988) |
| "Sixty-one patients with advanced gastric cancer who had received preoperative 5-FU dry syrup administration and who had also undergone curative resection between 1976 and 1982, in addition to postoperative chemotherapy (more than 20 mg MMC, 5,000 mg 5-FU), (Group A) were admitted to the present study." | ( Izuo, M; Miyamoto, Y; Takeshita, M, 1988) |
| "An 83-year-old patient with advanced gastric cancer was given repeated endoscopic administration of OK-432 combined with systemic immunochemotherapy." | ( Kanayama, M; Koyama, W; Maeda, M; Sakai, Y; Sakamoto, S; Totsuka, S, 1988) |
| "We treated 24 patients with gastric cancer for whom no surgery was indicated because of serious complications or patient's refusal." | ( Maeda, C; Muto, T; Nashimoto, A; Sasaki, K, 1988) |
| "The therapy of advanced stomach cancer is used to exemplify the clinicians' thoughts when confronted with the decision of adapting a standard treatment for a particular disease." | ( Kenis, Y, 1987) |
| "In most cases of metastatic gastric cancer, treatment with cytostatic drugs seems to be justified." | ( Hofmann-Preiss, K; Theobaldy, S; Walter, M, 1987) |
| "A case of unresectable advanced gastric cancer was treated with cis-dichlorodiammine platinum (CDDP) at a dosage of 30 mg/day for 5 days every month after operation." | ( Furuta, T; Kawata, R; Kishimoto, Y; Saji, S; Sakata, K; Tanemura, H, 1987) |
| "A 51-year-old man with recurrent gastric cancer was treated by combined administration of Cisplatin and Carmofur." | ( Abe, S; Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Kuwatsuru, R; Saifuku, K; Yamamoto, K; Yoon, S; Yoshida, K, 1987) |
| "The cases treated consisted of 7 of gastric cancer, 1 of pancreas cancer, 2 of lung cancer and 2 of breast cancer." | ( Fujisaki, M; Kikuchi, K; Kurihara, E; Suito, T; Takada, Y; Takahashi, R; Tamura, T; Uematsu, Y, 1987) |
| "There have been recent findings of gastric cancer in patients treated with cimetidine but too soon after treatment for that drug to have had a pathogenetic role." | ( Cardin, F; Di Mario, F; Farinati, F, 1985) |
| "Prior to 1974 gastric cancer was considered refractory to chemotherapy." | ( Green, M; Muggia, F; Wadler, S, 1985) |
| "A 69-year-old patient with advanced stomach cancer (Borrmann III) was treated with a combination chemotherapy regimen of cis-platinum administered one week after a course of PSK and FT-207." | ( Atarashi, J; Fukuo, Y; Hayashi, Y; Terashi, A; Yano, Y, 1985) |
| "Preoperative cancer chemotherapy for gastric cancer was reviewed with special emphasis on histologic findings and survival." | ( Endoh, F; Fujimoto, S; Kawata, S; Kurihara, M; Miyazaki, M; Ohta, M; Shimura, T; Sugasawa, H; Takahashi, O; Udagawa, I, 1985) |
| "Two patients who had advanced gastric cancer and metastatic liver tumors were treated with a combined chemotherapy using UFT and mitomycin C." | ( Hanawa, S; Hara, S; Joya, K; Nakata, K; Sato, K; Shigemitsu, M, 1985) |
| "An analysis of 3,630 gastric cancer cases from 412 institutions who were treated with 6 randomly-assigned protocols was carried out to study the effect of daily PSK and Futraful administration and the adjuvant effect of PSK and/or Picibanil (OK 5 KE) combined with MMC and FT." | ( Abe, O; Hattori, T; Inokuchi, K; Inoue, K; Kikuchi, K; Kondo, T; Nakajima, T; Ogawa, N; Taguchi, T; Tanabe, T, 1985) |
| "The median survival periods for stomach cancer (Stage 4) after non-radical surgery by means of intraarterial chemotherapy with and without noradrenaline were, respectively, 12 months (n = 8) and 5." | ( Katsumi, S; Kawaguchi, T; Murai, T; Sato, T, 1985) |
| "For patients with locally advanced gastric cancer, combined-modality therapy has resulted in long-term survival for approximately 15% of cases." | ( Schein, PS, 1985) |
| "Hypertensive chemotherapy of advanced gastric cancer is reported in this paper." | ( Bai, XW, 1985) |
| "In 161 cases of gastric cancer with liver metastasis but without peritoneal dissemination, evaluations were executed to find effective treatment." | ( Isono, K; Juan, IK; Koide, Y; Ochiai, T; Okuyama, K; Onoda, S; Satoh, H; Yamamoto, Y, 1985) |
| "For stage I and II gastric cancer, radical gastrectomy and postoperative immunotherapy for 3 months would be the best treatment." | ( Kim, JP, 1985) |
| "In this study, eight beagle dogs with gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine (ENNG) received weekly administration of 7-N-(p-hydroxyphenyl)-mitomycin C (M-83), a variant of mitomycin C." | ( Ochi, K; Tanaka, N, 1985) |
| "In a total of 45 patients with gastric cancer, tumor tissue level of 5-fluorouracil (5-FU) was determined at 2, 4, 6, 8, and 12 hours following the oral administration of drug, using a resected stomach specimen as material." | ( Isobe, K; Iwase, H; Kimura, K; Kuwabara, T; Sato, A; Suga, S; Takada, T; Yokoyama, Y; Yoshida, Y, 1982) |
| "Two cases of gastric cancer were treated with immunochemotherapy using Tegafur and Schizophyllan." | ( Abe, T; Fuse, Y; Nishida, K; Takino, T; Yokota, S; Yoshida, J, 1983) |
| "Immunotherapy for gastric cancer has been adopted by any institutes recently." | ( Haga, S; Kasihara, T; Kawata, H; Ogawa, K; Ogawa, T; Otani, Y; Sakakibara, N; Yakawa, H, 1984) |
| "Thirty patients with advanced gastric cancer were treated with a combination chemotherapy consisting of adriamycin 20-30 mg/m2 iv day 1 q3wks, mitomycin C 2." | ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Okada, Y; Usui, N, 1983) |
| "In the inoperable Borrmann type 4 Gastric cancer, which is to be used as a synonym of gastric scirrhus clinically, it is regrettable but effect is hardly expected from radiotherapy or immunotherapy, and the treatment relies entirely on chemotherapy." | ( Izumi, T; Kurihara, M; Maruyama, T; Miyasaka, K; Sasaki, Y, 1983) |
| "Splenectomy for gastric cancer at stage IV, particularly in combination with immunotherapy, produced augmentation of cell-mediated immunity and longer survival as well." | ( Gohchi, A; Iijima, T; Inoue, T; Kobayashi, T; Kojima, K; Miwa, H; Moriyama, M; Nakamura, K; Oka, T; Tsurumi, T, 1983) |
| "A group of 243 patients with gastric cancer was subjected to a prospective randomized trial of adjuvant chemotherapy after curative gastrectomy." | ( Kajitani, T; Kuno, K; Nakajima, T; Takagi, K; Takahashi, T, 1984) |
| "In 156 cases of gastric cancer, levamisole (LMS) was administered at a daily dose of 150 mg for three consecutive days every other week." | ( Kobayashi, T; Miwa, H; Moriyama, M; Nakamura, K; Oka, T; Ono, F; Orita, K, 1980) |
| "Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM)." | ( Allan, SG; Calman, KC; Carter, DC; Cunningham, D; Hutcheon, AW; Kaye, SB; McArdle, CS; Sangster, G; Smyth, JF; Soukop, M, 1984) |
| "Eighteen patients with gastric cancer in Stage IV who had failed combination chemotherapy were treated with cis-dichlorodiammineplatinum as a single agent." | ( Antón Aparicio, LM; Buesa, JM; Gracia Marco, JM; Izarzugaza, I; Lacave, AJ; Valle Pereda, M, 1983) |
| "We conclude that this drug is active in stomach cancer and that it warrants further trials in combination chemotherapy." | ( Beer, M; Cavalli, F; Ceci, G; Cocconi, G; Varini, M, 1983) |
| "Out of 42 gastric cancer cases treated with only anticancer drugs, 37 cases exhibited hardly cytologic changes in the smears of biopsied materials." | ( Asakawa, H; Nakano, N; Takeda, T, 1982) |
| "Thirty patients with gastric cancer were clinically studied by rectal administration of FT-207 suppository at a dose of 1500mg per day as a preoperative adjuvant chemotherapy." | ( Fukuzumi, N; Ikeda, Y; Kaga, F; Kitajima, M; Seki, M; Sohma, S; Yagita, A, 1982) |
| "In 26 patients with cancer of the stomach, bone marrow function, cell mediated immunity and plasma CEA level were examined after administration of ACN-U." | ( Inuo, T; Kaneko, H; Ohashi, A; Sekizawa, Y; Tsuchiya, S, 1982) |
| "Forty patients with gastric cancer and 30 patients with colon cancer were administered FT-207 prior to the operation." | ( Fukao, K; Ishikawa, A; Iwasaki, Y; Nagoshi, K; Okamura, T; Orii, K; Ozaki, A; Sarashina, H; Takase, Y; Takeshima, T; Todoroki, T, 1982) |
| "Twenty-one patients with advanced gastric cancer were treated with a combination chemotherapy of adriamycin and 5-fluorouracil (AF)." | ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Usui, N, 1983) |
| "Combinations of active agents in gastric cancer hold promise as effective surgical adjuvant therapy." | ( Haller, DG; Kisner, DL; Macdonald, JS, 1982) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "A patient with an abdominal tumor and gastric cancer was treated with intraperitoneal OK-432 alone." | ( Harada, Y; Hashimoto, I; Ishibashi, H; Kodama, M; Tanaka, T; Yamagishi, H, 1982) |
| "However, the incidence of gastric cancer in rats treated with MNNG alone was 25%." | ( Fujii, I; Ito, A; Naito, M; Naito, Y; Terada, Y; Watanabe, H, 1980) |
| "In the chemotherapy for gastric cancer, the most sensitive anticancer agent against individual tumors should be prescribed." | ( Hattori, T; Nishimawari, K; Nosoh, Y; Tani, T, 1981) |
| "Seven gastric cancer patients were treated in this manner, and 4 gastric cancer patients treated with 5-FU alone to serve as the control." | ( Nakazawa, I; Ouchi, E; Ouchi, K; Wagai, K, 1981) |
| "A case of AFP producing gastric cancer successfully treated with EAP therapy is reported with a review of the literature." | ( Gonda, T; Higuchi, T; Hirukawa, H; Hojo, I; Ishida, H; Mishima, Y; Nakajima, H, 1994) |
| "Twenty two surgical specimens of gastric cancer resected after administration of OK-432 for the skin reaction test were examined to determine whether the cancer cells had the same antigens as OK-432, a product of hemolytic streptococcus cells." | ( Hashimoto, S; Hirai, M; Kajiwara, T; Katsube, T; Ogawa, K; Saito, M; Yagawa, H; Yoshida, T, 1993) |
| "A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery." | ( Furukawa, T; Ishibiki, K; Kitajima, M; Kubota, T; Kumai, K; Saikawa, Y; Yoshino, K, 1994) |
| "Endoscopic therapy for early gastric cancer included strip biopsy, laser irradiation, and OK-432 injection." | ( Motoo, Y; Mouri, I; Ohta, H; Okai, T; Sawabu, N; Songür, Y; Watanabe, H; Yamaguchi, Y, 1995) |
| "A case of far advanced gastric cancer with multiple liver metastasis (H3) was treated with transarterial intermittent chemotherapy (5-FU: 250 mg/week, Farmorubicin: 10 mg/4 weeks, MMC: 4 mg/2 weeks) and intradermal administration of low molecular lipopolysaccharide (LPSp) extracted from Pantoea agglomerans." | ( Fukuma, E; Goto, S; Imai, I; Ishiyama, J; Kano, N; Kasugai, H; Kera, J; Miyajima, N; Takeuchi, S; Yamakawa, T, 1995) |
| "40813) on adjuvant chemotherapy in gastric cancer, results obtained after administration of the FAM2 regimen (fluorouracil [5-FU], doxorubicin, and mitomycin) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval." | ( Buyse, M; Dos Santos, JG; Duez, N; Fiorentino, M; Labianca, R; Lise, M; Marchet, A; Nitti, D; Rougier, P; Sahmoud, T, 1995) |
| "Fourteen advanced gastric cancer patients allocated to RT and Control group randomly and received each amino acid as protein source for 7 days TPN with 5-FU administration." | ( Endo, M; Goseki, N; Kando, F; Maruyama, M; Nagai, K; Shimoju, K; Wada, Y, 1995) |
| "We reported a patient with advanced gastric cancer and a liver metastasis, who responded remarkably to combination chemotherapy using THP, 5'-DFUR and CDDP." | ( Adachi, H; Kobori, O; Kurihara, M; Kurihara, T; Murakami, H; Saito, K; Tamura, Y, 1995) |
| "When this agent is administered to gastric cancer patients, it can be expected to be more effective in the above types of patients because of its characteristics." | ( Ishikawa, S; Katsube, T; Konno, S; Miura, K; Naritaka, Y; Ogawa, K; Shimakawa, T; Wagatsuma, Y; Wakasugi, S; Watanabe, T, 1995) |
| "A 71-year-old man with Borrmann type 3 gastric cancer with multiple liver metastases had been treated with 5'-DFUR 1400 mg/m2/day, p." | ( Ishihata, R; Kasukawa, R; Kuwana, T; Nishimaki, T; Obara, K, 1995) |
| "A 59-year-old-male with advanced gastric cancer and multiple liver metastasis was treated by intravenous administration of MMC (30 mg/body) and oral administration of HCFU (400mg/body/day) initially after palliative gastrectomy." | ( Iwata, K; Kondoh, Y; Mitomi, T; Miyaji, M; Ogoshi, K; Tajima, T, 1993) |
| "Seventeen patients with metastatic gastric cancer were treated with etoposide (120 mg/m2, i." | ( Adenis, A, 1994) |
| "61 cases of the gastric cancers have been treated with Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy." | ( Chen, CH; Sun, GZ; Wang, GM, 1994) |
| "Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study." | ( Cascinu, S; Catalano, G; Cordella, L; Del Ferro, E; Fronzoni, M, 1995) |
| "Recurrence of gastric cancer or colon cancer was observed in some patients who received 5-fluorouracil (5-FU) high-dose continuous Methotrexate (MTX)-Leucovorin (LV) therapy (FML therapy) previously." | ( Fujihara, T; Inokuchi, T; Kawano, K; Kimoto, K; Mori, F; Tamura, Y; Yoshioka, Y, 1994) |
| "We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy." | ( Ikeda, K; Shibata, N; Tamai, M, 1995) |
| "Chemotherapy for gastric cancer should be evaluated with survival advantages or rate of long-term survivors in future studies." | ( Miyata, Y; Ohtsu, A; Shimada, Y; Yoshida, S, 1995) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Lentinan was administered for gastric cancer in order to determine what type of changes would occur as a consequence." | ( Hamuro, J; Hirai, M; Kajiwara, T; Katsube, T; Miura, K; Ogawa, K; Suga, T; Wakasugi, S; Watanabe, T; Yagawa, H, 1994) |
| "Two cases of gastric cancer with multiple liver metastases were treated with 5'-DFUR and CDDP after the surgery." | ( Kikkawa, N; Kobayashi, K; Mishima, H; Shin, E; Takatsuka, Y; Tamaki, Y; Tono, T; Yagyu, T, 1994) |
| "A 75-year-old man with gastric cancer having multiple liver metastases was given intraarterial infusion therapy with sequential low-dose MTX (30 mg/body) and 5-FU (1,000 mg/body) for metastatic liver tumors one month after the primary gastric tumor was resected." | ( Hamanaka, Y; Hazama, S; Oka, M; Suzuki, T; Tangoku, A; Tsurumi, M, 1994) |
| "Eighteen patients with gastric cancer with peritoneal metastasis were treated with methotrexate/5-fluorouracil sequential therapy." | ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sejima, T; Sugaya, J; Takano, Y; Tomita, F, 1994) |
| "Some 113 patients with gastric cancer and serosal infiltration were randomly assigned intraperitoneal treatment with MMC-CH and no anti-cancer drugs." | ( Chohei, S; Hagiwara, A; Imanishi, T; Ohgaki, M; Ohyama, T; Ozaki, K; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1994) |
| "All three patients with gastric cancer showing a partial response (PR) to docetaxel had displayed no response to previous chemotherapy." | ( Taguchi, T, 1994) |
| "Thirty-four patients with advanced gastric cancer were treated with combination chemotherapy employing Tegafur-Uracil (UFT), etoposide, Adriamycin, and Cisplatinum (CDDP) (UFT-EAP therapy)." | ( Chin, K; Hattori, T; Hayakawa, M; Maeda, H; Morise, K; Morooka, Y; Saito, H; Sugihara, M, 1994) |
| "The treatment of advanced gastric cancer is unsatisfactory." | ( Desiderio, F; Fattori, PP; Gianni, L; Nicolini, M; Oliverio, G; Pasquini, E; Ravaioli, A; Scarpellini, M; Tononi, A, 1994) |
| "The persistent expression of PgR in gastric cancer cell lines and tumors, and the slight increase of tumor volumes in the progesterone-treated group suggests that progesterone and its receptors may be important in the pathogenesis of gastric cancer, but their biological function remains to be elucidated." | ( Chang, TJ; Chang, YF; Chi, CW; Lui, WY; P'Eng, FK; Wu, CW; Yeh, TH, 1994) |
| "FLP therapy for advanced or recurrent stomach cancer in outpatients was expected to improve the QOL." | ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Onodera, S; Rino, Y; Sairenji, M, 1994) |
| "A 67-year-old man with advanced gastric cancer with multiple liver metastases was treated by a new combination chemotherapy using 5-FU, THP and MMC (FTM)." | ( Kusano, F; Maekawa, N; Sakai, Y; Sasaki, N; Tajiri, K; Tazawa, J; Yamamoto, C, 1994) |
| "We described a case of advanced gastric cancer with multiple liver metastases, who was placed on neoadjuvant chemotherapy using CDDP and 5-FU (FP therapy) with a marked reduction in tumor load." | ( Igarashi, S; Kurosu, Y; Mori, K; Niki, M; Nishimura, G; Oohara, M; Osada, H; Takamoto, Y; Tsuzuki, H; Ueda, H, 1994) |
| "Three cases of postoperative gastric cancer with peritoneal dissemination were treated by combined administration of CDDP, 5-FU and Lentinan." | ( Mio, H; Terabe, K, 1994) |
| "CPT-11 showed activity against advanced gastric cancer, suggesting that further clinical studies of CPT-11 combined with other active chemotherapy agents are warranted." | ( Futatsuki, K; Kambe, M; Nakao, I; Ogawa, N; Sakata, Y; Shimada, Y; Taguchi, T; Wakui, A; Yoshino, M, 1994) |
| "A 51-year-old female with inoperable gastric cancer and with infiltration of pancreatic tail diagnosed by abdominal CT was treated with leucovorin (LV) and 5-fluorouracil (5-FU)." | ( Inamura, Y; Kanemitsu, T; Koike, A; Kojima, T; Matsumoto, K; Miwa, M; Nagata, H; Naruse, T; Ohiwa, Y; Suzumura, K, 1993) |
| "Thirty-six patients with advanced gastric cancer were treated with combination chemotherapy following surgery." | ( Acimovic, LJ; Jeremic, B; Matovic, M, 1993) |
| "An advanced gastric cancer patient with multiple retroperitoneal lymph node metastases and bone metastases was treated with sequential MTX and 5-FU." | ( Anai, H; Furuyama, M; Ikejiri, K; Maekawa, S; Muranaka, T; Saku, M; Takeo, S; Yakabe, S, 1994) |
| "The frequency of multiple early gastric cancer occurring in patients who had not received chemotherapy was 11." | ( Kumagai, K; Masuo, K; Nishida, Y; Yasui, A; Yoshitoshi, A, 1993) |
| "Two patients with unresectable gastric cancer accompanied with multiple liver metastases were treated with a 3-drug combination consisting of etoposide, adriamycin, and cisplatin (EAP) as neoadjuvant chemotherapy." | ( Chikamori, M; Genba, K; Ikubo, S; Kimura, I; Kiura, K; Matsumura, T; Matsuo, K; Ohnoshi, T; Tabata, M; Ueoka, H, 1994) |
| "In 6 advanced gastric cancer patients with peritoneal dissemination or extensive lymph node metastases, OK-432 20 KE was administered intraperitoneally during operation and the IL-6, IL-8 and IFN-gamma levels in ascitic fluid were measured from 0 to 5 postoperative days." | ( Abe, K; Asahi, H; Kuboi, M; Saito, K; Takagane, A; Terashima, M, 1993) |
| "Nine gastric cancer patients with simultaneous liver metastases were given intermittent transarterial administration of chemotherapeutics (adriamycin, mitomycin C or 5-fluorouracil) and biological response modifiers (BRM; OK-432 and interleukin (IL) -2) after gastrectomy." | ( Azuma, S; Furuta, T; Kato, M; Kida, H; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Umemoto, T, 1993) |
| "Forty gastric cancer patients and 29 colorectal cancer patients were treated by subselective intraarterial infusion chemotherapy." | ( Fujimoto, T; Kitada, M; Murotani, M; Okumura, Y; Saito, M; Shibata, T; Takada, T; Takami, M; Tsukahara, Y; Watanabe, Y, 1993) |
| "Fourteen patients with advanced gastric cancer were treated with EAP-F therapy." | ( Inada, T; Kano, Y; Ogata, Y; Suda, K, 1993) |
| "Recently, in the treatment of gastric cancer this biochemical modulation has been introduced into clinical practice and has also achieved good antitumor activity." | ( Akiyama, H; Kajiyama, Y; Matsuda, M; Ono, Y; Suzuki, M; Tsurumaru, M; Udagawa, H; Watanabe, G, 1993) |
| "A 59-year-old woman with advanced gastric cancer was treated with continuous 5-fluorouracil infusion for thirty-five days." | ( Kano, Y; Sasagawa, M; Seki, T; Suda, K, 1993) |
| "An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here." | ( Azuma, T; Doihara, H; Kirihara, Y; Miyahara, E; Ohashi, R; Sakamoto, N; Soga, H; Takiyama, W; Tanada, M; Yokoyama, N, 1993) |
| "In Japan, where treatment of gastric cancer has been more successful, possibly due to earlier diagnosis and more aggressive surgical approaches, mitomycin has been given intraperitoneally during surgery and postoperatively in combination with fluorinated pyrimidines or other agents." | ( Macdonald, JS; Schnall, S, 1993) |
| "Patients with advanced gastric cancer were randomized to receive modified FAMTX treatment or supportive measures only (control group)." | ( Murad, AM; Petroianu, A; Rausch, M; Rocha, PR; Rodrigues, MA; Santiago, FF, 1993) |
| "This metastatic model of human stomach cancer shows that locally growing and metastatic tumors may have different chemosensitivities, and provides the opportunity to test both with various treatment regimens." | ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Kuo, TH; Watanabe, M, 1993) |
| "In a 63-year-old male patient with gastric cancer having multiple liver metastases, the metastatic lesions responded well to postoperative staggered intraarterial infusion therapy with MTX and 5-FU." | ( Adachi, A; Nakano, Y; Ota, Y; Shirafuji, T; Yamaguchi, H; Yoshida, K, 1993) |
| "Three cases of gastric cancer with multiple liver metastases were treated with low-dose CDDP and high-dose 5'-DFUR after surgery." | ( Fukuda, K; Kikkawa, N; Kobayashi, K; Kobayashi, T; Mishima, H; Nakagawa, H; Shinn, E; Tono, T; Yagyu, T, 1996) |
| "Eight patients with gastric cancer were treated with low-dose daily bolus infusions of DDP to a total daily dose of 75 mg/m2 bid for 5 days." | ( Ando, N; Hoshiya, Y; Kitajima, M; Kubota, T; Kumai, K; Kurihara, N; Otani, Y, 1996) |
| "We identified patients with gastric cancer at high risk for recurrence before therapy using endoscopic ultrasonography (EUS)." | ( Botet, J; Brennan, M; Gerdes, H; Huang, Y; Karpeh, M; Kelsen, D; Klimstra, D; Lauers, G; Lightdale, C; Quan, V; Saltz, L; Schwartz, G, 1996) |
| "Increased mRNA was detected in gastric cancer MKN 45 cells after 3 h of treatment with vitamin D3 and increased enzyme activity was measured after 24 to 48 h." | ( Uchida, T; Watanabe, S, 1996) |
| "Seventy gastric cancer patients were treated after surgery with one of the following regimens; 5-FU 10 mg/kg/24 hrs c." | ( Hori, A; Isogai, M; Kawai, M; Kubota, T; Maeda, A; Yamada, T; Yamaguchi, A; Yamaguchi, R, 1996) |
| "In week 52, the incidence of gastric cancers, the NE concentration in the antral portion of gastric wall and the labelling index of antral epithelial cells were significantly greater in rats fed NaCl alone than in untreated control rats." | ( Baba, M; Ishi, H; Nakaizumi, A; Tatsuta, M; Uehara, H; Yano, H, 1996) |
| "We here reported a case of advanced gastric cancer remarkably responding to preoperative short-term UFT-E chemotherapy." | ( Iijima, K; Iwazaki, R; Maehiro, K; Miwa, H; Mizobuchi, N; Okura, R; Ono, Y; Ota, K; Sato, K; Sato, N; Urabe, M; Wada, R, 1996) |
| "The MKN-28 gastric cancer cells may be useful for the rapid screening of anti-HSV agents and, in particular, those that may be useful in therapy of gastrointestinal HSV infections in gastrointestinal herpetic infection." | ( De Clercq, E; Hashimoto, K; Igarashi, A; Kodama, E; Mori, S; Shigeta, S; Suzuki, T, 1996) |
| "A 79-year-old man having advanced gastric cancer with liver metastasis was treated by gastric dissection and gastro-jejunostomy." | ( Hyakuna, Y; Kushibiki, K; Matsuoka, H; Shimada, M; Yokomichi, H, 1996) |
| "There were 60 patients with advanced gastric cancer who were treated with IPHP (long-term study) group, and the survival of this group was compared with the outcome in 52 patients with advanced gastric cancer treated with surgery alone (control group)." | ( Fujimoto, S; Kobayashi, K; Kondoh, K; Mutou, T; Ohkubo, H; Takahashi, M; Toyosawa, T, 1996) |
| "Risks of stomach cancer appeared to be highest among workers employed in jobs with exposure to iron and coal dust, whereas significant increases in colorectal cancer were seen for loading and other dusty jobs and for administrative and sedentary jobs without dust exposure." | ( Blot, WJ; Brown, LM; Dosemeci, M; Fraumeni, JF; Guan, DX; Liu, LM; Pan, GW; Sheng, JH; Stone, BJ; Xiu, Q; Xu, Z, 1996) |
| "The results of chemotherapy against gastric cancer or esophageal squamous cell carcinomas cannot be generalized to adenocarcinomas of the esophagus." | ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| "Fifty-one patients with advanced gastric cancer who received PDC (30 with 5-fluorouracil peroral administration and the other 21 with intravenous administration of 5-fluorouracil and cisplatin) were studied." | ( Kumada, K; Nakamura, T; Nakano, H; Namatame, K; Sakai, H; Suzuki, T; Takahashi, H, 1996) |
| "Neoadjuvant chemotherapy for proximal gastric cancer has shown promise in early clinical trials." | ( Crellin, A; Guillou, PJ; Hassan, S; Macadam, R; Reynolds, JV; Sadek, SA; Somers, SS; Windsor, AC, 1995) |
| "A 60-year-old female patient with gastric cancer and lymph node and liver metastases was treated with a combination of tegafur and uracil (UFT) (375 mg/m2/day) and mitomycin C (MMC) (5 mg/m2 once weekly)." | ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996) |
| "The response rate of advanced gastric cancer to cisplatin monotherapy averages 20% and in colorectal cancer no activity of cisplatin monotherapy has been detected in initial studies." | ( Jelić, S; Popov, I; Radulović, S; Tomasević, Z, 1996) |
| "A case of gastric cancer with liver metastasis who responded well to low-dose PMUE (CDDP, MMC, UFT, etoposide) therapy is reported." | ( Hirono, T; Hirosawa, H; Izumi, R; Kadoya, N; Konishi, I; Ohta, N; Saito, K; Ueda, N; Yoshimitsu, Y, 1996) |
| "Patients with 24 advanced gastric cancers and 36 colonic cancers were randomly divided into a preoperatively administered group and a non-administered group." | ( Arano, Y; Hirano, M; Ishikawa, N; Kikuchi, T; Kitsukawa, H; Kurokawa, M; Murakami, N; Nagao, S; Saito, H, 1996) |
| "Thus, we suggest that the prognosis of gastric cancer may be poor if a multidrug resistance (MDR)-related regimen is used in the presence of p-gp after neoadjuvant chemotherapy with an adriamycin-based regimen, even if the initial response is good." | ( Chung, HC; Gong, SJ; Kim, BS; Kim, JH; Lee, KB; Min, JS; Noh, SH; Roh, JK; Yoo, NC, 1996) |
| "One case of esophageal cancer, 7 of gastric cancer, 2 of colorectal cancer, 1 of carcinomatous peritonitis from unknown origin, and 1 of hepatocellular carcinoma, were treated by daily low-dose cisplatin combined with 5-FU or tegafur, and their ECOG Performance Status Score (PS), number of lymphocytes, and CD3 zeta chain expression of peripheral blood lymphocytes were studied to compare with the effects of treatment." | ( Hada, M; Horigome, M; Iida, B; Koshizuka, K; Mutoh, S; Nakagomi, H; Tada, Y; Takano, K; Watanabe, K; Yamadera, Y, 1997) |
| "Though treatment of recurrent gastric cancer with liver metastasis is often ineffective, this case suggests that a combination therapy of cisplatin and carmofur might be effective." | ( Inomata, Y; Inoue, K; Kuroda, T; Mizutani, H; Sakuyama, T; Tadaoka, N; Takahashi, N; Yamada, T; Yoshinaga, K, 1997) |
| "A 42-year-old female with stage III gastric cancer underwent radical gastrectomy and was given mitomycin-C at 10 mg/m2 intravenously every four weeks as adjuvant therapy." | ( Chen, LT; Chen, YM; Liu, JM; Liu, SM; Whang-Peng, J; Wu, DC; Yang, S, 1997) |
| "A 71-year-old man with Borrmann type 3 gastric cancer and peritonitis carcinomatosa was treated with 5'-DFUR 600 mg/body p." | ( Ando, S; Katanuma, A; Maekubo, H; Mori, M; Tsuji, K, 1997) |
| "We reported two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil (5-FU), cisplatin (CDDP) and cytarabine (Ara-C), 5-FU (300-350 mg/body) was given by continuous intravenous infusion." | ( Hizawa, Y; Itoh, J; Munakata, A; Saitoh, S; Satoh, T; Tamura, Y; Tsushima, K; Yamada, Y, 1997) |
| "In 56 patients with a 3d stage gastric cancer regional intraarterial chemotherapy with 5-fluorouracil was used pre- and postoperatively." | ( Makarkin, NA; Tikhonov, VI; Tuzikov, SA; Zyrianov, BN, 1996) |
| "In addition, the PHREG analysis in 1453 gastric cancer patients showed that MF therapy (mitomycin C i." | ( Nishiyama, M; Toge, T, 1997) |
| "The subjects were 39 patients with gastric cancer and 44 patients with colorectal cancer divided into a group administered 400 mg/day of UFT orally for 2 weeks preoperatively (UFT group) and a group administered 400 mg/day of UFT as well as 40 mg/m2 (i." | ( Fuchino, Y; Ikeda, S; Kimura, H; Mitsuishi, K; Tanaka, S; Tomita, A; Umeno, T, 1997) |
| "In advanced or recurrent gastric cancer, the estimation of either CA 19-9 or CA-50 and CEA serum values may help in checking the prognosis, determining the efficacy of palliative treatment modalities, and recognizing recurrences." | ( Athanassiou, A; Dimitriades, M; Kostopoulou, M; Mylonakis, A; Papadopoulou, M; Pectasides, D; Triantafillis, D; Varthalitis, J, 1997) |
| "Treatment of human gastric cancer TMK-1 cells with transcription and translation inhibitors rapidly triggered cell apoptosis." | ( Chang, TC; Chu, JT; Chu, LL; Hung, MW; Jiang, SY; Tsai, LC, 1997) |
| "Thirteen patients with advanced gastric cancer treated by palliative radiotherapy were retrospectively analyzed." | ( Akiyama, T; Kita, I; Kosaka, T; Nakano, Y; Ooguchi, M; Saito, H; Sejima, T; Sugaya, J; Takashima, S; Tamamura, H; Tomita, F, 1997) |
| "A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery." | ( Oka, M; Ueno, T, 1997) |
| "Eighty gastric cancer patients with peritoneal dissemination were analyzed to evaluate the effect of intraperitoneal chemo- and/or immunotherapy on abdominal ascites." | ( Kajiura, Y; Kondoh, Y; Makuuchi, H; Mitomi, T; Miyaji, M; Nakamura, K; Ogoshi, K; Tajima, T, 1997) |
| "After en bloc resection of gastric cancer without gross or microscopic evidence of residual disease from April 1991 to December 1992, 100 patients were randomized to 6 months of 5-fluorouracil 1,000 mg/m2/day administered as continuous infusion for 5 days, cisplatin 60 mg/m2/day as intravenous infusion for 1 day with or without levamisole (50 mg every eight hours P." | ( Ahn, MJ; Choi, JS; Kim, JC; Kim, SH; Kim, SK; Kim, SW; Kim, WG; Lee, JH; Lee, JS; Lee, KH; Lee, MS; Park, KC; Suh, CW; Zang, DY, 1997) |
| "We reported a case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate (MTX) and 5-fluorouracil (5-FU) sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil." | ( Kamei, M; Kawabata, H; Matsuda, K; Nishioka, M; Sasahara, K; Uchida, Y, 1998) |
| "A 69-year-old male patient with gastric cancer complaining severe jaundice was readmitted for the purpose of chemotherapy." | ( Hoshiko, M; Iwamoto, M; Kawabata, S; Shirouzu, K; Takeda, J; Yasumoto, K, 1998) |
| "We studied 20 gastric cancer patients who had undergone total gastrectomy and immunochemotherapy and 6 normal controls." | ( Bae, JM; Kim, JP; Park, JW; Yang, HK, 1998) |
| "An advanced gastric cancer patient with T3N1M0 successfully underwent a curatively total gastrectomy combined with distal pancreatectomy and lymphnode dissection following ELF-P combined chemotherapy." | ( Kamiyama, H; Kawashima, K; Koike, N; Morishita, Y; Ogawa, T; Ohwada, S; Sato, Y; Takeyoshi, I, 1998) |
| "Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion." | ( Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET, 1998) |
| "Of 125 cases of advanced gastric cancer, 41 cases received intraarterial chemotherapy (A group) and the rest were given systemic infusion (S group)." | ( Akiyama, T; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sugaya, J; Takashima, S; Tomita, F; Ueshige, N, 1998) |
| "Patients with advanced and recurrent gastric cancer were treated with this regimen as early phase II trial and its efficacy and toxicity were assessed." | ( Inada, T; Kikuyama, S; Miyakita, M; Ogata, Y, 1998) |
| "Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks." | ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1998) |
| "The Austrian Working Group for Stomach Cancer, a subgroup of the Austrian Working Group for Surgical Oncology, initiated a multicentric phase III trial to evaluate the safety and efficacy of this treatment regimen." | ( Czeijka, M; Holzberger, P; Jatzko, G; Lisborg, P; Neudorfer, H; Potrc, S; Rabl, H; Repse, S; Rosen, HR; Sandbichler, P; Zacherl, J, 1998) |
| "Adjuvant intraperitoneal therapy of gastric cancer by mitomycin bound to activated carbon particles is associated with an increased rate of postoperative complications." | ( Czeijka, M; Holzberger, P; Jatzko, G; Lisborg, P; Neudorfer, H; Potrc, S; Rabl, H; Repse, S; Rosen, HR; Sandbichler, P; Zacherl, J, 1998) |
| "We report 42 cases of gastric cancer with peritoneal carcinosis treated with intraperitoneal chemohyperthermia." | ( Bienvenu, J; François, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Peyrat, PP; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 1997) |
| "The induction of gastric cancer cell apoptosis may play a role in the anticarcinogenic effect of retinoic acid and folic acid, both of which are potential agents for the treatment of human gastric cancer." | ( Fang, JY; Xiao, SD, 1998) |
| "For these studies, MKN-74 gastric cancer cells and MDA-MB-468 breast cancer cells were exposed to either no drug, 1 microgram/ml MMC alone, 300 nM flavopiridol alone, or a combination of chemotherapy with flavopiridol for 24 h." | ( Farsi, K; Kelsen, DP; Maslak, P; Schwartz, GK; Spriggs, D, 1997) |
| "Twenty-eight patients with advanced gastric cancer were treated with the simultaneous continuous intravenous (i." | ( Baba, H; Emi, Y; Kohnoe, S; Maehara, Y; Sugimachi, K; Takahashi, I, 1998) |
| "32 patients with advanced gastric cancer were treated with oral etoposide (100 mg), leucovorin (3 x 100 mg), and tegafur (3 x 200 mg) over 14-21 days for a maximum of six cycles." | ( Brodowicz, T; Fiebiger, WC; Hejna, MH; Kornek, GV; Miholic, J; Raderer, M; Scheithauer, W; Valencak, JB; Weinlaender, G, 1998) |
| "A 74-year-old Japanese woman with early gastric cancer was successfully treated with uracil and tegafur (UFT)." | ( Akahoshi, K; Chijiiwa, Y; Hamada, S; Hara, K; Matsui, N; Nakamura, K; Nawata, H, 1998) |
| "We observed that gastric cancer cells treated with paclitaxel have shown a cyclin-dependent kinase (CDK)4 down-regulation." | ( Choi, JY; Kang, YK; Kim, CS; Kim, JS; Kim, YH; Lee, KH; Park, JK; Shin, SW; Yoo, YD, 1998) |
| "In week 52, the incidence of gastric cancers was significantly greater in rats fed sodium chloride than in untreated control rats." | ( Baba, M; Iishi, H; Nakaizumi, A; Tatsuta, M; Uehara, H; Yano, H, 1999) |
| "The role of chemotherapy in metastatic gastric cancer (MGC) is predominantly palliative, therefore regimens with mild toxicity and acceptable activity should be preferred." | ( Adamo, V; Altavilla, G; Ferraro, G; Laudani, A; Maisano, R; Pergolizzi, S; Scimone, A; Zanghì, M, 1999) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "A patient with advanced gastric cancer was treated with combined administration of CPT-11 CDDP and 5-FU before operation." | ( Fukuda, S; Kume, S; Nagamoto, N; Okamura, K; Sakaguchi, T; Tanabe, D, 1999) |
| "Thirty-four patients with gastric cancer in stage II and III were enrolled, after curative resection, in a pilot study to assess the feasibility and the impact on relapse of a double modulation of 5-Fluorouracil (5FU) by Methotrexate (MTX) and 1-Leucovorin (LFA) as adjuvant chemotherapy." | ( Auriemma, A; Catalano, G; De Vita, F; Infusino, S; Orditura, M, 1999) |
| "We studied how gastric cancer tissues and cells changed as a result of preoperative chemotherapy." | ( Chen, Z; Li, G; Liu, F, 1997) |
| "In week 52, the incidence of gastric cancers, the labeling index and ODC activity were significantly higher and the apoptotic index was significantly lower in rats given sodium chlolide than in untreated control rats." | ( Baba, M; Iishi, H; Sakai, N; Tatsuta, M; Uedo, N; Yano, H, 1999) |
| "Progress in the detection of early gastric cancer has made endoscopic mucosal resection (EMR) possible for the treatment of gastric cancer instead of only conventional surgical resection." | ( Chino, O; Kise, Y; Makuuchi, H; Shimada, H; Tanaka, H, 1999) |
| "The prognosis for gastric cancer remains dismal; novel agents that target specific molecular pathways are needed as adjuvant therapy." | ( Evers, BM; Hwang, KO; Kim, M; Litvak, DA; Papaconstantinou, HT; Townsend, CM, 1999) |
| "Thirty-two patients with advanced gastric cancer underwent continuous hyperthermic peritoneal perfusion (CHPP) combined with surgery: to prevent peritoneal recurrence in 15 patients without peritoneal metastasis (prophylactic CHPP) and to treat 17 patients with peritoneal metastases (therapeutic CHPP)." | ( Hirose, K; Iida, A; Katayama, K; Kusaka, Y; Nakagawara, G; Umeda, S; Yamaguchi, A, 1999) |
| "In week 52, the incidence of gastric cancers was significantly lover in rats treated with the C-erbB-2 antisense oligonucleotide than in rats treated with the sense oligonucleotide." | ( Baba, M; Hirasawa, R; Iishi, H; Nakaizumi, A; Sakai, N; Tatsuta, M; Uedo, N; Uehara, H; Yano, H, 1999) |
| "A patient with stage IVb advanced gastric cancer, who was Group 4 lymph node metastasis positive, underwent two postoperative courses of low-dose CDDP-tegafur therapy (800 mg/body/day of tegafur + 5 mg/body/5 administrations, 2 days of rest, of cisplatin)." | ( Fujino, R; Hayashi, N; Hirose, Y; Matsumura, M; Nagano, T; Oshita, M; Otsuka, T; Sumitomo, M; Takai, S; Taki, S, 1999) |
| "Nineteen patients with advanced gastric cancer (all were above Stage II) were treated: 10 had undergone total gastrectomy and 9 distal gastrectomy." | ( Fujiwara, Y; Itoh, R; Kusunoki, M; Nakagawa, K; Nakao, K; Yamamura, T, 1999) |
| "We analyzed 26 patients with advanced gastric cancer in whom at least one of the tumor markers CEA, CA19-9 and CA125 was elevated before systemic chemotherapy with regard to the relationship between the change in serum tumor marker level and response assessment by imaging studies throughout the treatment course." | ( Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T, 1999) |
| "For advanced irresectible gastric cancer, sequential high-dose methotrexate and 5-fluorouracil (both on day 1) combined with adriamycin on day 15 (FAMTX regimen), cycled every 28 days, is a fairly effective but toxic treatment, with a high incidence of neutropenic fever, dose reductions and dose delays." | ( Boot, H; Craanen, M; Gerritsen, WR; Swart, M; Taal, BG; Westermann, AM, 2000) |
| "In vitro treatment of human gastric cancer MKN-1 cells with exogenous IL-8 enhanced the expression of epidermal growth factor receptor, type IV collagenase (metalloproteinase-9), vascular endothelial growth factor, and IL-8 mRNA." | ( Fidler, IJ; Haruma, K; Kajiyama, G; Kitadai, Y; Matsutani, N; Mukaida, N; Ohmoto, Y; Sumii, K; Tahara, E; Yamamoto, S; Yasui, W, 2000) |
| "In patients with T3 gastric cancer who were treated with curative gastrectomy, however, FU-based chemotherapy did not affect survival of either patients with TS-positive tumors or with TS-negative tumors." | ( Gomyo, Y; Hirooka, Y; Kaibara, N; Konishi, I; Matsumoto, S; Oka, S; Suzuki, K; Tsujitani, S, 2000) |
| "In patients with stage 4 gastric cancer, however, MFL treatment showed similar effects as UFT on the postsurgical survival of the patients." | ( Kitaoka, A; Ohsumi, K; Tokuka, A; Tokunaga, Y; Yagi, T, 2000) |
| "Two patients with liver metastasis from gastric cancer who responded remarkably to a combined therapy of 5'-DFUR and PSK are reported." | ( Arai, K; Inoue, S; Iwasaki, Y; Kawahara, Y; Kitamura, M; Maeshiro, T; Miyamoto, Y; Ohashi, M; Saiura, A; Takahashi, T; Tanaka, S; Umekita, N, 2000) |
| "We analyzed 15 gastric cancer patients with synchronous liver metastases, and studied the significance of hepatic resection with multimodality therapy." | ( Harada, K; Ikeda, R; Maeda, M; Nasu, J; Takata, N; Yoshinaka, I, 2000) |
| "Because of the low chemosensitivity of gastric cancer to conventionally available agents, several approaches were investigated to design "order made" treatments using chemosensitivity tests, including the histoculture drug response assay (HDRA) which was useful in evaluating the appropriate cancer chemotherapy for the patients with Stage III/IV gastric cancer." | ( Kubota, T, 2000) |
| "We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection." | ( Hattori, T; Hirano, K; Kase, H; Kobayashi, K; Ogawa, M; Teramoto, T; Tokura, N; Washizawa, N, 2000) |
| "Human gastric cancer cell lines AGS and MKN-28 were treated with various concentrations (0." | ( Cho, CH; Chun-Yu Wong, B; Jiang, SH; Jiang, XH; Kung, HF; Lai, KC; Lam, SK; Lin, MC; Wong, BC; Yuen, ST, 2001) |
| "The human gastric cancer cell line, MKN45 was transplanted into nude mice, and the intratumoral administration of bax gene was performed using the bax cDNA plasmid complexed with a cationic lipopolyamine." | ( Kim, R; Minami, K; Nishimoto, N; Toge, T, 2001) |
| "We have experienced a case of advanced gastric cancer with liver metastasis effectively treated by intra-hepatic arterial infusion of 5-fluorouracil (5-FU), mitomycin C (MMC) and peroral administration of 5-FU." | ( Aoyagi, K; Koufuji, K; Murakami, N; Shirouzu, K; Takeda, J; Terasaki, Y; Yamasaki, Y; Yano, S, 2000) |
| "In advanced gastric cancer, we investigated feasibility and activity of sequential chemotherapy with docetaxel after an intensive weekly regimen consisting of cisplatin, epidoxorubicin, fluorouracil, leucovorin (PELF) plus filgrastim." | ( Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R, 2001) |
| "Most solid tumors, including gastric cancers, respond poorly to non-surgical treatments which are expected to induce an apoptosis-dependent involution." | ( Izawa, M; Teramachi, K, 2000) |
| "We report an AFP-producing gastric cancer that showed a partial response to low-dose CPT-11 and low-dose cisplatin combination chemotherapy." | ( Aida, K; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Saito, M; Sanada, Y; Sasaya, S, 2001) |
| "A 77-year-old man who had advanced gastric cancer with multiple liver metastases was treated by combined chemotherapy with 5-fluorouracil and low-dose cisplatin for 1 and half courses (1 course = 4 weeks)." | ( Ikeda, S; Iwamoto, M; Nagata, S; Niiya, F; Shirouzu, K, 2001) |
| "Adjuvant chemotherapy of gastric cancer after curative resection is still subject to discussion." | ( Andreoli, F; Boffi, B; Cini, G; Francesconi, D; Mazzanti, R; Medi, F; Mercatelli, A; Moretti, R; Neri, B; Romano, S; Siliani, L; Tarquini, R, 2001) |
| "A patient with recurrent gastric cancer which infiltrated the pelvic muscle after the treatment of paraaortic lymph node and ovarian metastases was successfully managed by a novel oral anticancer drug, TS-1." | ( Higaki, K; Ikeda, T; Kobayashi, N; Ninomiya, M; Ohno, S; Okamura, S; Onoda, T; Shiozaki, S; Takakura, N, 2001) |
| "We report here a case of advanced gastric cancer with histopathologically confirmed metastases in 15 regional lymph nodes, in which the recurrent tumor was sensitive to combination chemotherapy." | ( Gochi, A; Isozaki, H; Matsuno, T; Naomoto, Y; Shigemitsu, K; Tanaka, N, 2001) |
| "We operated on 3 patients with advanced gastric cancer after successful treatment with novel oral 5-fluorouracil derivatives (TS-1)." | ( Fukuda, S; Inoue, K; Okamura, K; Osako, T; Taneda, T; Tsuruzoe, S, 2001) |
| "Preoperative chemoradiotherapy for gastric cancer can be delivered safely and is well tolerated." | ( Ajani, JA; Feig, BW; Janjan, N; Lowy, AM; Mansfield, PF; Pisters, PW; Rich, TA, 2001) |
| "We report two elderly gastric cancer patients responding to chronomodulation chemotherapy (tegafur + cisplatin + Isovorin) based on circadian rhythms plus a new antitumor drug, S-1." | ( Kobayashi, A; Yamaguchi, M, 2001) |
| "The subjects were 50 advanced gastric cancer patients treated with FP." | ( Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Shinkai, T; Yoshida, S, 2001) |
| "Sixty patients with advanced measurable gastric cancer and performance status 0 to 2, who had received at most one prior chemotherapy regimen, were treated with paclitaxel 210 mg/m2 over three hours following a short-course premedication with dexamethasone, diphenhydramine and ranitidine administered 30 min prior to the delivery of paclitaxel." | ( Boku, N; Hyodo, I; Miyata, Y; Ohtsu, A; Saitoh, H; Shirao, K; Taguchi, T; Yamada, Y, 2001) |
| "Surgical treatment of gastric cancer patients is dismal because advanced tumor is often noted at diagnosis." | ( Chen, JH; Chi, CW; Liu, TY; Wu, CW, 2001) |
| "A 67-year-old male patient with gastric cancer of Borrmann type 2 and liver and intra-abdominal lymph node metastases was treated by combined chemotherapy of TS-1 and CDDP TS-1 (100 mg/day) was administered for 14 days followed by 14 days rest as one course." | ( Hiraiwa, A; Indo, T; Iwase, H; Iyo, T; Kaida, S; Mizuno, T; Nakamura, M; Nakarai, K, 2001) |
| "We report a case of recurrent gastric cancer that responded significantly to the short-term administration of TS-1." | ( Fukuda, H; Sugihara, Z; Tasaka, K; Tomofuzi, Y, 2001) |
| "In the gastric cancer cell line, the percentage of apoptotic cells (apoptotic index: AI) did not change after 48 h incubation with low-dose CDDP (1 microg/ml), whereas the AI explosively increased between 12 and 24 h treatment with high-dose CDDP (10 microg/ml)." | ( Ikeguchi, M; Kaibara, N, 2001) |
| "Although the prognosis of gastric cancer with a high level of lymph node metastasis is poor, TS-1 therapy may have a potent efficacy in gastric cancer patients with a high level of lymph node metastasis such as the current case." | ( Hongo, S; Kusumoto, Y; Nakagawa, M; Sado, S; Tamaki, H; Watanabe, A; Yamada, T; Yoriki, R, 2001) |
| "Four gastric cancer cell lines with different p53 status, AGS and MKN-45 (wild type p53); MKN-28 and SGC-7901 (mutant p53) were observed as to cell growth inhibition and induction of apoptosis in response to triptolide treatment." | ( Jiang, SH; Jiang, XH; Kung, HF; Lam, SK; Lin, MC; Wong, BC; Yang, D; Zhu, GH, 2001) |
| "M17, a subclone of human gastric cancer cell line MGC-803, was treated in vitro with ATP(0." | ( Cai, X; Hao, C; Lü, G, 1999) |
| "A case of AFP producing early gastric cancer successfully treated with a small dose of CDDP and 5-FU therapy administered intermittedly is reported with a review of the literature." | ( Aoki, T; Fujimitsu, Y; Koyanagi, Y; Moritani, M; Niido, T; Shinohara, M; Tsuchida, A, 2001) |
| "We have experienced a case of advanced gastric cancer with para-aortic lymph node metastasis effectively treated by neoadjuvant continuous low dosage 5-fluorouracil and cisplatin (FP regimen)." | ( Aoyagi, K; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Takeda, J; Yano, S, 2001) |
| "Human gastric cancer SGC-7901 cells were regularly incubated in the presence of VES at 5, 10 and 20mg x L(-1) (VES was dissolved in absolute ethanol and diluted in RPMI 1640 complete condition media correspondingly to a final concentration of VES and 1 mL x L(-1) ethanol), succinic acid and ethanol equivalents as vehicle (VEH) control and condition media only as untreated (UT) control." | ( Guo, J; Li, Y; Liu, BH; Liu, F; Wu, K; Yu, WP; Zhao, Y, 2002) |
| "The prognosis of scirrhous gastric cancer remains poor when it is treated with surgical resection alone or chemotherapy alone." | ( Boku, N; Inoue, K; Kinoshita, T; Konishi, M; Nakagouri, T; Ohtsu, A; Ono, M; Sugitou, M; Takahashi, S; Yoshida, S, 2001) |
| "A patient with advanced gastric cancer complicated with liver and lymph node metastases was successfully treated with a novel oral anticancer drug, TS-1, TS-1 was administered at a dose of 100 mg/day." | ( Funakoshi, A; Iguchi, H; Matsuo, S; Miyagi, Y; Ouchi, J; Sumii, T; Uchimura, K; Yokota, M, 2002) |
| "Thus, gastric cancer was treated by chemotherapy and esophageal cancer by concurrent chemoradiotherapy with chemotherapy used for gastric cancer." | ( Hiraiwa, A; Indo, T; Iwase, H; Iyo, T; Kaida, S; Mizuno, T; Nakamura, M; Nakarai, K, 2002) |
| "Fifteen patients with advanced gastric cancer undergoing palliative chemotherapy with etoposide, leucovorin and 5-fluorouracil (ELF) received for 10 days (beginning 3 days before chemotherapy) daily i." | ( Clemm, C; Draczynski, T; Linde, K; Melchart, D; Saller, R; Wagner, H; Weber, B; Weidenhammer, W; Worku, F, 2002) |
| "Glycyrrhiza can induce human gastric cancer cell line MGC-803 to apoptosis by p53-independent pathway and can be used as a potential, natural apoptosis-inducing agent for gastric cancer therapy." | ( Liang, D; Ma, J; Peng, W, 2000) |
| "Most patients diagnosed with gastric cancer in the United States and the Western World will either present with advanced disease or have recurrence after surgery, requiring discussions of chemotherapy." | ( Fuchs, CS; Meyerhardt, JA, 2002) |
| "Twenty-five gastric cancer patients were administered UFT at 370 mg/m(2)/day for 21 days and cisplatin at 15 mg/m(2)/day for 2 days." | ( Ishii, R; Koda, K; Miyazaki, M; Oda, K; Ooshima, H; Suzuki, H; Takiguchi, N, 2002) |
| "Treatment failure of surgically treated gastric cancer is attributed to the spread of gastric cancer cells into the abdominal cavity and lymphatic or hematogenic canals." | ( Fan, Y; Hagiwara, A; Huang, Y; Ma, D; Qi, X; Su, G; Wang, W, 2002) |
| "We treated 60 patients with advanced gastric cancer with 120 mg/m2 etoposide, 300 mg/m2 folinic acid, and 500 mg/m2 5-FU, on d 1-3." | ( Rudi, J; Schulze-Bergkamen, H; Stremmel, W; Teufel, A; Zuna, I, 2002) |
| "We report three patients with recurrent gastric cancer responding to TS-1 therapy after combination chemotherapy with 5-fluorouracil, mitomycin C and cisplatin." | ( Hayashi, K; Iijima, S; Koyama, Y; Miyazawa, K; Morikawa, A; Murakami, M; Okabe, R; Ozaki, K; Sugiyama, A; Suzuki, A, 2002) |
| "Standard chemotherapy for advanced gastric cancer remains undefined." | ( Haller, DG; Misset, JL, 2002) |
| "To increase the options for agents for gastric cancer chemotherapy, we performed a phase II clinical trial on the use of a 3-h infusion of paclitaxel to confirm its efficacy and the feasibility of its use in patients with advanced gastric cancer." | ( Horikoshi, N; Kanamaru, R; Kasai, Y; Koizumi, W; Otani, T; Saitoh, S; Sakata, Y; Tada, M; Taguchi, T; Takiuchi, H; Yamaguchi, K, 2002) |
| "We encountered a patient with advanced gastric cancer, with Virchow's lymph node metastasis, who subsequently underwent curative resection after neoadjuvant chemotherapy with the newly developed oral anticancer drug, TS-1." | ( Iwazawa, T; Kanoh, T; Kinuta, M; Matsui, S; Monden, T; Nakano, Y; Okada, K; Okamoto, S; Tamagaki, S; Tono, T; Yano, H; Yasue, A, 2002) |
| "Advanced gastric cancer cannot be treated with surgery or conventional cancer therapy, which has prompted a search for new therapeutic modalities." | ( Cho, YK; Choi, J; Joo, CH; Kim, J; Kim, JH; Kim, YK; Lee, B; Lee, H, 2002) |
| "Previously untreated advanced gastric cancer patients with normal renal function were randomly assigned into either group I (heptaplatin 400 mg/m(2) i." | ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "The most effective treatment for gastric cancer is complete surgical resection with lymphadenectomy." | ( Andou, K; Fujisaki, S; Fukuzawa, M; Nezu, T; Shibata, M; Tomita, R, 2002) |
| "We report three gastric cancer patients responding to chronomodulation chemotherapy (tegafur + cisplatin + Isovorin) based on circadian rhythms plus a new antitumor drug, CPT-11." | ( Hirose, T; Kobayashi, A; Yamada, T, 2002) |
| "We report 2 patients with advanced gastric cancer treated with a new combination chemotherapy of low-dose FP and daily oral administration of low-dose etoposide." | ( Araki, H; Kato, T; Miwa, Y; Moriwaki, H; Nagaki, M; Naito, T; Uematsu, T; Yasuda, I, 2002) |
| "The results of treatment of gastric cancer with docetaxel have scarcely been reported." | ( Ideguchi, K; Ikeda, Y; Mori, T; Nakagawa, K; Okamoto, K; Sakata, K; Yasumitsu, T, 2002) |
| "We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy." | ( Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y, 2002) |
| "Reg treatment of MKN45 gastric cancer cells resulted in tyrosyl-phoshorylation of several cellular proteins and subsequent activation of classical MAPK, ERK1/2." | ( Adachi, K; Chiba, T; Ishihara, S; Kadowaki, Y; Kazumori, H; Kinoshita, Y; Miyaoka, Y; Okamoto, H; Rumi, MA; Sato, H; Takasawa, S, 2002) |
| "Five patients with inoperable advanced gastric cancer were treated with combination chemotherapy of TS-1 and cisplatin (CDDP)." | ( Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Nakaguchi, K; Nakamura, M; Sue, F; Tanaka, J; Yokouchi, H; Yoshihara, W, 2002) |
| "Human gastric cancer SGC-7901 cells were treated with VES at 5, 10, 20 mg x L(-1), succinic acid and vitamin E as vehicle control and condition media only as untreated (UT) control." | ( Li, Y; Shan, YJ; Wu, K; Xia, W; Yu, WP; Zhao, L; Zhao, Y, 2002) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| "A case of AFP-producing gastric cancer successfully treated with CPT-11 and cisplatin combined therapy is reported together with a review of the literature." | ( Asami, T; Imada, T; Kokawa, A; Morimoto, M; Saito, T; Shirato, K; Sugimori, K; Tanaka, K; Tomita, N, 2002) |
| "This is a rare case of gastric cancer showing complete response to chemotherapy using a peroral carcinosatatic alone." | ( Endo, I; Iijima, K; Ikeya, S; Imai, J; Kamiya, T; Kashimura, J; Kuroki, M; Ojima, T; Saito, Y; Sato, K; Takahashi, M, 2002) |
| "In the treatment of gastric cancer R0 surgical resection is the only hope for cure." | ( Cseke, L; Horváth, OP; Kalmár, K; Káposztás, Z, 2002) |
| "In the field of gastric cancer treatment, especially for patients showing multiple resistance to anticancer drugs, an effective therapy is critically needed." | ( Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Ushio, J; Yamamoto, W, 2002) |
| "pylori therapy in family members of gastric cancer patients." | ( Bueno, ML; Castro, LP; Coelho, LG; Lopes, LG; Martins, GM; Miranda, CH; Passos, MC; Sanches, BS, 2003) |
| "When gastric cancer cells were transfected with various concentrations of Prx II antisense plasmid, pPrxII/AS, and then treated with the same concentrations of cisplatin, Prx II antisense enhanced cisplatin-induced cell death." | ( Ahn, CM; Chung, YM; Kim, HJ; Kim, SK; Park, JK; Yo, YD, 2002) |
| "Twenty-four patients with gastric cancers who underwent the intraoperative systemic chemotherapy were taken as controls." | ( Chen, D; Lai, Y; Peng, B; Xiao, Q; Zhang, S, 2001) |
| "We treated a case of advanced gastric cancer with paclitaxel and TS-1." | ( Kokai, H; Nikkuni, K; Saito, M; Tsukahara, A, 2003) |
| "Case 1: A 52-year-old male patient with gastric cancer and multiple liver metastases was treated by weekly infusion of paclitaxel as a 2nd line chemotherapy." | ( Chida, N; Imai, G; Ishibashi, J; Iwabuchi, M; Matsuda, Y; Mochida, A; Shiina, M; Suzuki, S; Suzuki, T; Tadokoro, K; Takahashi, H; Yamada, K; Yokoyama, H, 2003) |
| "Five relapsed gastric cancer patients were treated every 2 weeks with a starting dose of CPT-11 (30 mg/m(2)) and a fixed dose of cisplatin (30 mg/m(2))." | ( Aoki, F; Kaminishi, M; Mafune, K; Shimizu, N; Shimoyama, S; Tatsutomi, Y, 2003) |
| "Understanding mechanisms of gastric cancer angiogenesis provides a basis for a rational approach to the development of an anti-angiogenic therapy in patients with gastric cancer." | ( Crivellato, E; Marzullo, A; Nico, B; Ria, R; Ribatti, D; Vacca, A, 2003) |
| "Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens." | ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003) |
| "For development of gastric cancer, any one of the three active-treated groups did not reach statistically significant reduction." | ( Hu, Y; Jin, G; Li, R; Mason, J; Qian, Z; Russell, R; Shi, Y; Sohg, H; Wahg, M; Wu, G; Xia, D; Xiao, S; Xie, Y; Zhang, L; Zhou, Y; Zhu, S, 2003) |
| "Patients with advanced or recurrent gastric cancer were given oral capecitabine 828 mg/m(2) twice daily for 3 weeks, followed by 1 week of no treatment." | ( Koizumi, W; Saigenji, K; Sakata, Y; Taguchi, T; Terashima, M; Ujiie, S, 2003) |
| "We report a case of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1." | ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Tamura, M; Tsuge, T; Watabe, S, 2003) |
| "We treated 12 patients with advanced gastric cancer with 80 mg/m2 of S-1 for 21 days and 60 mg/m2 of cisplatin (CDDP) on day 8 every 5 weeks." | ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2003) |
| "Proliferation of gastric cancer cell lines treated with octreotide or aspirin was determined by (3)H-thymidine incorporation." | ( Tang, C; Tang, L; Wang, C, 2003) |
| "We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration." | ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| "In untreated metastatic gastric cancer, median survival is 3-4 months." | ( Van Cutsem, E; Wilke, HJ, 2003) |
| "21 patients with metastatic gastric cancer, who progressed while on or within 6 months after discontinuing palliative first-line chemotherapy, participated in this study." | ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, KE; Schüll, B, 2003) |
| "Ten cases of advanced and metastatic gastric cancer treated by weekly administration of paclitaxel were studied." | ( Dousei, T; Emoto, T; Fujii, M; Fujikawa, M; Komaki, T; Naka, Y; Nezu, R; Yoshikawa, K; Yoshioka, Y, 2003) |
| "We treated a patient with gastric cancer considered to be unresectable due to peritoneal metastasis, who responded remarkably to treatment with TS-1." | ( Adachi, I; Emoto, T; Fujii, M; Fujikawa, M; Kamei, A; Komaki, T; Naka, Y; Nezu, R; Yokota, T; Yoshikawa, K; Yoshioka, Y, 2003) |
| "Effective chemotherapy for advanced gastric cancer is yet to be established." | ( Fujiwara, Y; Hasegawa, S; Miyoshi, Y; Monden, M; Noguchi, S; Takiguchi, S; Urano, N; Yano, M; Yasuda, T, 2003) |
| "Patients with gastric cancer staged IB to IV(M0) were treated with chemoradiotherapy after curative resection with extensive (D2) lymph node dissection." | ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, DY; Kim, K; Kim, S; Kim, WS; Kim, YI; Lee, KW; Lee, MH; Lim, DH; Noh, JH; Park, CH; Park, CK; Park, JO; Park, K; Park, SH; Sohn, TS, 2003) |
| "Whether this adjuvant therapy in gastric cancer patients that have undergone a D2 lymph node dissection impacts on survival or reduces the incidence of relapses remains to be studied." | ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, DY; Kim, K; Kim, S; Kim, WS; Kim, YI; Lee, KW; Lee, MH; Lim, DH; Noh, JH; Park, CH; Park, CK; Park, JO; Park, K; Park, SH; Sohn, TS, 2003) |
| "Patients with histologically confirmed gastric cancer were treated with the regimen." | ( Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T, 2003) |
| "The incidence of gastric cancer (GC) increases significantly after the fifth decade and palliative chemotherapy is the ultimate treatment in the majority of patients." | ( Beretta, GD; Cascinu, S; Catalano, V; Graziano, F; Labianca, R; Lai, V; Mosconi, S; Santini, D; Testa, E; Tonini, G, 2003) |
| "A 62-year-old advanced gastric cancer patient with bulky N2 lymph node metastases was treated by neoadjuvant chemotherapy with TS-1 and CDDP." | ( Kameyama, H; Nashimoto, A; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H, 2003) |
| "Treatment of gastric cancer cells MGC80-3 with TPA not only up-regulated expression of PLC-gamma2 protein, but also induced PLC-gamma2 translocation from the cytoplasm to the nucleus." | ( Chen, MC; Lin, XF; Liu, S; Wu, Q; Ye, XF; Zhang, B, 2003) |
| "We report a 77-year-old patient with gastric cancer who has survived 5 years after multidisciplinary treatment for both liver and brain recurrences." | ( Arai, K; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Takahashi, K; Yamaguchi, T, 2003) |
| "Twenty-four gastric cancer (GC) patients entered this study and were examined twice, once before and then following a 14-day treatment with Vioxx at a dose of 25 mg twice daily." | ( Bielanski, W; Hahn, EG; Hartwich, A; Kania, J; Konturek, PC; Konturek, SJ; Rehfeld, JF; Zuchowicz, M, 2003) |
| "We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP." | ( Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Motoyama, H; Tasaki, A, 2003) |
| "Forty-eight patients with advanced gastric cancer were divided into treatment group (L-OHP+LV+5-FU+VP-16) and control group(DDP+LV+5-FU+VP-16) using non-randomized method." | ( Jiang, Q; Ju, AP; Xu, GH; Zhang, WM; Zheng, YT, 2003) |
| "Nineteen patients with advanced gastric cancer who underwent staging laparoscopy and intraperitoneal chemotherapy before surgical resection or systemic chemotherapy between June 1999 and September 2001 were enrolled in this study." | ( Azama, T; Fujiwara, Y; Ishii, T; Monden, M; Mori, T; Sugita, Y; Takiguchi, S; Taniguchi, K; Yamazaki, K; Yano, M; Yasuda, T, 2004) |
| "Among the 18 new cases of gastric cancers that developed, no overall reduction was observed in participants who received H pylori eradication treatment (n = 7) compared with those who did not (n = 11) (P =." | ( Chen, JS; Ching, CK; Feng, RE; Fong, DY; Ho, J; Hu, WH; Lai, KC; Lam, SK; Leung, SY; Wong, BC; Wong, WM; Yuen, ST; Zheng, TT, 2004) |
| "We found that the incidence of gastric cancer development at the population level was similar between participants receiving H pylori eradication treatment and those receiving placebo during a period of 7." | ( Chen, JS; Ching, CK; Feng, RE; Fong, DY; Ho, J; Hu, WH; Lai, KC; Lam, SK; Leung, SY; Wong, BC; Wong, WM; Yuen, ST; Zheng, TT, 2004) |
| "In patients with early gastric cancer serum lipid levels should be checked before operation, and the use of minimal local treatments must be considered carefully in male patients with hyperlipidaemia." | ( Fujii, S; Hatano, K; Kaisaki, S; Kitayama, J; Nagawa, H; Suzuki, H, 2004) |
| "We demonstrated here that AFP-producing gastric cancer (AFP-gastric cancer) could be treated by a combination therapy with a low dose of Mitomycin-C (MMC) and lymphokineactivated killer T (LAK-T) cells." | ( Asai, K; Joh, T; Kataoka, H; Miura, Y; Nakanishi, M; Okada, H; Okada, N; Tada, T, 2004) |
| "A second-line chemotherapy for advanced gastric cancer has not been established." | ( Akiba, Y; Hibi, T; Hosoe, N; Ishii, H; Izumiya, M; Mori, S; Nagata, H; Suzuki, J; Takaishi, H; Ueda, T; Yamagishi, Y, 2004) |
| "Human gastric cancer cell lines (SGC-7901) were treated with vitamin E succinate (VES) at 5, 10, 20 mg/L." | ( Li, GC; Wu, K; Yu, WP; Zhao, Y, 2004) |
| "We report a case of advanced gastric cancer with metastasis to the paraaortic lymph nodes that showed a remarkable response to treatment with a combination of weekly paclitaxel and doxifluridine (5'-DFUR)." | ( Hata, T; Hikino, H; Kanazawa, A; Nagaoka, S; Nakamura, K; Ozaki, N; Sugimoto, S; Tokuka, A; Yamada, T, 2004) |
| "administration in peritoneal gastric cancer (MKN45) xenografts." | ( Inoue, K; Kato, Y; Machida, Y; Michiura, T; Nakai, K; Nakane, Y; Onishi, H; Sato, M; Yamamichi, K, 2004) |
| "We report 3 gastric cancer patients with peritoneal dissemination who failed to take TS-1 due to adverse effects and who were successfully treated with weekly paclitaxel administered intravenously." | ( Hata, T; Hikino, H; Kanazawa, A; Nakamura, K; Ozaki, N; Sugimoto, S; Tokuka, A; Yamada, T, 2004) |
| "We report 2 patients with recurrent gastric cancer treated by combined chemotherapy of TS-1 and low-dose cis-platinum (TS-1/LCDDP)." | ( Baba, M; Hiramatsu, Y; Kamiya, K; Kondo, K; Konno, H; Nakamura, S; Ohta, M; Tanaka, T; Terada, H, 2004) |
| "The potential place of docetaxel in gastric cancer is not restricted to metastatic disease and the same three-therapy with TCF is currently under evaluation as a neoadjuvant or adjuvant treatment in resectable lesions." | ( Boige, V; Ducreux, M; Roth, A, 2004) |
| "Thirty-six patients with advanced gastric cancer underwent (99m)Tc-MIBI scintigraphy before chemotherapy." | ( Iwata, S; Kanai, M; Kawata, K; Sasada, T; Takabayashi, A; Yamamoto, N, 2004) |
| "Untreated metastatic gastric cancer is associated with a median survival of only 3-4 months, but this can be increased to 8-10 months, associated with improved quality of life, with combination chemotherapy." | ( Cunningham, D; Dickson, JL, 2004) |
| "Scirrhous gastric cancer is resistant to chemotherapy in comparison to other types of gastric cancers, and cancer cell-stromal fibroblast interactions play an important role in progression of scirrhous gastric cancer." | ( Matsuda, S; Nakajima, K; Okita, Y, 2004) |
| "We report a patient with unresectable gastric cancer who was effectively treated with an anticancer drug, S-1, after receiving an improved gastrojejunostomy." | ( Amano, S; Kaneda, H; Kanou, H; Kawasaki, A; Kuboi, Y; Mimatsu, K; Oida, T, 2004) |
| "We report a case of advanced gastric cancer with bulky N2 lymph node metastases resected after successful treatment with novel oral anticancer drug TS-1 as a neoadjuvant chemotherapy (NAC)." | ( Hirata, K; Inoue, D; Kashiwagi, K; Maeda, H; Sasaki, K; Shibuya, H; Takashima, T, 2004) |
| "Sixteen patients with highly-advanced gastric cancer were administered low-dose TS-1 and CDDP as a first-line treatment, followed by either paclitaxel or CPT-11/CDDP as a second-line treatment." | ( Furukawa, H; Ishii, K; Kamata, T; Kanno, M; Senda, K; Tajima, H; Takeda, T; Yoshimoto, K, 2004) |
| "NF-kappaB is activated in human gastric cancer in response to chemotherapy and may result in inducible chemoresistance." | ( Brank, A; Camp, ER; Hochwald, SN; Li, J; MacKay, SL; Minnich, DJ; Moldawer, LL, 2004) |
| "Eighty-two patients with stage II - IV gastric cancer were postoperatively randomized into two groups; 46 patients in treatment group who received IHCP combined with intravenous chemotherapy for three times and 36 patients in control group who received intravenous chemotherapy only for six times." | ( Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004) |
| "Athymic nude mice, with gastric cancer cells (AGS) orthotopically implanted into the gastric wall, treated with nicotine (50 or 200 microg/ml) in their drinking water for 3 months developed larger tumor areas than mice in the control group." | ( Cho, CH; Koo, MW; Liu, ES; Luo, JC; Shin, VY; So, WH; Wu, WK; Ye, YN, 2004) |
| "A 56-year-old gastric cancer patient with multiple lung metastases and dilated cardiomyopathy was treated by chemotherapy with TS-1." | ( Ishiguro, S; Isobe, N; Iwabuchi, H; Kawabe, A; Yamamoto, T; Yamasaki, S, 2004) |
| "In subgroups of gastric cancer patients, chemotherapy treatments carry a high risk of toxicity without any clear evidence of antitumor activity." | ( Cecchin, E; Toffoli, G, 2004) |
| "The various treatments for advanced gastric cancer have limitations and induce only marginal survival benefit." | ( Chung, HC; Gong, SJ; Jin, CJ; Rha, SY, 2004) |
| "Treatment of advanced gastric cancers with peritonitis carcinomatosa is very difficult, because none of the various therapies (operation, chemotherapy, hyperthermia etc." | ( Doi, K; Horiuchi, T; Nakamura, T; Okubo, Y; Shimada, K; Tanabe, S; Tanaka, K; Tanaka, S; Uchinami, M; Yoshida, M, 2004) |
| "The prognosis in T3-T4 or N+ gastric cancer is dismal, and the role of adjuvant therapy remains uncertain." | ( Barone, C; Basso, M; Brunetti, IM; Cassano, A; D'Ugo, D; Longo, R; Persiani, R; Picciocchi, A; Pozzo, C; Schinzari, G, 2004) |
| "Treatment of human stomach cancer KATO III cells with hot-water extracts from adzuki beans led to their growth inhibition as well as apoptosis induction." | ( Fujishiro, K; Furuichi, Y; Hibasami, H; Itoh, T; Itoh, Y; Komiya, T; Mizutani, M, 2004) |
| "About 60% of gastric cancer cells demonstrated apoptosis after a 24-48 hour treatment with both TXL and TXT." | ( Gotoh, M; Hoshino, M; Hoshino, Y; Kanzaki, N; Kashimura, S; Kogure, M; Matsuyama, S; Ogata, T; Ohto, H; Otani, S; Soeta, N; Terashima, M, 2004) |
| "We have experienced a case of gastric cancer with multiple liver metastases resistant to combined treatment of TS-1 and CDDP." | ( Ando, M; Maruyama, M; Nagahama, T, 2004) |
| "We treated a 65-year-old female with gastric cancer who underwent peritoneal dissemination after 6 successive weeks of paclitaxel intraperitoneal therapy (90 mg/body), and obtained a disappearance of ascites and a reduction of the primary carcinoma." | ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Nagahama, T; Oobu, M; Takashima, I, 2004) |
| "administration should be tried in gastric cancer patients with malignant peritoneal effusion." | ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "Palliative surgery in late stage gastric cancer followed by combination chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin is a safe therapeutic modality with promising short-term effectiveness and mild side effects." | ( Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004) |
| "In cases of inoperable advanced gastric cancer, TS-1/CDDP combination chemotherapy showed higher efficacy regardless of the pathological alterations, and higher and sustained improvement of QOL was also observed with the addition of Lentinan to the protocol." | ( Andou, K; Hibi, T; Kurosawa, Y; Nagahashi, S; Nishiwaki, M; Okuda, K; Sugihara, T; Suzuki, H; Terada, S, 2004) |
| "A Case of Advanced Gastric Cancer with Multiple Liver Metastases Successfully Treated with TS-1 and CDDP: Akihiro Tsukahara, Kazuhiro Kaneko and Syuji Tanaka (Dept." | ( Kaneko, K; Tanaka, S; Tsukahara, A, 2004) |
| "He was diagnosed with gastric cancer duodenum invasion, obstructive jaundice and lymphangitis carcinomatosa, and began weekly TXL as second-line chemotherapy on March 26." | ( Hihara, J; Mizuiri, H; Shimizu, K; Suzuki, T; Tanabe, K; Taomoto, J; Wada, Y; Yoshida, K, 2004) |
| "We report two cases of gastric cancer with multiple lung metastases responding well to weekly administration for 3 weeks followed by a week discontinuation of paclitaxel (80 mg/m2)." | ( Abe, Y; Anan, K; Iwashita, T; Mitsuyama, S; Nishihara, K; Suehara, N; Tamae, K, 2004) |
| "A case of recurrent gastric cancer with metastases to the skin and lung was treated successfully with low-dose paclitaxel after oral TS-1 administration." | ( Fujiwara, Y; Iwasaki, H; Kaneko, M; Lee, S; Nishizawa, S; Osugi, H; Takemura, M; Tanaka, Y, 2004) |
| "Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted." | ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004) |
| "In general, treatment for gastric cancer with peritoneal dissemination or recurrent gastric cancer is outside the scope of surgery." | ( Kawasaki, H; Kobori, H; Maruyama, M; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Yamada, K, 2005) |
| "Case 1 of type 3 advanced gastric cancer underwent surgery after one week interval following oral administration of TS-1 at a daily dose of 80 mg/body for 2 weeks." | ( Koizumi, H; Nakamura, K; Nakane, Y; Nakano, K; Okugawa, K; Osaka, Y; Sako, H; Tanabe, S; Tsuchiya, K, 2005) |
| "We report a patient with far-advanced gastric cancer treated by weekly administration of paclitaxel (TXL) over 2 years." | ( Aoki, Y; Fukada, T; Horiguchi, K; Kobayashi, J; Kobayashi, N; Miyazaki, M; Morishima, Y; Nakano, M; Shiramatsu, K; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yokoyama, K, 2005) |
| "Human gastric cancer SGC-7901 cells were divided into three treatment groups,namely sulindac treatment group, MMC treatment group and combined sulindac with MMC treatment group." | ( Ma, L; Xie, YL; Yu, Y; Zhang, QN, 2005) |
| "A total of 156 gastric cancer patients were randomized into 3 groups, and underwent the combined therapy (treatment group 1), intraoperative chemotherapy (treatment group 2), and peritoneal lavage with distilled water (control group), respectively." | ( Bi, JW; Fang, GE; Hua, JD; Nie, MM; Shen, XJ; Wei, G; Xue, XC, 2005) |
| "The proliferation of gastric cancer cells expressing HERG protein was inhibited in a time- and dose-dependent manner when treated with cisapride (P<0." | ( Fan, DM; Hao, ZM; Hong, L; Shao, XD; Wu, KC; Zhang, J, 2005) |
| "TS-1 was administered for recurrent gastric cancer because the duodenal stump was histologically positive and the serum CA19-9 level elevated after temporary regression." | ( Kegoya, Y; Kodoi, A; Nagamine, I; Nakayama, H; Seto, Y; Takashima, I, 2005) |
| "Patients with early gastric cancer may be treated by minimally invasive surgery." | ( Aikou, T; Arigami, T; Ehi, K; Hokita, S; Natsugoe, S; Uenosono, Y, 2005) |
| "Patients with measurable metastatic gastric cancer, progressive after previous chemotherapy that consisted either of a 5-FU-based regimen followed by second-line chemotherapy containing taxanes or a 5-FU and taxane combination were treated with irinotecan and cisplatin." | ( Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB, 2005) |
| "Treatment of AGS gastric cancer cells with SC236 caused a significant elevation of the pro-apoptotic protein Bak, release of cytochrome c to the cytosol, and activation of caspase-3." | ( Fan, XM; Liu, HY; Ma, YH; Wong, BC; Zheng, FS, 2005) |
| "Patients with advanced or recurrent gastric cancer were treated with escalating doses of weekly paclitaxel as a 60 min intravenous (i." | ( Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W, 2005) |
| "Low differential human gastric cancer line BGC-823 were treated with GA at different doses and different times, the inhibitory rates were detected by MTT assay." | ( Gu, HY; Guo, QL; Liu, W; You, QD; Yuan, ST; Zhao, L, 2005) |
| "Human gastric cancer xenografts SC-2, St-40, and SC-4 inoculated into nude rats were treated with TS-1 alone (TS-1 12 mg/kg/day, day 1-14), TXT alone (TXT 2 mg/kg/day, day 1 or day 8), and combination of both drugs." | ( Emi, Y; Fukushima, M; Kakeji, Y; Maehara, Y; Takahashi, I; Uchida, J, 2005) |
| "We report here a case of recurrent gastric cancer that responded to third-line chemotherapy with CPT-11 and CDDP." | ( Hihara, J; Ohta, K; Tanabe, K; Toge, T; Yamaguchi, Y; Yoshida, K, 2005) |
| "All had previously untreated metastatic gastric cancer." | ( Ajani, JA; Baez, L; Becerra, CR; Cohn, A; De Jager, R; Feit, K; Kamida, M; Major, P; Silva, A; Takimoto, C, 2005) |
| "Although many treatments for advanced gastric cancer have been developed, only poor treatment results have generally been obtained." | ( Bae, SH; Chun, SH; Do, YR; Hyun, MS; Kim, KO; Kim, MK; Kwon, KY; Lee, KH; Ryoo, HM; Shin, SJ; Song, HS, 2005) |
| "PC exhibited promising activity against gastric cancer for the previously untreated patients as a first-line treatment with an acceptable toxicity profile." | ( Bae, SH; Chun, SH; Do, YR; Hyun, MS; Kim, KO; Kim, MK; Kwon, KY; Lee, KH; Ryoo, HM; Shin, SJ; Song, HS, 2005) |
| "The role of second-line chemotherapy in gastric cancer is not yet established." | ( Köster, W; Müller, C; Stahl, M; Wilke, H, 2005) |
| "For this gastric cancer, clinical Stage IIIA (cT3N1HOPOMO), neoadjuvant chemotherapy with TS-1/CDDP was planned." | ( Inoue, S; Kawahara, Y; Kitamura, M; Kusano, T; Shioiri, T; Umekita, N; Warabi, M, 2005) |
| "One case with type 4 gastric cancer who had right hydronephrosis and malignant abdominal ascites underwent curative resection after successful treatment with TS-1." | ( Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S, 2005) |
| "We report a patient with gastric cancer successfully treated with TS-1 and low-dose CDDP as neoadjuvant chemotherapy." | ( Ebina, T; Kawasaki, H; Kobori, H; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Tanaka, M; Yamada, K, 2005) |
| "We reported 2 cases with advanced gastric cancer, successfully treated with TS-1 and CDDP." | ( Ando, K; Ishihara, C; Ishiwa, N; Morinaga, S; Noguchi, Y; Ogoshi, T; Shotsu, M; Takeda, A; Yamamoto, Y; Yoshida, S; Yoshikawa, T, 2005) |
| "2 patients with advanced gastric cancer repeatedly received 5-FU/cisplatin combination chemotherapy." | ( Al-Batran, SE; Goekkurt, E; Hossfeld, DK; Stoehlmacher, J; Wolschke, C, 2005) |
| "The subjects were 55 unresectable gastric cancer patients treated with irinotecan (70 mg/m(2), Days 1 and 15) and cisplatin (80 mg/m(2), Day 1)." | ( Ando, M; Boku, N; Hasebe, T; Hyodo, I; Miyata, Y; Nagashima, F; Ochiai, A; Ohtsu, A; Saito, H; Sakata, Y; Yoshida, S, 2005) |
| "We divided gastric cancer and the colorectal cancer patients, who performed chemotherapy, into two groups of cimetidine administrated group and a non-administration group, and reviewed whether cimetidine inhibited an expression of E-selectin on vascular endothelial cells by measuring E-selectin in plasma." | ( Imaeda, Y; Kawase, J; Kobayashi, K; Matsumoto, S; Umemoto, S, 2005) |
| "Our data showed that chemotherapy for gastric cancer should be performed as a means of clinical study." | ( Furukawa, H; Imamura, H; Kishimoto, T; Tatsuta, M; Yamamoto, K, 2005) |
| "In a 67-year-old male with advanced gastric cancer, renal dysfunction occurred during TS-1 administration as its adverse event." | ( Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Oshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K, 2005) |
| "The prognosis of liver metastasis of gastric cancer is generally poor, and there is no comprehensive therapy." | ( Amano, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M, 2005) |
| "Standard chemotherapy for advanced gastric cancer remains undefined." | ( Cai, XC; Chen, Q; Chen, YG; Fan, NF; Guo, ZQ; Lu, X; Ouyang, XN; Wu, XA; Xu, S; Yang, JW; Zhang, YH, 2005) |
| "These results suggest that gastric cancer,in which liver metastasis is considered to be a prognostic factor,can be effectively treated by combination therapy with hepatic arterial infusion therapy, followed by thermochemotherapy for the primary lesion." | ( Aoki, T; Hamaya, M; Kouno, T; Nishida, J; Ogata, T; Sato, S; Seo, K; Tsuchida, A; Yoshida, K, 2005) |
| "We report herein a case with stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy." | ( Jingu, K; Kagaya, A; Ochiai, T; Sasagawa, K, 2005) |
| "After 5-aza-dC treatment of a gastric cancer cell line (AGS) 579 genes were upregulated 16-fold or more, using an oligonucleotide microarray with 39,000 genes." | ( Moriguchi, K; Tatematsu, M; Tsujino, Y; Ushijima, T; Yamashita, S, 2006) |
| "Twenty patients with advanced gastric cancer received preoperative docetaxel-based chemotherapy." | ( Doki, Y; Fujiwara, Y; Kim, SJ; Miyata, H; Miyoshi, Y; Monden, M; Noguchi, S; Takiguchi, S; Urano, N; Yano, M; Yasuda, T, 2006) |
| "Three cases with unresectable advanced gastric cancer with liver metastases were successfully treated by the combination therapy of TS-1 and cisplatin( CDDP)." | ( Goto, H; Ina, K; Inagaki, J; Ito, A; Ito, N; Kataoka, T; Matsui, W; Nagao, S, 2006) |
| "Although her primary gastric cancer was in remission after previous treatment, carcinomatous arthritis was suggested by the osteolytic radiographic findings and refractoriness to nonsteroidal anti-inflammatory drugs, which was then confirmed by synovial fluid cytopathology." | ( Choi, CW; Choi, IK; Choi, SJ; Hong, SJ; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Lee, JH; Park, KH; Rho, YH; Seo, JH; Shin, SW; Song, GG, 2006) |
| "Adjuvant chemotherapy for gastric cancer after potentially curative surgery has been under clinical investigation for more than four decades." | ( Hejna, M; Raderer, M; Schmidinger, M; Wöhrer, S, 2006) |
| "We report a case of gastric cancer with peritoneal recurrence that responded to chemotherapy with paclitaxel and TS-1." | ( Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2006) |
| "We report a 37-year-old patient with gastric cancer who suffered two distinct episodes of generalized tonic-clonic seizures during ongoing chemotherapy with cisplatin and 5-fluorouracil." | ( Aktas, O; Dieste, FJ; Kreitsch, P; Paul, F; Vogel, HP; Zipp, F, 2006) |
| "An 83-year-old male with Stage IV gastric cancer of performance status 1 (PS 1) was treated with fluoropyrimidine (TS-1) since January 2003 in our department." | ( Aita, K; Goto, T; Matsubara, T; Nemoto, H; Sanada, Y; Sasaya, S; Shirahata, A; Yoshizawa, Y, 2006) |
| "MGC-803 human gastric cancer cells were treated with 5-ALA at various concentrations followed by laser irradiation." | ( Ding, LS; Huang, ZH; Jiang, XD; Li, Z; Xu, RX; Yu, JL; Zhou, GJ, 2006) |
| "Sixty gastric cancer patients were divided randomly into three groups (20 each group) before operation: group one:5'-DFUR oral administration at the dose of 800-1200 mg/d for 3 - 5 d, group two: 500 mg 5-FU + 200 mg/d CF by venous drip for 3 - 5 d,group three (control group)." | ( Ding, W; Luo, B; Ma, ZM; Sheng, JM; Teng, LS; Wang, M; Wang, SF; Wu, FS; Zhao, WH, 2006) |
| "Because patients with advanced gastric cancers have less than 50% chance of cure after R0 resection, the need for an adjuvant treatment to eradicate residual microscopic disease is clear." | ( Yu, W, 2006) |
| "Patients with serosa-positive gastric cancer are most likely to benefit from adjuvant intraperitoneal chemotherapy." | ( Yu, W, 2006) |
| "SC236 treatment induced apoptosis in gastric cancer cells and caused activation of p38 and stress-activated protein kinase/jun kinase, but down-regulated Akt/PKB." | ( Chan, AO; Ching, YP; Fan, XM; Gu, Q; He, H; Jiang, XH; Kung, HF; Lin, MC; Wong, BC; Xia, HH; Yuen, MF, 2006) |
| "The current treatment for metastatic gastric cancer (MGC) consists of cisplatin and/or fluorouracil (5-FU) based combination chemotherapy, but cisplatin-based regimens are associated with considerable toxicity." | ( Bae, JM; Choi, IJ; Chun, JH; Kim, CG; Kim, HK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW; Yu, MS, 2006) |
| "A 37-year-old female with gastric cancer underwent a curative operation, followed by adjuvant chemotherapy consisting of 5-FU and epirubicin." | ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "In chemotherapy of gastric cancer, outpatient chemotherapy was not spread in the last decade, because the chemotherapy protocol of gastric cancer was not fit for outpatient chemotherapy." | ( Kandabashi, K; Maeda, Y; Mikoshiba, M; Okamoto, R; Omuro, Y; Sasaki, E; Sasaki, T, 2006) |
| "We administered UFT to patients with gastric cancer preoperatively to prevent cancers from advancing while they await surgery or down staging." | ( Endo, Y; Mitsuya, T; Sanada, Y; Tajiri, T; Uyama, R; Yoshizawa, Y, 2006) |
| "We administered UFT to 24 gastric cancer patients at 360 mg/m(2)/day for longer than 3 weeks as a preoperative chemotherapy." | ( Endo, Y; Mitsuya, T; Sanada, Y; Tajiri, T; Uyama, R; Yoshizawa, Y, 2006) |
| "Seven patients with gastric cancer were treated with IMRT." | ( Chmura, SJ; Farrey, K; Garofalo, MC; Heimann, R; Jani, AB; Milano, MT; Rash, C, 2006) |
| "Several known RTKs are upregulated in gastric cancer being prime targets of a tailored therapy." | ( Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H, 2006) |
| "Standard treatment for highly advanced gastric cancer (AGC) has not been established yet." | ( Fukushima, M; Hasegawa, S; Nagayama, S; Okabe, H; Ozaki, N; Sakai, Y; Satoh, S; Takabayashi, A; Watanabe, G, 2006) |
| "Here, we report a patient with advanced gastric cancer achieving a complete response (CR) after 2 weeks of administration of S-1 as neoadjuvant chemotherapy." | ( Higuchi, K; Kishimoto, H; Mori, S; Tauchi, K, 2006) |
| "Recent advances in the management of gastric cancer, especially in the arena of chemotherapy, are paving the way for optimization of treatment that maximizes effectiveness while minimizing toxicity." | ( Lenz, HJ; Park, DJ, 2006) |
| "The group of 14 patients with advanced gastric cancer received combination chemotherapy with S-1 and cis-diamminedichloroplatinum (CDDP) as a neoadjuvant chemotherapy (NAC)." | ( Fujii, M; Kaiga, T; Kanamori, N; Kobayashi, M; Kochi, M; Takahashi, T; Takayama, T, 2006) |
| "The response of gastric cancer with peritoneal dissemination to systemic chemotherapy may be negatively affected by poor drug delivery due to the blood-peritoneal barrier." | ( Hatori, S; Imada, T; Kunisaki, C; Oshima, T; Yamada, R, 2006) |
| "Therapy for patients with advanced gastric cancer is not satisfactory." | ( Ajani, JA, 2006) |
| "In cases with advanced/recurrent gastric cancer undergoing single therapy with TS-1, we retrospectively discussed the antitumor effects and adverse events and considered the clinical utility of TS-1." | ( Hatori, S; Imada, T; Kunisaki, C; Makino, T; Ohshima, T; Rino, Y; Suda, T; Takanashi, Y; Yamada, R; Yamazaki, Y, 2006) |
| "Here we report a case of gastric cancer with diffuse abdominal wall invasion treated with weekly low-dose paclitaxel therapy." | ( Aiba, T; Furukawa, K; Igarashi, K; Ikeda, H; Iwamoto, Y; Kuwabara, S; Shibuya, H; Shobugawa, K; Takizawa, K; Tsukioka, S; Waguri, N; Yabe, M; Yoneyama, O, 2006) |
| "The failure to treat gastric cancer is often due to the recurrence or dismal metastasis of cancer and the poor response to traditional chemotherapeutic or radiotherapeutic regimens." | ( Wang, B; Wang, N; Wang, YJ, 2006) |
| "We report a case of N 3 gastric cancer successfully treated by TS-1 followed by curative resection." | ( Hara, S; Hashizume, S; Ishikawa, H; Iwasaki, K; Kamohara, R; Kondou, M; Minami, H; Sumida, Y; Tokunaga, T; Yoshida, K, 2006) |
| "A 71-year-old male with gastric cancer was treated for multiple brain metastasis by gamma knife radiosurgery (GKR) in September, 2004." | ( Goto, M; Higashi, T; Mizumatsu, S; Nishimura, T; Sakai, K; Sugatani, H, 2006) |
| "We report a 29-year-old woman with gastric cancer who developed Trousseau's syndrome, a malignancy-related thromboembolism, during chemotherapy." | ( Asada, M; Chiba, T; Fukui, T; Nishio, A; Ohashi, S; Yazumi, S, 2006) |
| "We have experienced three gastric cancer cases successfully treated by the combination therapy of CDDP and TS-1." | ( Hatakeyama, G; Hosoi, Y; Koeda, K; Obuchi, T; Sugimura, Y, 2006) |
| "The patient was diagnosed with type III gastric cancer by gastroendoscopy post-operatively, and TS-1/CDDP therapy was started on the 28th day after surgery." | ( Hagiwara, C; Hirama, K; Matsumoto, R; Ohguro, H; Sakamoto, Y, 2006) |
| "Adjuvant chemotherapy for gastric cancer has been extensively explored in Japan since the 1950s, and a combination of oral fluorinated pyrimidines (o-FP) and mitomycin C (MMC) has been mainly utilized for adjuvant chemotherapy." | ( Kobayashi, M; Kodera, Y; Morita, S; Oba, K; Sakamoto, J; Tsuburaya, A, 2006) |
| "Selective targeting of gastric cancer cells with the activated beta-catenin pathway may be a novel and effective therapy in gastric cancer." | ( Arber, N; Dvory-Sobol, H; Kazanov, D; Liberman, E; Sagiv, E, 2007) |
| "Treatment of localized gastric cancer relies primarily on surgical intervention, although growing evidence suggests that the addition of chemoradiation may improve disease-free intervals and overall survival." | ( Anderson, C; Kim, J; Nijagal, A, 2006) |
| "Postoperative chemoradiotherapy in gastric cancer improves locoregional control and survival." | ( Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Oppedijk, V; Porritt, B; Saunders, MP; Stroom, J; Valdés Olmos, R; Verheij, M, 2007) |
| "In Epstein-Barr virus-associated gastric cancer, Epstein-Barr virus is found in virtually all tumor cells, but rarely in normal epithelial cells, thus implying that Epstein-Barr virus-targeting therapies are likely to be an effective treatment strategy." | ( Ho Kim, W; Ji Jung, E; Lan Lee, B; Mie Lee, Y; Soo Chang, M, 2007) |
| "Human gastric cancer cells were treated with 75 microm hydrogen peroxide, which alleviated many of the malignant characteristics." | ( Guo, DA; Li, G; Sun, YX; Wang, ZR; Zheng, QS, 2006) |
| "We report herein a case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP/Lentinan combination chemotherapy." | ( Fujisaki, M; Hirahata, S; Irino, T; Maeda, D; Ohyama, T; Takahashi, T; Tokura, H, 2006) |
| "The prognosis for inoperable gastric cancer is not promising and there is no established treatment guideline, however, there are cases in which TS-1+CDDP therapy has made surgery possible, and with the anticipation of extended survival, can be considered a useful therapy method." | ( Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y, 2006) |
| "A 38-year-old female patient with gastric cancer, of which histological type was a poorly differenciated adenocarcinoma and a clinical finding was T3N1MO (Stage IIIA), underwent total gastrectomy with D2 lymphadenectomy as the surgical treatment." | ( Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K, 2006) |
| "Diagnosis and treatment of gastric cancer has now been established, and prevention is thought to be of importance to overcome this disease." | ( Kaminishi, M; Nomura, S; Nozaki, K; Shimizu, N; Tatematsu, M; Tsukamoto, T; Yamaguchi, H; Yoshikawa, A, 2007) |
| "A 72-year-old male with advanced gastric cancer (cT3N2M0H0P0CY1, cStage IV) was treated with TS-1/CDDP as neoadjuvant chemotherapy." | ( Hiraoka, K; Mizutani, S; Nakahara, M; Oyama, T; Takahashi, H; Tori, M; Tsujimoto, M; Uchikoshi, F; Ueshima, S; Yamagami, Y; Yoshidome, K, 2007) |
| "For in vitro studies, human gastric cancer cell lines were used to determine S6K1, 4E-BP-1 and HIF-1alpha activation and cancer cell motility upon rapamycin treatment." | ( Bataille, F; Bolder, U; Ellis, LM; Gaumann, A; Geissler, EK; Hofstaedter, F; Klein, D; Koehl, GE; Lang, SA; Schlitt, HJ; Seidel, U; Stoeltzing, O, 2007) |
| "Human gastric cancer BGC-823 cells were treated with various concentrations of ATRA and the cell growth was then determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide viability assay." | ( Chen, XY; Li, JS; Zhang, JP, 2007) |
| "In this study, both gastric cancer and normal epithelial cells were treated with capsaicin and examined for apoptosis by Annexin V binding." | ( Chai, J; Chow, J; Norng, M; Zhang, J, 2007) |
| "No re-growth of gastric cancer has been seen for three years with chemotherapy of TS-1." | ( Ichinari, H; Kawano, F; Matsuda, S; Mine, K; Taneda, Y; Yonei, A, 2007) |
| "Among the patients with T3/T4 gastric cancer, postoperative oral fluorouracil treatment was effective in those who were pAkt-positive." | ( Ikeguchi, M; Katano, K; Murakami, D; Osaki, T; Saito, H; Tatebe, S; Tsujitani, S, 2007) |
| "Patients with metastatic/recurrent gastric cancer treated with sequential outpatient chemotherapy were analyzed retrospectively." | ( Fukushima, M; Hasegawa, S; Kawashima, K; Matsumoto, S; Nagayama, S; Nomura, A; Okabe, H; Sakai, Y; Satoh, S; Watanabe, G; Yoshibayashi, H, 2007) |
| "Hence, gastric cancer harbors attractive molecular targets for therapy with Hsp90 inhibitors, which could lead to improved efficacy of antineoplastic therapy regimens." | ( Bolder, U; Dahlke, MH; Dietmaier, W; Gaumann, A; Geissler, EK; Glockzin, G; Klein, D; Lang, SA; Moser, C; Schlitt, HJ; Stoeltzing, O, 2007) |
| "Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months." | ( López-Brea, MF; Rivera, F; Vega-Villegas, ME, 2007) |
| "With poor cure rates in gastric cancer using surgery alone, the safety, efficacy and feasibility of preoperative and postoperative chemotherapy was investigated." | ( Archer, S; Boyer, M; Cullingford, G; Davidson, A; Della-Fiorentina, S; Dhillon, H; Findlay, M; Gebski, V; Goldstein, D; Hargreaves, C; Johnston, P; Richardson, G; Storey, D; Trotter, J; Truskett, P; Yuen, J, 2007) |
| "50 patients diagnosed as advanced gastric cancer were administered continuous infusion of 5-FU (300 mg/m(2)/day, x 14 days) and intermittent infusion of CDDP (3 mg/m(2)/day, day 1-5 and 8-12) before surgery." | ( Koda, K; Miyazaki, M; Oda, K; Seike, K; Takano, S; Takiguchi, N, 2007) |
| "A 37-year-old female with advanced gastric cancer and liver metastases was treated with S-1." | ( Koizumi, W; Munakata, M; Sakata, Y; Shitara, K, 2007) |
| "From January 1998 to January 2003, 400 gastric cancer patients at high risk for recurrence including patients with serosal invasion (stage pT3 N0) and/or lymph node metastasis (stage pT2 or pT3 N1, N2, or N3), were enrolled in a trial of adjuvant chemotherapies; 201 patients were randomly assigned to receive the PELFw regimen, consisting of eight weekly administrations of cisplatin (40 mg/m2), LV (250 mg/m2), epidoxorubicin (35 mg/m2), 5-FU (500 mg/m2), and glutathione (1." | ( Aitini, E; Ardizzoia, A; Arnoldi, E; Barni, S; Barone, C; Beretta, GD; Bertetto, O; Carnaghi, C; Cascinu, S; Cassano, A; Catalano, V; Chiara, S; Cortesi, E; Floriani, I; Foa, P; Frontini, L; Gasparini, G; Giordani, P; Labianca, R; Mansutti, M; Mosconi, S; Nardi, M; Piazza, E; Pozzo, C; Pucci, F; Rabbi, C; Ravaioli, A; Rimassa, L; Rota, S; Santoro, A; Silva, RR; Sobrero, A; Torri, V, 2007) |
| "EGCG inhibits the growth of gastric cancer by reducing VEGF production and angiogenesis, and is a promising candidate for anti-angiogenic treatment of gastric cancer." | ( Cai, SR; He, YL; Li, ZR; Ma, JP; Peng, JS; Wang, Z; Zhan, WH; Zhang, CH; Zhu, BH, 2007) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "Human gastric cancer lines SGC-7901, MKN-45, MKN-74 were treated with OM in the absence and presence of NM-3." | ( Chen, JL; Da, W; Song, MQ; Wang, L; Zhang, WP; Zhu, JS; Zhu, L, 2007) |
| "We report 3 gastric cancer patients with peritoneal dissemination who were successfully treated with weekly paclitaxel and cisplatin." | ( Horiba, K; Ishikawa, N; Kanazawa, Y; Katsuta, M; Koizumi, M; Kudoh, H; Ohkawa, K; Seya, T; Shinji, S; Shirakawa, T; Tajiri, T; Tanaka, N; Yamada, T; Yamashita, K; Yokoi, K; Yoshioka, M, 2007) |
| "In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone." | ( Cartenì, G; Catalano, G; Ciardiello, F; Colucci, G; De Vita, F; Di Martino, N; Galizia, G; Gebbia, V; Giuliani, F; Maiello, E; Manzione, L; Montemurro, F; Orditura, M; Romito, S, 2007) |
| "A 43 year-old man with advanced gastric cancer was enrolled in a phase II trial where he was treated with pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2 every 3 weeks." | ( Amoroso, V; Ferrari, VD; Grisanti, S; Marini, G; Pittiani, F; Simoncini, E; Valcamonico, F, 2007) |
| "We report a case with gastric cancer and lung metastasis,who responded remarkably to combination chemotherapy using S-1 and weekly CDDP." | ( Akamatsu, M; Karimata, H; Nagahama, M; Nishimaki, T; Takaesu, H; Teruya, J, 2007) |
| "A total of 145 patients with advanced gastric cancer where randomly assigned to weekly FU 3,000 mg/m2/24 hours (HD-FU), FU 2,600 mg/m2/24 hours plus dl-FA 500 mg/m2 or l-FA 250 mg/m2 (HD-FU/FA), or FU 2000 mg/m2/24 hours plus FA plus biweekly Cis 50 mg/m2, each administered for 6 weeks with a 1-week rest." | ( Balleisen, L; Bethe, U; Debois, M; Hegewisch-Becker, S; Jansen, RL; Jeziorski, K; Joossens, E; Lutz, MP; Praet, M; Van Cutsem, E; Vanhoefer, U; Wagener, DJ; Wilke, H; Wils, J, 2007) |
| "In advanced gastric cancer few data are available on the efficacy or safety of new drug combination regimens after progression following first-line chemotherapy." | ( Astone, A; Barone, C; Basso, M; Cassano, A; D'Argento, E; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007) |
| "Advanced gastric cancer patients scheduled to receive S-1 monotherapy (80 mg/day for days 1-28, every 6 weeks) were registered throughout Japan between 1999 and 2000 (n = 3758)." | ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007) |
| "We treated hepatic metastasis of gastric cancer with CPT-11 therapy and obtained complete remission of the hepatic tumor that has been maintained for than 2 years postoperatively." | ( Kohno, H; Ogawa, A; Okajima, A; Taguchi, T; Takenouchi, Y; Tsugane, K, 2007) |
| "We report a case of recurrent gastric cancer with peritoneal dissemination and paraaortic lymph node metastases, successfully treated with weekly administration of paclitaxel." | ( Hirata, K; Ito, T; Sato, T; Takashima, T, 2007) |
| "We report a case of gastric cancer with ascites treated with chemotherapy." | ( Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H, 2007) |
| "We report a case of unresectable gastric cancer, who had been treated with S-1 alone for 3 years without cancerous symptoms." | ( Aoki, Y; Kobayashi, J; Kuroiwa, N; Miyazaki, M; Mori, M; Morishima, Y; Nakano, M; Satomi, D; Shiramatsu, K; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yoshida, Y, 2007) |
| "She was diagnosed as primary gastric cancer with peritoneal dissemination and received systemic chemotherapy after distal gastrectomy for a primary lesion." | ( Cho, H; Hasegawa, S; Kobayashi, O; Osaragi, T; Sairenji, M; Tsuburaya, A; Yoshida, T; Yoshikawa, T, 2007) |
| "Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status." | ( Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2007) |
| "Human gastric cancer cell lines, MKN45 and SGC7901 were treated with trichostatin A, rapamycin and/or LY294002, a PI3K inhibitor." | ( Fang, JY; Gu, WQ; Li, EL; Shen, GF; Sun, DF; Tian, XQ; Zhang, YJ; Zhu, HY, 2007) |
| "The major obstacle for the treatment of gastric cancer is recurrence and metastasis; yet, its molecular mechanism is largely unknown." | ( Chen, PM; Chi, CW; Chiou, SH; Chu, YR; Kao, CL; Ku, HH; Lin, HL; Liou, JP; Lo, JF; Wu, CW; Yang, MH; Yang, YP, 2007) |
| "We report a case of advanced gastric cancer with multiple liver metastases,in which a complete resection was performed following a bypass operation and chemotherapy." | ( Hatakeyama, K; Kobayashi, T; Kurosaki, I; Kurosaki, R; Matsuo, H; Ohashi, M; Yajima, K, 2007) |
| "Human gastric cancer cells SGC-7901 were implanted into SCID mice and mice were treated with paclitaxel and NM-3." | ( Chen, GQ; Li, Q; Song, MQ; Sun, Q; Zhang, Q; Zhu, JS, 2007) |
| "In distal gastric cancer patients, the effect of proton pump inhibitor-based triple therapy for H." | ( Bae, JM; Choi, IJ; Hong, EK; Kim, CG; Kim, YW; Kook, MC; Lee, JH; Lee, JY; Park, S; Ryu, KW; Song, HJ, 2008) |
| "We report 2 cases of advanced gastric cancer with synchronous liver metastases who were successfully downstaged using S-1 plus low-dose cisplatin chemotherapy followed by surgical resection." | ( Aiba, K; Aoki, H; Kashiwagi, H; Koyama, T; Mitsumori, N; Nimura, H; Takahashi, N; Yanaga, K, 2007) |
| "We hypothesised that gastric cancer outcome could be improved with more effective and intensified postoperative chemoradiotherapy." | ( Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M, 2007) |
| "Fifty-one patients with T3 or T4 gastric cancer received systemic 5-fluorouracil-based adjuvant chemotherapy, and intratumoral expression of TS and TP in 51 gastric cancer tissue samples was tested by real-time quantitative PCR." | ( Deng, JZ; Hua, D; Huang, ZH; Mao, Y, 2007) |
| "Adjuvant chemotherapy for advanced gastric cancer has not yet been established." | ( Gotoh, M; Hashimoto, Y; Hoshino, Y; Kashimura, S; Kogure, M; Odashima, Y; Osuka, F; Otani, S; Saito, T; Saze, Z; Soeta, N; Terashima, M; Watanabe, K, 2007) |
| "Sixty advanced gastric cancer patients were assigned to two groups randomly, the control group treated with chemotherapy alone and the treated group treated with SQFZI combined chemotherapy." | ( Shi, LR; Wu, AZ; Zhao, JM, 2007) |
| "Using this method, the 17 gastric cancer biopsy specimens, before undergoing S-1 based neoadjuvant chemotherapy, were assessed in order to determine the expression levels of the thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT) and dihydropyrimidine dehydrogenase (DPD) which determines S-1 efficacy." | ( Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakafusa, Y; Satoh, S; Tanaka, M; Tokunaga, O, 2007) |
| "The results showed that the growth of gastric cancer cells was significantly suppressed by treatment with AT1R antagonist." | ( Huang, W; Jiang, FX; Tian, XL; Wu, YL; Yu, LF; Zhong, J, 2008) |
| "Surgical treatments for early gastric cancer, such as endoscopic procedures, are currently performed as standard therapy." | ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S, 2007) |
| "We experienced two cases of advanced gastric cancer effectively treated by sequential therapy of docetaxel and paclitaxel." | ( Abe, S; Honda, K; Kondo, H; Makino, K; Mizushima, T; Oura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "We report a patient with unresectable gastric cancer who was effectively treated with S-1 after gastrojejunostomy." | ( Fujii, M; Hirota, M; Matsuda, C; Mikata, S; Morimoto, Y; Nishikawa, K; Tanaka, Y, 2007) |
| "A 58-year-old male with advanced gastric cancer underwent a total gastrectomy after neoadjuvant chemotherapy with paclitaxel and cisplatin." | ( Hoshi, Y; Kameda, K; Munakata, M; Muto, O; Sakata, Y; Shitara, K, 2007) |
| "The positive rate of SSTR-2 in gastric cancers treated with celecoxib (48%) was significantly higher than that of control group (12%) after surgery (P<0." | ( Chen, ZX; Huang, MH; Huang, MT; Liu, R; Tang, CW; Wang, CH; Wei, B; Zhang, B, 2007) |
| "Treatment of various human gastric cancer cells with honokiol led to the induction of GRP94 cleavage, but did not affect GRP78." | ( Lan, KH; Liu, SH; Sheu, ML, 2007) |
| "Patients in Japan with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph-node dissection were randomly assigned to undergo surgery followed by adjuvant therapy with S-1 or to undergo surgery only." | ( Arai, K; Fujii, M; Furukawa, H; Higashino, M; Imamura, H; Kinoshita, T; Kurita, A; Nakajima, T; Nashimoto, A; Ohashi, Y; Sakuramoto, S; Sasako, M; Yamaguchi, T; Yamamura, Y, 2007) |
| "We report a recurrent case of gastric cancer with para-aortic lymph node metastasis that showed a marked response to systemic chemotherapy consisting of S-1 alone." | ( Chikuba, A; Chikuba, H; Nakamoto, M; Nezu, M; Shimamura, H; Suzuki, T; Takiue, T; Teraishi, F, 2007) |
| "We reported a case of unresectable gastric cancer presenting pylorus stenosis treated orally by S-1 therapy in a 72-year-old man who underwent gastrojejunostomy." | ( Matsui, K; Morita, S; Shinbo, M; Tazawa, K; Tsukada, K; Yamada, A; Yamagishi, F; Yoshida, T, 2007) |
| "We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1." | ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007) |
| "Exponentially growing human gastric cancer SGC-7901 cells were divided into six treatment groups: (1) control group (RPMI 1640 medium); (2) negative control group (2% DMSO); (3) positive control group (50 mg/L 5-Fluorouracil, 5-FU); (4) low-dose group (LSC, final concentration of schisandrin B, 25 mg/L); (5) moderate-dose group (MSC, final concentration of schisandrin B, 50 mg/L); (6) high-dose group (HSC, final concentration of schisandrin B, 100 mg/L)." | ( Jin, XD; Li, L; Li, YZ; Liu, XN; Zhang, CY; Zheng, XZ, 2007) |
| "Fifty-eight advanced gastric cancer patients with previous chemotherapy were enrolled into the study." | ( Akbulut, H; Boruban, MC; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Sencan, O; Senler, FC; Yalcin, B, 2008) |
| "An early detection and treatment of gastric cancer with peritoneal dissemination are rather difficult so that a clinical trial has been neglected." | ( Doki, Y; Fujiwara, Y; Miyata, H; Monden, M; Nishida, T; Takiguchi, S; Yamazaki, M, 2007) |
| "This report describes three cases of gastric cancer treated with S-1 based chemotherapy after surgical bypass, which resulted in the long-term survival and an improvement of the patients' quality of life." | ( Egawa, C; Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M, 2007) |
| "Treatment of human gastric cancer cells with proton pump inhibitors significantly attenuated cell viability in a time- and dose-dependent manner." | ( Cheong, JY; Cho, SW; Kim, DK; Lee, KJ; Park, HJ; Yeo, M, 2008) |
| "A 70-year-old man with gastric cancer of Borrmann type 3, liver metastases and peritoneal dissemination was treated by combination therapy of S-1 and docetaxel (DOC)." | ( Akiyama, N; Arai, F; Funakoshi, K; Ikarashi, S; Ito, H; Kato, T; Motoyama, H; Sasaki, S, 2008) |
| "AGS-E human gastric cancer cell line stably expressing cholecystokinin-2 receptor was treated with amidated gastrin-17." | ( Anant, S; Berg, DE; Dieckgraefe, BK; Houchen, CW; May, R; Pothoulakis, C; Ramalingam, S; Subramaniam, D; Wang, TC, 2008) |
| "Sixty-two patients with advanced gastric cancer previously treated were eligible for the study." | ( Choi, CW; Choi, IK; Choi, YS; Kim, BS; Kim, DS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sung, HJ, 2009) |
| "Patients with potentially resectable gastric cancer treated with preoperative CRT are found to be ineligible for surgery principally because of peritoneal progression." | ( Ajani, JA; Badgwell, BD; Crane, CH; Das, P; Delclos, ME; Janjan, NA; Kim, MM; Krishnan, S; Mansfield, PF; Maru, D; Phan, AT, 2008) |
| "pylori eradication prevented gastric cancer to the greatest extent when antibiotics are given at an early point of infection, but that eradication therapy given at a later time point delayed the development of severe dysplastic lesions." | ( Fox, JG; Ge, Z; Lee, CW; Rickman, B; Rogers, AB; Wang, TC, 2008) |
| "Neoadjuvant chemotherapy in gastric cancer is now standard in the Western world; however, only 30-40% of the patients respond to induction therapy." | ( Becker, K; Höfler, H; Keller, G; Lordick, F; Ott, K; Siewert, J; Ulm, K, 2008) |
| "As prognosis of advanced gastric cancer is still poor, a standard regimen after first-line fluorouracil (FU)-based chemotherapy has not yet been established." | ( Boku, N; Fukuda, H; Hamaguchi, T; Honma, H; Hyodo, I; Imamura, T; Koizumi, W; Mukai, T; Ohtsu, A; Seki, S; Shirao, K; Yamamichi, N; Yamamoto, S; Yoshida, S, 2008) |
| "Analysis of 50 consecutive resected gastric cancer patients who received adjuvant chemotherapy with Tegafur for polymorphisms of genes DPYD1 (A/G; Ile543Val), DPYD2 (C/T; Arg29Cys) and CDA (A/C; Lys27Gin)." | ( Bombí, JA; Caballero, M; Campayo, M; Conill, C; Domingo-Domenech, J; Grau, JJ; Monzó, M; Muñoz-García, C; Navarro, A, 2008) |
| "Human gastric cancer cell lines, MKN45 and SGC7901 were treated with 5-aza-dC, rapamycin and/or LY294002." | ( Chen, Y; Fang, J; Lu, R; Sun, D; Toan, X; Wang, X; Zhang, Y, 2008) |
| "Early gastric cancer can be successfully treated by laser therapy with few complications and good prognosis." | ( Higashiyama, M; Hokari, R; Kawaguchi, A; Komoto, S; Miura, S; Nagao, S; Takebayashi, K, 2008) |
| "PTPRG gene methylation in the gastric cancer cell line changed into negative and PTPRG mRNA expression in the cell line was recovered after 5-Aza-2'-deoxycytidin treatment." | ( Dai, DQ; Wang, JF, 2008) |
| "Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events." | ( Feng, GS; Lam, SK; Li, J; Li, JY; Liu, WD; Ma, JL; Pan, KF; Shen, L; Wong, BC; Xia, HH; You, WC; Zhang, L; Zhang, XD, 2008) |
| "A 74-year-old male with advanced gastric cancer(cT3N1M0H0P0CY0, cStage III A)was treated with paclitaxel/ CDDP as neoadjuvant chemotherapy." | ( Hosaka, N; Kusama, K; Mikami, K; Munakata, Y; Okita, K; Sakon, M; Seki, H; Sekino, Y, 2008) |
| "One-hundred and sixteen patients with gastric cancer were treated with 5-FU-based adjuvant chemotherapy." | ( Hua, D; Huang, ZH; Li, LH, 2009) |
| "Although the prognosis of gastric cancer with carcinomatous peritonitis is poor, we here reported a patient with StageIV gastric cancer who markedly responded to FT therapy, which made surgical resection possible with the anticipation of extended survival." | ( Harano, M; Masumura, K; Ninomiya, M; Nishizaki, M; Ohno, S; Takakura, N; Takata, S, 2008) |
| "Sixty-eight patients with advanced gastric cancer and performance status 0-2 were treated with 80 mg/m2 paclitaxel over 1 h following a short course of premedication with dexamethasone, diphenhydramine, and ranitidine administered 30 min prior to the delivery of the paclitaxel." | ( Emi, Y; Kakeji, Y; Kohnoe, S; Maehara, Y; Orita, H; Takahashi, I; Yamamoto, M, 2008) |
| "Celecoxib prevented gastric cancer in MNU-pretreated H." | ( Crowe, SE; Futagami, S; Gudis, K; Hamamoto, T; Horie, A; Kawagoe, T; Kusunoki, M; Miyake, K; Sakamoto, C; Shindo, T; Suzuki, K; Tsukui, T, 2008) |
| "Twenty-one patients with PC (12 gastric cancer, 5 colorectal cancer, 2 ovarian cancer, 1 pseudomyxoma peritonei, 1 malignant mesothelioma) were treated with CRS + HIPEC with hydroxycamptothecin 20 mg and mitomycin C 30 mg in 12,000 mL of normal saline at 43 +/- ." | ( al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW, 2009) |
| "Gastrojejunostomy for incurable gastric cancer contributes not only to improving quality of life (QOL), but to prolonging survival through the induction and maintenance of S-1-based chemotherapy." | ( Hatakeyama, K; Hirota, M; Kanda, T; Kobayashi, T; Kosugi, S; Ohashi, M; Yajima, K, 2008) |
| "Fifty-seven patients with advanced gastric cancer treated with paclitaxel and cisplatin combination chemotherapy were enrolled in the present study." | ( Chae, YS; Chung, HY; Do, YR; Hyun, MS; Jung, JS; Kim, GC; Kim, JG; Kim, MK; Kwon, KY; Lee, KH; Lee, WS; Sohn, CH; Sohn, SK; Song, HS; Yu, W, 2009) |
| "The level of apoptosis in gastric cancer SGC7901 cells treated with doxorubicin was gradually increasing." | ( Ai, YW; Hu, XW; Li, H; Luo, HS; Yang, Y; Yu, HG; Yu, JP, 2008) |
| "Treatment of patients with advanced gastric cancer associated with pulmonary carcinomatous lymphangitis is quite difficult and there is no scientific evidence to select anti-cancer drugs for these patients." | ( Ishikawa, T; Isozaki, Y; Kiyota, K; Kokura, S; Matsuyama, R; Nagao, Y; Okita, M; Oyamada, H; Suzuki, K; Yoshikawa, T, 2008) |
| "Twenty patients with advanced gastric cancer accepted 2 courses of neo-adjuvant chemotherapy with S- 1 and cisplatin." | ( Ami, K; Ando, M; Fukuda, A; Ganno, H; Maruyama, M; Nagahama, T, 2008) |
| "Recently, standard therapies for either gastric cancer or colorectal cancer have been established through the development of multidrug systemic chemotherapy and the appearance of molecular targeting drugs." | ( Ando, K; Emi, Y; Endo, K; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Saeki, H; Sugiyama, M, 2008) |
| "Treatment of the gastric cancer cells with TSA activates the DLC-1 promoter activity through Sp1 sites located at -219 and -174 relative to the transcription start site." | ( Bang, YJ; Jong, HS; Jung, M; Kim, IS; Kim, TY; Lee, JW, 2008) |
| "Accurate staging of gastric cancer at primary diagnosis is essential for adequate treatment." | ( Bosscha, K; Dassen, AE; Hoekstra, CJ; Lips, DJ; Pruijt, JF, 2009) |
| "Advanced or metastatic gastric cancer, which is one of the most common malignancies in Korea, is difficult to cure by surgery alone and generally requires combination chemotherapy." | ( Ahn, JS; Jung, JY; Kim, HJ; Kim, I; Kim, JH; Kwon, JH; Lee, JA; Lee, KS; Park, YI; Song, HH; Zang, DY, 2009) |
| "We report a case of advanced gastric cancer that showed a complete histological response to neoadjuvant chemotherapy." | ( Fukumoto, T; Hachiya, O; Kamio, Y; Kimura, W; Nomura, T; Shibata, K; Takasu, N, 2009) |
| "The levels of specific cytokines in 60 gastric cancer patients were detected by flow cytometry before and after chemotherapy with FOLFOX4." | ( Gao, J; Han, CZ; Liu, XL; Qiao, LJ, 2008) |
| "A 59-year-old man diagnosed as gastric cancer with peritonitis carcinomatosa was treated with paclitaxel and TS-1; 60 mg/m(2)/day of paclitaxel was given on days 1 and 8, and 60-80 mg/m(2)/day of TS-1 was given for 2 weeks." | ( Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T; Yoneoka, Y, 2009) |
| "We studied gastric cancer patients from a phase II trial of S-1 monotherapy with a 2-week treatment and 1-week rest schedule." | ( Ahn, JB; Chung, HC; Im, CK; Jeung, HC; Noh, SH; Park, CH; Rha, SY; Roh, JK; Shin, SJ, 2009) |
| "Patients who had gastric cancer with CY1 status but no other residual disease received postoperative chemotherapy with S-1 (1M tegafur-0." | ( Fujiwara, M; Ito, S; Kodera, Y; Kojima, H; Kojima, T; Kondo, K; Koshikawa, K; Matsui, T; Mochizuki, Y; Nakao, A; Suzuki, N; Takase, T; Tsuboi, K, 2009) |
| "Forty patients with gastric cancer received neoadjuvant chemotherapy." | ( Baldus, S; Bollschweiler, E; Brabender, J; Drebber, U; Hölscher, AH; Metzger, R; Mönig, S; Schneider, PM; Vallböhmer, D; Warnecke-Eberz, U, 2009) |
| "Because treatment of advanced gastric cancer (AGC) patients after failure with first-line chemotherapy remains controversial, we performed this retrospective analysis based on the data obtained from 1455 patients registered in a first-line treatment cohort with respect to receiving or not receiving subsequent chemotherapy." | ( Chang, MH; Ji, SH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lim, DH; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY, 2009) |
| "We report a patient with an advanced gastric cancer complicated by pyloric stenosis who was effectively treated by S-1 mono-therapy after gastrojejunostomy." | ( Fujiwara, Y; Hayashi, C; Kobayashi, M; Koishi, K; Kojima, S; Matsumoto, T; Miwa, H; Sasako, M; Tanaka, J; Tomita, N; Yamamoto, N; Yamamura, T, 2009) |
| "We report a patient with advanced gastric cancer responding remarkably to neoadjuvant combination chemotherapy consisting of paclitaxel and S-1." | ( Hashimoto, R; Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Mizuno, A; Okochi, O; Takami, Y; Takeda, S; Tsuboi, K, 2009) |
| "The prognosis of scirrhous gastric cancer remains poor despite extended surgery or adjuvant or neoadjuvant chemotherapy." | ( Furukawa, H; Kaji, M; Katai, H; Kinoshita, T; Miyashiro, I; Ninomiya, M; Sano, T; Sasako, M; Tsuburaya, A, 2009) |
| "Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy." | ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009) |
| "The role of GSTP1 in gastric cancer sensitivity to chemotherapy is, however, not known." | ( Hou, K; Hu, X; Jing, W; Liu, Y; Qu, X; Teng, Y; Yang, X; Zhang, J; Zhang, Y, 2009) |
| "Sixty consecutive patients treated for gastric cancer either with 3D-CRT (n = 27) and IMRT (n = 33) were evaluated." | ( Boda-Heggemann, J; Hermes, P; Hieber, U; Hochhaus, A; Hofheinz, RD; Lohr, F; Mai, SK; Massner, B; Mennemeyer, P; Post, S; Weiss, C; Wenz, F; Wertz, H, 2009) |
| "Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study." | ( Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Harada, M; Kato, K; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Tanaka, R, 2009) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "Two unresectable advanced gastric cancer cases with peritoneal metastases were successfully treated by the combination therapy of S-1 and paclitaxel." | ( Ando, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Nishio, T, 2009) |
| "We report a case of gastric cancer with simultaneous multiple liver metastasis that was successfully treated by paclitaxel and UFT-E." | ( Fujiwara, H; Ichikawa, D; Ikoma, H; Kikuchi, S; Kokuba, Y; Kubota, T; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Otsuji, E; Sakakura, C; Sonoyama, T; Taniguchi, H, 2009) |
| "In a gastric cancer cell line with a very low 15-PGDH expression (TMK-1), the 15-PGDH promoter was methylated and treatment with a demethylating agent 5-aza-2'-deoxycytidine restored 15-PGDH expression." | ( Ganesan, A; Haglund, C; Hemmes, A; Junnila, S; Kokkola, A; Monni, O; Mrena, J; Nykänen, A; Petrova, TV; Ristimäki, A; Tai, HH; Thiel, A, 2009) |
| "14 patients with early gastric cancer after endoscopic treatments were included." | ( Fujita, T; Kashiwagi, H; Mitsumori, N; Narimiya, N; Nimura, H; Ohdaira, H; Takahashi, N; Yanaga, K, 2009) |
| "Treatment of AGS or MKN45 cells, human gastric cancer cell lines, with SKF96365, an agent known to inhibit TRPC channels, arrested cell cycle in G2/M phase and suppressed cell growth." | ( Cai, R; Ding, X; Ge, R; Jin, Y; Ren, G; Shi, Y; Wang, Y; Zhou, K, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | ( Dai, H; Yan, D, 2009) |
| "104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept." | ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009) |
| "Locally advanced gastric cancer with extensive lymph node metastasis is usually considered unresectable and so treated by chemotherapy." | ( Fujitani, K; Fukushima, N; Imamura, H; Ito, S; Kawashima, Y; Oshita, H; Sano, T; Sasako, M; Yamamoto, S; Yoshikawa, T, 2009) |
| "Patients with gastric cancer with extensive lymph node metastasis received two or three 28-day cycles of induction chemotherapy with irinotecan (70 mg/m(2) on days 1 and 15) and cisplatin (80 mg/m(2) on day 1), and then underwent gastrectomy with curative intent with D2 plus para-aortic lymphadenectomy." | ( Fujitani, K; Fukushima, N; Imamura, H; Ito, S; Kawashima, Y; Oshita, H; Sano, T; Sasako, M; Yamamoto, S; Yoshikawa, T, 2009) |
| "Seventy-nine patients with PC from gastric cancer were treated with NIPS." | ( Endou, Y; Hirano, M; Ichinose, M; Ikeda, M; Ikeda, S; Kimura, H; Masuda, S; Matsuda, T; Matsuki, N; Miura, M; Mizumoto, A; Mizuno, M; Nakajima, G; Sasaki, T; Shinbo, M; Takao, N; Yonemura, J; Yonemura, Y; Yuuba, T, 2009) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "Ki23057 was administered orally to gastric cancer models created by orthotopic inoculation of diffuse-type gastric cancer cells, OCUM-2MLN." | ( Hirakawa, K; Kaizaki, R; Matsuoka, T; Matsuzaki, T; Miwa, A; Nakamura, K; Ohira, M; Shinto, O; Tendo, M; Yashiro, M, 2009) |
| "Treatment of gastric cancer cells with cyclopamine, a specific inhibitor of Hh signaling pathway, reduced proliferation and induced apoptosis of gastric cancer cells." | ( Baek, SY; Han, ME; Kim, BS; Kim, JB; Lee, YS; Oh, SO, 2009) |
| "Incidence of gastric cancer in the two groups was determined based on the results of annual endoscopy and questionnaire surveys, as well as Yamagata Prefectural Cancer Registry data, and was compared between the two groups and by results of H pylori therapy." | ( Fukase, K; Kawata, S; Mabe, K; Matsuda, T; Oizumi, H; Shibata, A; Takahashi, M; Takeda, H; Tsukuma, H, 2009) |
| "We encountered a patient with gastric cancer demonstrating peritoneal dissemination, who was successfully treated by combination therapy using S-1 and docetaxel." | ( Futagawa, S; Kitajima, M; Konishi, N; Marusasa, T; Nishimura, K; Ochiai, T; Satoh, G; Watanabe, T, 2009) |
| "We report a 75-year-old female gastric cancer patient with paclitaxel-induced peripheral neuropathy, which was successfully treated by the H2-blocker, lafutidine." | ( Anami, S; Fujii, C; Fujino, M; Fujita, Y; Furukawa, H; Imamura, H; Kishimoto, T; Matsumura, T; Miyazaki, Y; Sumita, R; Takada, N; Yasui, Y, 2009) |
| "The subjects were patients with gastric cancer who had disease progression or recurrence while receiving fluoropyrimidine-based chemotherapy." | ( Akiya, T; Higuchi, K; Koizumi, W; Nakayama, N; Sakuyama, T; Sasaki, T; Sato, A; Sekikawa, T; Tanabe, S; Yamaguchi, K, 2009) |
| "Nevertheless, when gastric cancer cells were treated with different NSAIDs, the non-Cox-2-inhibiting R-flurbiprofen was most effective at reducing proliferation of gastric cancer cells in vitro." | ( Fan, D; Gao, L; Hong, L; Jin, H; Li, X; Liang, J; Liu, L; Liu, N; Pan, Y; Shi, H; Sun, L; Wang, Z; Wu, K; Wu, Q; Yang, Z; Zhao, H, 2010) |
| "Human gastric cancer MKN45 cells were treated with a combination of 5FU and MMC, and the changes in cell viability and apoptosis-related proteins were determined by a tetrazolium dye-based cytotoxicity assay and Western blot analysis, respectively." | ( Alpers, DH; Hara, A; Hirayama, R; Kaai, K; Kohno, S; Komoda, T; Matsunaga, T; Tsuji, Y, 2010) |
| "We hypothesized that the sensitivity of gastric cancer to 5-FU treatment might be related to the rate of glucose transport (GLUT), and investigated the expressions of GLUT1, 2, 3, and 4 in two different gastric cancer cells (SNU-216, moderately differentiated gastric adenocarcinoma; and SNU-668, signet ring cell gastric carcinoma)." | ( Baik, HH; Cho, HY; Ha, E; Ha, TK; Hur, SJ; Kim, YH; Kwon, SJ; Suh, SI; Won, HJ, 2010) |
| "The standard of care for metastatic gastric cancer (MGC) is systemic chemotherapy which leads to a median survival of 6-15 months." | ( Avital, I; Berger, A; Duffy, A; Giaccone, G; Goldspiel, BR; Kammula, US; Kemp, CD; Kerkar, SP; Kwong, KF; Quezado, M; Rosenberg, SA; Schrump, DS; Steinberg, SM; Toomey, MA; Venkatesan, A; Walker, M, 2009) |
| "The subjects were type 4 advanced gastric cancer cases from October 2002 to December 2007 who underwent st-lap, as well as 7 P0 and CY0 [P(-)] cases (the operative group), and 18 P(+) cases which underwent chemotherapy (the chemotherapy group)." | ( Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M; Yoshioka, Y, 2009) |
| "We reported a case of P1CY1 gastric cancer with intraperitoneal chemotherapy after surgery for more than four years." | ( Cyoda, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohnishi, T; Ohno, S; Ojima, Y; Sasada, S; Shiozaki, S; Urano, S; Watanabe, S; Watanabe, Y, 2009) |
| "A case of type 4 unresectable gastric cancer was reported that the postoperative chemotherapy of S-1 was effective." | ( Ikari, H; Izumino, K; Kajihara, K; Kunizaki, T; Sasaki, N; Shigemasa, Y; Shimizu, T; Yonemitsu, N, 2009) |
| "Most gastric cancer patients with peritoneal dissemination die within a few months, and there is no standard treatment for peritoneal dissemination from gastric cancer." | ( Asami, S; Hirata, M; Idani, H; Kin, H; Kubo, S; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yamashita, T; Yoshioka, T, 2009) |
| "But second primary gastric cancer was detected in antrum 26 months after primary therapy." | ( Fukushima, Y; Hashimoto, K; Hiraki, M; Matsumoto, S; Matsuyama, J; Morimoto, T; Morita, S; Naitou, A; Nishishou, I; Nomura, T; Sasaki, Y; Yokoyama, S, 2009) |
| "A 58-year-old man of unresectable gastric cancer was treated with S-1 (120 mg/body/day) after gastrojejunostomy." | ( Furuya, T; Hayashi, H; Inoue, Y; Ishigaki, N; Saeki, T; Yahara, N; Yanai, H, 2009) |
| "Recently, chemotherapy against gastric cancer has been diversified with an appearance of new agents such as S-1, capecitabine, CPT-11, oxaliplatin, paclitaxel and docetaxel." | ( Ami, K; Andou, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kurokawa, T; Nagahama, T; Ohara, T; Tei, S, 2009) |
| "Based on the diagnosis of stage IV gastric cancer, S-1 therapy was started." | ( Arimori, K; Hanada, N; Hidaka, H; Hidaka, M; Kawaguchi, H; Kawano, Y; Nakamura, C; Tomiyama, N, 2010) |
| "We report two cases of advanced gastric cancer successfully treated with combination S-1 and docetaxel (DOC) therapy." | ( Hasegawa, H; Kijima, T; Kitahara, M; Kubo, H; Miyahara, M; Tada, K, 2010) |
| "The standard therapy for gastric cancer with peritoneal metastasis has remained unclear." | ( Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H, 2010) |
| "A 49-year-old female with advanced gastric cancer complicated with peritoneal dissemination underwent distal gastrectomy, and thereafter she was treated with a combined chemotherapy of S-1 and paclitaxel for 5 months, followed by treatment with S-1 alone." | ( Kitagawa, M; Koh, T; Kondo, Y; Nakagawa, N; Nanri, M; Oguro, A; Yamasaki, J, 2010) |
| "The optimal adjuvant treatment for gastric cancer remains controversial." | ( Bamias, A; Bobos, M; Christodoulou, Ch; Dimopoulos, MA; Fountzilas, G; Karina, M; Kostopoulos, I; Papakostas, P; Pectasides, D; Pentheroudakis, G; Samantas, E; Vourli, G, 2010) |
| "In contrast, non-scirrhous gastric cancer cells were not affected by TGF-beta1 or Ki26894 treatment." | ( Hirakawa, K; Kawajiri, H; Miwa, A; Shimizu, K; Shimizu, T; Shinto, O; Yashiro, M, 2010) |
| "We reported a patient with advanced gastric cancer successfully treated with S-1 chemotherapy for three weeks." | ( Fukuoka, T; Ikehara, T; Kanazawa, A; Nishiguchi, Y; Sakurai, K; Shimizu, S; Takemura, M; Tsukamoto, T; Xiang, Z; Yamamoto, A; Yamamoto, S; Yamashita, Y; Yoshida, K, 2010) |
| "Malignant ascites caused by gastric cancer are chemotherapy resistant and carry a poor prognosis." | ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010) |
| "In advanced gastric cancer with peritoneal metastasis, adjuvant chemotherapy after primary tumor resection showed considerably poor prognosis with a median survival time of only 232 days." | ( Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Tanemura, H; Yamada, M, 2010) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | ( Chen, XQ; Li, FH; Li, YH; Luo, HY; Qiu, MZ; Wang, F; Xu, RH; Zhou, ZW, 2010) |
| "CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy." | ( Ito, S; Kodera, Y; Kojima, T; Mochizuki, Y; Nakanishi, H; Yamamura, Y, 2010) |
| "So far, the only curative treatment for gastric cancer is surgery." | ( Farhat, FS; Ghosn, MG; Kattan, J, 2010) |
| "We report here two cases of recurrent gastric cancer after post operative adjuvant chemotherapy, in which S-1 has been effective to control the recurrence and provided long-term survival." | ( Saito, T; Sasaki, H; Tokunaga, Y, 2010) |
| "Apoptosis of four human gastric cancer cell lines was induced by treatment with noscapine." | ( Dong, WG; Lei, XF; Liao, F; Liu, M; Luo, XJ, 2011) |
| "Patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | ( Jiang, T; Li, QF; Liang, J; Liu, KW; Lv, HY; Yao, RY, 2010) |
| "We report a case of advanced gastric cancer, with cervical, axillary, and abdominal paraaortic lymph node metastases, that was successfully treated with chemotherapy and surgery." | ( Chin, K; Hatake, K; Hijioka, S; Seto, Y; Yamamoto, N, 2010) |
| "Patients with T3-4 gastric cancer received one course of S-1 (80mg/m(2) daily for 3 weeks) and cisplatin (60mg/m(2) on day 8) chemotherapy and then underwent D2 or D3 gastrectomy with curative intent." | ( Fujii, M; Kobayashi, O; Nakajima, T; Nashimoto, A; Omura, K; Takabayashi, A; Yamada, T; Yamaguchi, T; Yamaue, H; Yoshikawa, T, 2010) |
| "Sixteen gastric cancers and four adenomas were treated in this study." | ( Goda, K; Gostout, CJ; Ikeda, K; Imazu, H; Kato, T; Kawamura, M; Ohya, TR; Saito, S; Sumiyama, K; Tajiri, H, 2010) |
| "Due to advanced gastric cancer with abdominal para-aortic lymph node metastases, we performed a curative operation in three cases in which S-1/CDDP combination therapy proved effective." | ( Imai, T; Kanematsu, M; Kawai, M; Kunieda, K; Matsuhashi, N; Nagao, N; Nishina, T; Sakuratani, T; Sasaki, Y; Tajima, JY; Tanaka, C; Yamada, A, 2010) |
| "Patients with advanced gastric cancer, naive to chemotherapy or not refractory to fluoropyrimidine, were enrolled." | ( Boku, N; Hironaka, S; Kojima, T; Machida, N; Muro, K; Shitara, K; Taku, K; Ueda, S; Yamazaki, K; Yokota, T, 2010) |
| "Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery)." | ( Alakus, H; Baldus, S; Bollschweiler, E; Brabender, J; Dietlein, M; Hölscher, AH; Metzger, R; Mönig, SP; Schmidt, M; Schneider, PM; Vallböhmer, D, 2010) |
| "All patients with gastric cancers who received adjuvant treatment at the National Cancer Centre Singapore between 1996 and 2006 were reviewed." | ( Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Tham, CK; Toh, HC; Wang, ML, 2010) |
| "In addition, gastric cancer cells were cultured and treated with a GSK-3beta inhibitor lithium chloride (LiCl) for immunoblot analysis." | ( Cho, SJ; Cho, YJ; Kim, JH; Kim, WH; Ko, YS; Lee, BL; Lee, HE; Lee, HS; Park, JW; Yoon, J, 2010) |
| "Two patients with advanced gastric cancer and metastatic pancreatic cancer who received 5-fluorouracil-based chemotherapy presented with acute mental change and hyperammonemia." | ( Kim, SR; Lee, J; Lee, SY; Park, CH; Park, JO; Park, S, 2010) |
| "No re-growth of gastric cancer has been seen for 9 months with this chemotherapy." | ( Hachisuka, T; Hattori, K; Kinoshita, T; Miyauchi, M; Mori, T; Shikano, T; Shinohara, M; Yamamoto, T, 2010) |
| "Currently, no transplantable gastric cancer syngeneic animal models exist; therefore, we set out to establish a mouse gastric carcinoma cell line, which was named mouse gastric carcinoma cell line 3I (MGCC3I), from forestomach carcinoma developed in benzo[a]pyrene-treated ICR mice." | ( Chen, YL; Fang, JH; Hsu, HP; Lai, MD; Lin, CY; Lin, PW; Shan, YS; Yen, MC, 2011) |
| "As only 10% of patients with advanced gastric cancer treated with chemotherapy survive 2 years, new approaches for preventing and controlling the disease are required." | ( Hong, SS; Jung, KH; Lee, H; Lee, JH, 2010) |
| "For advanced gastric cancer (AGC), second-line chemotherapy after the failure of S-1 has not yet been established." | ( Hamaguchi, T; Hirashima, Y; Kato, K; Nishitani, H; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Takeshita, S; Yamada, Y, 2010) |
| "The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory." | ( Ishiyama, A; Ito, H; Ito, S; Kinoshita, T; Kodera, Y; Mochizuki, Y; Nakao, A; Sakamoto, J; Tsuburaya, A; Yokoyama, H; Yoshikawa, T, 2010) |
| "Paeonol treatment in gastric cancer cell line MFC and SGC-790 cells significantly reduced the expression of Bcl-2 and increased the expression of Bax in a concentration-related manner." | ( Fan, LL; Li, N; Sun, GP; Wan, XA; Wang, H; Wang, ZG; Wu, Q, 2010) |
| "Human gastric cancer cell line SGC-7901 was cultured and treated with different concentration of AG1478 and celecoxib, the proliferation of SGC-7901 cells was determined by MTT." | ( Li, RK; Liao, J; Qiang, O; Wang, CH, 2010) |
| "Moreover, SNU gastric cancer cell lines over-expressing kinase dead GSK-3β and the same cells treated with a GSK-3β inhibitor showed that GSK-3β inhibition did not alter either the protein expression or transcriptional activity of β-catenin." | ( Cho, SJ; Cho, YJ; Kim, JH; Kim, SY; Kim, WH; Ko, YS; Lee, BL; Park, JW; Yoon, J; Youn, HD, 2010) |
| "We encountered a case of AFP-producing gastric cancer that accompanied early gastric cancer and was treated effectively by S-1." | ( Amaya, S; Fujisawa, K; Iida, Y; Ishii, H; Koizumi, H; Mitsui, T; Miura, S; Munemoto, Y; Sato, Y; Terada, T, 2010) |
| "Because gastric cancer demonstrates limited sensitivity to radiotherapy, a radiosensitizer might therefore be useful to enhance the radiosensitivity of patients with advanced gastric carcinoma." | ( Chaudhary, P; Che, X; Li, H; Liao, X; Long, H; Zhang, D; Zhao, W, 2010) |
| "Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | ( Jiang, J; Jiang, T; Li, QF; Liang, J; Lü, HY; Song, SA; Sun, YY; Yao, RY, 2010) |
| "Twenty-one patients with advanced gastric cancer who had failed first-line therapy received irinotecan on days 1 and 8 plus capecitabine on days 1-14 for a 21-day cycle." | ( Dong, CM; Kang, MF; Liu, Y; Luo, MQ, 2010) |
| "In patients with Stage III-IV (M0) gastric cancer, adjuvant 5-fluorouracil/cisplatin chemotherapy was tolerable, but did not seem to confer survival advantage." | ( Bang, YJ; Choe, KJ; Heo, DS; Im, SA; Kim, DW; Kim, JS; Kim, MA; Kim, NK; Kim, TM; Kim, TY; Kim, WH; Lee, KU; Lee, SH; Oh, DY; Yang, HK, 2011) |
| "The NCI-N87 Her2/neu overexpressing gastric cancer cell line xenograft mouse model was treated with IDL or docetaxel-loaded liposomes (DL)." | ( Horiuchi, A; Kikuchi, S; Kojima, Y; Kuwabara, J; Matsuno, Y; Morimoto, M; Sato, K; Sato, M; Sugishita, H; Watanabe, Y; Yamamoto, Y; Yoshida, M, 2011) |
| "Selected patients with oesophagogastric cancer who relapse or progress >3 months after initial treatment with PF +/- epirubicin may benefit from re-introduction of PF-based chemotherapy." | ( Asghar, U; Ashley, S; Ashton, J; Chau, I; Cunningham, D; Hawkes, E; Jackson, K; Okines, AF, 2010) |
| "The prognosis of type 4 advanced gastric cancer is extremely poor, even the use of multidisciplinary treatment cannot provide satisfactory results." | ( Hamada, H; Hayashi, S; Katsuki, Y; Kina, M; Kuraya, D; Takada, J; Watanabe, K, 2010) |
| "Because of gastric cancer with suspected invasion of the left hepatic lobe and pancreas, it was decided to perform preoperative chemotherapy (S-1 + CDDP) and then perform a total gastrectomy." | ( Hamada, H; Hayashi, S; Katsuki, Y; Kina, M; Kuraya, D; Takada, J; Watanabe, K, 2010) |
| "We here report three such cases of gastric cancer treated by S-1 and docetaxel (DOC) combination therapy." | ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, N; Kurokawa, T; Nagahama, T; Ohhara, T; Watayo, Y, 2010) |
| "In ovary metastasis of gastric cancer, even if accompanied by peritoneum metastasis, ovarian resection as a reduction surgery followed by chemotherapy may improve survival." | ( Fukunaga, M; Furukawa, H; Imamura, H; Kawabata, R; Kishimoto, T; Miwa, H; Miyanishi, K; Ohzato, H; Yamamoto, T, 2010) |
| "We treated five gastric cancer patients with chemoradiation therapy consisting of CDDP (6 mg/m2) and S-1 (100 mg/body)." | ( Doi, K; Hirano, Y; Kudo, K; Narita, Y; Ogata, K; Ohchi, T, 2010) |
| "Cancerous pleural effusion and gastric cancer was diagnosed, and the chemotherapy consisted of S-1 + DOC was started for Stage IV gastric cancer." | ( Chika, N; Dan, N; Goto, H; Hosokawa, T; Kakimoto, M; Kato, H; Koshiishi, H; Masuda, T; Matsuyama, T; Mitsuhashi, Y; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H; Yoshimura, T, 2010) |
| "Eligible patients with advanced gastric cancer were treated with capecitabine at a fixed dose 1,000 mg daily (days 1-28 continuously, every 5 weeks) until disease progression or significant toxicity." | ( He, S; Hong, L; Niu, D; Niu, L; Shen, J, 2012) |
| "Pretreatment of the gastric cancer cells with the ER stress inducer drastically decreased the apoptotic rate induced by cisplatin or doxorubicin." | ( Feng, R; Jin, H; Yang, HY; Zhai, WL; Zhang, QX, 2011) |
| "Patients with advanced gastric cancer with malignant ascites were treated with 1-h intravenous (i." | ( Iishi, H; Imamoto, H; Kakutani, C; Morimoto, T; Morita, S; Nakamura, M; Narahara, H; Oba, K; Oriuchi, N; Sakamoto, J; Shiozaki, H; Yumiba, T, 2011) |
| "Five gastric cancer cell lines, the MKN-1, MKN-28, MKN-45, NUGC-3 and TMK-1, were found to be sensitive to EGCG treatment." | ( Kobayashi, D; Kuribayashi, K; Nirasawa, S; Onoda, C; Tanaka, M; Tsuji, N; Watanabe, N, 2011) |
| "Athymic nude mice xenografted with gastric cancer cells were treated with Sphk1 LNA and assessed for tumor growth and Sphk1 target regulation, in vivo." | ( Crevenna, R; Fisker, N; Fuereder, T; Hansen, BJ; Hoeflmayer, D; Jaeger-Lansky, A; Rasin-Streden, D; Strommer, S; Wacheck, V, 2011) |
| "Though AFP-producing gastric cancer is known for its poor prognosis, combination treatment such as operation or hepatic arterial infusion chemotherapy may improve the prognosis in patients with advanced AFP-producing gastric cancer when systemic chemotherapy is effective." | ( Adachi, A; Azuma, K; Inoue, N; Kuriyama, D; Nakamura, T; Noguchi, M; Sawada, M; Someda, H; Uose, S; Yoshioka, M, 2011) |
| "Eight patients with inoperable advanced gastric cancer were treated with combination chemotherapy of S-1, low-dose cisplatin(CDDP)and Lentinan." | ( Dan, N; Fukuoka, T; Hirakawa, K; Hori, T; Ikehara, T; Nishino, H; Takatsuka, S; Tendo, M; Tezuka, K, 2011) |
| "We report the case of a male gastric cancer patient who had undergone outpatient chemotherapy with TAXOTAL+TS-1 for adrenal and lung metastases." | ( Ichihara, T, 2010) |
| "We report three cases of advanced gastric cancer successfully treated by combination therapy of S-1 and docetaxel (DOC)." | ( Amano, S; Fujii, S; Fukahori, M; Godai, T; Imada, T; Kunisaki, C; Makino, H; Masuda, M; Numata, M; Oshima, T; Rino, Y; Sato, T, 2011) |
| "TS-1 has been used for the treatment of gastric cancer, both in the adjuvant and metastatic setting, and is increasingly being used in other malignancies such as colon, pancreatic and non-small cell lung cancer." | ( Aw, CW; Lee, SC; Lim, R; Lim, TC; Tan, CS; Yeo, SW, 2011) |
| "A total of 126 gastric cancer patients received at least 6 cycles of modified FOLFOX4 adjuvant chemotherapy." | ( Ling, Y; Liu, BR; Liu, YP; Zhang, YP, 2011) |
| "Although the treatment of early gastric cancer with endoscopic submucosal dissection (ESD) has been widely carried out, a standardized method of sedation for ESD has not been established." | ( Fujinaga, Y; Kashiwa, A; Kojima, Y; Matsuyama, K; Shimamoto, F; Takimoto, K; Toyonaga, T; Ueda, T; Yamauchi, H; Yoshikawa, T, 2011) |
| "Identification of HtrA1 in gastric cancer prior to chemotherapy indicates that levels of HtrA1 could be used to predict response to platinum-based combination therapies." | ( Alessandroni, P; Baldelli, AM; Baldi, A; Catalano, V; d'Avino, A; D'Emidio, S; De Nictolis, M; Fedeli, SL; Giordani, P; Graziano, F; Lorenzon, L; Mellone, P; Muretto, P; Rossi, D; Santini, D; Shridhar, V; Staccioli, MP; Testa, E, 2011) |
| "In patients with stage II/III gastric cancer, tumors often recur even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy." | ( Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T, 2011) |
| "Although docetaxel is active against gastric cancer, Grade 3 or 4 neutropenia occurs in the majority of patients in Japan when administered at 60 mg/m(2) every 3 weeks." | ( Danno, K; Imaoka, S; Iwazawa, T; Kagara, N; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Yano, H, 2011) |
| "Patients with advanced gastric cancer who had received prior chemotherapy were enrolled between April 2004 and March 2007." | ( Danno, K; Imaoka, S; Iwazawa, T; Kagara, N; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Yano, H, 2011) |
| "This paclitaxel-resistant gastric cancer with peritoneal recurrence proved responsive to docetaxel as third-line chemotherapy." | ( Danno, K; Imaoka, S; Imasato, M; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Yano, H, 2011) |
| "Patients with advanced/recurrent gastric cancer were randomized to receive tailored irinotecan and S-1 (arm A) therapy or S-1 therapy alone (arm B)." | ( Kimura, Y; Kitajima, M; Komatsu, Y; Oda, H; Saji, S; Sakamoto, J; Sakata, Y; Sakurai, J; Tajima, Y; Takahashi, M; Takahashi, Y; Tamura, S; Tatebe, S; Wakasugi, T, 2011) |
| "Patients with metastatic gastric cancer and progression after prior chemotherapy were eligible." | ( Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS, 2011) |
| "45 patients with gastric cancer underwent FDG- and FLT-PET before and 2 weeks after initiation of chemotherapy." | ( Becker, K; Buck, AK; Ebert, MP; Herrmann, K; Krause, BJ; Langer, R; Lordick, F; Ott, K; Peschel, C; Schuster, T; Schwaiger, M; Siewert, JR; Wester, HJ; Wieder, HA; Wilhelm, D; zum Büschenfelde, CM, 2011) |
| "Gluteal recurrence of the original gastric cancer was suggested, and systemic chemotherapy consisting of S-1 at 100 mg/day (3 weeks on, 1 week off) and CDDP (day 8) was started." | ( Deguchi, R; Iwata, Y; Mine, T; Numata, M; Ogasawara, F; Ohtani, Y; Sakuma, T; Sato, S; Takashimizu, S, 2011) |
| "The cases of 92 patients with advanced gastric cancer and severe peritoneal metastasis who received first-line chemotherapy at our hospital between May 2001 and February 2007 were retrospectively analyzed." | ( Hamaguchi, T; Iwasa, S; Kato, K; Nakajima, TE; Nakamura, K; Shimada, Y; Takashima, A; Yamada, Y, 2012) |
| "In Chinese advanced gastric cancer, Thymidine Phosphorylase positive & β-tubulin III negative might predict response and prognosis to capecitabine plus paclitaxel chemotherapy." | ( Gao, J; Li, YY; Lu, M; Shen, L; Yu, JW, 2011) |
| "Human gastric cancer (AGS) cells were treated with IL-6 (50 ng/mL) and EGCG at different concentrations." | ( Cai, SR; Chen, HY; He, YL; Wang, CY; Wang, Z; Zhan, WH; Zhang, CH; Zhu, BH, 2011) |
| "He was diagnosed with advanced gastric cancer,and S-1 plus cisplatin treatment was administered as neoadjuvant chemotherapy because bulky lymph node metastases were found at the time of the initial diagnosis." | ( Amano, S; Fukino, N; Kano, H; Kawasaki, A; Kida, K; Kuboi, Y; Mimatsu, K; Oida, T, 2011) |
| "Patients with gastric cancer receiving adjuvant chemotherapy after radical resection from January 2004 to December 2008 were included." | ( Cui, YH; Li, W; Liu, TS; Shen, KT; Shen, ZB; Sun, YH; Wang, ZM; Yu, YY, 2011) |
| "The prognosis of unresectable advanced gastric cancer has improved over the last decade due to advances in chemotherapy." | ( Hayakawa, Y; Hirata, Y; Kinoshita, H; Koike, K; Maeda, S; Nakagawa, H; Nakata, W; Sakamoto, K; Takahashi, R, 2011) |
| "SGC-7901 human gastric cancer cells was treated with chemotherapeutics (etoposide and doxorubicin) or by combined application of curcumin and chemotherapeutics." | ( Dai, N; Si, JM; Wu, JG; Yu, HG; Yu, LL, 2011) |
| "We experienced a case of advanced gastric cancer treated by curative operation after neoadjuvant chemotherapy with S-1/ CDDP." | ( Kobayashi, T; Kubota, Y; Ogino, T; Satomoto, K; Ueyama, S, 2011) |
| "Twenty-one patients with gastric cancer with PC and/or positive CFPW who underwent GD2 were treated with early, post-operative, intraperitoneal paclitaxel." | ( Imamoto, H; Imano, M; Itoh, T; Kato, H; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Shiraishi, O; Takeyama, Y; Yasuda, A; Yasuda, T, 2012) |
| "The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized, placebo-controlled trial designed to evaluate the efficacy of adding bevacizumab to capecitabine-cisplatin in the first-line treatment of advanced gastric cancer." | ( Kang, YK; Langer, B; Lim, HY; Ohtsu, A; Park, SR; Rha, SY; Sawaki, A; Shah, MA; Starnawski, M; Van Cutsem, E; Wu, J; Yamada, Y, 2011) |
| "After human gastric cancer cells (AGS) were treated with IL-6 (50 μg/L) and EGCG(0, 5, 10, 25 or 50 μmol/L), the expression levels of VEGF, total Stat3(tStat3), and activated Stat3(pStat3) in tumor cells were examined by Western blotting." | ( Cai, SR; Chen, HY; He, YL; Wang, Z; Zhan, WH; Zhang, CH; Zhu, BH, 2011) |
| "The prognosis for advanced gastric cancer is poor, with surgery as the only treatment for resectable advanced gastric cancer." | ( Fukada, J; Fukuda, K; Kawaguchi, O; Kitagawa, Y; Oyama, T; Saikawa, Y; Shigematsu, N; Takahashi, T; Takaishi, H; Takeuchi, H; Wada, N, 2011) |
| "The human gastric cancer cell line HGC-27 cells were cultured in vitro, and treated with different concentration of β-aminopropionitrile (BAPN)." | ( Han, M; Huang, L; Lin, JJ; Ma, BJ; Song, TG; Sun, BJ; Wang, YQ; Zhao, JN, 2011) |
| "Current chemotherapy protocols for gastric cancer present high toxicity." | ( Auby, D; Becouarn, Y; Bellera, C; Brunet, R; Cany, L; Dauba, J; Fonck, M; Legoux, JL; Mathoulin-Pélissier, S; Mertens, C; Rainfray, M; Smith, D; Soubeyran, P; Terrebonne, E; Traissac, L, 2011) |
| "Moreover, gene expression analysis of gastric cancer identified a collection of genes (ITGB5, TYMS, MYB, APOC1, CBX5, PLA2G2A, and KIF20A) whose expression was elevated in gastric tumor tissue and downregulated more than 2-fold by vorinostat treatment in gastric cancer cell lines." | ( Cho, JY; Choi, W; Claerhout, S; Kim, K; Kim, SB; Lee, JS; Lim, JY; Mills, GB; Park, YY, 2011) |
| "For patients with HER2-overexpressing gastric cancer, there is an improved prognosis with additional trastuzumab to chemotherapy with a platinum compound and a fluoropyrimidin in first-line therapy." | ( Dumke, K; Krüger, M; Reymond, M; Weissinger, F, 2011) |
| "In the gastric cancer cell line BGC-823, the expression and activity of PKG II were increased by infecting the cells with adenoviral construct encoding PKG II cDNA and treating the cells with the cGMP analogue 8-pCPT-cGMP." | ( Chen, Y; Lan, T; Qu, R; Sang, J; Wu, Y, 2012) |
| "The vincristine-resistant human gastric cancer cell line SGC7901/VCR and its parental cell line SGC7901 were treated with ROS, MMC (negative control), cyclosporine A+MMC (positive control) or ROS+MMC." | ( Hu, JF; Li, GQ; Su, Q; Xiao, X; Zhang, L, 2012) |
| "To sensitize gastric cancer cells to TRAIL, we treated gastric cancer MGC803 cells with TRAIL and cisplatin." | ( Hou, KZ; Jiang, YH; Liu, J; Liu, YP; Qu, XJ; Xu, L; Zhang, Y, 2011) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | ( He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH, 2011) |
| "Sixty-eight untreated gastric cancer patients (T3/T4 and/or N+) were enrolled." | ( Li, T; Song, Y; Yu, C; Yu, R; Zhu, W, 2012) |
| "In KRAS mutant gastric cancer cells, either p-ERK or p-STAT3 was also increased upon treatment of NVP-BKM120." | ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Oh, DY; Park, E; Park, J, 2012) |
| "pylori treatment failure, and gastric cancer in this population necessitate documentation of infection status at multiple time points over a patient's life." | ( Bruce, MG; Bruden, DL; Hennessy, TW; Hurlburt, D; McMahon, BJ; Miernyk, KM; Morris, J; Parkinson, AJ; Peters, H; Sacco, F, 2011) |
| "Seventy consecutive patients with gastric cancer treated with NAC followed by surgical resection between Jan 1, 2000, and Dec 31, 2009, at Osaka National Hospital were identified from a prospective database." | ( Fujitani, K; Hirao, M; Kodama, Y; Mano, M; Tsujinaka, T, 2012) |
| "Patients suffering from advanced gastric cancer still have a poor prognosis and treatment options are limited." | ( Bechter, O; Dlaska, M; Eisterer, W; Fridrik, MA; Greil, R; Grünberger, B; Mayrbäurl, B; Obrist, P; Russ, G; Thaler, J; Wöll, E; Zabernigg, A, 2011) |
| "Standard chemotherapy for advanced gastric cancer was changed to S-1/CDDP by SPIRITS phase III trial which was presented just after this trial was initiated, which would be a major cause of slow accrual." | ( Aoyama, T; Hasegawa, S; Kanemoto, A; Saze, Z; Tahara, H; Terashima, M; Tsuburaya, A; Yoshikawa, T, 2011) |
| "S-1 mono-therapy for advanced gastric cancer is hard to continue in some patients due to adverse events." | ( Aoyama, T; Cho, H; Hayashi, T; Kuwabara, H; Masuda, M; Mikayama, Y; Ogata, T; Rino, Y; Tsuburaya, A; Yoshikawa, T, 2011) |
| "Although chemotherapy is of choice for gastric cancer recurrence, in some cases radiotherapy can play an important role in local control even in peritoneal metastasis." | ( Fujiwara, T; Kagawa, S; Kanaya, N; Kunitomi, A; Ogawa, N; Uno, F, 2011) |
| "Scirrhous type of gastric cancer was suspected and gastric forceps biopsy was performed at many points under the retreated endoscopic examinations." | ( Fukunaga, M; Furukawa, H; Imamura, H; Kawabata, R; Kishimoto, T; Munakata, S; Ohzato, H; Takemoto, H; Yamamoto, T, 2011) |
| "We report a case of Stage IV inoperable gastric cancer demonstrating a cCR treated with S-1/PTX." | ( Ebisui, C; Kato, R; Kinuta, M; Makino, S; Murakami, M; Murata, K; Nishigaki, T; Okada, K; Okamura, S; Owada, Y; Yanagisawa, T; Yokouchi, H, 2011) |
| "We encountered a case of gastric cancer accompanied with liver metastasis, which had a good response to chemotherapy of S-1." | ( Amano, R; Hirakawa, K; Ito, G; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M, 2011) |
| "Our findings suggest that the risk of gastric cancer perforation should be borne in mind when we administer neoadjuvant chemotherapy to patients who have advanced gastric cancer with a deep ulcer." | ( Egawa, T; Eto, E; Hayashi, S; Inaba, Y; Irino, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Okamura, A; Segami, K, 2011) |
| "Case 1 with postoperative gastric cancer developed acute myocardial infarction (AMI) on the sixth day of the second chemotherapy course with conventional doses of cisplatin and tegafur gimeracil oteracil potassium." | ( Arihara, M; Hashimoto, S; Hyogo, M; Irie, H; Ito, D; Iwamura, Y; Kimura, M; Kohno, Y; Maruyama, N; Matsubara, H; Matsui, A; Matsumuro, A; Nakamura, T; Sawada, T; Shima, T; Shiraishi, J; Yokoi, H, 2012) |
| "Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only." | ( Bang, YJ; Button, P; Cho, JY; Chung, HC; Ji, J; Kim, YH; Kim, YW; Lee, KH; Lee, KW; Mok, YJ; Noh, SH; Noh, SI; Park, YK; Sirzén, F; Yang, HK; Yeh, TS, 2012) |
| "For patients with metastatic gastric cancer, the sequential administration of cisplatin, leucovorin, 5-FU, and docetaxel may be an effective palliative option and offers a far more favorable toxicity profile than the simultaneous use of docetaxel, cisplatin, and 5-FU." | ( Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; D'Emidio, S; Fiorentini, G; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2012) |
| "A panel of gastric cancer cell lines was treated with lapatinib, and we observed that cell proliferation was reduced by 70% and that the degree of HER2 amplification corresponds to sensitivity to lapatinib." | ( Chen, CT; Christensen, JG; Gao, S; Kim, H; Liska, D; Weiser, MR, 2012) |
| "The treatment of PBMCs from gastric cancer patients, with Tα1 (50 µg/mL) alone increased the percentage of CD4+CD25+Foxp3+ (suppressive antitumor-specific Tregs) from 1." | ( Fu, XL; He, HY; Lan, YZ; Li, J; Li, JT; Liu, KJ; Ni, B; Qian, F; Shen, ZG; Tian, Y; Wu, YZ; Yang, X; Yin, Y; Zhang, J, 2012) |
| "After SGC-7901 gastric cancer cells were treated with EP, the expression of HMGB1, RAGE, Akt, phosphorylated Akt (p-Akt) and some transcription factors was identified and the effects of EP on cell proliferation, invasion, cell cycle distribution and apoptosis were assessed." | ( Chen, NW; Chen, WX; Zhang, J; Zhou, Z; Zhu, JS, 2012) |
| "Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival." | ( Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M, 2012) |
| "Advanced gastric cancer patients received an S-1 + cisplatin regimen (S-1: 80-120 mg days 1-21; cisplatin: 60 mg/m(2) day 8, every 4-5 weeks), either as outpatient chemotherapy with oral hydration on days 9-10, or as inpatient chemotherapy with intravenous hydration on days 9-10, based on the results of an oral hydration test during days 1-7 of the first cycle." | ( Hamaguchi, T; Hashimoto, J; Kato, K; Nakajima, TE; Okazaki, S; Shimada, Y; Takahari, D; Tamura, K; Yamada, Y; Yamamoto, S, 2013) |
| "A 65-year-old male with type 5 gastric cancer and two lesions of liver metastases was initially treated with S-1/CDDP." | ( Higashiyama, M; Kato, T; Nakamura, Y; Nakayama, H; Nobutou, Y; Okamura, R; Wada, S; Yoh, T, 2012) |
| "A total of 107 patients with advanced gastric cancer treated in our hospital from December 2005 to November 2008 were included in this retrospective analysis." | ( Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH, 2011) |
| "Incomplete resection of gastric neoplasms by endoscopic treatment could lead to residual/local recurrence, which may be difficult to identify." | ( Hamada, Y; Horiki, N; Inoue, H; Katayama, N; Katsurahara, M; Kosaka, R; Ninomiya, K; Nishikawa, K; Takayama, R; Takei, Y; Tanaka, K; Tano, S; Toyoda, H, 2012) |
| "In a xenograft model of human gastric cancer in nude mice, we found that administration of γ-tocotrienol alone (1 mg/kg body weight, intraperitoneally 3 times/wk) significantly suppressed the growth of the tumor and this effect was further enhanced by capecitabine." | ( Fong, CW; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Tan, P, 2012) |
| "The standard of care for gastric cancer with peritoneal metastasis is chemotherapy." | ( Ishigami, H; Kaisaki, S; Kitayama, J, 2012) |
| "Human gastric cancer cell lines (MKN7, MKN74, and TMK-1) with and without pretreatment of IL-1 receptor antagonist (IL-1ra) were treated with IL-1β or infected with H." | ( Chan, AO; Cho, CH; Huang, FY; Rashid, A; Wong, DK; Yuen, MF, 2012) |
| "A 64-year-old man with advanced gastric cancer who underwent a curative total gastrectomy(LM, Less, Type 3, 70×55 mm, por1>tub2>sig, pT3(ss), med, INF b, ly3, v3, pN3b(41/61), pPM0, pDM0, pT3N3bM0, Stage III B)followed by adjuvant chemotherapy(paclitaxel+S-1)a year ago, revealed an increasing level of serum CEA and para-aortic lymphnode (#16b1)recurrence on abdominal CT." | ( Ikeda, T; Minamoto, K; Yuasa, I, 2012) |
| "We investigated 20 patients with gastric cancer who were treated with oral fluorouracil anti-cancer drugs as adjuvant chemotherapy." | ( Fukudome, I; Hanazaki, K; Kitagawa, H; Kobayashi, M; Namikawa, T; Okabayashi, T, 2012) |
| "Early diagnosis and treatment of gastric cancer patients is essential for improving prognosis." | ( Cai, Q; Chen, X; Li, J; Liu, B; Liu, W; Zhu, Z, 2012) |
| "Patients who had Japanese Gastric Cancer Association (JGCA) cStage IIIB gastric cancer were enrolled onto this study and received oral S-1 (65 mg/m(2)/day) administration and 50-Gy radiotherapy followed by radical surgery." | ( Hagiike, M; Inoue, T; Kimura, T; Okano, K; Suzuki, Y; Usuki, H; Yachida, S, 2012) |
| "Blocking OLFM4 expression can sensitize gastric cancer cells to H2O2 or TNF α treatment by increasing caspase-3 dependent apoptosis." | ( Ang, N; Bao, LM; Huang, Y; Jiang, X; Liu, RH; Wu, LY; Xiang, H; Yang, HA; Yang, MH; Yue, LW, 2012) |
| "Among 484 patients with metastatic gastric cancer, who had received chemotherapy in 4 Japanese hospitals, we identified 28 patients who had received either paclitaxel- or docetaxel-containing chemotherapy and who were refractory to the other taxane." | ( Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kitagawa, M; Mizoshita, T; Mizushima, T; Shimura, T; Tanida, S; Yamada, T; Yoshida, M, 2012) |
| "A total of 56 histologically proven gastric cancer patients, who were considered to be stage II or higher with metastatic lymph nodes and with or without distant metastasis (T2-4, N1-3, and M0-1), were treated with a neoadjuvant chemotherapy." | ( Bao, Y; Cao, JM; Li, GL; Li, JS; Liu, K; Wang, XL; Wu, B; Xu, J, 2012) |
| "HER2-positive gastric cancer seems to confer poorer prognosis, particularly in patients without diffuse-type tumor, treated with modified FOLFOX-6." | ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Keam, B; Kim, JW; Kim, M; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Oh, DY, 2012) |
| "We experienced two cases of Stage IV gastric cancer undergoing adjuvant surgery after down staging by chemotherapy." | ( Azuma, T; Inoue, T; Mori, Y; Ohtani, H; Tamamori, Y, 2012) |
| "Cisplatin is a widely used gastric cancer (GC) chemotherapy; however, genetic factors regulating GC responses to cisplatin remain obscure." | ( Cheng, LL; Gopalakrishnan, V; Huang, D; Ivanova, T; Lee, J; Lee, M; Liem, N; Ooi, CH; Qin, L; Rha, SY; Tan, IB; Tan, P; Teh, BT; Wu, J; Wu, Y; Yeoh, KG; Yong, WP; Zouridis, H, 2013) |
| "Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures." | ( Ajani, JA; Benedetti, JK; Blanke, CD; Estes, NC; Goldman, B; Gunderson, LL; Haller, DG; Hundahl, SA; Jessup, JM; Macdonald, JS; Martenson, JA; Smalley, SR; Stemmermann, GN, 2012) |
| "Consecutive 170 patients with gastric cancer who underwent curative surgery and received adjuvant S-1 chemotherapy were enrolled." | ( Bang, YJ; Choung, H; Khwarg, SI; Kim, HH; Kim, JH; Kim, N; Kim, S; Kim, YJ; Lee, JS; Lee, KW; Lee, MJ; Park, C; Park, DJ, 2012) |
| "To induce stomach cancer, rats except for CO and CC were orally treated with 100 mg/kg MNU on day 0 and 14, and s-NaCl twice-a-week for the first 3 weeks." | ( Klaikeaw, N; Patumraj, S; Sintara, K; Thong-Ngam, D, 2012) |
| "In patients with metastatic gastric cancer, median overall survival remains under 1 year and standard chemotherapy regimens are not able to substantially improve the prognosis of the patients." | ( Kołodziejczyk, P; Kulig, J; Kulig, P; Legutko, J, 2013) |
| "In patients with curable Stage IV gastric cancer, at least a D2 gastrectomy to reduce the absolute volume of tumor cells, followed by adjuvant chemotherapy, may be essential to improve their prognosis." | ( Edagawa, A; Eguchi, D; Ikeda, Y; Itoh, S; Kawanaka, H; Kawasaki, K; Korenaga, D; Koushi, K; Okuyama, T; Shinohara, S; Takenaka, K, 2013) |
| "Despite substantial developments in gastric cancer treatment, the majority of patients relapse after definitive surgery." | ( Hubert, A; Kadouri, L; Peretz, T; Rivkind, A; Rottenberg, Y; Sonnenblick, A; Vainer, GW; Wygoda, M, 2012) |
| "The survivals of gastric cancer (GC) patients are associated with early diagnosis and effective treatments." | ( Chang, CC; Chang, J; Chen, LY; Cheng, CC; Liao, MH; Lu, N; Mai, FD; Peng, CL; Wang, WM, 2012) |
| "The growth inhibition rate of the gastric cancer cells by treatment with DMS (1 micromol/L) was (10." | ( Hu, CY; Lan, KH; Lu, Q; Tang, W; Wang, SF; Yin, GJ, 2012) |
| "Several studies have been published on gastric cancer treatment through an active specific immunotherapy, aimed at improving the immunoregulatory response and increasing the circulating tumor-specific T cells." | ( Basso, D; Farinati, F; Maddalo, G; Zorzetto, V, 2012) |
| "Intraperitoneal chemotherapy for gastric cancer using a port is safe and feasible under appropriate management." | ( Emoto, S; Hidemura, A; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H, 2012) |
| "Eighty patients with advanced gastric cancer were treated in our surgery department from 2005 to 2009; 38 of these patients received mFOLFOX7 neoadjuvant chemotherapy, the other 42 patients assigned to the control group." | ( Cai, J; Chen, RX; Meng, H; Wang, KL; Wang, Y; Wu, GC; Zhang, J; Zhang, ZT, 2012) |
| "A total of 83 advanced gastric cancer patients receiving biweekly docetaxel/S-1 treatment (DS) were included in the study." | ( Akiyama, H; Endo, I; Kimura, J; Kosaka, T; Kunisaki, C; Makino, H; Ono, HA; Oshima, T; Takagawa, R; Takahashi, M, 2012) |
| "From 2008 to 2010, 80 patients with gastric cancers were enrolled onto therapy with all-trans-retinoic acid (ATRA)." | ( Cao, LY; Chen, FH; Ge, JF; Hu, KW; Li, H, 2012) |
| "Mean time from gastric cancer diagnosis to liver metastasis was significantly longer in the TAI group (n = 13) than in the systemic chemotherapy group (n = 29); 944 ± 231 days versus 506 ± 77 days." | ( Kan, ZX; Liu, R; Qian, S; Wang, JH; Wang, YY; Zhang, W, 2012) |
| "BGC-823 human gastric cancer cells were infected with adenoviral constructs encoding the cDNA of PKG II (pAd‑PKG II) to increase the expression of PKG II and treated with 8-pCPT‑cGMP to activate the enzyme." | ( Chen, Y; Jiang, L; Lan, T; Li, Y; Sang, J; Shao, G; Tao, Y; Wang, Y; Wu, Y, 2012) |
| "MKN28 human gastric cancer cells were treated with trypsin, a PAR-2 activator, and subjected to real-time reverse transcription polymerase chain reaction (qRT-PCR), western blotting and ELISA for gene expression analyses." | ( Gao, GR; Lv, CG; Zhang, BL; Zhang, C; Zhang, XF; Zhang, ZL, 2012) |
| "DCS/DOS is effective for advanced gastric cancer and in the setting of neoadjuvant chemotherapy." | ( Chi, Y; Cui, CX; Li, YS; Lü, N; Song, Y; Sun, YK; Wang, JW; Yang, L; Yuan, XH; Zhang, W; Zhou, AP, 2012) |
| "The prognosis of gastric cancer patients undergoing curability B surgery was retrospectively examined to determine the effectiveness of the administration of oral anti-cancer drugs as postoperative adjuvant chemotherapy." | ( Edagawa, A; Hashimoto, K; Higashi, T; Kawanaka, H; Korenaga, D; Morita, M; Nagata, S; Oki, E; Okuyama, T; Saeki, H; Takenaka, K; Tateishi, M; Uchiyama, H; Yaita, H, 2012) |
| "We report a gastric cancer patient with positive peritoneal lavage cytology (CY1) who achieved 20-month progression free survival by S-1 monotherapy." | ( Kiyokawa, T; Nishida, M; Seto, Y; Shimoyama, S, 2012) |
| "In this study, 111 patients with gastric cancer who consecutively underwent MDCT scan followed by radical surgical treatment at our hospital were retrospectively evaluated." | ( Basile, B; Bertocco, M; Calzolari, F; Garcea, D; Gardini, A; Mami, A; Morgagni, P; Petrella, E; Soro, A, 2012) |
| "32 operated gastric cancer patients (stage Ib or II) who were waiting for oral chemotherapy with the 5-FU prodrug doxifluridine were randomized 1:1 to receive additional therapy with aVQ or no additional therapy." | ( Eisenbraun, J; Huber, R; Kim, BS; Kim, KC; Yook, JH, 2012) |
| "Advanced gastric cancer (AGC) accompanied by disseminated intravascular coagulation(DIC)has a poor prognosis, and has no established therapy." | ( Harita, S; Kiguchi, T; Kimura, K; Kubo, T; Mannami, T; Masunari, T; Nakata, Y; Ninomiya, K; Okada, T; Seno, S; Sezaki, N; Sonobe, H; Suzuki, Y; Tamura, T, 2012) |
| "Chemotherapy for gastric cancer is improving continuously through conducting randomized clinical trials and developing new anti-cancer drugs." | ( Shimada, Y; Terazawa, T, 2012) |
| "Precise staging of gastric cancer is essential when selecting for the appropriate treatment approach." | ( Fujiwara, H; Harada, Y; Ichikawa, D; Ikoma, H; Koizumi, N; Kokuba, Y; Komatsu, S; Kubota, T; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Takamatsu, T, 2012) |
| "We report a case of advanced gastric cancer with pyloric stenosis, in which a curative resection was performed following gastrojejunostomy and S-1 based chemotherapy." | ( Kawai, T; Kinoshita, K; Kobayashi, S; Kusano, M; Miyagishima, T; Nagasako, Y; Ogasawara, K; Sunahara, M; Takahashi, M, 2012) |
| "Human gastric cancer cell line SGC7901 was treated with the NF-κB inhibitor PDTC, and the expression levels of E-cadherin and Snail were investigated by qPCR and western blot." | ( Hu, Z; Liu, X; Qiao, L; Tang, Z; Zhou, Y, 2013) |
| "He was diagnosed with recurrent gastric cancer in cervical lymph nodes, and treatment with S-1 (120 mg/ day) was initiated." | ( Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H, 2012) |
| "We report a case of recurrent gastric cancer successfully treated by a combination of CPT-11 and CDDP as the third- line chemotherapy." | ( Kataoka, M; Miyazawa, K; Oeda, Y; Tonooka, T; Wakatsuki, K; Yoshioka, S, 2012) |
| "Clinical data of 71 patients with gastric cancer treated with oxaliplatin plus S-1 as adjuvant chemotherapy in the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) from Jan 1(st), 2010 to Jan 1(st), 2012 were retrospectively reviewed." | ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012) |
| "A total of five advanced gastric cancer patients were treated." | ( Aono, T; Deguchi, K; Deguchi, T; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Nomura, M; Takagi, M; Tamagawa, H; Tanaka, Y; Umeda, S; Yoshida, H, 2013) |
| "Forty-three patients with gastric cancer treated with neoadjuvant chemotherapy followed by curative resection between September 2011 and February 2012 were analyzed." | ( Ang, J; Cao, CH; Chen, L; Hu, L; Huang, LN; Huang, PT; Wu, JX; Zheng, YX, 2012) |
| "Antagomirs were applied to treating gastric cancer cell derived xenograft in vivo." | ( Gu, H; Qian, H; Tao, Y; Wang, M; Xu, W; Zhang, L; Zhang, X; Zhao, C; Zhu, W, 2013) |
| "Furthermore, gastric cancer cells pretreated with PMA showed markedly enhanced invasiveness, which was partially abrogated by EGCG and siRNA-targeted RON and Egr-1." | ( Joo, YE; Jung, YD; Khoi, PN; Lang, SA; Lee, YH; Park, JS; Stoeltzing, O, 2013) |
| "Patients with locally advanced gastric cancer received 2 courses of preoperative chemotherapy with S-1 (40 mg/m(2) b." | ( Harada, K; Hayashi, T; Hirakawa, M; Hirata, K; Hirayama, M; Kato, J; Katsuki, S; Kobune, M; Maeda, M; Miyamoto, H; Miyanishi, K; Nobuoka, T; Ohnuma, H; Ono, M; Sagawa, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takahashi, Y; Takayama, T; Takimoto, R, 2013) |
| "Human gastric cancer cell lines SGC-7901 and MKN-45 were treated with diverse concentrations of MJ." | ( Huang, K; Li, D; Pu, J; Qi, M; Tong, L; Tong, Q; Xiang, X; Zheng, L, 2013) |
| "The trastuzumab for Gastric Cancer study newly defined tumors that were positive for human epidermal receptor-2 (Her-2) and created a Her-2-oriented treatment strategy that is also applicable in the adjuvant setting for stage 2/3 cancers." | ( Aoyama, T; Cho, H; Hayashi, T; Kameda, Y; Masuda, M; Miyagi, Y; Oshima, T; Rino, Y; Shirai, J; Tsuburaya, A; Yoshikawa, T; Yukawa, N, 2013) |
| "The sensitivity of SGC7901 gastric cancer cells to anticancer chemotherapy was investigated with the MTT method, while cell migration and invasion were examined by wound-healing and transwell assays, respectively." | ( Cao, FL; Li, NY; Li, YP; Liu, YQ; Lv, CL; Xu, M, 2013) |
| "A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles)." | ( Bai, Y; Gao, J; Gong, YF; Jiang, B; Liu, F; Yuan, HH; Zhang, WJ; Zhang, WY, 2013) |
| "Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options." | ( Bodoky, G; Celik, I; Chung, HC; Gorbunova, V; Götte, H; Kang, YK; Kurteva, G; Lordick, F; Melezínková, H; Moehler, M; Moiseyenko, VM; Oh, SC; Park, JO; Salman, P; Sawaki, A; Volovat, C, 2013) |
| "Our data suggested that gastric cancer patients harboring ERCC1‑118 C/C and XRCC1‑399 A/G or A/A genotypes may benefit from receiving OXA‑based adjuvant chemotherapy, and carrying at least one variant XRCC1 Arg399Gln or GSTP1 Ile105Val allele may contribute to the occurrence of adverse drug effects associated with OXA‑based chemotherapy." | ( Ling, Y; Liu, YP; Pan, YD; Qi, QF; Wang, MH; Zhang, CS; Zhang, YP; Zhu, CT, 2013) |
| "Although the treatment of gastric cancer improves the clinical outcomes, the survival of gastric cancer patients with peritoneal metastasis is still very poor." | ( Imano, M; Okuno, K, 2014) |
| "Viable cells and apoptotic cells in gastric cancer cells treated with hTERT siRNA or/and the COX2 inhibitor celecoxib were measured using Trypen blue exclusion and flow cytometry." | ( Björkholm, M; Jia, J; Li, B; Liang, X; Liu, T; Xu, D, 2013) |
| "To improve outcome of resectable gastric cancer, several treatment strategies have been evaluated." | ( Bang, YJ; Oh, DY, 2013) |
| "Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups." | ( Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X, 2013) |
| "We found that gastric cancer cells treated with LY294002 showed a significant inhibition of PI3K/Akt activity." | ( Gao, Q; Tang, B; Xie, X; Zhang, P; Zhou, J, 2013) |
| "Cytoplasmic proteins in gastric cancer cells before and after TSA treatment were immunoprecipitated with anti-acetylated lysine antibodies, separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis gel and silver-stained to detect the proteins by mass spectrometry after removal of the gel." | ( Fang, WL; Li, GM; Ma, JL; Shi, M; Wang, N; Wang, T; Wang, YG; Wei, J, 2013) |
| "Survival of the 5-FU-resistant gastric cancer cell line, SNU-620-5FU/1000, was not significantly reduced even by a high dose of 5-FU treatment." | ( Choi, MG; Park, H; Park, JM; Xian, XS, 2013) |
| "A 35-year-old female with scirrhous stomach cancer (stage IV) was treated with a combination of 5-aminolevulinic acid (ALA), sodium dichloroacetate (DCA), hyperthermotherapy, and immunotherapy as terminal care." | ( Goto, S; Kamigaki, T; Saito, M; Yano, K, 2013) |
| "Metastatic gastric cancer patients who failed first and (or) second line chemotherapy, were enrolled." | ( Huang, XE; Huo, JG; Tang, JH; Wang, XN; Wei, GL, 2013) |
| "Ghrelin treatment must be avoided for gastric cancer patients." | ( Hu, D; Ji, J; Tian, C; Zhang, L, 2013) |
| "The prognosis for stage 3 gastric cancer is not satisfactory, even with S-1 adjuvant chemotherapy." | ( Fukushima, R; Hirabayashi, N; Ito, Y; Iwahashi, M; Kimura, Y; Matsui, T; Mikata, S; Miyashiro, I; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Takiguchi, N; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2014) |
| "AFP-producing gastric cancer with peritoneal metastasis has a poor prognosis, but chemotherapy, mainly with S-1 and trastuzumab, was effective for it." | ( Ishikawa, H; Ishioka, K; Ko, S; Matsusaka, M; Mukogawa, T; Nishiwada, S; Watanabe, A; Yoshikawa, T, 2013) |
| "Here, we present a case of recurrent gastric cancer during S-1 adjuvant therapy that showed partial response to CDDP + capecitabine therapy." | ( Ebata, T; Fukaya, M; Hirata, A; Igami, T; Itatsu, K; Nagino, M; Sugawara, G; Tsunoda, N; Uehara, K; Usui, H; Yokoyama, Y; Yoshioka, Y, 2013) |
| "Combined modality therapy for advanced gastric cancer diagnosed with stage IV can be an effective treatment, so we hope that it will be established as a standard therapy." | ( Doyama, H; Endo, N; Kadoya, S; Kurumatani, H; Murakami, N; Shimada, M; Tanada, Y; Yamada, T, 2013) |
| "S-1/CDDP as a NAC regimen for advanced gastric cancer appears to be an effective treatment." | ( Eshita, Y; Ogawa, F, 2013) |
| "Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment." | ( Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T, 2013) |
| "Locally advanced, marginally resectable gastric cancer with poor prognosis, such as large type 3 or 4 tumors, para-aortic and/or bulky nodal disease, and serosa-positive gastric cancer, is the main target of neoadjuvant chemotherapy." | ( Fujitani, K, 2013) |
| "The proliferation and apoptosis of AGS gastric cancer cells treated with EGCG were observed by cell counting kit (CCK)-8 and flow cytometry." | ( Li, G; Ma, J; Shi, M; Wang, N; Wang, T; Wang, Y; Wei, J, 2013) |
| "Treatment of gastric cancer remains a major challenge, and new anticancer drugs are urgently required." | ( Bai, X; Han, J; Meng, X; Sun, H; Wang, B; Zhang, X; Zhang, Z, 2013) |
| "Patients with metastatic gastric cancer (mGC) who do not respond to or who experience progression with second-line chemotherapy have no treatment options that clearly confer a survival benefit." | ( Bai, Y; Cheng, Y; Guo, W; Ji, D; Li, J; Liu, X; Qin, S; Sun, G; Tao, M; Wang, L; Wang, Z; Xiong, J; Xu, J; Xu, N; Yang, Y; Yu, H; Zheng, L; Zhu, X, 2013) |
| "Adjuvant chemotherapy trial of TS-1 for gastric cancer study demonstrated that postoperative S-1 chemotherapy for 1 year improved overall survival of locally advanced gastric cancer (LAGC) patients." | ( Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH, 2013) |
| "Nine advanced gastric cancer patients who underwent chemotherapy at the University of Tokushima were included in this study." | ( And, RN; Iwata, T; Komatsu, M; Kurita, N; Miyatani, T; Morimoto, S; Nishioka, M; Sato, H; Shimada, M; Yoshikawa, K, 2013) |
| "Patients with Stage II or III gastric cancer who underwent curative surgery were randomly assigned to receive standard daily S-1 administration [group A: 80-120 mg/day S-1 depending on body surface area (BSA); days 1-28 every 6 weeks for 1 year] or alternate-day administration (group B: 80-120 mg/day S-1 depending on BSA; alternate days for 15 months)." | ( Ikeguchi, M; Kanayama, H; Kurisu, Y; Nakamura, S; Nishidoi, H; Ogawa, H; Shimizu, T; Tatebe, S; Tsujitani, S; Yamane, N, 2014) |
| "We compared the viability of gastric cancer cells and epithelia cells in buffered and unbuffered culture conditions with PPZ treatment by WST-8 assay." | ( Chen, M; Ding, X; Huang, S; Zhang, X; Zou, X, 2013) |
| "Herein, we developed a human MDR gastric cancer cell subline, SGC7901/CDDP, by repeated selection of resistant clones of parental sensitive cells, and further investigated the chemosensitizing effects and the underlying mechanisms of adenovirus-mediated IL-24 (Ad-IL-24) gene therapy plus CDDP for the human MDR gastric cancer cells SGC7901/CDDP in vitro and in vivo." | ( Bian, G; Dong, X; He, S; Mao, Z; Sheng, W; Yang, J, 2013) |
| "The long-term outcomes of advanced gastric cancer (AGC) patients treated with S-1 plus cisplatin (SP) combination chemotherapy remain unclear." | ( Ando, M; Kadowaki, S; Komori, A; Kondo, C; Muro, K; Narita, Y; Nitta, S; Takahari, D; Taniguchi, H; Ura, T; Yamaguchi, K, 2014) |
| "Patients with advanced gastric cancer that progressed after one or two lines of systemic chemotherapy were randomly assigned to everolimus 10 mg/d (assignment schedule: 2:1) or matching placebo, both given with BSC." | ( Ajani, JA; Al-Batran, SE; Bai, YX; Bang, YJ; Chin, K; Chung, HC; Costantini, C; Ferry, D; Kim, YH; Lebwohl, D; Muro, K; Ohtsu, A; Pan, HM; Rizvi, S; Sahmoud, T; Shen, L; Smith, H; Tebbutt, NC; Van Cutsem, E; Yeh, KH, 2013) |
| "Overexpression of miR-29c in gastric cancer BGC-823 cells suppressed cell proliferation, stimulated cell apoptosis, induced cell cycle arrest in S phase and increased the chemotherapy sensitivity to drug docetaxel (all were P < 0." | ( Cai, JC; Luo, QC; Ma, XQ; Wang, LP, 2013) |
| "Therefore, autophagy protects human gastric cancer cell line SGC7901 against DDP-induced apoptosis, inhibition of autophagy can promote apoptosis, and combination therapy with DDP and chloroquine may be a promising therapeutic strategy for gastric cancer." | ( Fang, N; He, B; Liao, YQ; Lu, S; Wan, YY; Zhang, HQ, 2013) |
| "Additionally, 56 gastric cancer patients treated with a modified FOLFOX regimen(biweekly oxaliplatin plus 5-FU and folinic acid) were retrospectively analyzed to further evaluate the prognostic and predictive impact of SULF2 methylation in gastric cancer." | ( Bian, X; Guan, W; Liu, B; Qian, X; Shen, J; Sun, X; Wang, H; Wang, L; Wei, J; Xie, L; Yang, Y; Yu, L; Yue, G; Zou, Z, 2013) |
| "MKN45, a gastric cancer cell line, was treated with each single agent alone or a combination of FGF19, PD and 5-Fu." | ( Hu, S; Shi, YQ; Wang, GJ; Wen, JG; Ye, YW; Zhang, XF; Zhao, CL; Zhou, Y; Zong, H, 2013) |
| "Twenty-eight patients with advanced gastric cancer underwent gastrectomy without preoperative chemotherapy." | ( Fujita, I; Kanazawa, Y; Kato, S; Onodera, H; Uchida, E, 2013) |
| "We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 2001 and 2011, comparing the outcome of patients with first-line chemotherapy and those who received second-line chemotherapy." | ( Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W, 2013) |
| "We report a patient with advanced gastric cancer responding remarkably to neoadjuvant chemotherapy consisting of weekly paclitaxel." | ( Ikeda, M; Ishida, N; Kurayoshi, M; Mandai, K; Nakano, R; Nakatani, T; Sadamoto, S; Saito, Y; Takahashi, T; Toyota, K, 2013) |
| "Changes in gastric cancer cell proliferation in response to zerumbone treatment were measured by WST-1 assay." | ( Aggarwal, BB; Guha, S; Koide, S; Matsuo, Y; Morimoto, M; Shamoto, T; Shibata, T; Sung, B; Takahashi, H; Takeyama, H; Tsuboi, K, 2014) |
| "Resveratrol treatment arrested gastric cancer cells in the G1 phase and led to senescence instead of apoptosis." | ( Jia, J; Li, W; Liu, Z; Wang, B; Wang, X; Yang, Q; Zang, W, 2013) |
| "Three gastric cancer cell lines, AGS, MKN-74 and SC-M1, were treated with either all‑trans retinoic acid (ATRA) or ATPR, and their growth and distribution in different cell cycle phases were assessed using an MTT assay and propidium iodide (PI) staining followed by flow cytometry." | ( Chen, FH; Ge, JF; Han, WX; Hu, KW; Li, HJ; Pan, XH; Qin, R; Wu, FR; Wu, LM; Yin, CL; Zhu, HG, 2014) |
| "The role of second-line therapy in gastric cancer patients mostly stemmed from clinical trials with monochemotherapy carried out in Asian countries." | ( Amodio, A; Barba, M; Belli, F; Boggia, S; Di Lauro, L; Fattoruso, S; Giannarelli, D; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P, 2013) |
| "In this study, we investigated whether gastric cancer with hypoxia-induced resistance to 5-fluorouracil (5-FU) could be re-sensitized following treatment with low-dose dichloroacetate (DCA), an inhibitor of the glycolytic pathway." | ( Cho, YK; Ham, IH; Han, SU; Hur, H; Kim, YB; Lee, G; Lee, JY; Shim, W; Xuan, Y; Yun, J, 2014) |
| "As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone." | ( Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K, 2014) |
| "Eighty-five patients with advanced gastric cancer (stage IIB and IIIC) were randomly divided into two groups: neoadjuvant chemotherapy group (40 cases) and surgery alone group (45 cases)." | ( Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Wang, D; Yang, PG; Zhang, ZD; Zhao, Q; Zhao, XF, 2013) |
| "Thirty-eight patients with recurrent gastric cancer who underwent curative D2 surgery and received S-1 adjuvant chemotherapy between June 2002 and December 2011 were examined." | ( Aoyama, T; Cho, H; Fujikawa, H; Hayashi, T; Kitani, Y; Masuda, M; Ogata, T; Oshima, T; Ozawa, Y; Rino, Y; Wada, H; Yoshikawa, T; Yukawa, N, 2013) |
| "We report 2 cases of stage IV gastric cancer in which the primary tumor was resected after chemotherapy combined with trastuzumab was administered." | ( Hakamada, K; Kawasaki, H; Kimura, A; Nakai, M; Nakayama, Y; Wajima, N; Yonaiyama, S, 2013) |
| "We report a case of advanced gastric cancer successfully treated with preoperative S-1/Lentinan (LTN)chemotherapy followed by curative gastrectomy." | ( Aono, T; Deguchi, K; Deguchi, T; Endo, S; Fujitani, K; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Noguchi, Y; Nomura, M; Okumura, Y; Takagi, M; Tamagawa, H; Tanaka, Y; Yoshida, H, 2013) |
| "Fifty-five cases of advanced gastric cancer received pre-operative treatment with S-1 and CDDP." | ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Kamikozuru, H; Nagahama, T; Seki, R; Takasaki, J; Tei, S, 2013) |
| "We encountered a patient with gastric cancer who achieved long-term quality of life( QOL) by undergoing chemotherapy with weekly administration of paclitaxel and placement of an expandable metallic stent." | ( Kudoh, K; Narita, Y; Ogata, K; Ohchi, T, 2013) |
| "We report a case of gastric cancer accompanied by disseminated carcinomatosis of the bone marrow treated with S-1 and cisplatin( CDDP) combination chemotherapy." | ( Amagasa, H; Ami, K; Ando, M; Aoki, N; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Imai, K; Kamikozuru, H; Nagahama, T; Ohbu, M; Takeuchi, S; Tei, S, 2013) |
| "A 70-year-old man with advanced gastric cancer was treated with neoadjuvant chemotherapy consisting of S-1 plus cisplatin( CDDP)." | ( Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Oshima, S, 2013) |
| "A 77-year-old woman with Stage IV gastric cancer was admitted to our hospital because of high fever, poor appetite, and abdominal pain during combined chemotherapy with S-1 and cisplatin( CDDP)." | ( Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Kuroda, K; Lee, T; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Tanaka, H, 2013) |
| "Patients with advanced gastric cancer and lymph node metastasis who were treated by our institution between 2011 and 2012 were eligible for inclusion." | ( Fukada, J; Fukuda, K; Kawaguchi, O; Kawakubo, H; Kitagawa, Y; Matsuda, S; Saikawa, Y; Shigematsu, N; Takahashi, T; Takeuchi, H, 2014) |
| "For resectable gastric cancer, both postoperative chemoradiotherapy and perioperative chemotherapy demonstrate high-level evidence for improved survival in Western populations." | ( Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I, 2014) |
| "The human gastric cancer cell line AGS, was infected with adenoviral constructs encoding cDNA of PKG II (Ad-PKG II) to increase the expression of PKG II and was treated with 8-pCPT-cGMP to activate the kinase." | ( Chen, Y; Jiang, L; Lan, T; Li, Y; Qian, H; Wang, Y; Wu, M, 2014) |
| "Cells of the human gastric cancer line AGS were infected with adenoviral constructs bearing the PKGII cDNA in order to increase its endogenous expression, and were treated with 8‑pCPT‑cGMP to activate the PKGII enzyme." | ( Chen, Y; Lan, T; Li, Y; Qian, H; Wang, Y, 2014) |
| "Patients with metastatic or recurrent gastric cancer refractory to S-1-based first-line chemotherapy were randomly assigned to receive BIRIP (irinotecan 60mg/m(2) plus cisplatin 30mg/m(2), every 2weeks) or irinotecan alone (irinotecan 150mg/m(2), every 2weeks)." | ( Amagai, K; Azuma, M; Higuchi, K; Hosaka, H; Kanda, T; Koizumi, W; Moriwaki, T; Nakayama, N; Sakuyama, T; Sasaki, E; Sasaki, T; Sekikawa, T; Shimada, K; Takahashi, F; Takeda, Y; Takeuchi, M; Tanabe, S, 2014) |
| "BGC-823 human gastric cancer cells were treated with 1,25(OH)2D3 or cisplatin alone, or a combination of both agents." | ( Bao, A; Li, Y; Tong, Y; Wei, C; Wu, W; Zheng, H, 2014) |
| "Treatment of gastric cancer cells with genistein reduced its chemoresistance to 5-Fu (fluorouracil) and ciplatin." | ( Huang, W; Huang, Z; Luo, Q; Wan, C, 2014) |
| "A total of 100 gastric cancer patients who received curative D2 gastrectomy were enrolled in this study and were randomly assigned to either XELOX group (oral capecitabine combined with intravenous oxaliplatin chemotherapy) or the control group (surgery alone)." | ( He, Y; Huang, C; Ji, J; Liang, H; Liu, Y; Shi, Y; Sun, Y; Wu, A; Yan, M; Ye, Y; Zhan, Y, 2014) |
| "Accuracy of the radiologic diagnosis of gastric cancer staging after neoadjuvant chemotherapy remains unclear." | ( Aoyama, T; Hasegawa, S; Hayashi, T; Ito, Y; Kimura, Y; Matsui, T; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2014) |
| "40 patients with locally advanced gastric cancer received intensity-modulated radiotherapy (IMRT) at a dosage of 45-50." | ( Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014) |
| "Recent studies found that gastric cancer patients with Helicobacter pylori infection had a better response to chemotherapy and had an improved overall prognosis compared with those without." | ( Su, J; Zhang, G; Zhou, X; Zhu, L, 2014) |
| "Eleven eligible articles including 1274 gastric cancer patients with platinum-based treatment were enrolled in our meta-analysis." | ( Ma, J; Wang, SY; Xu, J; Zhou, JW; Zong, HT, 2014) |
| "Patients with unresectable or recurrent gastric cancer who experienced progression despite fluoropyrimidine-containing treatment were studied." | ( Goto, M; Hara, T; Koizumi, W; Miyata, Y; Muro, K; Nishina, T; Sasaki, Y; Toh, Y; Tsuji, A; Yasui, H, 2014) |
| "Here we report a case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy." | ( Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y, 2014) |
| "Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death." | ( Bilici, A, 2014) |
| "Epithelium with low-grade atypia on gastric cancer tissue, which may develop from gastric cancer cells, is frequently present after successful eradication therapy." | ( Boda, T; Chayama, K; Ito, M; Kitamura, Y; Matsuo, T; Oka, S; Tanaka, S; Yoshihara, M, 2014) |
| "The standard of care for stage II/III gastric cancer in Japan is D2 dissection followed by adjuvant S-1 monotherapy." | ( Ishigure, K; Ishiyama, A; Ito, S; Kobayashi, D; Kodera, Y; Kurimoto, K; Matsui, T; Mochizuki, Y; Nakao, A; Nakayama, H; Sakamoto, J; Tanaka, N, 2015) |
| "BGC-823 gastric cancer cells were used to investigate migration following treatment of these cells with the c-Src inhibitors, PP2 and SU6656." | ( Bai, ZG; Wu, GC; Yang, Y; Yin, J; Zhang, ZT, 2014) |
| "Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy." | ( Friess, HM; Novotny, AR; Reim, D; Schuhmacher, C, 2014) |
| "We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer drugs including S-1/CDDP." | ( Sakamoto, K; Sakashita, K; Sawada, R; Sunami, T; Tauchi, J; Yukimoto, K, 2014) |
| "The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer." | ( Al-Sakaff, N; Bang, YJ; Chung, HC; Gotovkin, EA; Hamamoto, Y; Hill, J; Kang, YK; Moiseyenko, VM; Ohtsu, A; Satoh, T; Urspruch, A; Van Cutsem, E; Weber, HA, 2014) |
| "Three and five years survival of gastric cancer patients subjected to adjuvant chemoradiotherapy was 53 and 41% respectively." | ( Isa O, N; López V, H; Russo N, M, 2014) |
| "The diagnostic value of PET-CT, in gastric cancer is well known, but the prognostic value of pretreatment PET-CT has not been adequately evaluated." | ( Choi, SR; Kim, JM; Kim, KS; Koo, TH; Park, IC, 2014) |
| "The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy." | ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014) |
| "Advanced gastric cancer or gastro-oesophageal junction cancer after a failure of first line chemotherapy have poor outcome." | ( Beuzeboc, P; Kirova, Y; Louvet, C; Pernin, V; Peurien, D, 2014) |
| "In 62 gastric cancer patients treated with S-1 alone, data relating to the occurrence of gastrointestinal toxicity (diarrhea, vomiting, and nausea) and possible contributing factors were retrospectively collected, and logistic regression analysis was performed." | ( Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y, 2014) |
| "PAM treatment induced apoptosis of gastric cancer cells through generation and uptake of ROS." | ( Fujii, T; Fujiwara, M; Hori, M; Iwata, N; Kajiyama, H; Kanda, M; Kobayashi, D; Kodera, Y; Koike, M; Mizuno, M; Nakamura, K; Nakayama, G; Natsume, A; Nomoto, S; Saya, H; Sugimoto, H; Tanahashi, K; Tanaka, C; Tanaka, H; Torii, K; Yamada, S, 2015) |
| "While the prognosis of gastric cancer patients with pulmonary lymphangitis carcinomatosa is extremely poor, some patients may have survival benefit from chemotherapy." | ( Boku, N; Endo, M; Fukutomi, A; Funakoshi, T; Kenmotsu, H; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2014) |
| "Forty-six cases of senile advanced gastric cancer patients with a mean age of 70 years were prospectively divided into two groups according to individual acceptance of CIK cells: 25 patients receiving autologous CIK cell treatment combined with XELOX regimen (trial group) and 21 patients receiving simple chemotherapy (control group)." | ( Bai, B; Cui, Y; Kuang, S; Wen, Y, 2014) |
| "New treatment options for gastric cancer are in great demand." | ( Aiello, E; Colarossi, C; Colarossi, L; Espina, V; Iuppa, A; Liotta, L; Memeo, L; Mueller, C, 2014) |
| "Patients with advanced gastric cancer receiving first line chemotherapy were retrospectively collected, and divided into two groups, receiving DCF (docetaxel, cisplatin and fluorouracil) or ECF (epirubicin, cisplatin and fluorouracil) regimens." | ( Kemal, Y; Kut, E; Teker, F; Yilmaz, B; Yucel, I, 2014) |
| "Human gastric cancer cell line MGC803 cells were treated with various concentration of silibinin." | ( Cai, H; Jiang, G; Wang, YX; Wu, H; Zhou, TB, 2014) |
| "Patients with locally advanced gastric cancer (n = 32) received preoperative chemotherapy under the XELOX (capecitabine plus oxaliplatin) regimen." | ( Ding, DY; Hou, RZ; Li, YC; Song, B; Sun, LB; Zhao, GJ, 2014) |
| "Radiotherapy (RT) planning of gastric cancer is important because of the low radiation tolerance of surrounding critical organs." | ( Adas, YG; Aktas, C; Akyurek, S; Andrieu, MN; Atakul, T; Dirican, B; Ergocen, S; Gokce, SC; Hicsonmez, A; Yilmaz, S, 2014) |
| "Furthermore, gastric cancer cells pretreated with IL-1β showed markedly enhanced invasiveness, which was partially abrogated by treatment with IL-6 siRNA, piperine, and inhibitors of p38 MAPK and STAT3." | ( Chay, KO; Joo, YE; Jung, YD; Khoi, PN; Kim, KK; Lian, S; Xia, Y; Yoon, HJ, 2015) |
| "We present a case of bone metastatic gastric cancer treated with zoledronic acid at first and later with denosumab." | ( Cappetta, A; Evangelista, L; Opocher, G; Pastorelli, D; Spano, L; Zovato, S, 2015) |
| "We report a case of gastric cancer with peritoneal dissemination that was successfully treated with low-dose S-1 or capecitabine chemotherapy over a 5-year period." | ( Hara, Y; Minami, Y; Nakamura, T; Ueda, S, 2014) |
| "Potent chemotherapy for advanced gastric cancer has not been completely established." | ( Fukuda, K; Hosoi, Y; Inoue, M; Iwabuchi, Y; Kanda, H; Oshima, M; Shibata, H; Uehara, Y; Yamakoshi, H, 2015) |
| "Using a transgenic mouse model of gastric cancer in which β-catenin, cyclooxygenase 2, and microsomal prostaglandin E synthase 1 activation is induced, we examined a curcumin analog with the most enhanced potential for treating gastric cancer through oral administration." | ( Fukuda, K; Hosoi, Y; Inoue, M; Iwabuchi, Y; Kanda, H; Oshima, M; Shibata, H; Uehara, Y; Yamakoshi, H, 2015) |
| "Human SGC7901 and MKN45 gastric cancer cells were treated with different concentrations of β-elemene." | ( Chang, S; Che, XM; Chen, R; Fan, L; He, SC; Li, L; Liu, JS; Qiu, GL; Zhang, ZL, 2014) |
| "The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009." | ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014) |
| "The migration of gastric cancer cells treated with CQ at 12, 24 and 36 h was measured by wound healing assay." | ( Li, R; Li, Y; Ma, Y; Wang, H; Wang, Y; Zhang, Y, 2015) |
| "Patients with stage II-IIIB gastric cancer who underwent curative D2 gastrectomy were randomly assigned (1:1) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m(2) twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m(2) on day 1) for 6 months or observation alone." | ( Bang, YJ; Chen, JS; Choi, JH; Chung, HC; Chung, IJ; Ha, S; Ji, J; Kim, HH; Kim, HK; Kim, SW; Lee, JI; Lim, Y; Noh, SH; Park, SR; Shin, DB; Yang, HK; Yu, W, 2014) |
| "Patients who underwent ESD for gastric cancer were randomized to two groups and treated with esomeprazole 20 mg per day for 4 wk (4W group) or 2 wk (2W group)." | ( Arai, M; Katsuno, T; Maruoka, D; Matsumura, T; Minemura, S; Nakagawa, T; Okimoto, K; Oyamada, A; Saito, K; Tanaka, T; Yokosuka, O, 2014) |
| "Elucidation of molecular subtypes of gastric cancer may contribute to our understanding of gastric cancer biology and to the development of new molecular markers that may lead to improved diagnosis, therapy, or prognosis." | ( Dominguez, RL; Gulley, ML; Kuan, PF; Martinez, E; Meyers, MO; Morgan, DR; Speck, O; Tang, W, 2015) |
| "In an in vitro study, gastric cancer cell line SGC-7901 was treated with curcumin at serial concentrations and co-administrated with the KATP opener, diazoxide." | ( He, X; Liu, X; Song, A; Sun, K; Zhang, X, 2014) |
| "Celecoxib (COX-2 inhibitor) inhibits gastric cancer cell proliferation, but with low treatment efficacy, limiting its applications." | ( Aziz, F; Wang, X; Yan, Q; Yang, X, 2015) |
| "Furthermore, we treated the primary gastric cancer cells with celecoxib, anti-LeY antibody or the combination, and analyzed their therapeutic efficacy on CA724, GRN and COX-2 expression by Western blot, flow cytometry and ELISA." | ( Aziz, F; Wang, X; Yan, Q; Yang, X, 2015) |
| "A number of 415 patients of gastric cancer that received platinum-based chemotherapy were enrolled in the present study." | ( Ding, LH; Gao, S; Li, CB; Liu, ZY; Wang, ZY; Wu, XL; Zhou, J, 2015) |
| "The standard treatment for stage IV gastric cancer is chemotherapy, but outcomes remain poor." | ( Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O, 2014) |
| "A total of 59 patients with stage IV gastric cancer received induction chemotherapy with S-1 and cisplatin." | ( Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O, 2014) |
| "Treatment of stage IV gastric cancer with S-1 and cisplatin induction chemotherapy followed by R0 resection is safe and may improve survival compared with chemotherapy alone." | ( Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O, 2014) |
| "The treatment strategy for gastric cancer was changed in one patient." | ( Choi, JY; Kim, JJ; Lee, JH; Min, BH; Rhee, PL; Tae, CH, 2015) |
| "A total of 53 stage III/IV gastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy." | ( Huang, H; Li, PH; Lu, MD; Qi, DS; Sun, WJ; Wang, FH; You, T; Yu, YJ; Zhang, Y; Zheng, ZQ, 2014) |
| "AFP-producing gastric cancer with a PVTT has an extremely poor prognosis, but long-term survival was achieved for this dismal condition by salvage surgery after chemotherapy." | ( Hirakawa, K; Hori, T; Inaba, M; Ishikawa, T; Kuroda, K; Nakao, S; Nakata, B; Tendo, M, 2015) |
| "Synchronous bone metastases from early gastric cancer are extremely rare, and a good outcome was achieved in the present case through induction chemotherapy." | ( Iwanaga, T; Iwasaki, Y; Ohashi, M; Oohinata, R; Takishita, C; Yajima, K, 2014) |
| "Untreated advanced gastric cancer patients randomly received docetaxel and cisplatin at 60 mg/m(2) (day 1) followed by fluorouracil at 600 mg/m(2)/day (days 1-5; mDCF regimen) or cisplatin at 75 mg/m(2) (day 1) followed by fluorouracil at 600 mg/m(2)/day (days 1-5; CF) every 3 weeks." | ( Ba, Y; Bai, Y; Chen, W; Dai, G; Fan, N; Jiao, S; Li, J; Liu, T; Liu, Y; Ma, D; Qin, S; Shen, L; Shu, Y; Wang, J; Xu, J; Xu, R; Zheng, L, 2016) |
| "Treatment of gastric cancer cells with a Src inhibitor was shown to significantly reduce cetuximab‑induced phosphorylation of IGF‑IR as well as Src, which resulted in enhanced sensitivity to cetuximab treatment." | ( Li, H; Li, X; Liu, Y; Luo, Y; Qu, X; Xu, L; Zhao, L; Zhu, Z, 2015) |
| "In the present study, AGS and MKN-45 gastric cancer cell lines were treated with Ara-C to determine its role in cell prolife-ration and apoptosis." | ( Gao, FH; He, W; Sun, Y; Tao, HR; Wang, HW; Xu, MH; Yang, GL; Zhang, C; Zhang, LD; Zhao, JM, 2015) |
| "In particular, patients with gastric cancer who experienced recurrences after chemotherapy tended to exhibit low levels of miR-29c expression in their tumors, suggesting that miR-29c activation may contribute to the chemotherapeutic efficacy." | ( Chen, J; Dong, L; Gong, J; Jia, H; Kong, Y; Li, J; Lin, H; Liu, C; Luo, M; Ma, Y; Su, R; Wang, F; Wang, Y; You, L; Yu, J; Zhang, J; Zhang, Z, 2015) |
| "Patients with unresectable gastric cancer initially exhibiting one noncurative factor may obtain a survival benefit from chemotherapy and subsequent curative surgery." | ( Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, O, 2015) |
| "In patients with advanced gastric cancer, standard doses of axitinib plus therapeutic doses of cisplatin and capecitabine could be administered in combination." | ( Bang, YJ; Chen, Y; Doi, T; Lee, KW; Oh, DY; Park, SR; Shirao, K; Valota, O; Yang, L, 2015) |
| "A total of 185 patients with gastric cancer and abdominal lymph node metastasis were enrolled and divided into 2 groups: group A received chemotherapy alone (n = 102); group B received HIFU combined with chemotherapy (n = 83)." | ( Liu, L; Liu, P; Lu, K; Shu, Y; Wang, J; Wang, R; Zhang, M, 2015) |
| "In patients with gastric cancer and abdominal lymph node metastasis, the combination of HIFU and chemotherapy can provide clinical benefits." | ( Liu, L; Liu, P; Lu, K; Shu, Y; Wang, J; Wang, R; Zhang, M, 2015) |
| "We report a case of advanced gastric cancer that was successfully treated with second-line chemotherapy followed by curative conversion gastrectomy." | ( Asaoka, T; Endo, S; Fujitani, K; Fukuda, Y; Fukui, A; Fushimi, H; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Iwase, K; Kawada, J; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takagi, M; Yamamoto, K, 2014) |
| "The patient died from recurrence of gastric cancer 69 months after completion of the initial chemotherapy and 2 months after the stent insertion." | ( Ishiyama, S; Iwasaki, Y; Maeda, Y; Natsume, S; Oohinata, R; Takahashi, K; Yajima, K; Yuu, K, 2014) |
| "We identified a case of gastric cancer showing response to first-line capecitabine/CDDP therapy after lymph node recurrence following the administration of S-1 as postoperative adjuvant chemotherapy." | ( Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N, 2014) |
| "A 55-year-old man suffering from gastric cancer associated with metastases to the lymph node, gallbladder, and liver was administered chemotherapy with S-1 and cisplatin." | ( Akiyama, Y; Hasuike, Y; Higuchi, I; Miyamoto, M; Tanigawa, T; Yamamoto, M, 2014) |
| "Standard pretreatment staging for gastric cancer includes CT of the chest, abdomen, and pelvis; gastroscopy; and laparoscopy." | ( Duong, C; Hicks, RJ; Kaneko, Y; Link, E; Murray, WK, 2015) |
| "It may provide a new, useful method for gastric cancer chemotherapy." | ( Hang, Q; Jiang, C; Li, Y; Sun, R, 2015) |
| "In a gastric cancer xenograft model, administration of IH alone (1 mg/kg body weight, i." | ( Ahn, KS; Alharbi, SA; Arfuso, F; Chinnathambi, A; Kumar, AP; Li, F; Manu, KA; Ramachandran, L; Sethi, G; Shanmugam, MK; Siveen, KS; Zayed, ME, 2015) |
| "106 cases of gastric cancer patients were randomly divided into preoperative one week EN group (trial group) and early postoperative EN group (control group), which were continuously treated with EN support until the postoperative 9th day according to different treatment protocols." | ( Ding, D; Feng, Y; Gao, S; Song, B; Zhao, J, 2015) |
| "pylori-induced gastric cancer, irrespective of the timing of antibiotic administration." | ( Aponte-Pieras, JR; Lee, DS; Morrissey, R; Moss, SF; Rogers, AB; Zhang, S, 2015) |
| "In patients with metastatic gastric cancer, the prognosis is poor with a median overall survival of 11 months since curative treatments are excluded; however, this case illustrated that a personalized treatment with chemotherapy and surgery can allow a curative strategy in selected patients with HER2-negative advanced gastric cancer." | ( Anselmi, E; Banchini, F; Bodini, FC; Capelli, P; Cavanna, L; Michieletti, E; Stroppa, EM; Zangrandi, A, 2014) |
| "Human gastric cancer MKN28, MGC803 and SGC7901 cells were treated with 100 µM deoxycholic acid (DCA) or chenodeoxycholic acid (CDCA) with or without acidified media in the presence or absence of the c-myc inhibitor 10058-F4 for 24 h." | ( Jia, P; Lu, S; Sun, X; Wang, H; Wang, X; Wei, G; Yao, J; Zhang, L; Zheng, J; Zhou, P, 2015) |
| "A 26-year-old man with metastatic gastric cancer with multiple liver lesions was treated with everolimus after failure of 1st-line and 2nd-line chemotherapy." | ( Kang, YK; Na, YS; Park, JH; Park, SR; Park, YS; Rhoo, BY; Ryu, MH, 2015) |
| "Clinical reports of 190 gastric cancer patients treated with S-1 chemotherapy, with or without PSK, at Kochi Medical School between 2007 and 2012 were investigated retrospectively to analyze survival." | ( Fukudome, I; Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Munekage, M; Namikawa, T; Ogawa, M; Shiga, M, 2015) |
| "To explore the sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 (COX-2) expression in cancer tissue." | ( Qiu, ZQ; Qiu, ZR, 2015) |
| "STIM1 silencing in the gastric cancer cells significantly inhibited cell proliferation by arresting the cell cycle at the G0/G1 phase, and increasing the apoptotic rate following treatment of the SGC7901 cells with pGPU6-shSTIM1, indicated using an MTT cell viability assay and flow cytometery, respectively." | ( Liu, B; Luo, ZY; Xiao, F; Ye, HL; Yu, HH, 2015) |
| "We herein describe a rare case of gastric cancer that was treated with chemotherapy during pregnancy." | ( Anbe, K; Fukusada, S; Inoue, T; Iwasaki, H; Kachi, K; Mizushima, T; Nishie, H; Okumura, F; Ozeki, T; Sano, H; Suzuki, Y, 2015) |
| "Tumor-resident GC-MSCs promote gastric cancer growth and progression more efficiently than GCN-MSCs or BM-MSCs through a considerable secretion of IL-8, which could be a possible target for gastric cancer therapy." | ( Huo, J; Li, W; Wu, H; Yang, J; Zhang, H; Zhang, T; Zhang, X; Zhao, S; Zheng, P; Zhou, Y, 2015) |
| "The prognosis for locally advanced gastric cancer (AGC) remains unsatisfactory, even with S-1 adjuvant chemotherapy." | ( Aizawa, M; Matsuki, A; Migita, K; Nashimoto, A; Yabusaki, H, 2016) |
| "Recent advances in gastric cancer chemotherapy have made macroscopic complete resection possible in some patients with stage IV disease." | ( Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Tajima, H; Takamura, H; Tsukada, T, 2015) |
| "Forty-nine gastric cancer patients diagnosed with synchronous liver metastasis initially treated with chemotherapy were categorized into the following two groups: surgery group: 25 patients who underwent gastrectomy and subsequently received postoperative chemotherapy and control group: 24 patients who received chemotherapy alone." | ( Bu, Z; Fan, B; Ji, J; Li, S; Li, Z; Ren, H; Shan, F; Tang, L; Wu, A; Wu, X; Zhang, L; Zong, X, 2015) |
| "Most gastric cancer patients are asymptomatic until the advanced stages, for which current therapeutic treatments are suboptimal." | ( Chang, YJ; Chen, CL; Chen, WY; Cheng, WL; Huang, CY; Huang, MT; Hung, CS; Liu, YN; Tai, CJ, 2015) |
| "Patients who diagnosed with gastric cancer and received treatment at six academic referral centers were investigated for the incidence and time of cholelithiasis and the degree of CBD dilatation after treatment by analysis of 5-year follow-up CTs." | ( Han, JH; Hwang, JC; Jeong, S; Kim, DJ; Kwon, CI; Lee, TH; Song, TJ; Yoon, H, 2015) |
| "In the context of gastric cancer, lymph node target volume delineation for post-operative radiotherapy is currently built on the traditional system of dividing the stomach and 2-D treatment methods." | ( Conghua, X; Haijun, Y; Qiuji, W; Yahua, Z; Yong, H; Yunfeng, Z; Zhengkai, L; Zhenming, F, 2015) |
| "During the study period, 313 advanced gastric cancer patients treated in our institution." | ( Kodaira, T; Kondoh, C; Muro, K; Nomura, M; Shitara, K; Tachibana, H; Takahari, D; Tomita, N; Ura, T, 2015) |
| "SGC-7901 gastric cancer cell line was treated with 5-fluorouracil (5-FU) or/and autophagy inhibitor bafilomycin A1." | ( Chen, H; Li, LQ; Pan, D; Xie, WJ; Zhang, L, 2016) |
| "Drug resistance in gastric cancer largely results from the gastric cancer stem cells (GCSCs), which could be targeted to improve the efficacy of chemotherapy." | ( George, SK; Gong, A; Huang, H; Jiang, X; Jiao, Z; Xu, M; Yang, H; Zhang, Y, 2015) |
| "For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment." | ( Ohi, H; Ozaki, T; Seki, H; Yabusaki, H, 2016) |
| "This study included 304 consecutive gastric cancer patients treated with adjuvant S-1 monotherapy for 1 year at Shizuoka Cancer Center." | ( Boku, N; Fukutomi, A; Hamauchi, S; Ichinose, M; Kashiwagi, H; Machida, N; Mori, K; Onozawa, Y; Tabuse, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2016) |
| "We also observed a stage IV gastric cancer patient with MET amplification who experienced tumor shrinkage and clinical benefit after 3 weeks of crizotinib as fourth-line treatment." | ( Guan, W; Lin, Z; Liu, B; Qian, X; Rosell, R; Shen, J; Sun, X; Teixido, C; Wei, J; Wu, N; Yang, Y; Yu, L; Zou, Z, 2016) |
| "We treated the gastric cancer cells with CagA followed by Rg3, and analyzed their ability to induce apoptosis by evaluating the role of FUT4 as well as SP1 and HSF1 expressions by Western blot, flow cytometry and ELISA." | ( Aziz, F; Liu, J; Wang, X; Yan, Q, 2016) |
| "The prognosis of advanced gastric cancer was significantly related to the start of S-1 adjuvant treatment within 6 weeks after surgery." | ( Egashira, A; Ikeda, Y; Kinjo, N; Minami, K; Morita, M; Okamura, T; Sakaguchi, Y; Toh, Y; Yamaguchi, S; Yamamoto, M, 2016) |
| "The treatment of advanced gastric cancer is changing with the development of novel agents." | ( Choi, M; Kim, R; Mahipal, A, 2015) |
| "In this study, the possibility of gastric cancer treatment with an antiplatelet agent, mainly aspirin, was examined both in vivo and in vitro." | ( Doki, Y; Kurokawa, Y; Mikami, J; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2016) |
| "The BAK expression indexes of 69 gastric cancer specimens before preoperative chemotherapy (including docetaxel treatment) were determined by multiplying numerical values describing the degrees of BAK positivity and staining intensity observed." | ( Hasegawa, T; Himuro, N; Hirata, K; Ishikawa, K; Kato, J; Kawano, Y; Kobune, M; Kubo, T; Miyanishi, K; Mori, M; Murase, K; Nobuoka, T; Sato, T; Sato, Y; Sugita, S; Takada, K; Takayama, T; Takimoto, R, 2016) |
| "BAK expression in gastric cancer is thus predictive of chemotherapeutic responses to docetaxel and clinical prognosis in patients treated with preoperative chemotherapy." | ( Hasegawa, T; Himuro, N; Hirata, K; Ishikawa, K; Kato, J; Kawano, Y; Kobune, M; Kubo, T; Miyanishi, K; Mori, M; Murase, K; Nobuoka, T; Sato, T; Sato, Y; Sugita, S; Takada, K; Takayama, T; Takimoto, R, 2016) |
| "Locally advanced gastric cancer (LAGC) is best treated with surgical resection." | ( Du, N; Kang, HR; Li, XS; Ma, J; Yao, FF; Yao, S, 2015) |
| "Unresectable gastric cancer is associated with poor outcomes, with few treatment options available after failure of cytotoxic chemotherapy." | ( Huynh, H; Ong, R; Zopf, D, 2015) |
| "The expression of miR-29b in gastric cancer cell line treated with cisplatin concentration gradient was detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blotting." | ( Chen, DD; Feng, LC; He, YQ; Wang, YD; Ye, R, 2015) |
| "A total of 64 patients with advanced gastric cancer were prospectively enrolled and examined by PET with (18)F-fluorodeoxyglucose (FDG) and (18)F-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT) at baseline and 14 days after treatment initiation." | ( Guo, W; Ji, D; Li, J; Li, W; Liu, X; Tao, Z; Wang, C; Zhang, X; Zhang, Y; Zhou, M; Zhu, X, 2016) |
| "The prognosis of gastric cancer remains poor, due to the biological characteristics of the primary tumor as well as the recurrence after treatment." | ( Chen, L; Li, Q; Wang, LA; Wei, X, 2016) |
| "The human gastric cancer cell line HGC‑27 was infected with an adenoviral construct encoding cDNA of PKG II (Ad‑PKG II) to increase the expression of PKG II and treated with 8‑(4‑chlorophenylthio)guanosine‑3',5'‑cyclic monophosphate (8‑pCPT‑cGMP) to activate the kinase." | ( Chen, Y; Qian, H; Wu, M; Wu, Y; Yao, X; Zhu, M, 2016) |
| "Three hundred patients with advanced gastric cancer treated with paclitaxel and capecitabine combination chemotherapy were enrolled in the present study." | ( Gan, P; Liu, Q; Yao, Q; Zha, Y, 2016) |
| "The study included 127 gastric cancer patients, who underwent preoperative or postoperative chemoradiotherapy." | ( Maslyk, B; Polanowski, P; Tukiendorf, A; Wydmanski, J, 2016) |
| "The clinicopathological data of 110 gastric cancer patients who developed recurrence or second primary malignancies after radical gastrectomy and adjuvant chemotherapy with FOLFOX4 regimen or docetaxel plus FOLFOX4 regimen were analyzed retrospectively." | ( Du, C; Guo, C; Wang, J; Xu, Q; Zhou, A, 2015) |
| "S-1 is first-line therapy for advanced gastric cancer in Asia and is used with increased frequency in Western counties." | ( Lodder, P; Mohammad, NH; Ngai, LL; Samaan, M; Ter Veer, E; van Laarhoven, HW; van Oijen, MG, 2016) |
| "YM155 may be a promising agent for gastric cancer treatment." | ( Cheng, XJ; Ding, YF; Lin, JC; Tu, SP; Ye, J; Zhu, L, 2016) |
| "Advanced gastric cancer patients with PALM can obtain a survival benefit from neoadjuvant chemotherapy, subsequent surgery and radiotherapy." | ( He, Q; Li, G; Li, Y; Ma, L, 2016) |
| "Peritoneal dissemination of gastric cancer is still a dismal disease and has extremely poor prognosis even with systemic intensive chemotherapy." | ( Emoto, S; Hata, K; Ishigami, H; Ishihara, S; Kawai, K; Kazama, S; Kitayama, J; Kiyomatsu, T; Nishikawa, T; Nozawa, H; Sunami, E; Tanaka, J; Tanaka, T; Watanabe, T; Yamaguchi, H, 2016) |
| "The microsatellite-instable gastric cancer subtype, because of its supposed high antigenic potential, is a promising candidate for immunotherapy." | ( Andrikou, K; Bianconi, M; Bittoni, A; Bracci, R; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Mandolesi, A; Scarpelli, M; Scartozzi, M, 2017) |
| "Since 20 % of gastric cancer patients show high level of c-Met expression, c-Met has been identified as a good candidate for targeted therapy in gastric cancer." | ( Chae, CH; Cho, SY; Choi, SU; Ha, JD; Jang, IY; Jung, H; Kim, HR; Lee, CO; Lee, HK; Park, CH, 2016) |
| "The standard treatment of gastric cancer patients with PD is combination therapy with S-1 and cisplatin (SP therapy)." | ( Akita, H; Fujiwara, Y; Gotoh, K; Hara, T; Kobayashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2015) |
| "We encountered a case of resected gastric cancer, which occurred concomitantly with intrahepatic cholangiocarcinoma after S-1 plus cisplatin chemotherapy, in a patient who was previously diagnosed with metastatic liver tumor before treatment." | ( Danno, K; Fujitani, K; Iwase, K; Kawada, J; Kitagawa, A; Kubota, M; Matsuda, C; Matsuura, N; Miyazaki, S; Motoori, M; Nakatsuka, R; Nishimura, M; Nomura, M; Okumura, Y, 2015) |
| "The patient was diagnosed with gastric cancer with liver metastasis, Stage Ⅳ, and treated with chemotherapy (S-1 plus CDDP)." | ( Ishigami, E; Kawamoto, J; Miyazaki, M; Nakada, S; Shinoda, K; Teranaka, R; Yoichi, T, 2015) |
| "Here, we report 2 patients with gastric cancer and peritoneal dissemination who were successfully treated with chemotherapy after undergoing treatment for an oncologic emergency caused by peritoneal dissemination." | ( Akita, H; Fujiwara, Y; Gotoh, K; Kobayashi, S; Miyata, H; Miyoshi, N; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2015) |
| "Here, we report a case of advanced gastric cancer that demonstrated CR after treatment with S-1 and paclitaxel." | ( Koga, Y; Kudoh, K; Ogata, K; Ohchi, T; Ootao, R, 2015) |
| "We report a case of recurrent gastric cancer with left cervical and para-aortic lymph node close to the hilum of the right kidney that was successfully treated with TS-1 monotherapy and surgical resection." | ( Endo, S; Fujitani, K; Fushimi, H; Hama, N; Haraguchi, N; Hirao, M; Ikeda, M; Kawada, J; Maeda, S; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Sekimoto, M; Yamamoto, K, 2015) |
| "Even when treated successfully, gastric cancer patients have a high risk of tumor recurrence and acquired drug resistance." | ( Ernst, M; O'Donoghue, RJ; Poh, AR; Putoczki, TL, 2016) |
| "A 78-year-old man with advanced gastric cancer was treated with S-1 and oxaliplatin chemotherapy." | ( Goto, Y; Inagaki, S; Kaneko, S; Kobayashi, T; Wakita, S; Yoshimitsu, M, 2015) |
| "We report a case of advanced gastric cancer that responded completely to S-1 neoadjuvant chemotherapy." | ( Akashi, Y; Inagaki, Y; Inagawa, S; Kemmochi, A; Ohkohchi, N; Satomi, K, 2016) |
| "Patients aged 20-75 years with advanced gastric cancer with a single non-curable factor confined to either the liver (H1), peritoneum (P1), or para-aortic lymph nodes (16a1/b2) were randomly assigned (1:1) in each country to chemotherapy alone or gastrectomy followed by chemotherapy by a minimisation method with biased-coin assignment to balance the groups according to institution, clinical nodal status, and non-curable factor." | ( Bang, YJ; Fujitani, K; Hahn, S; Han, SU; Hyung, WJ; Iwasaki, Y; Kim, YW; Kurokawa, Y; Mizusawa, J; Nakamura, K; Park, BJ; Park, CH; Park, DJ; Sasako, M; Takagane, A; Terashima, M; Tsujinaka, T; Yang, HK; Yoshikawa, T, 2016) |
| "In advanced gastric cancers, a significant correlation exists between the response to chemotherapy in primary gastric cancers and patient prognosis." | ( Asakuma, Y; Kitano, M; Kudo, M; Matsui, S, 2015) |
| "Thirteen advanced oesophagogastric cancer patients treated with capecitabine and oxaliplatin were included by convenience sampling, recruited from one academic hospital, and interviewed at home or in the hospital." | ( Boesveldt, S; de Vries, YC; Helmich, E; Karsten, MD; van Laarhoven, HW; Winkels, RM, 2016) |
| "Four human gastric cancer cell lines (AGS, MKN-28, SNU-484, and SNU-638) were treated with various concentrations of deferasirox to determine the IC50 for each cell line." | ( Choi, JH; Kim, JS; Lee, YY; Park, BB; Uhm, J; Won, YW, 2016) |
| "Sixty-eight patients with advanced gastric cancer treated with first-line chemotherapy or chemoradiotherapy were classified into two groups based on tumor response." | ( Arigami, T; Ishigami, S; Kijima, T; Kijima, Y; Kita, Y; Kurahara, H; Maemura, K; Mori, S; Nakajo, A; Natsugoe, S; Okubo, K; Okumura, H; Uchikado, Y; Uenosono, Y; Yanagita, S, 2016) |
| "Melittin can induce apoptosis of human gastric cancer (GC) cells through the mitochondria pathways, and it may be a potent agent in the treatment of human GC." | ( Bo, P; Diao, YL; Fang, PH; Kong, GM; Qian, F; Tao, WH; Wang, JJ, 2016) |
| "Studies in gastric cancer patients treated with S-1 investigating the expression variations of 5-fluorouracil metabolic enzymes were included after having been identified systematically." | ( Wang, D; Wang, X; Yu, X, 2016) |
| "The treatment of Topotecan (TPT) on gastric cancer (GC) is limited by its toxicity and the potential drug resistance." | ( Du, HZ; Feng, SY; Li, RM; Lin, S; Luo, XJ; Qian, CM; Sun, L; Yu, BY; Yu, XW; Yuan, ST; Zhang, LY; Zhao, RP, 2016) |
| "Patients with unresectable gastric cancer may obtain a survival benefit from preoperative chemotherapy via intra-arterial and intravenous administration and subsequent surgery." | ( He, Q; Ji, X; Li, G; Li, Y; Ma, L, 2016) |
| "The treatment of gastric cancer requires a multidisciplinary approach in which surgery plays the main role." | ( Caruso, R; D'Andrea, V; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ferronetti, A; Ielpo, B; Malave, L; Plaza, C; Quijano, Y; Vicente, E, 2016) |
| "20 advanced gastric cancer patients who received platinum-based chemotherapy were recruited." | ( Chu, JK; Wang, LL; Zhang, X; Zhang, XH, 2016) |
| "The prognosis for stage III gastric cancer is unsatisfactory by D2 gastrectomy and S-1 adjuvant chemotherapy." | ( Aoyama, T; Cho, H; Fujita, J; Fujitani, K; Hayashi, T; Ito, Y; Kimura, Y; Matsui, T; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2016) |
| "Patients with esophageal or gastric cancer who were scheduled to receive HEC including at least 60 mg/m of cisplatin as the first-line treatment were randomly assigned to receive AGD (oral aprepitant 125 mg on day 1 and 80 mg on days 2-3; intravenous granisetron 3 mg on day 1; intravenous dexamethasone 6." | ( Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S; Wada, T; Yano, T, 2016) |
| "The majority of gastric cancer patients who achieve an initial response to trastuzumab-based regimens develop resistance within 1 year of treatment." | ( Aprile, G; Boschi, F; Carbone, C; Cataldo, I; de Manzoni, G; Di Nicolantonio, F; Giacopuzzi, S; Melisi, D; Merz, V; Mina, MM; Piro, G; Santoro, R; Sbarbati, A; Scarpa, A; Simionato, F; Tortora, G; Zanotto, M, 2016) |
| "This study raises a new insight into gastric cancer prevention and therapy, and provides evidence that green tea could be used as a nutraceutical beverage." | ( Du, W; Yang, C; Yang, D, 2016) |
| "Cultured MGC-803 human gastric cancer cells were treated with bevacizumab in combination with chemotherapy treatment in different time sequences." | ( Chang, L; Li, Q; Liu, W; Liu, Y; Lv, Y; Song, L; Zhang, X; Zhou, X, 2017) |
| "AGS human gastric cancer cell line was infected with adenoviral constructs encoding the cDNA of PKG II (Ad‑PKG II), to increase the expression of PKG II, and treated with 8‑pCPT‑cGMP to activate the kinase." | ( Chen, Y; Jiang, L; Lan, T; Qian, H; Wu, M; Wu, Y, 2016) |
| "Importantly, in a preclinical gastric cancer xenograft mouse model, drug co-treatments led to increased mouse survival as well as a synergistic reduction in tumor size and the inhibition of tumor angiogenesis." | ( Chen, J; Chen, Z; Guo, J; Liu, M; Pang, X; Wang, J, 2016) |
| "For 64 patients with advanced gastric cancer, 30 cases were treated with docetaxel, cisplatin, and 5-fluorouracil (DCF group, control group), and 34 cases were treated with paclitaxel liposome and capecitabine (PC group, experimental group)." | ( Lu, M; Wang, J; Wang, T, 2016) |
| "For 64 patients with advanced gastric cancer, 30 cases were treated with docetaxel, cisplatin, and 5-fluorouracil (DCF group, control group), and 34 cases were treated with paclitaxel liposome and capecitabine (PC group, experimental group)." | ( Lu, M; Wang, J; Wang, T, 2016) |
| "In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response." | ( Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H, 2016) |
| "Since gastric cancer (GC) cells exhibited higher grades of SHP-2 encoded by PTPN11 than normal cells, it would be intriguing to explore whether PTPN11 single nucleotide polymorphisms (SNPs) would influence chemotherapy effectiveness and GC prognosis among a Chinese population." | ( Chen, C; Chen, G; Jiang, D; Li, J; Lin, C; Lin, X; Shao, M; Tian, H; Wang, L; Zhuo, C, 2016) |
| "Recent studies in esophagogastric cancer help clarify the role of radiation therapy in surgical management, as well as the role of chemotherapeutic and targeted agents." | ( Ilson, DH, 2016) |
| "We show that gastric cancer cells generated characteristic kinetic patterns that corresponded to the treatment order of therapeutics." | ( Kang, M; Ku, M; Suh, JS; Yang, J, 2016) |
| "Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed." | ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017) |
| "A total of 337 patients with resected gastric cancer treated at Zhongnan Hospital of Wuhan University from 2004 to 2012 were retrospectively analyzed." | ( Dai, J; Gong, J; Peng, J; Qin, Y; Wei, Y; Xie, C; Xiong, B; Zhong, Y; Zhou, F; Zhou, Y, 2016) |
| "A cohort of 60 gastric cancer patients for chemotherapy was randomly divided into two groups (n=30 per group), who were orally treated with either supplemental CSPE or placebo apart from chemotherapy." | ( Hu, XF; Wan, HP; Wu, LP; Yu, JH; Yu, YM; Zhang, GQ, 2016) |
| "Many patients with metastatic gastric cancer after first-line chemotherapy received salvage chemotherapy in routine clinical practice." | ( Cheng, SY; Du, J; Li, J; Li, KC, 2016) |
| "Clinical data of 50 patients with gastric cancer, who had not received treatment preoperatively and underwent gastrectomy in Department of Gastrointestinal Surgery, Wuhan Union Hospital, between October 2014 and August 2015, were retrospectively analyzed." | ( Chen, MM; Du, HS; Long, YP; Ma, MG; Wang, H; Zhu, GS, 2016) |
| "Metastatic gastric cancer patients with stable disease or a better response after the completion of first-line chemotherapy were randomized to oral UFT (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity or to observation (OBS)." | ( Chen, Z; Guo, W; Huang, M; Li, J; Li, W; Liu, X; Qiu, L; Wang, H; Zhang, W; Zhao, X; Zhu, X, 2017) |
| "The main treatment for advanced gastric cancer is fluoropyrimidine and platinum-based chemotherapy." | ( Beijnen, JH; Cats, A; Deenen, MJ; Joerger, M; Meulendijks, D; Rozeman, EA; Schellens, JHM; Sikorska, K, 2017) |
| "Because most advanced HER2-positive gastric cancers are ulcers, we should always consider the risk of gastric cancer perforation while administering HXP therapy, which has a high cytoreductive effect." | ( Endo, S; Fujita, I; Horii, J; Matsueda, K; Murakami, T; Sakata, M; Toyokawa, T; Ueda, Y, 2017) |
| "We report 2 cases ofgastric cancer with portal vein tumor embolus treated using gastrectomy and thrombectomy." | ( Hatanaka, N; Hirao, T; Iwamoto, K; Kono, E; Mizuno, H; Morimoto, Y; Noro, H; Son, C; Takaichi, S; Yamasaki, Y; Yasumasa, K, 2016) |
| "Advanced gastric cancer patients with malignant ascites cannot tolerate S-1 plus cisplatin-containing therapy." | ( Hoshino, H; Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T, 2016) |
| "Patients with advanced gastric cancer with malignant ascites were treated with 60mg/m2 paclitaxel, followed by 500 mg/m2 5-FU and 250 mg/m2 l-LV on days 1, 8, and 15." | ( Hoshino, H; Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T, 2016) |
| "We experienced a case of advanced gastric cancer with multiple liver metastases successfully treated with capecitabine, cisplatin, and trastuzumab." | ( Akiyama, Y; Egawa, C; Inatome, J; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S, 2016) |
| "We report a case of advanced gastric cancer with a pathological complete response after neoadjuvant chemotherapy." | ( Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S, 2016) |
| "PTBP3 might serve as a biomarker of gastric cancer or potential target for anti-cancer therapy." | ( Li, J; Liang, X; Lin, S; Liu, J; Qi, Y; Qiu, C; Shi, H; Yang, L; Zhao, A, 2017) |
| "Elderly patients with advanced gastric cancer may benefit from concurrent apatinib with local radiation therapy when chemotherapy is not tolerated or successful." | ( Cao, X; Deng, W; Duan, Z; Liu, B; Lv, B; Shi, X; Zhang, M; Zhao, H, 2017) |
| "For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response." | ( Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I, 2017) |
| "Esophagogastric cancers were prospectively captured with associated histopathological tumor regression grades following neoadjuvant chemotherapy." | ( Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I, 2017) |
| "HGC‑27 and MKN‑45 human gastric cancer cells were treated with metformin at different concentrations and for different durations." | ( Chen, L; Huang, X; Li, P; Lu, C; Song, Z; Wei, B, 2017) |
| "The patients diagnosed with metastatic gastric cancer who were given mDCF as first-line therapy were retrospectively reviewed." | ( Bozkaya, Y; Demirci, NS; Doğan, M; Erdem, GU; Yazıcı, O; Zengin, N, 2017) |
| "Although diagnosis and treatment of gastric cancer have improved, the prognosis of patients remains poor." | ( Guo, Y; Li, N; Li, Y; Qin, X; Wu, Y; Yang, Y; Zhou, L, 2017) |
| "We herein report a case of advanced gastric cancer involving long-term management with a single administration of nab-paclitaxel." | ( Enami, C; Hyodo, I; Iwai, K; Matano, D; Moriwaki, T; Nagase, M; Niisato, Y; Suganuma, D; Takagi Taketa, K; Tange, Y; Yamamoto, Y; Yamaura, M, 2017) |
| "Patients with hereditary diffuse gastric cancer (HDGC), a cancer predisposition syndrome associated with germline mutations of the CDH1 (E-cadherin) gene, have few effective treatment options." | ( Abisoye-Ogunniyan, A; Beane, JD; Bian, Y; Chen, I; Ferrer, M; Gryder, B; Guha, R; Li, D; Mathews-Greiner, L; Ravichandran, S; Ray, S; Rudloff, U; Shukla, V; Thomas, C; Zacharia, A; Zhang, X, 2017) |
| "In addition, curcumin treatment induced gastric cancer cell apoptosis in a dose‑responsive manner." | ( Li, H; Li, W; Yang, J; Zhang, H; Zheng, P; Zhou, Y, 2017) |
| "BACKGROUND Gastric cancer (GC) is the second leading cause of cancer-related death worldwide, but little progress has been achieved in the treatment of advanced or metastatic GC." | ( Chen, Y; Liu, Y; Tian, P, 2017) |
| "Overexpression of Notch1 in gastric cancer cells partially rescued the effects on cell migration, proliferation, HUVECs tube formation, and VM formation induced by luteolin treatment." | ( Hu, L; Li, J; Liu, B; Yan, M; Zang, M; Zhang, B; Zhu, Z, 2017) |
| "Cancer stem cells (CSCs) in gastric cancer (GC) have been established recently as key therapeutic targets for the successful treatment of GC." | ( Bai, B; Cao, Y; Cui, D; Gao, J; Li, L; Li, Y; Nie, Z; Yang, L; Ye, L; Zhu, L, 2017) |
| "Thirty patients with locally advanced gastric cancer underwent neoadjuvant DCS therapy at Dokkyo Medical University Hospital between June 2013 and October 2015." | ( Ito, J; Kato, H; Kubo, T; Kurayama, E; Miyachi, K; Nakajima, M; Onodera, S; Otsuka, K; Sasaki, K; Satomura, H; Takahashi, M; Yamaguchi, S, 2017) |
| "However, the therapies to prevent gastric cancer are still limited and the emergence of drug resistance leads to development of new anti-cancer drugs and combinational chemotherapy regimens." | ( Gao, CC; Ma, TH; Wang, HG; Wu, SN; Xie, R; Yan, W; Yang, XZ; Zhang, JL, 2017) |
| "Patients diagnosed with CY+ advanced gastric cancer and treated with S-1-based therapy were enrolled." | ( Chin, K; Hiroki, O; Ichimura, T; Matsushima, T; Nakayama, I; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2017) |
| "Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy." | ( Akashi, K; Arimizu, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Inadomi, K; Kajitani, T; Komoda, M; Kusaba, H; Kuwayama, M; Makiyama, A; Makiyama, C; Matsushita, Y; Oda, H; Ohmura, H; Shinohara, Y; Shirakawa, T; Uchino, K, 2018) |
| "To identify predictive markers for gastric cancer treatment in Chinese patients, we evaluated the association between polymorphisms of the gene encoding cytochrome P450 2A6 (CYP2A6) and outcomes of S-1 plus oxaliplatin (SOX) chemotherapy treatment." | ( Hu, S; Shu, C; Song, Y; Sun, YK; Yang, L; Yang, Y; Yuan, X; Zhang, W; Zhou, A; Zou, S, 2017) |
| "Osteosarcoma (MG63) and gastric cancer (SGC7901) cells, respectively, were treated with hBMSC-derived exosomes in the presence or absence of a small molecule inhibitor of Hedgehog pathway." | ( Chen, H; Jiao, Z; Li, Y; Qi, J; Wang, X; Yang, L; Zhao, Y; Zhou, Y; Zhu, H, 2017) |
| "Most patients with advanced gastric cancer eventually succumb to the disease despite the fact that some patients respond initially to chemotherapy." | ( Gu, D; Liu, B; Xie, J; Yu, B; Zhang, X, 2017) |
| "The apoptotic index in gastric cancer cells was significantly increased in the curcumin treatment group." | ( Chang, N; Lin, HP; Wang, QX; Wang, XP, 2017) |
| "Here, we report a case of gastric cancer that developed in the presence of CMV gastritis, which had been present for at least 4 years and was refractory to treatment." | ( Mizuno, M; Shimodate, Y; Ueno, M; Yamamoto, H; Yamamoto, S, 2017) |
| "Human gastric cancer cells were co-cultured with HL-60N cells or treated with the conditioned medium (CM) of cancer-activated HL-60N cells." | ( Chen, J; Gu, J; Ji, R; Qian, H; Xu, W; Zhang, P; Zhang, W; Zhang, X, 2017) |
| "However, the therapies to suppress gastric cancer are still limited and the emergence of drug resistance makes it necessary to develop new and effective anticancer drugs and combinational chemotherapy schemes." | ( Gao, HY; Gao, SH; Jiang, X; Wei, F, 2017) |
| "Recent gastric cancer clinical trials have aimed to establish the efficacy of combination therapy over monotherapy, however, the role for genomic biomarkers in these trials has remained largely unexplored." | ( Das, K; Imamura, H; Nishikawa, K; Sugimoto, N; Taguri, M; Tan, P; Tsuburaya, A; Yoshida, K, 2018) |
| "Twenty-two gastric cancer patients treated with postoperative chemoradiotherapy were retrospectively evaluated." | ( Çepni, K; Ergen, ŞA; Kaydıhan, N; Öksüz, DÇ; Şenocak, MŞ, 2017) |
| "pylori eradication therapy to prevent gastric cancer." | ( Mori, H; Suzuki, H, 2018) |
| "BACKGROUND Gastric cancer (GC) with cisplatin resistance is one of the leading causes of limitations to therapy." | ( Huang, C; Li, L; Yu, J, 2017) |
| "This study included 115 superficial gastric neoplasms that were treated by ESD at Hiraka General Hospital between April 2015 and January 2017." | ( Fushimi, S; Horikawa, Y; Kato, Y; Mimori, N; Mizutamari, H; Okubo, S; Sato, S, 2018) |
| "To examine the effect in advanced gastric cancer, we compared survival for patients treated with surgery-only or adjuvant chemotherapy on the basis of H." | ( Fukushima, N; Iwaya, T; Koeda, K; Nakatochi, M; Nishizuka, SS; Ohmori, Y; Sumida, C; Takahashi, T; Tamura, G, 2018) |
| "The incidence and mortality of gastric cancer is steadily increasing annually around the world, which required further investigation about alternative therapy strategies." | ( Huang, Q; Zhu, C; Zhu, H, 2018) |
| "In total, 240 gastric cancer patients undergoing radical gastrectomy followed by adjuvant chemotherapy were randomly assigned into 2 groups." | ( Chen, Z; Guo, Q; Ji, R; Liu, X; Lu, L; Wang, Y; Yuan, H; Zhou, Y, 2017) |
| "Treatment of patients with gastric cancer was highly variable." | ( Abrams, T; Fuchs, C; Hess, LM; Liepa, AM; Schelman, W; Zhu, YE, 2018) |
| "We reported a case of recurrent gastric cancer with grade(gr)3 proteinuria caused by RAM plus PTX therapy." | ( Fujita, J; Furukawa, H; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Makari, Y; Mikami, J; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2017) |
| "Although the prognosis of gastric cancer with synchronous liver metastases is very poor, it is possible for survival to be prolonged with multimodality therapy." | ( Ebisui, C; Fukuchi, N; Hamano, R; Kinuta, M; Kitahara, T; Minoji, T; Murata, K; Ohishi, K; Okamura, S; Yanagisawa, T; Yokouchi, H, 2017) |
| "On the other hand, the 2014 Japanese gastric cancer treatment guidelines(ver." | ( Choda, Y; Harano, M; Idani, H; Ishida, M; Kubota, T; Matsukawa, H; Miyake, S; Morito, T; Nakano, K; Ojima, Y; Okajima, M; Sato, D; Shiozaki, S; Sumitani, D, 2017) |
| "Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2 /day on days 1-14 plus docetaxel 35 mg/m2 on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2 /day on days 1-14 plus cisplatin 60 mg/m2 on day 1) every 3 weeks." | ( Cheong, JH; Chung, HC; Hyung, WJ; Jung, I; Jung, M; Kang, SY; Kim, BS; Kim, HS; Kim, KH; Lee, CK; Lee, KH; Lee, MH; Noh, SH; Rha, SY; Shin, DB; Zang, DY, 2019) |
| "Advanced gastric cancer patients treated with ramucirumab in combination with paclitaxel or with ramucirumab monotherapy in a Korean EAP were evaluated." | ( Baek, JH; Cho, JY; Choi, DR; Han, HS; Hong, YS; Hwang, IG; Jung, M; Kang, M; Kang, YK; Kim, JS; Kim, KH; Kim, S; Kim, YH; Koo, DH; Lee, HW; Lee, KE; Lee, KW; Lee, MH; Lee, N; Maeng, CH; Oh, DY; Park, YL; Rha, SY; Ryu, MH; Shim, BY; Song, EK; Song, HS; Sym, SJ; Yang, SH; Zang, DY, 2018) |
| "However, the role of Gln in gastric cancer (GC) metabolism is unknown and Gln-targeted therapy against GC remains scarce." | ( Chen, W; Huang, J; Huang, Q; Lin, X; Wang, J; Xu, J; Ye, J; Zhong, W, 2018) |
| "After curative resection of gastric cancer with D2 lymph node dissection, postoperative adjuvant chemotherapy with S-1 or capecitabine plus oxaliplatin (XELOX) is considered to be standard therapy in Eastern countries." | ( Chae, H; Kim, HI; Kim, IH; Kim, MC; Kwon, IK; Lee, CM; Lee, HH; Lee, SI; Min, JS; Park, SS, 2018) |
| "According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer." | ( Creemers, A; de Waal, L; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH, 2018) |
| "(2)Treatment of advanced gastric cancer: the major update is the application of immunotherapy (Pembrolizumab, Nivolumab combined with Ipilimumab)." | ( Qiu, H; Zhou, Z, 2018) |
| "In this trial, patients with resectable gastric cancer were randomised before start of treatment between adjuvant chemotherapy or adjuvant chemoradiotherapy following neoadjuvant chemotherapy plus gastric cancer resection." | ( Braak, JPBM; Cats, A; Claassen, YHM; de Steur, WO; Dikken, JL; Hartgrink, HH; Jansen, EPM; Meershoek-Klein Kranenbarg, WM; Putter, H; Trip, AK; van Berge Henegouwen, MI; van de Velde, CJH; van Grieken, NCT; van Sandick, JW; Verheij, M, 2018) |
| "We compared the age-specific risk of gastric cancer in a large cohort of subjects who received H pylori eradication therapy vs a matched general population." | ( Chan, EW; Chen, L; Cheung, KS; Graham, DY; Leung, WK; Wong, AYS; Wong, ICK; Wong, IOL; Yeung, KF, 2018) |
| "Despite the improvement in gastric cancer (GC) treatment, multidrug resistance (MDR) is still a significant reason for chemotherapy failure." | ( Lei, C; Li, T; Ni, Z; Shi, Y; Wu, Q; Zhu, F, 2018) |
| "Current treatment of gastric cancer includes surgery and chemotherapy as the main modalities, but the potentially severe side-effects of chemotherapy present a considerable challenge." | ( Chiu, YM; Ho, TY; Hsieh, CT; Lee, YJ; Shieh, DC; Tsai, CL; Tsay, GJ; Wu, YY, 2018) |
| "For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial." | ( Chang, B; Jiang, X; Kariminia, S; Li, Q; Li, Y; Yan, H; Yang, L; Zhen, H, 2018) |
| "We report a case of Stage IV gastric cancer showing pathological complete response(pCR)after neo-adjuvant chemotherapy( NAC)using S-1 and oxaliplatin(SOX)." | ( Kaibe, N; Kikuchi, S; Kurahashi, Y; Nakao, E; Niwa, H; Oshima, T; Ozawa, R; Sasako, M; Shinohara, H; Takii, M, 2018) |
| "Human gastric cancer cell lines (AGS, SNU1 and Hs746T) were cultured and treated with different concentrations of CuD (0, 0." | ( Wang, CF; Zhang, LF; Zhang, YZ, 2018) |
| "Mice with disseminated peritoneal gastric cancer were separated into 4 groups: (i) control (no treatment); (ii) tra-IR700 i." | ( Choyke, PL; Kobayashi, H; Maruoka, Y; Nagaya, T; Ogata, F; Okuyama, S, 2018) |
| "In this study, human and mouse gastric cancer organoids were generated to model the disease and perform drug testing to delineate treatment strategies." | ( Aust, DE; Baretton, GB; Gaebler, AM; Grützmann, K; Klink, B; Koo, BK; Krause, M; Merker, SR; Rothe, A; Schölch, S; Schweitzer, C; Seidlitz, T; Sommer, U; Stange, DE; Uhlemann, H; von Neubeck, C; Weitz, J; Welsch, T; Werner, K; Zakrzewski, F, 2019) |
| "Synchronous double superficial gastric cancer with gastritis cystica profunda (GCP) and submucosal lipoma is a rare disease and is difficult to diagnose and treat." | ( Huang, D; Sun, Q; Yang, S; Zhan, Q; Zhou, Z, 2018) |
| "Patients with gastric cancer with pre-existing ILD, particularly those presenting with a UIP pattern, undergoing this combination treatment, should be carefully monitored for the development of treatment-related pneumonitis." | ( Katayanagi, S; Kawachi, S; Koyama, N, 2018) |
| "AZD1208 treatment decreased gastric cancer cell proliferation rates and induced autophagy only in long-term culture systems." | ( Bang, YJ; Ha, DH; Im, SA; Jang, H; Jeong, WJ; Kim, J; Kim, S; Kim, SH; Kim, TY; Lee, KH; Lee, M; Lim, JM; Min, A; Oh, DY; Suh, KJ; Yang, YW, 2019) |
| "All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively." | ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018) |
| "For locally advanced gastric cancer patients, the DOS regimen showed more benefit than the XELOX regimen as preoperative chemotherapy, without any added toxicity effects." | ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018) |
| "Human gastric cancer MKN‑28 cells, as a model in vitro, were treated with aclidinium bromide and dimethyl sulfoxide." | ( Cui, P; Liu, J; Ma, J; Wang, Y; Wu, H, 2018) |
| "Treatment of gastric cancer cells with TNF-α induced miR-135b-5p in a NF-κB-dependent manner." | ( Chen, Z; El-Rifai, W; Lu, H; Peek, R; Romero-Gallo, J; Shao, L; Soutto, M; Zhang, S; Zhu, S, 2019) |
| "YAP enhances gastric cancer cell proliferation and attenuates sensitivity to cisplatin potentially through targeting the EGFR signaling, indicating that YAP/EGFR signaling axis may serve as a potential target for treatment of gastric cancer." | ( Lu, T; Sun, L; Zhu, X, 2018) |
| "A total of 183 patients with advanced gastric cancer who underwent 3 cycles of PLF regimen chemotherapy before surgery and received surgery 2 weeks after chemotherapy were enrolled as a treatment group." | ( Chen, Q; Lin, X; Shi, C; Wang, X; Yang, B, 2019) |
| "Both 24(R/S),25-EC and 27HC suppressed gastric cancer proliferation, which was not altered by LXRα-siRNA treatment." | ( Bai, Q; Chen, Z; Guo, F; Hong, W; Li, X; Xu, D; Yang, M, 2018) |
| "Further analysis of the AGS gastric cancer cells revealed that AIE led to the induction of apoptosis and a high accumulation of cells in the G1 cell phase following treatment with AIE in a dose-dependent manner." | ( Kim, GD; Ngabire, D; Niyonizigiye, I; Patil, MP; Seo, YB; Seong, YA, 2018) |
| "Human NCI-N87 gastric cancer cells were treated with 15 μM quercetin or dimethyl sulfoxide (as a control) for 48 h." | ( Gu, W; Shen, Z; Wu, M; Zeng, Y, 2018) |
| "In metastatic gastric cancer, the addition of ramucirumab, an antivascular endothelial growth factor receptor 2-targeted antibody, to first-line chemotherapy did not improve survival over chemotherapy alone." | ( Ilson, DH, 2018) |
| "Exploration on conversion therapy for gastric cancer is still at initial stage, and reports that have been published are mostly single-centered with limited sample, lacking of sufficient evidence on its feasibility, safety and efficacy." | ( Chen, X; Chen, Y; Li, G; Lin, Z; Liu, H; Luo, J; Yu, J; Zhu, Y, 2018) |
| "We enrolled 48 HER2-positive advanced gastric cancer patients treated with trastuzumab-containing first-line chemotherapy and had paired biopsies at baseline and after progression." | ( Ahn, JY; Jung, HY; Kang, YK; Lee, GH; Park, SR; Park, Y; Park, YS; Ryoo, BY; Ryu, MH; Seo, S, 2019) |
| "From our established gastric cancer database, patients with pathological stage II and III gastric cancer who received adjuvant chemotherapy after D2 gastrectomy at Zhongshan Hospital of Fudan University were analyzed." | ( Cheng, X; Cui, Y; Ji, Y; Jiang, H; Li, W; Liu, F; Liu, TS; Shen, Z; Sun, Y; Tang, C; Wang, X; Wang, Y; Yu, S; Yu, Y, 2019) |
| "Human gastric cancer SGC-7901 cells were treated with EEC for 48 h." | ( Chen, Y; Lang, M; Li, X; Shen, Z; Shi, L; Xie, H, 2019) |
| "However, gastric cancer patients can be difficult to treat with the recommended dose because of the high incidence of adverse toxicities." | ( Akiyama, H; Endo, I; Fujii, Y; Kimura, J; Kosaka, T; Kunisaki, C; Miyamoto, H; Saigusa, Y; Sato, K; Sato, S; Taguri, M; Takagawa, R; Takahashi, M; Tanaka, Y; Yamanaka, T; Yukawa, N, 2018) |
| "They are involved in tumorigenesis of gastric cancer and have potential to be used as markers in response to the therapy." | ( Asghari, F; Baradaran, B; Haghnavaz, N; Kazemi, T; Khaze, V; Shanehbandi, D; Shekari, N, 2019) |
| "We treated a patient of metastatic gastric cancer for which lapatinib plus ipilimumab was effective after progression on trastuzumab." | ( Jiao, S; Ju, Y; Sun, S, 2018) |
| "Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes." | ( Boku, N; Hamaguchi, T; Higuchi, K; Honma, Y; Iwasa, S; Kato, K; Shoji, H; Takashima, A; Yamaguchi, T, 2019) |
| "In the latest Japanese gastric cancer treatment guidelines, PAM plus paclitaxel(PTX)was positioned as a second-line chemotherapy for advanced gastric cancer." | ( Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T, 2018) |
| "We report a case of P0CY1 gastric cancer that is successfullytreated with gastrectomyand S-1/Lentinan combined chemotherapyand has not recurred for long time postoperatively." | ( Cho, H; Okamoto, S, 2018) |
| "We encountered a case of type 4 gastric cancer with esophageal invasion that responded to neoadjuvant chemotherapy containing S-1 and oxaliplatin(SOX)followed by surgery, which could be curative resection." | ( Fujimura, T; Hagino, S; Izumi, R; Kitagawa, H; Kurata, T; Saito, K; Sasaki, S; Shoji, Y; Terada, I; Yoshikawa, A, 2018) |
| "He was diagnosed with gastric cancer, T4aN2M1(LYM), cStage ⅣB, and was administered chemotherapy." | ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nanishi, K; Okamoto, K; Otsuji, E; Shiozaki, A; Shoda, K, 2018) |
| "Dissemination of gastric cancer tends to be difficult to treat and has a poor prognosis." | ( Ajioka, Y; Alexey, A; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A, 2018) |
| "A total of 597 patients with gastric neoplasms treated with ESD between January 2010 and June 2017 were enrolled." | ( Amano, Y; Harada, H; Hayasaka, K; Katsuyama, Y; Murakami, D; Nagasaka, T; Nakahara, R; Sagami, R; Suehiro, S; Ujihara, T, 2019) |
| "Ninety-one patients with gastric cancer treated with neoadjuvant chemotherapy were enrolled in this study and then underwent operation." | ( Chen, L; Cong, X; Hao, Y; Li, S; Song, H; Xue, Y; Zhu, L; Zou, M, 2019) |
| "Although the prognosis ofypStage Ⅰgastric cancer was comparatively good, the regimen and courses ofpostoperative chemotherapy should be evaluated in a prospective study." | ( Akamaru, Y; Azama, T; Kitada, M; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R, 2019) |
| "The subjects were patients with gastric cancer aged younger than 75 years who underwent SOX or SP-SH therapy at our hospital." | ( Akamatsu, H; Furukawa, K; Kishi, K; Mikamori, M; Ohtsuka, M; Saito, T; Suzuki, Y; Tamaoka, K; Tanemura, M; Tei, M, 2019) |
| "Some gastric cancer studies have reported that MSI has no apparent impact on prognosis after patients receive 5-FU-based adjuvant chemotherapy." | ( Ahmad, R; Ma, Z; Ren, D; Shen, G; Wang, Z; Yuan, X; Zhao, F; Zhao, J; Zheng, F, 2019) |
| "She was diagnosed with stage IV gastric cancer (T4N3M1) and underwent seven cycles of 5-weekly TS-1, a novel oral fluoropyrimidine derivative, plus cisplatin therapy." | ( Kaji, K; Kaneko, M; Kitade, M; Kitagawa, K; Mitoro, A; Mori, H; Nakai, T; Nakanishi, K; Namisaki, T; Obayashi, C; Okura, Y; Otani, T; Ozutsumi, T; Sato, S; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H, 2019) |
| "The human gastric cancer cell lines MGC-803 and HGC-27 were treated with different concentrations of cordycepin (25 μM, 50 μM, 100 μM and 5 μM, 25 μM and 50 μM) for 48 h." | ( An, RB; Chen, LY; Li, ZH; Lin, ZH; Liu, TS; Lv, Y; Piao, YS; Ren, XS; Wang, Y; Yan, WD, 2019) |
| "PlGF gene expression in gastric cancer tissues could be a predictive indicator of AGC treatment by RAM." | ( Hayashi, K; Iwasaki, H; Kataoka, H; Kitagawa, M; Natsume, M; Okamoto, Y; Okuda, Y; Shimura, T, 2019) |
| "We report a case of recurrent gastric cancer that was successfully treated by S-1 chemotherapy." | ( Hata, M; Hoshino, H; Imamoto, H; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Ogino, T; Okano, M; Okuyama, M; Tanizaki, K; Tsujinaka, T, 2019) |
| "BACKGROUND Cisplatin-resistant gastric cancer (GC) occurs in patients with GC treated with cisplatin-based chemotherapy, which results in disease progression and early recurrence during the treatment." | ( Cai, Y; Deng, Z; Guo, G; Li, J; Li, L; Li, R; Li, X; Lu, Z; Tang, Y; Wang, H; Wang, Y; Yu, X, 2019) |
| "pFZD7-Stx1 was used to treat gastric cancer in vitro and in vivo." | ( He, N; Li, Z; Peng, L; Shen, M; Xia, Y; Xu, H, 2019) |
| "Here, targeting gastric cancer, a 2D magnesium boride nanosheet (MBN) is synthesized as a new type of acid-responsive hydrogen-releasing prodrug by an ultrasound-assisted chemical etching route, which is used to realize hydrogenochemotherapy by combination of facile oral administration of polyvinylpyrrolidone (PVP)-encapsulating MBN (MBN@PVP) pills with routine intravenous injection of doxorubicin (DOX)." | ( Chen, D; Fan, M; He, Q; Jin, Z; Lu, X; Wen, Y; Ye, D; Zhao, P, 2019) |
| "A patient with gastric cancer developed delirium and hyperammonemia after chemotherapy with the 5-fluorouracil pro-drug capecitabine." | ( Chu, G; Salzman, J, 2019) |
| "In patients with advanced esophageal or gastric cancer, it is highly likely that palliation of symptoms will become a focus of treatment." | ( Halpern, AL; McCarter, MD, 2019) |
| "For patients with stage I gastric cancer, PFC1 can be considered a high-risk prognostic factor, and adjuvant chemotherapy should be recommended for patients with PFC1." | ( Cao, G; Deng, P; Ding, P; Gao, Z; Hou, B; Lei, Y; Li, K; Zheng, C, 2019) |
| "Among gastric cancer patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy, patients who experienced a recurrence while receiving adjuvant therapy or within 6 months after completion and started systemic chemotherapy at four institutions between 2005 and 2015 were eligible." | ( Chin, K; Hara, H; Hasegawa, H; Hirao, M; Kadowaki, S; Mitani, S; Muro, K; Nishikawa, K; Tajika, M; Takahari, D; Wakatsuki, T, 2019) |
| "Secondary chemotherapy for gastric cancer in the Yamaguchi prefecture has a standard regimen selection according to guidelines." | ( Azuma, M; Hamano, K; Harada, E; Iida, M; Kanekiyo, S; Minami, Y; Miyazaki, K; Nagano, H; Okamoto, T; Sakaida, I; Suzuki, N; Takeda, S; Yoshino, S, 2019) |
| "Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy." | ( Cai, H; Du, C; Fang, Y; Huang, D; Huang, H; Jin, J; Li, G; Liu, X; Long, Z; Lu, Q; Ma, M; Sheng, W; Wang, Y; Wu, J; Xie, L; Yin, J; Zhang, Z; Zhao, G; Zhou, M; Zhou, Y; Zhu, H; Zhu, J; Zhu, X, 2019) |
| "Adjuvant chemotherapy for gastric cancer, particularly stage III, improves survival after curative D2 gastrectomy." | ( Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ, 2019) |
| "HER-2 is one of the key targets for the gastric cancer therapy." | ( Han, F; Hu, Y; Li, Y; Zhang, J; Zhao, T, 2019) |
| "The clinical treatment of gastric cancer (GC) is hampered by the development of anticancer drug resistance and the unfavorable pharmacokinetics, off-target toxicity, and inadequate intratumoral accumulation of the current chemotherapy treatments." | ( Guo, Y; Hong, C; Liang, J; Qin, J; Wang, D; Wang, J; Xia, J; Zhan, H; Zhu, Y, 2019) |
| "Outcome in adjuvant chemotherapy of gastric cancer (GC) has considerable stage-independent variability, which underscores the need for prognostic or predictive molecular markers." | ( Chen, X; Li, X; Shen, B; Shu, Y; Wang, D, 2019) |
| "For this purpose, rat gastric cancer cell line RGK36 was treated with L-arginine or N6-(1-iminoethyl)-L-lysine (L-NIL)." | ( Ito, H; Kurokawa, H; Matano, D; Matsui, H; Shigekawa, H; Taninaka, A; Terasaki, M, 2019) |
| "Four hundred gastric cancer patients who underwent treatment in our hospital between 2010 and 2012 were retrospectively analyzed." | ( Li, X; Liu, C, 2019) |
| "Drug resistance prevails in gastric cancer therapy." | ( Deng, H; Dong, W; He, P; Liu, Y; Ma, J, 2019) |
| "Prognosis for metastatic esophagogastric cancer remains poor despite modern systemic therapy regimens." | ( Basunia, A; Berger, MF; Boyar, MS; Capanu, M; Chalasani, SB; Chou, JF; Desai, AM; Dos Santos Fernandes, G; Gabler, A; Goldberg, Z; Hechtman, JF; Ilson, DH; Janjigian, YY; Jonsson, P; Kelsen, DP; Ku, GY; Moy, RH; Schattner, M; Schultz, N; Solit, DB; Tang, LH; Taylor, BS, 2020) |
| "Radiotherapy is used to treat gastric cancer (GC); however, radioresistance challenges the clinical outcomes of GC, and the mechanisms of radioresistance in GC remain poorly understood." | ( Ding, L; Huang, T; Jiang, H; Liang, Y; Liu, Y; Sattar, S; Shang, Y; Wang, M; Wei, Y; Wu, B; Yang, T; Zhang, D; Zhou, F, 2019) |
| "Co-treatment of gastric cancer cells with vitamin C in its IC50 dose in addition to cisplatin in both IC50 (10 µg/ml) and five times less (2 µg/ml) doses could increase the cytotoxicity effect of cisplatin in a synergistic manner." | ( Ghavami, G; Sardari, S, 2020) |
| "Some postoperative gastric cancer patients have to terminate systemic intravenous chemotherapy early due to adverse drug reactions." | ( Cao, T; Han, X; Li, G; Li, H; Liu, H; Wang, C; Yan, L, 2019) |
| "We also observed that gastric cancer cells demonstrated in cell death by MN-ZnONPs treatments." | ( Huo, X; Liang, W; Tang, Q; Wei, X; Xia, H, 2020) |
| "Herein, SGC-7901 and MGC-803 gastric cancer cells were treated with PADM (Ac-Phe-Lys-PABC-ADM), a prodrug of doxorubicin/adriamycin (ADM), and the combined antitumor effects of the two drugs were evaluated." | ( Huang, C; Mo, J; Sun, J; Tan, S; Zhang, Z; Zou, Y, 2019) |
| "Currently, gastric cancer treatment is mainly based on first-line intervention with oxaliplatin (OXA) after surgical resection, but the application of OXA has been limited due to the toxic side effects caused by the cumulative dose." | ( Chen, S; Gu, Z; Li, Q; Qin, M; Ren, L; Tan, Q; Zhang, T; Zhang, Y, 2019) |
| "Current treatment paradigms in gastric cancer probably negate further study of this regimen." | ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020) |
| "Aberrant over-expressions of FGF9 in gastric cancer (GC) and its high-affinity receptor FGFR3c in bladder cancer (BC) provide possibilities for the treatment of GC and BC via targeting FGF9." | ( Chen, L; Guo, Q; Huang, Y; Li, R; Lin, X; Tan, X; Wang, H; Wang, J; Wu, X; Zeng, X, 2020) |
| "Diffuse type gastric cancer has the worst prognosis due to notorious resistance to chemotherapy and enrichment of cancer stem-like cells (CSC) associated with the epithelial-to-mesenchymal transition (EMT)." | ( Liao, XH; Liu, HK; Lu, KP; Lu, WX; Wang, JC; Wang, L; Yang, DY; Yu, WX; Zhang, S; Zhang, ZZ; Zheng, M; Zhou, XZ, 2020) |
| "To improve the treatment of gastric cancer, the development of effective and innovative antitumor agents toward invasion and proliferation is needed." | ( Fang, E; Jiang, Y; Liu, Y; Luo, J; Tong, Q; Tong, S; Wang, Z; Wu, H; Yang, Y; Zhou, R, 2019) |
| "We found that treatment of gastric cancer cells with WZ35 exerted stronger anti-tumor activities than curcumin." | ( Chen, H; Chen, S; Chen, T; Lin, X; Sun, H; Wang, L; Wu, W; Zeng, T; Zhao, L; Zheng, B; Zhong, S, 2020) |
| "HGC-27 and BGC-823 gastric cancer cells were treated with aloin." | ( Cai, T; Qi, S; Qi, Z; Tang, T; Tao, H; Wang, S; Wang, Z; Zhang, Q, 2020) |
| "Thirty-two patients with colorectal or gastric cancer randomly received N-acetylcysteine (two 600 mg tablets) or placebo tablets 1 h before receiving oxaliplatin in dose in XELOX (oxaliplatin and capecitabine regimen) for eight courses of chemotherapy." | ( Allahyari, A; Barri, A; Bondad, N; Boostani, R; Elyasi, S, 2020) |
| "During seven years, no reported case of gastric cancer was done among 2,220 persons who underwent serological screening and treatment." | ( Chekh, SA; Kotelevets, SM, 2020) |
| "We report a case of advanced gastric cancer with stenosis under severe malnutrition, in which nutritional treatment along with chemotherapy using an elemental diet(ED)tube led to complete resection of the tumor." | ( Deguchi, S; Hirakawa, K; Hori, T; Ishikawa, T; Masuda, G; Nakata, B; Sakimura, C; Tani, N; Tendo, M, 2019) |
| "A 61-year-old man with advanced gastric cancer underwent distal gastrectomy after chemotherapy." | ( Akamaru, Y; Azama, T; Hokkoku, D; Ikeshima, R; Kitada, M; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R, 2019) |
| "We report a case of advanced gastric cancer with right gastroepiploic vein tumor thrombus treated using preoperative S-1 plus cisplatin(CDDP)in which pathological complete response was achieved." | ( Arai, S; Goseki, N; Koike, M; Kuwabara, H; Nakamura, N; Sanada, T; Sato, T; Tomi, Y; Yoshida, T, 2019) |
| "As compared with gastric cancer model group, the general states of rats were improved significantly after treated with different dose Weining granule." | ( Deng, X; Fu, L; Jiang, M; Liang, J; Liang, M; Liang, X; Wang, X; Zhao, X; Zhou, X, 2019) |
| "The prognosis of gastric cancer with para-aortic or bulky lymph node metastases is poor, but the JCOG 0405 study showed relatively good outcomes of neoadjuvant chemotherapy and gastrectomy with para-aortic lymph node dissection." | ( Endo, S; Ikenaga, M; Sasaki, YO; Tamura, S; Yamada, T, 2020) |
| "Using taxane-treated gastric cancer patient biopsies, we demonstrated that absence of drug-target engagement was correlated with clinical taxane resistance." | ( Betel, D; Cleveland, K; Galletti, G; Giannakakou, P; Gjyrezi, A; Powell, S; Shah, MA; Thakkar, PV; Zhang, C; Zhang, J, 2020) |
| "Seven patients with gastric cancer had previously been treated with immune checkpoint inhibitors." | ( Asayama, M; Fukuoka, S; Hara, H; Hirano, N; Kawazoe, A; Kojima, T; Kotani, D; Kuwata, T; Mikamoto, Y; Nishikawa, H; Nomura, S; Sato, A; Shitara, K; Takahashi, N; Tamura, H; Togashi, Y; Wakabayashi, M; Yoshii, T, 2020) |
| "At present, the treatment of gastric cancer involves a combination of surgery and chemotherapy." | ( Tang, C; Wu, J; Xu, J, 2020) |
| "The survival of esophageal and gastric cancer patients treated with chemotherapy is rarely assessed outside of clinical trials." | ( Ebrahim, F; Ekheden, I; Henriksson, R; Ólafsdóttir, H; Raaschou, P; Wettermark, B; Ye, W, 2020) |
| "In patients with advanced gastric cancer refractory to chemotherapy, the treatment options are limited." | ( Ando, M; Honda, K; Kadowaki, S; Kato, K; Komori, A; Kondoh, C; Masuishi, T; Mitani, S; Muro, K; Narita, Y; Oze, I; Tajika, M; Tanaka, T; Taniguchi, H, 2020) |
| "FOLFOX therapy has been used for gastric cancer in Japan since 2017." | ( Cho, H; Funasaka, C; Kanemasa, Y; Omuro, Y; Shimoyama, T, 2020) |
| "Patients with advanced gastric cancer more than 18 years old were eligible and received low-dose apatinib (500 mg or 250mg per day) therapy." | ( Cao, Q; Cheng, H; Du, Y; Hu, W; Hu, Z; Ji, C; Jiang, C; Jiang, Z; Li, L; Li, X; Liang, H; Lu, D; Ning, Z; Sun, G; Wang, D; Wang, G; Wang, J; Wang, S; Xie, H; Xu, T; Xu, Y; Yu, C; Zhang, J; Zhang, Y; Zhao, Y; Zhou, C; Zhou, J, 2020) |
| "One of the most common treatment for gastric cancer is chemotherapy, however, multiple drug resistance (MDR) induce the therapeutic effect which result in the failure of anticancer therapy." | ( Dong, T; Huang, M; Jiang, M; Lv, J; Wu, M; Xu, L; Xue, M, 2020) |
| "In advanced gastric cancer treatment, carbon nanoparticle injection into no." | ( Chen, Z; Huang, Y; Mu, G; Qin, X; Wei, C; Wu, X; Zeng, Y, 2020) |
| "The clinical management of gastric cancer still remains challenge due to its poor response to chemotherapy." | ( Li, Z; Shan, C; Tong, X; Xu, D, 2021) |
| "The patients with advanced gastric cancer who were treated in gastrointestinal surgery in our hospital from January 2017 to December 2018 were divided into two groups." | ( Cui, Z; Xu, L; Zhang, J, 2020) |
| "Diagnosing the invasion depth of gastric cancer (GC) is necessary to determine the optimal method of treatment." | ( Koike, K; Minatsuki, C; Nagao, S; Niimi, K; Sakaguchi, Y; Seto, Y; Tada, T; Takahashi, Y; Tsuji, Y; Yamamichi, N; Yamashita, H, 2020) |
| "The findings indicated that gastric cancer chemotherapy induces cytotoxicity effects in various ways including a decrease of cell viability, colony formation, metastasis, tumor growth, and weight, as well as elevation of apoptosis pathway, oxidative stress pathway compared to the control group." | ( Farhood, B; Haghi-Aminjan, H; Mortezaee, K; Najafi, M; Rahimifard, M, 2020) |
| "As risk for gastric cancer development is high in Japan, determining whether the "test-and-treat" strategy can be recommended in children has become an urgent matter." | ( Fujimura, S; Gold, BD; Ida, S; Ishige, T; Kamiya, S; Kato, S; Konno, M; Kuwabara, K; Nakayama, Y; Shimizu, T; Toyoda, S; Ushijima, K; Yoshimura, N, 2020) |
| "Most gastric cancer patients are diagnosed at mid- to late-stage and lose the chance of radical surgery, medical treatment is especially important to prolong the survival of patients." | ( Chen, X; Guo, Z; Han, J; Han, Z; Hui, Y; Sun, S; Wang, J; Wang, Y; Wu, Z, 2020) |
| "Bufothionine had been used for gastric cancer (GC) treatment, and this study managed to uncover the underlying mechanisms." | ( Ding, HX; Hu, XM; Hu, ZH; Li, RX; Wang, GJ; Wang, ZY; Zhu, TY, 2020) |
| "Few patients affected by gastric cancer peritoneal metastasis (GCPM) are offered locoregional treatment, despite several proof-of-efficacy trials." | ( Abatini, C; Di Giorgio, A; El Halabieh, MA; Inzani, F; Pacelli, F; Rodolfino, E; Romanò, B; Rotolo, S; Schena, CA; Strippoli, A; Vita, E, 2020) |
| "The AGS gastric cancer cell line were pretreated with three different sub-toxic concentration of metformin and then treated with various concentrations of 5-FU and docetaxel." | ( Fatehi-Agdam, M; Jeddi, F; Najafzadeh, N; Panahizadeh, R; Vatankhah, MA, 2021) |
| "We present a case of an advanced gastric cancer patient with chronic renal failure, who was treated with 5FU/leucovorin (LV) infusion chemotherapy (2-h infusion of LV and 5FU bolus followed by 46-h 5FU continuous infusion on day 1; repeated every 2 weeks) and developed hyperammonemia, with the aim of exploring an appropriate hemodialysis (HD) schedule to resolve its symptoms." | ( Funakoshi, T; Horimatsu, T; Ikeda, A; Imamaki, H; Kataoka, S; Matsubara, T; Muto, M; Nakagawa, S; Nishikawa, Y; Oura, M; Ozaki, Y; Watanabe, N; Yanagita, M; Yonezawa, A, 2020) |
| "KEY WORDS: Adjuvant chemotherapy, Gastric cancer, Liver infarction, Hepatic necrosis." | ( Carlei, F; De Donato, MC; Di Cesare, E; Di Sibio, A; Ficorella, C; Giuliani, A; Latessa, M; Monti, R; Parisi, A; Romano, L; Schietroma, M; Varrassi, M; Venditti, O, 2020) |
| "However, the mechanisms underlying gastric cancer (GC) resistance to chemotherapy are still unclear." | ( Li, W; Wang, H; Xu, L; Yang, S; Yao, X; Yu, J; Zhang, F; Zhao, L, 2021) |
| "Hereby, we report a case of type 4 gastric cancer with peritoneal dissemination successfully treated with conversion surgery after intensive SOX chemotherapy." | ( Iwasaki, K; Kitamura, K; Koide, N; Koyama, M; Matsumura, T; Nomori, H; Obana, A; Sato, Y; Suwa, T; Usui, S; Yoshida, R, 2021) |
| "In the latest Japanese gastric cancer treatment guidelines, paclitaxel(PTX)plus ramucirumab(RAM)was positioned as a second-line chemotherapy for advanced gastric cancer." | ( Itoh, R; Miyamoto, K; Tadano, Y, 2021) |
| "We experienced 2 cases of untreated gastric cancer with massive ascites due to peritoneal dissemination, to whom chemotherapy was successfully introduced as a result of improvement of general conditions achieved by CART." | ( Abe, S; Ami, K; Hamasaki, S; Harada, T; Katsuno, A; Kitagawa, Y; Machida, T; Nakanishi, A; Tamura, N; Umetani, N, 2020) |
| "We herein report 2 cases of gastric cancer treated by S-1 and oxaliplatin combination therapy before later undergoing gastrectomy." | ( Akita, H; Amagasa, H; Andou, M; Aoki, N; Fukuda, A; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Kawamura, Y; Maeda, F; Tei, S; Toukairin, Y; Yamada, A, 2020) |
| "We report a case of advanced gastric cancer with peritoneal metastasis achieved pathological complete response by chemotherapy." | ( Danno, K; Ikeda, K; Kawagishi, S; Nishigaki, T; Oka, Y; Sugimoto, K; Takahashi, K; Takeyama, H; Taniguchi, H; Tokunaga, T; Toyoda, Y; Yamamoto, H; Yamashita, M, 2020) |
| "However, gastric cancer cells are usually insensitive to TRAIL so reducing this drug resistance may improve the treatment of gastric cancer." | ( Guo, J; Li, H; Liang, Z; Liu, S; Lv, J; Ma, Y; Qi, W; Qiu, W; Wang, S; Wang, Y, 2021) |
| "The Japanese Gastric Cancer Treatment Guidelines recommend S-1 and S-1 plus docetaxel as postoperative chemotherapy for pathological stage II and III gastric cancer (GC)." | ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Noda, M; Ohtsuka, T; Okubo, K; Sasaki, K; Tanaka, T; Tsuruda, Y, 2021) |
| "The low proportion of gastric cancer (GC) patients with high HER2 expression limits the clinical application of trastuzumab, a humanized epidermal growth factor receptor 2 (HER2) antibody targeting for GC treatment." | ( Guo, Z; Tian, Y; Wu, J; Zhang, X; Zhao, Q; Zhao, Y, 2021) |
| "Despite improvements in gastric cancer treatment, the mortality associated with advanced gastric cancer is still high." | ( Doki, Y; Eguchi, H; Fujimoto, M; Ishida, T; Kobayashi, T; Koh, M; Kurokawa, Y; Makino, T; Miyazaki, Y; Naka, T; Nakajima, K; Saito, T; Serada, S; Takahashi, T; Tanaka, K; Wada, N; Yamasaki, M; Yamashita, K, 2021) |
| "Although unresectable or recurrent gastric cancers (GC) are frequently treated with platinum-based chemotherapy, response to treatment remains unpredictable." | ( Asai, R; Harada, K; Hattori, T; Honma, R; Kuraoka, K; Maruyama, R; Morii, E; Murai, J; Ohdan, H; Sakamoto, N; Sasaki, AT; Takashima, T; Tanabe, K; Taniyama, D; Thang, PQ; Ukai, S; Yasui, W; Yasumoto, M, 2021) |
| "Although the prognosis of gastric cancer with dissemination is very poor, it is possible to prolong survival with chemotherapy." | ( Fujita, S; Iimori, N; Kametani, N; Kato, Y; Matsunaga, Y; Natsuki, S; Nishimura, S; Noda, E; Okuno, T; Taenaka, N; Yamada, N; Yamamoto, A, 2021) |
| "However, they were less reported for gastric cancer therapy." | ( Kang, HQ; Li, YH; Liu, HM; Ma, LY; Tao, YY; Zhang, XH; Zhao, JR, 2021) |
| "Treatment of gastric cancer cell lines with a CAMKK2 inhibitor, STO-609, resulted in decreased cell migration, invasion, and colony-forming ability and a G1/S-phase arrest." | ( Chatterjee, A; Gowda, H; Modi, PK; Najar, MA; Prasad, TSK; Ramesh, P; Sidransky, D, 2021) |
| "Advanced gastric cancer (AGC) patients are not tolerant to the toxicities of traditional chemotherapy and its second-line therapeutic regimens are limited." | ( Chen, M; He, H; Qin, R; Qiu, ZY; Tian, GY; Wang, Y; Xi, Y; Zhang, Z, 2021) |
| "We report a case of gastric cancer in which pCR was obtained in the primary lesion, although stenosis appeared after the neoadjuvant chemotherapy." | ( Hiramoto, H; Ishimoto, T; Kosuga, T; Masuyama, M; Matsui, T; Mochizuki, S; Nakamichi, N; Nakashima, S; Tsujiura, M, 2021) |
| "Some gastric cancers (GCs) express ERs, and preclinical studies suggest the potential of estrogen-targeting hormone therapy on GC; however, the clinical relevance of this hormone therapy on GC treatment has not been well elucidated." | ( Hiramatsu, T; Hongo, K; Iida, Y; Ishihara, Y; Kita, Y; Kobayashi, R; Kuriki, K; Onoda, T; Takabayashi, N, 2021) |
| "In untreated MGC-803 gastric cancer cells, the expression of cIAP1 was higher and the expression of TRAF3 was lower than in normal gastric mucosa cell line GES-1." | ( Shuai, LY; Zhu, DL, 2021) |
| "The standard of care for resectable gastric cancers (GCs) includes perioperative chemotherapy (CT) or postoperative chemo/chemoradiotherapy (CRT) strategies." | ( Kumar, S; Maria Das, KJ; Misra, S; Singh, RK; Singh, S; Yeshala, SK, 2021) |
| "For successful treatment of early gastric cancers (EGCs), it is crucial to define the horizontal border of the lesion with high accuracy." | ( Baek, DH; Hong, SM; Kim, DM; Kim, GH; Lee, BE; Lee, MW; Song, GA, 2022) |
| "In brief, the undifferentiated human gastric cancer cell HGC-27 was used, which was treated with different concentrations of PIP." | ( Guo, L; Han, C; Ruan, S; Sheng, Y; Wang, J; Yang, Y, 2021) |
| "Precancerous lesion of gastric cancer(PLGC) is a critical stage for preventing the occurrence of gastric cancer, and PLGC therapy has frequently been investigated in clinical research." | ( Liu, HY; Lu, YT; Mao, YJ; Ouyang, GZ; Shang, JJ; Yang, L, 2021) |
| "We report a case of advanced gastric cancer that was successfully treated with mFOLFOX6 therapy." | ( Fukada, A; Hashimoto, Y; Hirose, H; Kawada, J; Kidogami, S; Kishimoto, T; Mizuno, M; Mokutani, Y; Murotani, M; Nagano, S; Nakano, M; Sasaki, Y; Tamura, S; Yoneda, N; Yoshioka, S, 2021) |
| "In this study, 98 patients with gastric cancer who were treated in the hospital were selected as the research subjects." | ( Chen, Q; Ding, R; Wang, X; Wang, Z, 2021) |
| "The prognosis of patients with advanced gastric cancer (GC) remains unsatisfactory owing to distant metastasis and resistance to concurrent systemic therapy." | ( Chen, F; Chen, H; Chen, W; Ding, N; Jiang, H; Lin, Z; Liu, X; Ni, J; Wang, J; Wang, L; Wang, Z; Xue, M; Zheng, S, 2021) |
| "The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive." | ( Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z, 2022) |
| "Hypoxia is a major obstacle to gastric cancer (GC) therapy and leads to chemoresistance as GC cells are frequently exposed to the hypoxia environment." | ( Kim, TW; Lee, HG, 2021) |
| "The prognosis of gastric cancer patients with peritoneal metastasis (PM) remains dismal with standard systemic chemotherapy." | ( Hiraki, Y; Imano, M; Kato, H; Momose, K; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T, 2022) |
| "We enrolled 52 gastric cancer patients with PM who were treated with single i." | ( Hiraki, Y; Imano, M; Kato, H; Momose, K; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T, 2022) |
| "Chemoresistance is a main obstacle in gastric cancer (GC) treatment, but its molecular mechanism still needs to be elucidated." | ( Chen, W; Cui, Y; Liu, T; Shen, Z; Tang, C; Wang, Y; Yu, S; Zhang, P; Zhu, M, 2022) |
| "Because recurrent gastric cancer is often a progressive condition, post-treatment might be promptly transferred to the other posterior regimen without 5-FU as required." | ( Hirano, S; Ichinokawa, M; Kumagai, K; Kuwabara, S; Matsumoto, J; Murakawa, K; Ono, K; Takeuchi, Y; Wada, H, 2022) |
| "We herein report 3 cases of advanced gastric cancer with multiple liver metastases who was successfully treated with systemic chemotherapy and underwent conversion surgery with liver resection." | ( Chika, N; Chikatani, K; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Ishikawa, H; Ito, T; Kumagai, Y; Maki, A; Mochiki, E; Sugino, A; Toyomasu, Y; Yamamoto, A; Yamamoto, E, 2021) |
| "The inhibition rate of gastric cancer cells after treatment with curcumin was increased from 6% to 67% for 24h, from 8% to 75% for 48h, from 10% to 83% for 72h." | ( Alam, J; Dilnawaz, F; Hussain, T; Mukhopadhyay, AK; Pati, S; Sahoo, SK; Singh, DV, 2022) |
| "Chemotherapy to patients with advanced gastric cancer, exhibits greater drug resistance to standard chemotherapy drugs." | ( Jia, B; Velu, P; Wu, H; Zhang, L, 2022) |
| "Two hundred patients with gastric cancer with serosal invasion who received neoadjuvant therapy from January 2012 to December 2020 were retrospectively analyzed." | ( Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JP; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2021) |
| "Radiotherapy is a key strategy in gastric cancer (GC) treatment." | ( Liu, G; Liu, Y; Qiu, H; Shi, L; Song, J; Sun, J; Xu, Y; Yang, S, 2022) |
| "A 61-year-old patient with advanced gastric cancer was treated with ramucirumab plus albumin-suspended paclitaxel as second-line treatment." | ( Igarashi, Y; Ito, K; Kikuchi, Y; Kimura, Y; Nakao, T; Namiki, M; Wakabayashi, M; Yamaguchi, K, 2022) |
| "A 70s man diagnosed with advanced gastric cancer with S3 solitary liver metastasis, and received a chemotherapy with S-1 and cisplatin." | ( Goto, A; Inaba, K; Ito, A; Matsuoka, H; Nakamura, K; Nakauchi, M; Shibasaki, S; Suda, K; Tanaka, T; Umeki, Y; Uyama, I, 2022) |
| "In trastuzumab-resistant HER2-positive gastric cancer, glycolysis fluctuates with a circadian oscillation regulated by the BMAL1-CLOCK-PER1-HK2 axis, which can be disrupted with a metformin-based chronotherapy to overcome trastuzumab resistance." | ( Hu, K; Hu, X; Huang, Q; Jiang, Y; Liang, B; Liao, W; Ma, Z; Rong, X; Shi, M; Wang, C; Wang, J; Wang, Y; Wu, Q; Wu, Z; Xu, X; Yao, G; Zhang, S, 2022) |
| "A selection of gastric cancer cell lines (Hs746T, MKN1, MKN7 and NCI-N87) was treated with EGF, cetuximab, trastuzumab or afatinib for a period of 4 or 24 h." | ( Arnold, R; Barbaria, E; Ebert, K; Geffers, R; Haffner, I; Hasenauer, J; Hollerieth, V; Keller, S; Lordick, F; Luber, B; Maier, D; Raimúndez, E; Walch, A; Wirtz, R; Zwingenberger, G, 2022) |
| "Palliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established." | ( Ishikawa, Y; Jingu, K; Katagiri, Y; Kishida, K; Kubozono, M; Sakayauchi, T; Suzuki, Y; Takahashi, N; Takeda, K; Umezawa, R; Yamamoto, T, 2022) |
| "Palliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy." | ( Ishikawa, Y; Jingu, K; Katagiri, Y; Kishida, K; Kubozono, M; Sakayauchi, T; Suzuki, Y; Takahashi, N; Takeda, K; Umezawa, R; Yamamoto, T, 2022) |
| "Surgery remains the cornerstone of gastric cancer treatment, and new strategies with adjuvant chemotherapy are currently gaining more and more acceptance." | ( Duan, Z; Fan, D; Jiang, H; Liu, Y; Ma, P; Mi, Y; Shen, S, 2022) |
| "Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included." | ( Dazai, M; Harada, K; Ishiguro, A; Ito, YM; Kawamoto, Y; Komatsu, Y; Meguro, T; Muto, O; Nakamura, M; Okada, K; Okuda, H; Sakamoto, N; Sakata, Y; Sato, A; Sawada, K; Sekiguchi, M; Shindo, Y; Sogabe, S; Tsuji, Y; Yuki, S, 2022) |
| "Biomarkers for selecting gastric cancer (GC) patients likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy (sequential paclitaxel) were investigated using tissue samples of patients recruited into SAMIT, a phase III randomized controlled trial." | ( Grabsch, HI; Guan, J; Masuda, M; Miyagi, Y; Oshima, T; Rino, Y; Sakamoto, J; Tan, P; Tanaka, S; Tsuburaya, A; Yoshida, K; Yoshikawa, T, 2022) |
| "Postoperative chemotherapy for gastric cancer often causes multidrug resistance (MDR), which has serious consequences for therapeutic effects." | ( Cai, X; Hu, H; Li, H; Li, L; Li, N; Ma, J; Pang, L; Yi, T; Zeng, Y; Zhan, Y, 2022) |
| "5-Fluorouracil (5-FU) is widely used in gastric cancer treatment, yet 5-FU resistance remains an important clinical challenge." | ( Han, FH; Hu, H; Huang, J; Luo, ML; Tan, JN; Yang, B; Zhang, W; Zhong, GY; Zhou, SN, 2022) |
| "This was a real-world study of gastric cancer patients with peritoneal metastasis who have been treated with AS or SOX regimen as first-line chemotherapy." | ( Cui, Y; Li, Q; Li, W; Liu, T; Wang, Y; Yu, S; Yu, Y; Zhang, J; Zhang, L, 2022) |
| "Accurate staging of gastric cancer is essential for the selection and optimization of therapy." | ( Chan, WH; Chen, AH; Chen, CM; Lai, YC; Lee, YH, 2022) |
| "Determining the prognosis of gastric cancer is the most crucial step in the treatment process." | ( Chen, P; Liu, Q; Liu, Y; Wang, B; Zheng, X, 2022) |
| "Improving the diagnosis rate of gastric cancer and exploring new treatments are urgent issues in the clinical field." | ( Ding, J; Feng, M; Feng, Q; Guan, W; Kang, X; Li, Z; Liu, J; Qiao, T; Tan, J; Wang, J; Wang, X, 2022) |
| "Currently, the treatment of gastric cancer is still dominated by radiotherapy, chemotherapy and surgery." | ( Chen, Z; Li, X; Mu, M; Qu, C; Shi, J; Sun, X; Wang, X; Ye, C; Zhao, C; Zhao, W; Zhu, L, 2023) |
| "Our study indicates that gastric cancer cells can be endowed with stemness traits via EID3-NAMPT-Wnt/β-catenin axis in response to radiochemotherapy." | ( Lu, Y; Zhang, X, 2022) |
| "Post-surgical gastric cancer patients could benefit substantially from anti-diabetes and antihypertensive therapy." | ( Chen, X; Fan, Z; Hu, D; Lin, J; Lin, X; Lin, Y; Peng, F; Wang, L; Yan, X; Yu, J; Zhang, S, 2022) |
| "However, especially for gastric cancer, two endoscopic procedures are required to administer these two tracers, which burdens the patients and practitioners." | ( Endo, R; Hayashi, H; Matsubara, H; Toyota, T; Uehara, T; Zhang, Y, 2022) |
| "In patients with gastric cancer at high risk of peritoneal carcinomatosis, we propose aggressive surgical treatment with radical gastrectomy, removal of organs at risk of harbouring tumour cells, and HIPEC." | ( Abatini, C; Bonavina, L; De Luca, M; Di Giorgio, A; Garattini, S; Gerardi, C; Melotti, G; Pacelli, F; Rulli, E; Santullo, F; Torri, V, 2022) |
| "In patients with gastric cancer at high risk of peritoneal carcinomatosis, we propose aggressive surgical treatment with radical gastrectomy, removal of organs at risk of harbouring tumour cells, and HIPEC." | ( Abatini, C; Bonavina, L; De Luca, M; Di Giorgio, A; Garattini, S; Gerardi, C; Melotti, G; Pacelli, F; Rulli, E; Santullo, F; Torri, V, 2022) |
| "However, its role in gastric cancer treatment remains unknown." | ( Bai, Y; Chen, Z; He, S; Li, B; Song, J; Wang, N; Xu, X; Zhang, S, 2023) |
| "We have profiled the activity of DZB in gastric cancer (GC) as monotherapy and combined with paclitaxel, and explored means of stratifying patients for treatment." | ( Bachmann, F; El Shemerly, M; Forster-Gross, N; Hermann, N; Kellenberger, L; Lane, HA; McSheehy, PMJ; Roceri, M; Spickermann, J, 2023) |
| "Patients with advanced gastric cancer who had been previously treated with ≥2 lines of chemotherapy received E7389-LF 2." | ( Hamakawa, T; Hirao, M; Iwasa, S; Kawazoe, A; Komatsu, Y; Machida, N; Okumura, S; Oshima, T; Sato, Y; Semba, T; Shitara, K; Suzuki, T; Takase, T; Teng, A; Yamaguchi, K; Yonemori, K; Yuki, S; Zimmermann, B, 2023) |
| "A resection biopsy revealed gastric cancer metastasis, and PTX plus RAM therapy was started." | ( Hattori, S; Itoh, Y; Matsuno, Y; Nagasawa, S; Suematsu, Y; Taguchi, K; Takahashi, M; Takane, Y; Teranishi, N; Uetake, H; Wakabayashi, K; Yan, M, 2022) |
| "Chemotherapy resistance in advanced gastric cancer (GC) patients has largely limited the effectiveness of therapy, resulting in disease recurrence and poor prognosis." | ( Huang, C; Shen, B; Tao, Z; Wang, D; Wang, M; Wang, Q; Xu, J; Zhang, H; Zhao, Y; Zhou, C; Zhu, W, 2023) |
| "However, their combined treatment for gastric cancer (GC) has not been illuminated." | ( Feng, L; Li, F; Li, J; Xu, QY; Xue, S; Zhang, YQ; Zhang, YY, 2023) |
| "Patients with advanced gastric cancer (AGC) who underwent NIVO or IRI treatment between November 2016 and June 2018 at three institutions were retrospectively reviewed." | ( Bando, H; Hara, H; Kadowaki, S; Kumanishi, R; Masuishi, T; Matsushima, T; Mitani, S; Muro, K; Narita, Y; Ogata, T; Tajika, M; Yasui, H, 2023) |
| "The results showed that gastric cancer patients with pMMR can benefit from 5-FU-based adjuvant chemotherapy, but those with dMMR cannot." | ( Dong, Q; Gao, L; Li, E; Li, Z; Liu, Z; Ma, J; Ren, D; Shen, G; Wang, M; Xie, Q; Zhao, F; Zhao, J; Zhao, Y, 2023) |
| "Patients with advanced inoperable gastric cancer could benefit probably from conversion chemotherapy and subsequence conversion surgery." | ( Chen, ZL; Deng, YY; Jiang, DY; Liu, Q; Lu, H; Pan, SY; Yang, L; Zhang, X; Zhu, PF, 2023) |
| "In this study, we treated gastric cancer cells with γ-T3, collect and deposit the cells." | ( Xie, L; Yan, J, 2023) |
| "Human gastric cancer cells HGC-27 were treated with 0, 5, 10 or 20 mg/L rhein respectively for 24, 48 and 72 h in vitro, three duplicate wells were set in each group." | ( Chen, JY; Chen, YT; Chu, ZH; Fu, JW; Tao, JY, 2022) |
| "Patients with advanced gastric cancer who had previously failed at least two lines of chemotherapy received oral apatinib until disease progression, death or unacceptable toxicity." | ( Ba, Y; Bai, Y; Deng, W; Gao, F; Guo, W; He, Y; Hou, Z; Huang, Y; Jia, T; Jiang, D; Li, J; Li, W; Lin, X; Liu, L; Lu, L; Qin, S; Sun, G; Sun, Y; Wang, J; Wang, L; Wang, Q; Wen, L; Wu, X; Wu, Y; Xie, Z; Yang, J; Ye, F; Yi, T; Yin, L; Yu, G; Yuan, Y; Zhang, G; Zhao, J; Zhong, H, 2023) |
| "Advanced gastric cancer is associated with poor survival despite chemotherapy." | ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| "50 patients with advanced gastric cancer, who had achieved response or had stable disease after 6 cycles of Docetaxel, Cisplatin, and 5-Flurouracil (D 75 mg/m2, C 75 mg/m2, FU 750 mg/m2/d d1-d5, q3 weeks) chemotherapy were prospectively selected to receive maintenance chemotherapy with capecitabine (1000mg/ m2 bid d1-d14 q21 days) until progression." | ( Chaudhari, K; Doval, DC; Goel, V; Goyal, P; Koyyala, VPB; Maheshwari, U; Patnaik, N; Talwar, V, 2023) |
| "In locally advanced gastric cancer (GC), FLOT represents the standard perioperative regimen and combination with immunotherapy is under investigation." | ( Belluomini, MA; Catanese, S; Cremolini, C; Fontanini, G; Fornaro, L; Giannini, R; Giordano, M; Lencioni, M; Masi, G; Massa, V; Pallabazzer, G; Pecora, I; Salani, F; Santi, S; Ugolini, C; Vasile, E; Vivaldi, C, 2023) |
| "Human gastric cancer MGC-803 cells treated with 100, 200 and 300 μg/mL aloin were examined for changes in cell viability, proliferation and migration abilities using CCK-8, EdU and Transwell assays." | ( Chen, Q; Chen, X; Cheng, Z; Ge, F; Qi, Z; Wan, M, 2023) |
| "Xanthurenic acid (XA) was measured in gastric cancer cells treated with H." | ( Du, W; Geng, L; Gong, S; Huang, L; Liang, X; Pan, W; Xiang, L; Xie, Y; Xu, W; Yang, F; Zheng, F, 2023) |
| "Patients suffering from invasive gastric cancer had been treated with preoperative immunonutrition with glutamine, and they were compared to patients without nutritional treatment." | ( Jurczuk, A; Kamocki, Z; Kedra, B; Matowicka-Karna, J; Milewska, A; Niewinski, A; Zareba, K, 2023) |
| "Data were collected from gastric cancer patients who received chemotherapy at a single public hospital in Japan from 2008 to 2021." | ( Endo, A; Fukasawa, Y; Ishii, Y; Itaya, K; Iwasaki, S; Izumi, T; Kato, S; Koike, Y; Matsumura, M; Murai, T; Nakagawa, S; Nakamura, M; Nishikawa, S; Nomura, A; Ohshima, T; Okazaki, N; Ono, Y; Tsuji, T; Watanabe, A; Yokota, I; Yoshizawa, A, 2023) |
| "We applied CIdrgn to identify gastric cancer and itsf chemotherapy (capecitabine and oxaliplatin) -responsive network based on the Cancer Dependency Map." | ( Imoto, S; Miyano, S; Park, H, 2023) |
| "A recent study of cyclin D1 in gastric cancer was associated with lymph node involvement, metastasis, poor prognosis, and a lack of response to platinum chemotherapy." | ( Cahyanur, R; Rahadiani, N; Utari, AP, 2023) |
| "It has been demonstrated that gastric cancer mesenchymal stem cells (GC-MSCs) can promote the progression, metastasis, and chemoresistance of GC through various mechanisms, but the effect of GC-MSCs on GC during chemotherapy is still unknown." | ( Chen, Z; Cui, L; Huang, C; Shen, B; Shen, J; Wang, M; Zhao, Y; Zhu, M; Zhu, W, 2024) |
| "pylori-related gastric cancer, but the treatment should simultaneously remove H." | ( Du, Y; He, J; Li, B; Liu, S; Lv, X; Zhang, X; Zhang, Y, 2023) |
| "The Japanese Gastric Cancer Treatment Guidelines recommend doublet chemotherapy (S-1 plus another chemotherapy) over S-1 alone for patients with pStage III gastric cancer who underwent radical gastrectomy." | ( Akita, H; Hara, H; Haraguchi, N; Hasegawa, S; Kanemura, T; Matsuda, C; Mikamori, M; Miyata, H; Mukai, Y; Nishimura, J; Ohue, M; Omori, T; Shinno, N; Sugase, T; Takeoka, T; Wada, H; Yamamoto, M; Yasui, M, 2023) |
| "The prognosis for advanced gastric cancer patients treated with multimodal therapy after surgery remains discouraging." | ( Che, G; Chen, Y; Ding, Y; He, C; Teng, F; Teng, L; Wang, H; Yang, Y; Zhang, J; Zhou, D; Zhou, Z, 2024) |
| "However, the effectiveness of TH-302 in gastric cancer combined immunotherapy remains unclear." | ( Cai, J; Cao, D; Chen, Z; Dong, R; Li, Y; Wang, Z; Zhu, M; Zuo, X, 2023) |